<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003460.pub3" GROUP_ID="IBD" ID="733801112210280009" MERGED_FROM="" MODIFIED="2013-02-21 14:51:37 +0000" MODIFIED_BY="John MacDonald" REVIEW_NO="40" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2013-02-21 14:51:37 +0000" MODIFIED_BY="John MacDonald">
<TITLE MODIFIED="2009-11-27 15:41:51 -0500" MODIFIED_BY="[Empty name]">Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome</TITLE>
<CONTACT MODIFIED="2013-02-21 14:51:37 +0000" MODIFIED_BY="John MacDonald"><PERSON ID="14361" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Otto</FIRST_NAME><LAST_NAME>Quartero</LAST_NAME><EMAIL_1>quartero@huisartsensalland.nl</EMAIL_1><ADDRESS><ORGANISATION>Huisartspraktijk Diepenveen</ORGANISATION><ADDRESS_1>Dorpsstraat 16</ADDRESS_1><CITY>Diepenveen</CITY><ZIP>7431 CK</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31  570 591244</PHONE_1><FAX_1>+31 570 593680</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-02-21 14:51:37 +0000" MODIFIED_BY="John MacDonald"><PERSON ID="78199248468590007788091119160241" ROLE="AUTHOR"><FIRST_NAME>Lisa</FIRST_NAME><LAST_NAME>Ruepert</LAST_NAME><EMAIL_1>lisaruepert@gmail.com</EMAIL_1><EMAIL_2>L.Ruepert@students.uu.nl</EMAIL_2><ADDRESS><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>P.O. Box 85060</ADDRESS_1><CITY>3508 AB Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="14361" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Otto</FIRST_NAME><LAST_NAME>Quartero</LAST_NAME><EMAIL_1>quartero@huisartsensalland.nl</EMAIL_1><ADDRESS><ORGANISATION>Huisartspraktijk Diepenveen</ORGANISATION><ADDRESS_1>Dorpsstraat 16</ADDRESS_1><CITY>Diepenveen</CITY><ZIP>7431 CK</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31  570 591244</PHONE_1><FAX_1>+31 570 593680</FAX_1></ADDRESS></PERSON><PERSON ID="14346" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Niek</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>de Wit</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>n.j.dewit@umcutrecht.nl</EMAIL_1><EMAIL_2>njdewit@planet.nl</EMAIL_2><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 253 8511</PHONE_1><FAX_1>+31 30 253 9028</FAX_1></ADDRESS></PERSON><PERSON ID="6E9F1EEB82E26AA201AFF01290272DA6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Geert</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>van der Heijden</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Associate Professor of Clinical Epidemiology</POSITION><EMAIL_1>g.vanderheijden@umcutrecht.nl</EMAIL_1><MOBILE_PHONE>+31 6 83224640</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Otorhinolaryngology &amp; Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><ADDRESS_2>Internal postal address STR 6.131</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7559377</PHONE_1></ADDRESS></PERSON><PERSON ID="D32C994F82E26AA20080535F417DEC0A" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gregory</FIRST_NAME><LAST_NAME>Rubin</LAST_NAME><POSITION>Professor of General Practice and Primary Care</POSITION><EMAIL_1>g.p.rubin@durham.ac.uk</EMAIL_1><EMAIL_2>greg.rubin@sunderland.ac.uk</EMAIL_2><ADDRESS><ORGANISATION>Durham University</ORGANISATION><ADDRESS_1>School of Medicine and Health, Wolfson Research Institute</ADDRESS_1><ADDRESS_2>Queen's Campus, University Boulevard</ADDRESS_2><CITY>Stockton on Tees</CITY><ZIP>TS17 6BH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0191 3340031</PHONE_1><PHONE_2>07733179737</PHONE_2></ADDRESS></PERSON><PERSON ID="14358" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jean</FIRST_NAME><MIDDLE_INITIALS>WM</MIDDLE_INITIALS><LAST_NAME>Muris</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>jean.muris@hag.unimaas.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>Maastricht University</ORGANISATION><ADDRESS_1>Maastricht University Medical Centre, Care and Public Health Research Institute (CAPHRI)</ADDRESS_1><ADDRESS_2>PO Box 616</ADDRESS_2><CITY>Maastricht</CITY><ZIP>6200 MD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31433882310</PHONE_1><FAX_1>+31433640586</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-09-29 10:54:25 -0400" MODIFIED_BY="John MacDonald">
<UP_TO_DATE>
<DATE DAY="20" MONTH="3" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2013-02-21 09:36:16 -0500" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-21 09:36:16 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="21" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Correction of minor errors in additional tables</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-02-21 09:35:33 -0500" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-21 09:35:33 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="29" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Change in address for contact author </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-09-29 11:05:11 -0400" MODIFIED_BY="John K MacDonald">
<DATE DAY="26" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>Change in authors, conclusions changed due to new data</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-09-29 11:05:15 -0400" MODIFIED_BY="John K MacDonald">
<DATE DAY="26" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>New search, new studies included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-02-20 14:43:28 -0500" MODIFIED_BY="John K MacDonald">
<SUMMARY MODIFIED="2011-06-20 12:55:52 -0400" MODIFIED_BY="John K MacDonald">
<TITLE MODIFIED="2010-05-27 11:17:28 -0400" MODIFIED_BY="John K MacDonald">Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2011-06-20 12:55:52 -0400" MODIFIED_BY="John K MacDonald">
<P>This review evaluates the effectiveness of medical therapies for patients with irritable bowel syndrome (IBS). We considered studies involving bulking agents (a fibre supplement), antispasmodics (smooth muscle relaxants) or antidepressants (drugs used to treat depression that can also change pain perceptions) that used outcome measures including improvement of abdominal pain, global assessment (overall relief of IBS symptoms) or symptom score. We found that bulking agents are not effective for treating IBS. There is evidence that antispasmodics including cimetropium/dicyclomine peppermint oil, pinaverium and trimebutine are effective for the treatment of IBS. Antidepressants are effective for the treatment of IBS. The side effects of these medications were not evaluated in this review. Physicians should be aware of the limitations of drug therapies and discuss these limitations with their patients before prescribing medication for IBS.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-06-20 12:55:31 -0400" MODIFIED_BY="John K MacDonald">
<ABS_BACKGROUND MODIFIED="2011-06-20 12:53:40 -0400" MODIFIED_BY="John K MacDonald">
<P>Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder. The role of pharmacotherapy for IBS is limited and focused mainly on symptom control.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-06-20 12:53:41 -0400" MODIFIED_BY="John K MacDonald">
<P>The objective of this systematic review was to evaluate the efficacy of bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-06-20 12:53:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Computer assisted structured searches of MEDLINE, EMBASE, The Cochrane library, CINAHL and PsychInfo were conducted for the years 1966-2009. An updated search in April 2011 identified 10 studies which will be considered for inclusion in a future update of this review. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-06-20 12:53:49 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomized controlled trials comparing bulking agents, antispasmodics or antidepressants with a placebo treatment in patients with irritable bowel syndrome aged over 12 years were considered for inclusion. Only studies published as full papers were included. Studies were not excluded on the basis of language. The primary outcome had to include improvement of abdominal pain, global assessment or symptom score.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-06-20 12:53:53 -0400" MODIFIED_BY="John K MacDonald">
<P>Two authors independently extracted data from the selected studies. Risk Ratios (RR) and Standardized Mean Differences (SMD) with 95% confidence intervals (CI) were calculated. A proof of practice analysis was conducted including sub-group analyses for different types of  bulking agents, spasmolytic agents or antidepressant medication. This was followed by a proof of principle analysis where only the studies with adequate allocation concealment were included.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-06-20 12:55:28 -0400" MODIFIED_BY="John K MacDonald">
<P>A total of 56 studies (3725 patients) were included in this review. These included 12 studies of bulking agents (621 patients), 29 of antispasmodics (2333 patients), and 15 of antidepressants (922 patients). The risk of bias was low for most items. However, selection bias is unclear for many of the included studies because the methods used for randomization and allocation concealment were not described. No beneficial effect for bulking agents over placebo was found for improvement of abdominal pain (4 studies; 186 patients; SMD 0.03; 95% CI -0.34 to 0.40; P = 0.87), global assessment (11 studies; 565 patients; RR 1.10; 95% CI 0.91 to 1.33; P = 0.32) or symptom score (3 studies; 126 patients SMD -0.00; 95% CI -0.43 to 0.43; P = 1.00). Subgroup analyses for insoluble and soluble fibres also showed no statistically significant benefit. Separate analysis of the studies with adequate concealment of allocation did not change these results. There was a beneficial effect for antispasmodics over placebo for improvement of abdominal pain (58% of antispasmodic patients improved compared to 46% of placebo; 13 studies; 1392 patients; RR 1.32; 95% CI 1.12 to 1.55; P &lt; 0.001; NNT = 7), global assessment (57% of antispasmodic patients improved compared to 39% of placebo; 22 studies; 1983 patients; RR 1.49; 95% CI 1.25 to 1.77; P &lt; 0.0001; NNT = 5) and symptom score (37% of antispasmodic patients improved compared to 22% of placebo; 4 studies; 586 patients; RR 1.86; 95% CI 1.26 to 2.76; P &lt; 0.01; NNT = 3). Subgroup analyses for different types of antispasmodics found statistically significant benefits for cimteropium/ dicyclomine, peppermint oil, pinaverium and trimebutine. Separate analysis of the studies with adequate allocation concealment found a significant benefit for improvement of abdominal pain. There was a beneficial effect for antidepressants over placebo for improvement of abdominal pain (54% of antidepressants patients improved compared to 37% of placebo; 8 studies; 517 patients; RR 1.49; 95% CI 1.05 to 2.12; P = 0.03; NNT = 5), global assessment (59% of antidepressants patients improved compared to 39% of placebo; 11 studies; 750 patients; RR 1.57; 95% CI 1.23 to 2.00; P &lt; 0.001; NNT = 4) and symptom score (53% of antidepressants patients improved compared to 26% of placebo; 3 studies; 159 patients; RR 1.99; 95% CI 1.32 to 2.99; P = 0.001; NNT = 4). Subgroup analyses showed a statistically significant benefit for selective serotonin releasing inhibitors (SSRIs) for improvement of  global assessment and for tricyclic antidepressants (TCAs) for improvement of abdominal pain and symptom score. Separate analysis of studies with adequate allocation concealment found a significant benefit for improvement of symptom score and global assessment. Adverse events were not assessed as an outcome in this review. <BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-06-20 12:55:31 -0400" MODIFIED_BY="John K MacDonald">
<P>There is no evidence that bulking agents are effective for treating IBS.  There is evidence that antispasmodics are effective for the treatment of IBS. The individual subgroups which are effective include: cimetropium/dicyclomine, peppermint oil, pinaverium and trimebutine. There is good evidence that antidepressants are effective for the treatment of IBS. The subgroup analyses for SSRIs and TCAs are unequivocal and their effectiveness may depend on the individual patient. Future research should use rigorous methodology and valid outcome measures.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-02-20 14:43:28 -0500" MODIFIED_BY="John K MacDonald">
<BACKGROUND MODIFIED="2011-06-20 13:06:42 -0400" MODIFIED_BY="John K MacDonald">
<P>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by fluctuating complains of abdominal pain or discomfort and an altered bowel habit resulting in diarrhoea or constipation. The prevalence of IBS ranges from 5-18 % depending on the clinical setting and the diagnostic criteria that are used. IBS is slightly more common in females (<LINK REF="REF-Hungin-2003" TYPE="REFERENCE">Hungin 2003</LINK>; <LINK REF="REF-Hillila-2004" TYPE="REFERENCE">Hillila 2004</LINK>). IBS is associated with depressive and anxiety disorders as well with somatic co-morbidities including fibromyalgia, chronic fatigue syndrome and chronic pelvic pain (<LINK REF="REF-Riedl-2008" TYPE="REFERENCE">Riedl 2008</LINK>).</P>
<P>Research shows that IBS can result in impaired health-related quality of life and that IBS symptoms have a large impact on work productivity (<LINK REF="REF-Pare-2006" TYPE="REFERENCE">Pare 2006</LINK>; <LINK REF="REF-Creed-2001" TYPE="REFERENCE">Creed 2001</LINK>). IBS is also associated with increased health care utilization and costs (<LINK REF="REF-Longstreth-2003" TYPE="REFERENCE">Longstreth 2003</LINK>).</P>
<P>In the absence of a gold-standard for diagnosing IBS, classification models have been developed including the Kruis scoring system, Manning criteria and Rome I, II, and III criteria (<LINK REF="REF-Manning-1978" TYPE="REFERENCE">Manning 1978</LINK>; <LINK REF="REF-Drossman-2006" TYPE="REFERENCE">Drossman 2006</LINK>). Only the Rome I classification is validated (<LINK REF="REF-Ford-2010" TYPE="REFERENCE">Ford 2010</LINK>). These criteria are not widely used in clinical practice and the diagnosis of IBS is often made by a typical history, normal physical examination and the absence of alarm-symptoms such as gastrointestinal bleeding, weight loss, or an abdominal mass (<LINK REF="REF-Jones-2000a" TYPE="REFERENCE">Jones 2000a</LINK>).</P>
<P>The pathophysiology of IBS is still unclear. There are several putative mechanisms including visceral hypersensitivity, altered colonic motility, abnormal brain activation, serotine dysregulation, inflammation, abnormal colonic flora, stress, psychological factors and genetic factors (<LINK REF="REF-Talley-2006" TYPE="REFERENCE">Talley 2006</LINK>).</P>
<P>In the absence of a clear pathophysiology, explanation and reassurance are essential elements in the management of IBS (<LINK REF="REF-Jones-2000b" TYPE="REFERENCE">Jones 2000b</LINK>). Pharmacotherapeutic interventions are limited and focus mostly on symptom control. High fibres diets and bulking agents are traditionally advised for their effect on stools and transit time (<LINK REF="REF-Burkitt-1972" TYPE="REFERENCE">Burkitt 1972</LINK>). Antispasmodics are given for their supposed effect on gastrointestinal motility. The more recent therapeutic options include the use of antidepressants, which are also given for other diseases associated with chronic pain (<LINK REF="REF-Verdu-2008" TYPE="REFERENCE">Verdu 2008</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-06-20 13:06:35 -0400" MODIFIED_BY="John K MacDonald">
<P>The objective of this systematic review was to evaluate the efficacy of bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-06-20 13:06:34 -0400" MODIFIED_BY="John K MacDonald">
<SELECTION_CRITERIA MODIFIED="2011-06-20 13:06:34 -0400" MODIFIED_BY="John K MacDonald">
<CRIT_STUDIES MODIFIED="2011-06-20 13:06:34 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised controlled trials comparing bulking agents, antispasmodics or antidepressants with a placebo were considered for inclusion. Cross-over studies were eligible if data from the first phase were reported separately. Only studies published as a full paper were included. Studies were not excluded on the basis of language.  </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-06-20 13:06:33 -0400" MODIFIED_BY="John K MacDonald">
<P>Patients aged over 12 years with irritable bowel syndrome, diagnosed either using predefined diagnostic criteria (e.g. Manning or Rome) or on clinical grounds were considered for inclusion. Studies including patients with functional bowel disorders without separate data for IBS patients were also included if the proportion of IBS patients was more than 75% of the total included patients.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-06-20 13:06:31 -0400" MODIFIED_BY="John K MacDonald">
<P>Interventions including bulking agents, antispasmodics or antidepressants compared with a placebo treatment were considered for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-06-20 13:06:30 -0400" MODIFIED_BY="John K MacDonald">
<P>Outcome measures for clinical trials of interventions in IBS have been discussed in several studies (<LINK REF="REF-Irvine-2006" TYPE="REFERENCE">Irvine 2006</LINK>; <LINK REF="REF-Schoenfeld-2006" TYPE="REFERENCE">Schoenfeld 2006</LINK>). Primary outcome measures included:</P>
<UL>
<LI>Improvement of symptoms of abdominal pain;</LI>
<LI>Improvement of patients overall global assessment; and</LI>
<LI>Improvement of IBS-symptom score.</LI>
</UL>
<P> Subgroup analyses included:</P>
<UL>
<LI>Soluble and insoluble bulking agents;</LI>
<LI>Individual antispasmodics; and</LI>
<LI>Selective serotonin releasing inhibitors (SSRIs) and tricyclic antidepressants (TCAs).</LI>
</UL>
<P>A sensitivity analysis excluded studies with poor methodological quality.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-06-20 13:06:23 -0400" MODIFIED_BY="John K MacDonald">
<ELECTRONIC_SEARCHES MODIFIED="2011-06-20 13:06:23 -0400" MODIFIED_BY="John K MacDonald">
<P>Computer assisted structured searches of MEDLINE, EMBASE, The Cochrane Library, CINAHL and PsychInfo were conducted, searching entries from 1966 to March 2009. The following search strategies were used: </P>
<P>Title/abstract search: spastic colon, irritable colon, irritable bowel, functional bowel, colonic disease, colonic diseases, IBS, gastrointestinal syndrome, gastrointestinal syndromes</P>
<P>Combined with title/abstract search: bulking agent, bulking agents, fiber, fibers, fibre, fibres, psyllium, plantago ovata, husk, bran, ispaghula, wheat, oat, sterculia, karaya gum</P>
<P>Or combined with title/abstract search: antispasmodic, antispasmodics, parasympatholytic, parasympatholytics. spasmolytic , spasmolytics, mebeverine, rociverine, pinaverium bromide, otilonium bromide, cimetropium bromide, trimebutine, pirenzipine, alverine, scopolamine, butylscopolamine, hyoscine , muscarinic antagonist, peppermint oil, mint oil</P>
<P>Or combined with title/abstract search: antidepressant, antidepressants, antidepressive agent, antidepressive agents, tricyclic, TCA, TCAs, selective serotonin reuptake inhibitor, selective serotonin reuptake inhibitors, SSRI, SSRIs</P>
<P>No limits or filters were used.</P>
<P>An updated search in April 2011 identified 10 studies which will be considered for inclusion in a future update of this review (See <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-06-20 13:06:20 -0400" MODIFIED_BY="John K MacDonald">
<P>The reference lists of the retrieved articles and reviews were hand searched to identify additional studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-06-20 13:06:19 -0400" MODIFIED_BY="John K MacDonald">
<STUDY_SELECTION MODIFIED="2011-06-20 13:06:19 -0400" MODIFIED_BY="John K MacDonald">
<P>One author (LR) screened the title and abstract of all studies identified by the literature searches for eligibility . The full text articles were retrieved for all potentially eligible studies. The full text articles were screened according to predefined criteria by the same reviewer. All the doubtful articles were screened by a second reviewer (AOQ) and consensus on inclusions/ exclusion was achieved by discussion.</P>
<P>The predefined exclusion criteria included:</P>
<OL>
<LI>Not a randomised controlled trial</LI>
<LI>No placebo group</LI>
<LI>Inappropriate patient group</LI>
<LI>Patients younger than 12, diagnosis of functional bowel disorders not specified as IBS</LI>
<LI>Intervention not involving  bulking agent, antispasmodic or antidepressant or mixed preparations</LI>
<LI>An outcome measurement other than abdominal pain, global assessment or IBS-symptom score.</LI>
<LI>No extractable results or cross-over trial with no report of first phase data</LI>
<LI>Duplicate trials</LI>
</OL>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-06-20 13:06:13 -0400" MODIFIED_BY="John K MacDonald">
<P>All studies were blinded for the reviewers in respect of authors, date of publication and journal or database of publication. Data were extracted independently by two authors for each study. A standardized data extraction form was used. Where necessary data were extracted from figures. If essential data were absent, the author of the article was contacted and requested to provide additional information.  </P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-06-20 13:06:11 -0400" MODIFIED_BY="John K MacDonald">
<P>The methodological quality of included trials was independently assessed by two authors (AOQ and LR or NdW or GR).  </P>
<P>Quality assessment criteria included: method of randomisation, concealment of allocation, blinding of patients and outcome measurers and description of lost to follow-up.</P>
<P>Differences of opinion were resolved by discussion between two reviewers, and in case of disagreement by all the reviewers. A methodology expert (GvdH) was consulted for specific queries</P>
<P>In consultation with the Dutch Cochrane centre, concealment of allocation was used for additional analyses, since concealment of allocation is the only quality item that has proven to be associated with study outcome (Pidal 2007, Wood 2008).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-06-20 13:06:09 -0400" MODIFIED_BY="John K MacDonald">
<P>The analyses were conducted using RevMan 5.0 software. For the dichotomous outcomes the risk ratio (RR) with 95% confidence intervals were calculated. For the continuous data standardized mean difference (SMD) with 95% confidence intervals were calculated.</P>
<P>A fixed- or random-effects model was used, based on the heterogeneity between study data. Statistical heterogeneity was explored with the Chi square test with  significance set at P &lt;0.10. When statistically significant heterogeneity occurred, a random-effects model was used for the analyses.</P>
<P>There were differences in the direction of the scales for the continuous data. To correct for this the data from scales increasing with disease severity were multiplied by -1.</P>
<P>First, a proof of practice analysis was conducted, including all available data. This was followed by a proof of principle analysis where only the studies with adequate allocation concealment were included.</P>
</EFFECT_MEASURES>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-02-20 14:43:28 -0500" MODIFIED_BY="John K MacDonald">
<STUDY_DESCRIPTION MODIFIED="2011-06-20 13:12:59 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents </B>
</P>
<P>The search identified 1118 studies, of which, after screening title and abstract 72 were potentially eligible. After applying the exclusion criteria to the full-text publications of these 72 potentially eligible studies, 12 articles remained for review and meta-analysis.</P>
<P>Sixty articles were excluded (table of characteristics of excluded studies), of which twenty-six were not randomized controlled trials (exc1). Fourteen studies did not involve a placebo treatment (exc2). Four studies included patients with functional bowel disorders without providing extractable results for the patients with IBS (exc3 and exc4). Two studies involved an intervention with a mixed preparation (exc5). Two studies did not report the outcome of interest (exc6). Eleven studies were cross-over trials with no report of the first phase data or did not provide extractable results (exc7). One study was a duplicate publication (exc8).</P>
<P>Twelve papers remained for review and meta-analysis (Table of characteristics of included studies). Two studies had a cross-over design (<LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Lucey-1987" TYPE="STUDY">Lucey 1987</LINK>).  The studies were published between 1976 and 2005 (<LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>). The research setting was a GI out patients&#8217; clinic in 11 studies, in the other three the setting was unclear (<LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). Seven studies used a run-in period  of 1 to 4 weeks before beginning the actual trial (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). The studies included between 20 and 168 participants (<LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>). The mean age of the participants ranged from 28 years to 46 years (<LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>). The percentage of female participants included ranged from 20% to  83% (<LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>). Six studies used insoluble fibres as intervention (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>; <LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Lucey-1987" TYPE="STUDY">Lucey 1987</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>) and six studies used soluble fibres as intervention (<LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>). The intervention period lasted from 4 weeks (<LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>) to 16 weeks (<LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>).<I> </I>
</P>
<P>
<B>Antispasmodics </B>
</P>
<P>The search identified 444 studies, of which, after screening title and abstract, 144 were potentially eligible. After applying the exclusion criteria to the full-text publications of these 144 potentially eligible studies, 29 articles remained for review and meta-analysis.</P>
<P>One hundred and fifteen articles were excluded (table of characteristics of excluded studies). Thirty-eight were not randomised controlled trials (exc1). Thirty four studies did not involve a placebo treatment (exc2). Six studies included patients with functional bowel disorders without providing extractable results for the patients with IBS (exc3 and exc4). Three studies involved an intervention with a mixed preparation (exc5). Twelve studies did not report the outcome of interest (exc6). Nineteen studies had no extractable results or were cross-over trials with no report of the first phase data (exc7). Three were duplicate publications (exc8) (<LINK REF="STD-Baldi-1992" TYPE="STUDY">Baldi 1992</LINK>; <LINK REF="STD-Glende-2002" TYPE="STUDY">Glende 2002</LINK>; <LINK REF="STD-Koch-1998" TYPE="STUDY">Koch 1998</LINK>).</P>
<P>Twenty-nine papers remained review and meta-analysis (Table of characteristics of included studies; <LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Baldi-1991" TYPE="STUDY">Baldi 1991</LINK>; <LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>; <LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Czalbert-1990" TYPE="STUDY">Czalbert 1990</LINK>; <LINK REF="STD-d_x0027_Arienzo-1980" TYPE="STUDY">d'Arienzo 1980</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Dubarry-1977" TYPE="STUDY">Dubarry 1977</LINK>; <LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Gilvarry-1989" TYPE="STUDY">Gilvarry 1989</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Lech-1988" TYPE="STUDY">Lech 1988</LINK>; <LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Liu-1997" TYPE="STUDY">Liu 1997</LINK>; <LINK REF="STD-Mitchell-2002" TYPE="STUDY">Mitchell 2002</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>). Two studies had a cross-over design (<LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>). The studies were published between 1977  and 2007 (<LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>). The research setting was definitely defined as secondary care in 18 studies, none of the studies was definitely conducted in primary care. Fourteen studies used a run-in period  of 1 to 4 weeks before beginning the actual trial. Five of these used a placebo during the run-in period and one used a high fibre diet (<LINK REF="STD-Gilvarry-1989" TYPE="STUDY">Gilvarry 1989</LINK>). The studies included between 18 (<LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>) and 360 participants (<LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>). The mean age of the participants ranged from 26 years (<LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>) to 60.6 years (<LINK REF="STD-Baldi-1991" TYPE="STUDY">Baldi 1991</LINK>). The percentage of female participants included ranged from 35% (<LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>) to  100%  (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>). The intervention period lasted from 1 week (<LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>) to 6 months (<LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>). The antispasmodics are divided into ten pharmacological subgroups: Alverine (1 study), cimetropium/dicyclomine (4 studies), mebeverine (2 studies), Otilonium (6 studies), peppermint oil (5 studies), pinaverium (6 studies),pirenzepine (1 study), propinox (1 study), scopolamine derivates (4 studies), and trimebutine (3 studies).</P>
<P>
<I> </I>
</P>
<P>
<B>Antidepressants </B>
</P>
<P>The search identified 419 studies, of which, after screening title and abstract 56 were potentially eligible. After applying the exclusion criteria on the full-text publications of these 56 potentially eligible studies, 15 articles remained for review and meta-analysis.</P>
<P>Forty articles were excluded (table of characteristics of excluded studies). Twenty were not randomized controlled trials (exc1). Six studies did not involve a placebo treatment (exc2). One study involved an intervention with a mixed preparation (exc5). Four studies did not report the outcome of interest (exc6). Three studies had no extractable results or were cross-over trials with no report of the first phase data (exc7). Six studies were duplicate publications (exc8) (Kalpert 2005, <LINK REF="STD-Han-2009" TYPE="STUDY">Han 2009</LINK>; <LINK REF="STD-Marks-2008" TYPE="STUDY">Marks 2008</LINK>; <LINK REF="STD-Block-1983" TYPE="STUDY">Block 1983</LINK>; <LINK REF="STD-Tripathi-1983" TYPE="STUDY">Tripathi 1983</LINK>; <LINK REF="STD-Greenbaum-1987" TYPE="STUDY">Greenbaum 1987</LINK>).</P>
<P>Fifteen studies remained for review and meta-analysis (table of characteristics of included studies). One study had a cross-over design (<LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>). The studies were published between 1978 and 2009 (<LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>; <LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>). Two studies were partly conducted in primary care (<LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>), the remainder in secondary care. Three studies used a run-in period of 1 to 2 weeks before beginning the actual trial (<LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>). One study had a placebo run-in period of unspecified duration (<LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>). One study randomised patients who had completed a 7 week open-label high-fibre trial (<LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>). The studies included between 23 and 201 participants (<LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>). The mean age of the participants ranged from 32 years to 49 years (<LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>). The percentage of female participants included ranged from 13% (<LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>) to 100% (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>). Five studies used a SSRI as the intervention<BR/>(<LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>). Nine studies used a TCA the as intervention (<LINK REF="STD-Bahar-2008" TYPE="STUDY">Bahar 2008</LINK>; <LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>; <LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>). One study compared an SSRI and a TCA with placebo treatment (<LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>). The intervention period lasted from 4 weeks (<LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>) to 12 weeks (<LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>).<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-06-20 13:12:38 -0400" MODIFIED_BY="John K MacDonald">
<P>The results of the risk of bias assessment are shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.The risk of bias was low for most items. However, selection bias is unclear for many of the included studies because the methods used for randomization and allocation concealment were not described. </P>
<ALLOCATION MODIFIED="2011-06-20 13:12:36 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents</B>
<BR/>None of the twelve studies on bulking agents described the methods used for randomization and these studies were rated as unclear for this item. Five of the studies were rated as low risk for allocation concealment (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). The other seven studies were rated as unclear for allocation concealment. </P>
<P>
<B>Antispasmodics </B>
<BR/>Three studies reported on the methods used for randomization (<LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>) and were rated as low risk for this item. The other twenty-six studies did not report on methods used for randomization and were rated as unclear. Four studies were rated as low risk for allocation concealment (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>). The other studies were rated as unclear for this item.</P>
<P>
<B>Antidepressants</B>
<BR/>Seven studies were reported the methods used for randomization and were rated as low risk for this item (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>). The other studies were rated as unclear. Six studies were rated as low risk for allocation concealment (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>). The other studies were rated as unclear for this item. </P>
</ALLOCATION>
<BLINDING MODIFIED="2011-06-20 13:12:22 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents</B>
<BR/>Six studies were rated as low risk for blinding (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK> used a single blind design and was rated as a high risk of bias. The other studies did not describe methods used for blinding and were rated as unclear. </P>
<P>
<B>Antispasmodics </B>
<BR/>Eleven studies were rated as low risk for blinding (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Liu-1997" TYPE="STUDY">Liu 1997</LINK>; <LINK REF="STD-Mitchell-2002" TYPE="STUDY">Mitchell 2002</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>). The other studies did not describe methods used for blinding and were rated as unclear.</P>
<P>
<B>Antidepressants</B>
<BR/>Nine studies were rated as low risk for blinding (<LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>). <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK> used a single blind design and was rated as a high risk of bias. The other studies did not describe methods used for blinding and were rated as unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-06-20 13:12:14 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents</B>
<BR/>Eleven studies were rated as low risk for incomplete outcome date (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>; <LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). One study was rated as unclear for this item (<LINK REF="STD-Lucey-1987" TYPE="STUDY">Lucey 1987</LINK>).</P>
<P>
<B>Antispasmodics </B>
<BR/>Twenty-four studies were rated as low risk for incomplete outcome data (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Baldi-1991" TYPE="STUDY">Baldi 1991</LINK>; <LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>; <LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Dubarry-1977" TYPE="STUDY">Dubarry 1977</LINK>; <LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Gilvarry-1989" TYPE="STUDY">Gilvarry 1989</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Lech-1988" TYPE="STUDY">Lech 1988</LINK>; <LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Liu-1997" TYPE="STUDY">Liu 1997</LINK>; <LINK REF="STD-Mitchell-2002" TYPE="STUDY">Mitchell 2002</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>). Five studies were rated as unclear for this item (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Czalbert-1990" TYPE="STUDY">Czalbert 1990</LINK>; <LINK REF="STD-d_x0027_Arienzo-1980" TYPE="STUDY">d'Arienzo 1980</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>).</P>
<P>
<B>Antidepressants</B>
<BR/>Eleven studies were rated as low risk for incomplete outcome data (<LINK REF="STD-Bahar-2008" TYPE="STUDY">Bahar 2008</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>; <LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>). Four studies were rated as unclear for this item (<LINK REF="STD-Bergmann-1991" TYPE="STUDY">Bergmann 1991</LINK>; <LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>; <LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-06-20 13:12:06 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents </B>
<BR/>All twelve studies were rated as low risk for selective reporting (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>; <LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Lucey-1987" TYPE="STUDY">Lucey 1987</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>).</P>
<P>
<B>Antispasmodics </B>
<BR/>Twenty-six studies were rated as low risk for selective reporting (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Baldi-1991" TYPE="STUDY">Baldi 1991</LINK>; <LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>; <LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Dubarry-1977" TYPE="STUDY">Dubarry 1977</LINK>; <LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Gilvarry-1989" TYPE="STUDY">Gilvarry 1989</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Lech-1988" TYPE="STUDY">Lech 1988</LINK>; <LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Liu-1997" TYPE="STUDY">Liu 1997</LINK>; <LINK REF="STD-Mitchell-2002" TYPE="STUDY">Mitchell 2002</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>). Three studies were rated as unclear for this item (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Czalbert-1990" TYPE="STUDY">Czalbert 1990</LINK>; <LINK REF="STD-d_x0027_Arienzo-1980" TYPE="STUDY">d'Arienzo 1980</LINK>).</P>
<P>
<B>Antidepressants</B>
<BR/>Fourteen studies were rated as low risk for selective reporting (<LINK REF="STD-Bahar-2008" TYPE="STUDY">Bahar 2008</LINK>; <LINK REF="STD-Bergmann-1991" TYPE="STUDY">Bergmann 1991</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>; <LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>). One study was rated as unclear for this item (<LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-06-20 13:11:59 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents</B>
<BR/>All twelve studies were rated as low risk for other potential sources of bias (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>; <LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Lucey-1987" TYPE="STUDY">Lucey 1987</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). </P>
<P>
<B>Antispasmodics </B>
<BR/>Twenty-six studies were rated as low risk for other potential sources of bias <LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Baldi-1991" TYPE="STUDY">Baldi 1991</LINK>; <LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>; <LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Dubarry-1977" TYPE="STUDY">Dubarry 1977</LINK>; <LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Gilvarry-1989" TYPE="STUDY">Gilvarry 1989</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Lech-1988" TYPE="STUDY">Lech 1988</LINK>; <LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Liu-1997" TYPE="STUDY">Liu 1997</LINK>; <LINK REF="STD-Mitchell-2002" TYPE="STUDY">Mitchell 2002</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>). Three studies were rated as unclear for this item (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Czalbert-1990" TYPE="STUDY">Czalbert 1990</LINK>; <LINK REF="STD-d_x0027_Arienzo-1980" TYPE="STUDY">d'Arienzo 1980</LINK>).</P>
<P>
<B>Antidepressants</B>
<BR/>Fourteen studies were rated as low risk for other potential sources of bias (<LINK REF="STD-Bahar-2008" TYPE="STUDY">Bahar 2008</LINK>; <LINK REF="STD-Bergmann-1991" TYPE="STUDY">Bergmann 1991</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>;<LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>; <LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>). One study was rated as unclear for this item (<LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-02-20 14:43:28 -0500" MODIFIED_BY="John K MacDonald">
<P>
<B>Bulking agents</B>
</P>
<P>
<I>Improvement of abdominal pain (outcome 1)</I>
<BR/>One study with a total of 80 patients reported a dichotomous outcome for improvement of abdominal pain. The RR was 0.91 (95% CI 0.61 to 1.36) using a fixed-effect model. A planned subgroup analysis for insoluble compared to soluble bulking agents could not be performed because there was only one study with soluble (<LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>) bulking agents.</P>
<P>Four studies with a total of 186 patients reported a continuous outcome for improvement of abdominal pain. Two of these studies did not report sufficient data to calculate a SMD (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>). One study of an insoluble bulking agent with a total of 56 patients remained (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>). There was one study of a soluble fibre (<LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>). The pooled SMD was 0.03 (95% CI -0.34 to 0.40) using a fixed-effect model.</P>
<P>
<I>Improvement of global assessment (outcome 2)</I>
<BR/>Eleven studies, with a total of 565 patients reported a dichotomous outcome for improvement of global assessment. The chi-square test for heterogeneity was not statistically significant (P = 0.12). The pooled relative risk was not statistically significant using a random-effects model (RR 1.10; 95% CI 0.91 to 1.33). A RR of 0.95 (95% CI 0.76 to 1.19) was calculated for the studies using an insoluble bulking agent (244 patients) (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>; <LINK REF="STD-Lucey-1987" TYPE="STUDY">Lucey 1987</LINK>; <LINK REF="STD-Rees-2005" TYPE="STUDY">Rees 2005</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). In the six studies with a soluble bulking agent the RR was 1.28 (95% CI 0.91 to 1.78; 321 patients) (<LINK REF="STD-Arthurs-1983" TYPE="STUDY">Arthurs 1983</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Prior-1987" TYPE="STUDY">Prior 1987</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>).</P>
<P>One study of an insoluble bulking agent, comprising 56 patients, reported a continuous outcome for improvement of global assessment (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>). The standardized mean difference was not statistically significant (SMD -0.22; 95% CI -0.74 to 0.31).</P>
<P> </P>
<P>
<I>Improvement of IBS symptom score (outcome 3)</I>
<BR/>Three studies, with a total of 126 patients reported a continuous outcome for improvement of IBS symptom score. One study did not report sufficient data to calculate a SMD (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>). Two studies, both of insoluble fibre, with a total of 84 patients remained (<LINK REF="STD-Aller-2004" TYPE="STUDY">Aller 2004</LINK>; <LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>). The chi-square test for heterogeneity was not statistically significant (P = 0.16). The pooled SMD was not statistically significant (SMD 0.00; 95%CI -0.43 to 0.43).</P>
<P>The main results for the bulking agents studies are summarized in additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>
<B>Antispasmodics</B>
</P>
<P>
<I>Improvement of abdominal pain (outcome 4)</I>
<BR/>Thirteen studies with a total of 1392 patients reported a dichotomous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P = 0.01). The pooled RR was 1.32 (95% CI 1.12 to 1.55) using a random-effects model. Subgroup analyses showed statistically significant benefit for pinaverium bromide (RR 1.57; 95% CI 1.08 to 2.26; 158 patients) (<LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Dubarry-1977" TYPE="STUDY">Dubarry 1977</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>) and trimebutine (RR 1.32; 95% CI 1.07 to 1.64; 140 patients) (<LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>). There was no statistically significant benefit for scopolamine derivatives (RR 1.00; 95% CI 0.84 to 1.19; 360 patients) (<LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>). The other subgroups contained only one study each.<BR/>
<BR/>Eight studies comprising 455 patients reported a continuous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P &lt; 0.00001) The pooled SMD was 1.14 (95% CI 0.47 to 1.81) using a random-effects model. Statistically significant benefit was present for the subgroup cimetropium/dicyclomine (SMD 1.08; 95% CI 0.73 to 1.43; 146 patients) (<LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>). There was no statistically significant benefit for pinaverium (SMD 0.44; 95% CI -0.20 to 1.08; 114 patients) (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>). The other subgroups contained none or only one study each.</P>
<P>
<I> </I>
</P>
<P>
<I>Improvement of global assessment (outcome 5)</I>
<BR/>Twenty-two studies with a total of 1983 patients reported a dichotomous outcome for improvement of global assessment. The chi-square test for heterogeneity was statistically significant (P &lt; 0.0001). The pooled relative risk was statistically significant (RR 1.49; 95% CI 1.25 to 1.77) using a random-effects model. Statistically significant benefit was present for the subgroups cimetropium/dicyclomine (RR 1.78; 95% CI 1.15 to 2.75; 255 patients) (<LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>), otilonium (RR 1.79; 95% CI 1.31 to 2.44; 363 patients) (<LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>; <LINK REF="STD-d_x0027_Arienzo-1980" TYPE="STUDY">d'Arienzo 1980</LINK>; <LINK REF="STD-Piai-1979" TYPE="STUDY">Piai 1979</LINK>); peppermint-oil (RR 2.25; 95% CI 1.70 to 2.98; 225 patients) (<LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Lech-1988" TYPE="STUDY">Lech 1988</LINK>) and pinaverium bromide (RR 1.66; 95% CI 1.25 to 2.19; 308 patients) (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>). There was no statistically significant benefit for alverine (RR 1.20; 95% CI 0.80 to 1.80; 107 patients) (<LINK REF="STD-Mitchell-2002" TYPE="STUDY">Mitchell 2002</LINK>); mebeverine (RR 0.42; 95% CI 0.16 to 1.07; 80 patients) (<LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>), scolpamine derivates (RR 4.43; 95% CI 0.47 to 41.67; 426 patients) (<LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>) and trimebutine (RR 0.97; 95% CI 0.68 to 1.38; 120 patients) (<LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>).</P>
<P>
<BR/>Two studies comprising 331 patients reported a continuous outcome for improvement of global assessment. The pooled SMD could not be estimated because of lack of data provided by the studies (<LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>).</P>
<P> </P>
<P>
<I>Improvement of IBS symptom score (outcome 6)</I>
<BR/>Four studies with a total of 586 patients reported a dichotomous outcome for improvement of IBS symptom score. The chi-square test for heterogeneity was statistically significant (P = 0.004). The pooled relative risk was statistically significant (RR 1.86; 95% CI 1.26 to 2.76) using a random-effects model. Statistically significant benefit was present for the subgroups peppermint-oil (RR 1.94; 95% CI 1.09 to 3.46; 269 patients) (<LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Czalbert-1990" TYPE="STUDY">Czalbert 1990</LINK>) and otilonium (RR 1.64; 95% CI 1.15 to 2.34; 317 patients) (<LINK REF="STD-Battaglia-1998" TYPE="STUDY">Battaglia 1998</LINK>).<BR/>
<BR/>Four studies comprising 243 patients reported a continuous outcome for improvement of global assessment. The chi-square test for heterogeneity was statistically significant (P = 0.00001). The pooled SMD was statistically significant (SMD 2.39; 95% CI 0.50 to 4.29) using a random-effects model. A statistically significant benefit was found for the pinaverium subgroup (SMD 0.51; 95% CI 0.19 to 0.84; 158 patients) (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>). The other subgroups contained none or only one study each.</P>
<P>The main results for antispasmodics are summarized in additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. </P>
<P>
<B>Individual spasmolytic agents:<BR/>
</B>
<BR/>
<I>Cimetropium/dicyclomine</I>
<BR/>No statistically significant effect for improvement of abdominal pain was found for <I>Cimetropium/dicyclomine</I> (SMD 1.08; 95% CI 0.73 to 1.43; 146 patients) (<LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>). A statistically significant effect for improvement of global assessment was found for <I>Cimetropium/dicyclomine</I> (RR 1.88; 95% CI 1.04 to 3.42; 255 patients) (<LINK REF="STD-Centonze-1988" TYPE="STUDY">Centonze 1988</LINK>; <LINK REF="STD-Dobrilla-1990" TYPE="STUDY">Dobrilla 1990</LINK>; <LINK REF="STD-Page-1981" TYPE="STUDY">Page 1981</LINK>; <LINK REF="STD-Passaretti-1989a" TYPE="STUDY">Passaretti 1989a</LINK>).<BR/>
<BR/>
<I>Mebeverine</I>
<BR/>No statistically significant effect for improvement of global assessment was found for <I>Mebeverine</I> (RR 0.83; 95% CI 0.31 to 2.23; 149 patients) (<LINK REF="STD-Kruis-1986" TYPE="STUDY">Kruis 1986</LINK>).<BR/>
<BR/>
<I>Peppermint oil</I>
<BR/>A statistically significant effect for improvement of global assessment was found for <I>peppermint oil</I> (RR 2.25; 95% CI 1.70 to 2.98; 225 patients) (<LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Lech-1988" TYPE="STUDY">Lech 1988</LINK>). A statistically significant effect for improvement of IBS symptom score was found for <I>peppermint oil</I> (RR 1.94; 95% CI 1.09 to 3.46; 269 patients) (<LINK REF="STD-Capanni-2005" TYPE="STUDY">Capanni 2005</LINK>; <LINK REF="STD-Cappello-2007" TYPE="STUDY">Cappello 2007</LINK>; <LINK REF="STD-Czalbert-1990" TYPE="STUDY">Czalbert 1990</LINK>).<BR/>
<BR/>
<I>Pinaverium</I>
<BR/>
<I>Pinaverium</I> provided a statistically significant benefit for improvement of abdominal pain, RR 1.57 (95% CI 1.08 to 2.26; 158 patients) (<LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Dubarry-1977" TYPE="STUDY">Dubarry 1977</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>) and SMD 0.44 (95% CI -0.20 to 1.08; 114 patients) (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>). A statistically significant effect for improvement of global assessment, RR1.87 (95% CI1.41 to 2.48; 308 patients) (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Delmont-1981" TYPE="STUDY">Delmont 1981</LINK>; <LINK REF="STD-Levy-1977" TYPE="STUDY">Levy 1977</LINK>; <LINK REF="STD-Virat-1987" TYPE="STUDY">Virat 1987</LINK>) and IBS-symptom score was also found, SMD 0.51 (95% CI 0.19 to 0.84; 158 patients) (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>).<BR/>
<BR/>
<I>Scopolamine derivatives</I>
<BR/>No statistically significant effect for improvement of global assessment was found for <I>Scopolamine derivatives</I> (RR 1.42; 95% CI 0.94 to 2.14; 442 patients) (<LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Schafer-1990" TYPE="STUDY">Schafer 1990</LINK>).<BR/>
</P>
<P>
<I>Trimebutine</I>
<BR/>A statistically significant effect for improvement of abdominal pain was found for <I>Trimebutine</I> (RR 1.32; 95% CI 1.07 to 1.64; 140 patients) (<LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>; <LINK REF="STD-Moshal-1979" TYPE="STUDY">Moshal 1979</LINK>). No statistically significant effect for improvement of global assessment (RR 0.97; 95% CI 0.68 to 1.38; 120 patients) (<LINK REF="STD-Fielding-1980" TYPE="STUDY">Fielding 1980</LINK>; <LINK REF="STD-Ghidini-1986" TYPE="STUDY">Ghidini 1986</LINK>).<BR/>
<BR/>
<I>Other subgroups</I>
<BR/>There was not enough data to calculate a pooled estimate effect.</P>
<P> </P>
<P>
<B>Antidepressants</B>
</P>
<P>
<I>Improvement of abdominal pain (outcome 7) </I>
<BR/>Eight studies with a total of 517 patients reported a dichotomous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P = 0.01). The pooled relative risk was statistically significant (RR was 1.49; 95% CI 1.05 to 2.12) using a random-effects model. Subgroup analyses showed no benefit for SSRIs (RR 2.29; 95% CI 0.79 to 6.68; 197 patients) (<LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>), and a statistically significant benefit for TCAs (RR 1.26; 95% CI 1.03 to 1.55; 320 patients) (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Heefner-1978" TYPE="STUDY">Heefner 1978</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>).</P>
<P>Three studies with a total of 124 patients reported a continuous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P &lt; 0.00001). The pooled RR was 1.80 (95% CI -0.57 to 4.16). Subgroup analyses showed no significant benefit for TCA&#8217;s (SMD was 0.53; 95% CI -1.23 to 2.29; 101 patients) (<LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Rajagopalan-1998" TYPE="STUDY">Rajagopalan 1998</LINK>).</P>
<P> </P>
<P>
<I>Improvement of global assessment (outcome 8)</I>
<BR/>Twelve studies, with a total of 750 patients reported a dichotomous outcome for improvement of global assessment. The chi-square test for heterogeneity was statistically significant (P = 0.01). The pooled relative risk was statistically significant (RR 1.57; 95% CI 1.23 to 2.00) using a random-effects model. Subgroup analyses suggest a benefit for SSRIs (RR 1.79; 95% CI 1.01 to 3.20; P = 0.05; 227 patients) (<LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Masand-2009" TYPE="STUDY">Masand 2009</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>) and showed a statistically significant benefit for TCAs (RR 1.45; 95% CI 1.13 to 1.86; 523 patients) (<LINK REF="STD-Bergmann-1991" TYPE="STUDY">Bergmann 1991</LINK>; <LINK REF="STD-Boerner-1988" TYPE="STUDY">Boerner 1988</LINK>; <LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Myren-1982" TYPE="STUDY">Myren 1982</LINK>; <LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>; <LINK REF="STD-Vij-1991" TYPE="STUDY">Vij 1991</LINK>).</P>
<P>One study assessing an SSRI (<LINK REF="STD-Tack-2006a" TYPE="STUDY">Tack 2006a</LINK>), with a total of 22 patients reported a continuous outcome for improvement of global assessment. The pooled SMD was 3.32 (95% CI 1.95 to 4.68).</P>
<P> </P>
<P>
<I>Improvement of IBS symptom score (outcome 9)</I>
<BR/>Three studies with a total of 159 patients reported a dichotomous outcome for improvement of symptom score. The chi-square test for heterogeneity was not statistically significant (P = 0.12). The pooled RR was 1.99 (95% CI 1.32 to 2.99) using a fixed-effect model. Subgroup analyses showed a statistically significant benefit for TCAs (RR 3.16; 95% CI 1.59 to 6.29; 87 patients) (<LINK REF="STD-Bahar-2008" TYPE="STUDY">Bahar 2008</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>).</P>
<P>Two studies, with a total of 122 patients reported a continuous outcome for improvement of IBS symptom score. The chi-square test for heterogeneity was statistically significant (P = 0.07). The pooled SMD was 0.38 (95% CI -0.30 to 1.06) using a random-effects model.</P>
<P>The main results for antidepressants are summarized in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<P>
<B>Additional comparison: adequate concealment of allocation </B>
</P>
<P>
<I>Bulking agents abdominal pain (outcome 10.2)</I>
<BR/>Two studies of bulking agents with adequate concealment of allocation reported a continuous outcome for improvement of abdominal pain (<LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>). The chi-square test for heterogeneity was not statistically significant (P = 0.88). The pooled SMD using a fixed-effect model was -0.04 (95%CI -0.40 to 0.32; 119 patients).</P>
<P> </P>
<P>
<I>Bulking agents: global assessment (outcome 11.1)</I>
<BR/>Five studies of bulking agents with adequate concealment of allocation reported a dichotomous outcome for improvement of abdominal pain (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). Using a random-effects model, the pooled RR was 0.91 (95% CI 0.68 to 1.23; 193 patients).</P>
<P> </P>
<P>
<I>Antispasmodics: abdominal pain (outcome 12.1)</I>
<BR/>Two studies of spasmolytic agents with adequate concealment of allocation reported a continuous outcome for improvement of abdominal pain (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>). The chi-square test for heterogeneity was not statistically significant (P = 0.88). Using a fixed-effect model, the pooled SMD was 0.43 (95% CI 0.06 to 0.80; 115 patients).</P>
<P> </P>
<P>
<I>Antispasmodics: global assessment (outcome 13.1)</I>
<BR/>Three studies of spasmolytic agents with adequate concealment of allocation reported a dichotomous outcome for improvement of global assessment (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>). The chi-square test for heterogeneity was not statistically significant (P= 0.25). Using a fixed-effect model, the pooled RR was 1.35 (95% CI 0.85 to 2.12; 219 patients).</P>
<P> </P>
<P>
<I>Antidepressants: abdominal pain (outcome 14.1)</I>
<BR/>Five studies of antidepressant agents with adequate concealment of allocation reported a dichotomous outcome for improvement of abdominal pain. The chi-square test for heterogeneity was statistically significant (P = 0.06). Using a random-effects model, the pooled RR was 1.35 (95% CI 0.98 to 1.86; 364 patients) . Subgroup analyses showed no statistically significant benefit for SSRIs (RR 1.20; 95% CI 0.87 to 1.67) (<LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>) or TCAs (RR 2.19; 95% CI 0.59 to 8.11) (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>).</P>
<P> </P>
<P>
<I>Antidepressants: global assessment (outcome 15.1)</I>
<BR/>Four studies of antidepressant agents with adequate concealment of allocation reported a dichotomous outcome for global assessment. The chi-square test for heterogeneity was not statistically significant (P = 0.23). Using a fixed-effect model, the pooled RR was 1.42 (95% CI 1.12 to 1.80; 329 patients) (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>).</P>
<P>
<I> </I>
</P>
<P>
<I>Antidepressants: IBS symptom score (outcome 16.1)</I>
<BR/>One study of antidepressants with adequate concealment of allocation reported a continuous outcome for improvement of IBS symptom score (<LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>). Using a fixed-effect model, the SMD was 0.75 (95% CI 0.17 to 1.32; 50 patients).<B>
<BR/>
</B>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-06-20 13:30:38 -0400" MODIFIED_BY="John K MacDonald">
<P>
<I>Bulking agents</I>
<BR/>The pooled data suggest that bulking agents do not provide any benefit for the treatment of IBS. No statistically significant differences between bulking agents and placebo were found for abdominal pain, global assessment or symptom score. Only 7 of the included studies had more than 30 patients and all studies had quality limitations (i.e. method of randomisation, double-blinding, concealment of treatment allocation, description of withdrawals). There were five studies with adequate allocation concealment (<LINK REF="STD-Fowlie-1992" TYPE="STUDY">Fowlie 1992</LINK>; <LINK REF="STD-Jalihal-1990" TYPE="STUDY">Jalihal 1990</LINK>; <LINK REF="STD-Longstreth-1981" TYPE="STUDY">Longstreth 1981</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>; <LINK REF="STD-Soltoft-1976" TYPE="STUDY">Soltoft 1976</LINK>). A sensitivity analysis of those studies with adequate allocation concealment, did not change the results. Subgroup analyses for the different type of  bulking agents, soluble versus insoluble fibre, also gave no statistically significant findings.</P>
<P>
<BR/>We are aware of five systematic reviews of bulking agents for IBS. <LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK>, who used less strict exclusion criteria than the present review, also concluded from an analysis of 13 studies that the efficacy of bulking agents is not clearly established. When <LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK> separately analysed high and low quality trials, the conclusion remained the same (<LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK>). <LINK REF="REF-Akehurst-2001" TYPE="REFERENCE">Akehurst 2001</LINK> included 7 studies on bulking agents in a review of IBS therapies and concluded that there was little reason to believe that bulking agents were effective for IBS (<LINK REF="REF-Akehurst-2001" TYPE="REFERENCE">Akehurst 2001</LINK>). <LINK REF="REF-Lesbros_x002d_Pantoflickova-2004" TYPE="REFERENCE">Lesbros-Pantoflickova 2004</LINK> included 13 studies in their meta-analyses, of which 5 studies reported a statistically significant benefit of fibre treatment for the relief of global symptoms (OR 1.9; 95% CI 1.5 to 2.4). However, after exclusion of the low-quality trials, this effect was not statistically significant. In conclusion, they found no evidence to recommend bulking agents for the treatment of IBS (<LINK REF="REF-Lesbros_x002d_Pantoflickova-2004" TYPE="REFERENCE">Lesbros-Pantoflickova 2004</LINK>). <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> included 12 studies comparing fibre with placebo, and used persistent symptoms after treatment as an outcome measure. <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> calculated a RR of 0.87 (95% CI 0.76 to 1.00). A subgroup analysis identified a statistically significant benefit for ispaghula a soluble fibre (RR 0.78; 95% CI 0.63 to 0.96). <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> had almost the same strict inclusion criteria as our review but included different outcome analyses. <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> did not use an ITT-analyses, only extracted dichotomous outcome and pooled all the outcomes (global assessment of symptoms and  abdominal pain) as one. <LINK REF="REF-Bijkerk-2004" TYPE="REFERENCE">Bijkerk 2004</LINK> examined the separate effects of soluble and insoluble fibres, on global assessment and constipation. <LINK REF="REF-Bijkerk-2004" TYPE="REFERENCE">Bijkerk 2004</LINK> found a beneficial overall effect for fibre in general (RR 1.33; 95% CI 1.19 to 1.50) and soluble fibres for global assessment of IBS (RR 1.55; 95% CI 1.35 to 1.78). We could not reproduce these findings (outcomes 1.1 to 3.2). A possible explanation for this is that <LINK REF="REF-Bijkerk-2004" TYPE="REFERENCE">Bijkerk 2004</LINK> included cross-over trials (7 of the 17 included studies), which were excluded in this review. <LINK REF="REF-Bijkerk-2004" TYPE="REFERENCE">Bijkerk 2004</LINK> also included two studies with no placebo comparison.</P>
<P>
<I> </I>
</P>
<P>
<I>Antispasmodics</I>
<BR/>Spasmolytic agents compared to placebo provided a statistically significant benefit for abdominal pain, global assessment and IBS-symptom score. Spasmolytic agents are pharmacologically diverse and arbitrary choices were made regarding the pooling of results. We decided to treat peppermint-oil as an anti-spasmodic because of its known effect on smooth muscles. Trimebutine appears to be effective for abdominal pain, pinaverium for abdominal pain and global assessment, cimetropium/dicyclominand for global assessment and peppermint-oil for global assessment and symptom score. Only four studies had adequate allocation concealment (<LINK REF="STD-Awad-1995" TYPE="STUDY">Awad 1995</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Pulpeiro-2000" TYPE="STUDY">Pulpeiro 2000</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>). It is important to note that none of the studies involving peppermint-oil had adequate allocation concealment. When analysing the studies with adequate allocation concealment separately, the results get weaker and only improvement of abdominal pain has still a statistically significant benefit. Spasmolytics are extensively studied for their use in the treatment of IBS, however due to the diversity of types of spasmolytic agents, the number of studies for each compound are limited. Therefore most subgroups could not be pooled, and a type II error could have occurred.</P>
<P>Eight systematic reviews of antispasmodics for IBS have been published (<LINK REF="REF-Akehurst-2001" TYPE="REFERENCE">Akehurst 2001</LINK>; <LINK REF="REF-Brandt-2002" TYPE="REFERENCE">Brandt 2002</LINK>; <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK>; <LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK>; <LINK REF="REF-Lesbros_x002d_Pantoflickova-2004" TYPE="REFERENCE">Lesbros-Pantoflickova 2004</LINK>; <LINK REF="REF-Poynard-1994" TYPE="REFERENCE">Poynard 1994</LINK>; <LINK REF="REF-Poynard-2001" TYPE="REFERENCE">Poynard 2001</LINK>; <LINK REF="REF-Tack-2006b" TYPE="REFERENCE">Tack 2006b</LINK>). <LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK> included 13 studies and found that all of the 7 high-quality trials demonstrated a benefit, mainly for abdominal pain, less so for constipation. <LINK REF="REF-Akehurst-2001" TYPE="REFERENCE">Akehurst 2001</LINK> identified 12 studies and came to similar conclusions. <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> found consistent evidence of efficacy for otilonium (RR 0.55; 95% CI 0.31 to 0.97) and scopolamine (RR 0.63; 95% CI 0.51 to 0.78). <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> identified peppermint-oil as an individual group, included 4 studies and calculated a RR of 0.43 (95% CI 0.33 to 0.59). These results are almost identical to our own. However, <LINK REF="REF-Ford-2008" TYPE="REFERENCE">Ford 2008</LINK> used a different method to assess methodological quality (Jadad scale), and rated three studies as high quality, resulting in a greater effect than seen in this review. In an update of a 1994 meta-analysis, <LINK REF="REF-Poynard-2001" TYPE="REFERENCE">Poynard 2001</LINK> included 23 trials comprising 6 types of drugs. Using a fixed-effect model, there was a statistically significant benefit for global assessment (Peto OR 2.13; 95%CI 1.77 to 2.58) and pain (Peto OR 1.65; 95%CI 1.30 to 2.10) (<LINK REF="REF-Poynard-2001" TYPE="REFERENCE">Poynard 2001</LINK>).This review provides similar evidence of the efficacy of spasmolytic agents for IBS. The reviews from <LINK REF="REF-Lesbros_x002d_Pantoflickova-2004" TYPE="REFERENCE">Lesbros-Pantoflickova 2004</LINK> and <LINK REF="REF-Tack-2006b" TYPE="REFERENCE">Tack 2006b</LINK> concluded that there is some evidence that antispasmodic may improve symptoms of abdominal pain but are careful in recommending antispasmodics for the treatment of IBS due to the low methodological quality of the included RCTs.  </P>
<P> </P>
<P>
<I>Antidepressants</I>
</P>
<P>Antidepressants provide a statistically significant benefit over placebo for abdominal pain, global assessment and IBS-symptom score. Subgroup analyses for SSRIs and TCAs, showed a statistically significant improvement in global assessment for SSRIs and a statistically significant improvement in abdominal pain and symptom score for TCAs. A sensitivity analysis of the six studies with adequate allocation concealment showed a statistically significant benefit for improvement of symptom score and global assessment (<LINK REF="STD-Drossman-2003" TYPE="STUDY">Drossman 2003</LINK>; <LINK REF="STD-Kuiken-2003" TYPE="STUDY">Kuiken 2003</LINK>; <LINK REF="STD-Tabas-2004" TYPE="STUDY">Tabas 2004</LINK>; <LINK REF="STD-Talley-2008a" TYPE="STUDY">Talley 2008a</LINK>; <LINK REF="STD-Vahedi-2005" TYPE="STUDY">Vahedi 2005</LINK>; <LINK REF="STD-Vahedi-2008" TYPE="STUDY">Vahedi 2008</LINK>).</P>
<P>Given the significantly positive effects of antidepressant medication, the clinical indication of antidepressant medication in IBS needs to be discussed. Careful examination of the domain descriptions in the individual studies, shows no differences in patient population between studies investigating antidepressants, antispasmodics or bulking agents. Two studies performed a direct comparison of antidepressants with bulking agents or antispasmodics (<LINK REF="STD-Nigam-1984" TYPE="STUDY">Nigam 1984</LINK>; <LINK REF="STD-Ritchie-1979" TYPE="STUDY">Ritchie 1979</LINK>), but found no proof of the superiority of either compound. </P>
<P>We are aware of eight systematic reviews of antidepressants for IBS (<LINK REF="REF-Akehurst-2001" TYPE="REFERENCE">Akehurst 2001</LINK>; <LINK REF="REF-Brandt-2002" TYPE="REFERENCE">Brandt 2002</LINK>; <LINK REF="REF-Ford-2009" TYPE="REFERENCE">Ford 2009</LINK>; <LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK>; <LINK REF="REF-Jackson-2000" TYPE="REFERENCE">Jackson 2000</LINK>; <LINK REF="REF-Lesbros_x002d_Pantoflickova-2004" TYPE="REFERENCE">Lesbros-Pantoflickova 2004</LINK>; <LINK REF="REF-Tack-2006b" TYPE="REFERENCE">Tack 2006b</LINK>; <LINK REF="REF-Rahimi-2009" TYPE="REFERENCE">Rahimi 2009</LINK>). Most of these reviews are consistent with our results. <LINK REF="REF-Akehurst-2001" TYPE="REFERENCE">Akehurst 2001</LINK> concluded from two studies that antidepressants were effective.  <LINK REF="REF-Ford-2009" TYPE="REFERENCE">Ford 2009</LINK> included 13 RCTs and found a RR of 0.66 (95% CI 0.57 to 0.78) for persistent symptoms after treatment, and no difference between SSRIs and TCAs. The <LINK REF="REF-Jailwala-2000" TYPE="REFERENCE">Jailwala 2000</LINK> meta-analysis included 7 studies, all reporting beneficial effect, and concluded that it was not clear whether this was due to resolving abdominal symptoms, or to improved psychological health. The <LINK REF="REF-Jackson-2000" TYPE="REFERENCE">Jackson 2000</LINK> review included 11 studies on functional gastro-intestinal disorders, 8 of which were enrolled IBS patients exclusively. <LINK REF="REF-Jackson-2000" TYPE="REFERENCE">Jackson 2000</LINK> identified a statistically significant effect for overall assessment (7 studies; OR 4.2; 95% CI 2.3 to 7.9) and abdominal pain (9 studies; SMD 0.9; 95% CI 0.6 to 1.2). The <LINK REF="REF-Lesbros_x002d_Pantoflickova-2004" TYPE="REFERENCE">Lesbros-Pantoflickova 2004</LINK> review included 12 studies and found an OR: 2.6 (95% CI 1.9 to 3.5). They recommend antidepressant medication for the treatment of  patients with severe IBS symptoms, i.e. patients with daily or persistent pain. <LINK REF="REF-Rahimi-2009" TYPE="REFERENCE">Rahimi 2009</LINK> only investigated TCAs  and found clinically and statistically significant control of IBS symptoms. They advised that treatment with TCAs should be limited to patients with moderate to severe IBS.  </P>
<P>
<LINK REF="REF-Brandt-2002" TYPE="REFERENCE">Brandt 2002</LINK> and <LINK REF="REF-Tack-2006b" TYPE="REFERENCE">Tack 2006b</LINK> (a extended version of <LINK REF="REF-Brandt-2002" TYPE="REFERENCE">Brandt 2002</LINK>) reported no beneficial effect for antidepressant medication. This difference may be due to less strict inclusion criteria: both included cross-over studies with no report of the first phase data. They also failed to conduct a meta-analysis of the data.</P>
<P>
<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-06-20 13:29:39 -0400" MODIFIED_BY="John K MacDonald">
<IMPLICATIONS_PRACTICE MODIFIED="2011-06-20 13:29:39 -0400" MODIFIED_BY="John K MacDonald">
<P>The limitations of drug therapy should be discussed with the patient before deciding to prescribe medication for IBS. Agreement should be reached on treatment objectives, usually this will be relief of the most troublesome symptom. Our findings support the use of antispasmodics, although, it is not entirely clear whether one antispasmodic is more effective than another. Physicians will be limited to those antispasmodics which are locally available.</P>
<P>Antidepressants may also have a role for the treatment of IBS. Antidepressants could be used in patients who seek drug therapy and who have not responded to antispasmodics. The effectiveness of antidepressants may vary with individual patient features.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-06-20 13:29:31 -0400" MODIFIED_BY="John K MacDonald">
<P>It is likely that two different disease entities exist: constipation predominant IBS, and diarrhea predominant IBS. There may even be a third entity, patients with an alternating stool pattern. The pharmacological properties of bulking agents, spasmolytic agents and antidepressive medication suggest that different responses might be expected in these patient groups and this issue should be studied in future trials of &#8220;classic&#8221; drugs.</P>
<P>The variation in methods of outcome assessment in IBS studies is a validity problem. It is uncertain how precisely current outcome measures reflect the actual health status of the IBS patient. The need for more meaningful measures of response to treatment has led to the development of health-related quality of life measures including stool frequency and consistency, social, daily, physical and sexual functioning, sleep, pain, emotion, and change of health. Future research should use validated outcome measures for IBS, such as the IBS Quality of Life Questionnaire (IBSQOL), the IBS Quality of Life Measure (IBS-QOL), the Digestive Health Status Instrument (DHSI), the Functional Digestive Disorder Quality of Life questionnaire (FDDQOL), or the IBS-Q.<BR/>
</P>
<P>The concept of the brain-gut axis invites trials aimed at central and peripheral neural levels; apart from drug trials these may include cognitive behavioural therapy or other psychological interventions (e.g. hypnotherapy).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-06-21 09:18:13 -0400" MODIFIED_BY="John K MacDonald">
<P>Funding for the IBD/FBD Review Group (September 1, 2010 - August 31, 2015) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch (CON - 105529) and the CIHR Institutes of Nutrition, Metabolism and Diabetes (INMD); and Infection and Immunity (III).</P>
<P>Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-06-20 13:29:20 -0400" MODIFIED_BY="John K MacDonald">
<P>Greg Rubin owns shares in Glaxo Smith Kline and has received payment for consultancy from pharma companies. The other authors report no known declarations of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-06-20 13:29:24 -0400" MODIFIED_BY="John K MacDonald">
<P>Preparation of protocol<BR/>Coordination of reviewers<BR/>Data collection<BR/>Data review<BR/>Preparation of report</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-11-27 15:47:45 -0500" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES MODIFIED="2009-11-27 15:47:45 -0500" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-06-06 12:52:36 -0400" MODIFIED_BY="John K MacDonald">
<STUDIES MODIFIED="2011-06-06 12:38:18 -0400" MODIFIED_BY="John K MacDonald">
<INCLUDED_STUDIES MODIFIED="2011-06-06 12:38:18 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Aller-2004" MODIFIED="2010-06-08 13:23:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Aller 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 13:23:41 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aller R, de Luis DA, Izaola O, La Calle F, del Olmo L, Fernandez L, et al</AU>
<TI>Dietary intake of a group of patients with irritable bowel syndrome; relation between dietary fiber and symptoms</TI>
<SO>Nutrition</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>735-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arthurs-1983" MODIFIED="2010-06-08 13:24:25 -0400" MODIFIED_BY="John K MacDonald" NAME="Arthurs 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-06-08 13:24:25 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arthurs Y, Fielding JF</AU>
<TI>Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome</TI>
<SO>Ir Med J</SO>
<YR>1983</YR>
<VL>76</VL>
<NO>5</NO>
<PG>253</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:24:25 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awad-1995" MODIFIED="2010-06-08 13:24:47 -0400" MODIFIED_BY="John K MacDonald" NAME="Awad 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-06-08 13:24:47 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awad R, Dibildox M, Ortiz F</AU>
<TI>Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial</TI>
<SO>Acta Gastroenterol Latinoam</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>3</NO>
<PG>137-44</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:24:47 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bahar-2008" MODIFIED="2010-06-08 13:25:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Bahar 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-05-27 10:19:55 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bahar RJ, Collins BS, Steinmetz B, Ament ME</AU>
<TI>Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents</TI>
<SO>J Pediatr</SO>
<YR>2008 Dec</YR>
<VL>153</VL>
<NO>6</NO>
<PG>872</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-08 13:25:08 -0400" MODIFIED_BY="John K MacDonald"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldi-1991" MODIFIED="2010-06-08 13:25:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Baldi 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-08 13:25:46 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, et al</AU>
<TI>Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy</TI>
<SO>Ital J Gastroenterol</SO>
<YR>1991</YR>
<VL>23</VL>
<NO>8 Suppl 1</NO>
<PG>60-3</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:25:46 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battaglia-1998" MODIFIED="2011-05-26 14:50:37 -0400" MODIFIED_BY="John K MacDonald" NAME="Battaglia 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-05-26 14:50:37 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, et al</AU>
<TI>Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>10</NO>
<PG>1003-10</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:26:17 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergmann-1991" MODIFIED="2010-06-08 13:26:47 -0400" MODIFIED_BY="John K MacDonald" NAME="Bergmann 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-08 13:26:47 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergmann M, Heddergott A, Schlosser T</AU>
<TI>Therapy of irritable colon with trimipramine (Herphonal) - A controlled clinical study</TI>
<TO>Die therapie des colon irritabile mittrimipramin (Herphonal) - Eine kontrollierte studie</TO>
<SO>Z Klin Med</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>23</NO>
<PG>1621-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boerner-1988" MODIFIED="2010-06-08 13:27:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Boerner 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-08 13:27:07 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boerner D, Eberhardt R, Metz K, Schick E</AU>
<TI>Wirksamkeit ind vertraeglichkeit eines antidepressivums beim colon irritablie</TI>
<SO>Therapiewoche</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>201-8</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:27:07 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capanni-2005" MODIFIED="2010-06-08 13:27:48 -0400" MODIFIED_BY="John K MacDonald" NAME="Capanni 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-08 13:27:48 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1517; ID: 2284; ID: 2006301402" NOTES_MODIFIED="2010-06-08 13:27:48 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capanni M, Surrenti E, Biagini M R, Milani S, Surrenh C, Galli A</AU>
<TI>Efficacy of peppermint oil in the treatment of irritable bowel syndrome: A randomized, controlled trial</TI>
<SO>Gazz Med Ital Arch Sci Med</SO>
<YR>2005</YR>
<VL>164</VL>
<NO>2</NO>
<PG>119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cappello-2007" MODIFIED="2010-06-08 13:29:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Cappello 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-08 13:29:42 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1518; ID: 882; JID: 100958385; 0 (Placebos); 0 (Plant Oils); 8006-90-4 (peppermint oil); 2006/09/26 [received]; 2007/02/11 [revised]; 2007/02/12 [accepted]; 2007/04/08 [aheadofprint]; ppublish" NOTES_MODIFIED="2010-06-08 13:29:42 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L</AU>
<TI>Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial</TI>
<SO>Dig Liver Dis</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>6</NO>
<PG>530-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Centonze-1988" MODIFIED="2010-06-08 13:30:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Centonze 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-08 13:30:56 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O</AU>
<TI>Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome</TI>
<SO>Am J Gastroenterol</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>11</NO>
<PG>1262-6</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:30:56 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004" MODIFIED="2010-06-08 13:31:44 -0400" MODIFIED_BY="John K MacDonald" NAME="Chen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 13:31:44 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1543; ID: 2300; ID: 2004432621" NOTES_MODIFIED="2010-06-08 13:31:44 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen SJ, Li GX, Wang LJ, Sun LM, Si JM</AU>
<TI>SF-36 quality of life in effectiveness assessment for irritable bowel syndrome</TI>
<SO>World Chin J Dig</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>4</NO>
<PG>920-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czalbert-1990" MODIFIED="2010-06-08 13:32:14 -0400" MODIFIED_BY="John K MacDonald" NAME="Czalbert 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-08 13:32:14 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czalbert HJ, Neder M, Feher K</AU>
<TI>Experiences with colpermintherapy (Tillots-England) at patients of irritable colon syndrome</TI>
<SO>Gyogyszereszet</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>5</NO>
<PG>251-3</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:32:14 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-d_x0027_Arienzo-1980" MODIFIED="2010-06-08 13:32:30 -0400" MODIFIED_BY="John K MacDonald" NAME="d'Arienzo 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-06-08 13:32:30 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Arienzo A, d'Agotino L</AU>
<TI>L'ottilonio bromuro nel trattamento della sindrome del colon irritabile</TI>
<SO>Rass Int Clin Ter</SO>
<YR>1980</YR>
<VL>60</VL>
<NO>10</NO>
<PG>649-56</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:32:30 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmont-1981" MODIFIED="2010-06-08 13:33:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Delmont 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 13:33:05 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmont J</AU>
<TI>The value of adding an antispasmodic musculotropic agent in the treatment of painful constipation in functional colopathies with bran. Double-blind study</TI>
<TO>Interet de l'adjonction d'un antispasmodique musculotrope au traitement des constipations douloureuses des colopathies fonctionnelles par le son. Essai en double insu</TO>
<SO>Med Chir Dig</SO>
<YR>1981</YR>
<VL>10</VL>
<NO>4</NO>
<PG>365-70</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:33:05 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobrilla-1990" MODIFIED="2010-06-08 13:33:30 -0400" MODIFIED_BY="John K MacDonald" NAME="Dobrilla 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-08 13:33:30 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobrilla G, Imbimbo BP, Piazzi L, Bensi G</AU>
<TI>Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial</TI>
<SO>Gut</SO>
<YR>1990</YR>
<VL>31</VL>
<NO>3</NO>
<PG>355-8</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:33:30 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drossman-2003" MODIFIED="2010-06-08 13:34:34 -0400" MODIFIED_BY="John K MacDonald" NAME="Drossman 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-08 13:34:34 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al</AU>
<TI>Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>125</VL>
<PG>19-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubarry-1977" MODIFIED="2010-06-08 13:35:13 -0400" MODIFIED_BY="John K MacDonald" NAME="Dubarry 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-06-08 13:35:13 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubarry JJ, Quinton A</AU>
<TI>Effet a court terme du bromure de pinaverium dans les oesophagites, gastro-duodenites et colopathies fonctionnelles</TI>
<SO>Bordeaux Medical</SO>
<YR>1977</YR>
<VL>10</VL>
<NO>21</NO>
<PG>1457-9</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:35:13 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fielding-1980" MODIFIED="2010-06-08 13:35:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Fielding 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-06-08 13:35:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fielding JF</AU>
<TI>Double blind trial of trimebutine in the irritable bowel syndrome</TI>
<SO>Ir Med J</SO>
<YR>1980</YR>
<VL>73</VL>
<NO>10</NO>
<PG>377-9</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:35:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fowlie-1992" MODIFIED="2010-06-08 13:35:48 -0400" MODIFIED_BY="John K MacDonald" NAME="Fowlie 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-08 13:35:48 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fowlie S, Eastwood MA, Prescott R</AU>
<TI>Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation</TI>
<SO>J Psychosom Res</SO>
<YR>1992</YR>
<VL>36</VL>
<NO>2</NO>
<PG>175-80</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:35:48 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghidini-1986" MODIFIED="2010-06-08 13:36:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Ghidini 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-08 13:36:28 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghidini O, Saponati G, Intrieri L</AU>
<TI>Single drug treatment for irritable colon: Rociverine versus trimebutine maleate</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1986</YR>
<VL>39</VL>
<NO>4</NO>
<PG>541-8</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:36:28 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilvarry-1989" MODIFIED="2010-06-08 13:36:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Gilvarry 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-08 13:36:53 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 569; ID: 659; LR: 20071115; JID: 7806864; 28797-61-7 (Pirenzepine); ppublish" NOTES_MODIFIED="2010-06-08 13:36:53 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilvarry J, Kenny A, Fielding J F</AU>
<TI>The non-effect of pirenzepine in dietary resistant irritable bowel syndrome</TI>
<SO>Ir J Med Sci</SO>
<YR>1989</YR>
<VL>158</VL>
<NO>10</NO>
<PG>262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heefner-1978" MODIFIED="2010-06-08 13:37:10 -0400" MODIFIED_BY="John K MacDonald" NAME="Heefner 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-06-08 13:37:10 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heefner JD, Wilder RM, Wilson ID</AU>
<TI>Irritable colon and depression</TI>
<SO>Psychosomatics</SO>
<YR>1978</YR>
<VL>19</VL>
<NO>9</NO>
<PG>540-7</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:37:10 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jalihal-1990" MODIFIED="2010-06-08 13:37:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Jalihal 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-08 13:37:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jalihal A, Kurian G</AU>
<TI>Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction</TI>
<SO>J Gastroenterol Hepatol</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>5</NO>
<PG>507-13</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:37:27 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kruis-1986" MODIFIED="2010-06-08 13:37:40 -0400" MODIFIED_BY="John K MacDonald" NAME="Kruis 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-08 13:37:40 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kruis W, Weinzierl M, Schussler P, Holl J</AU>
<TI>Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome</TI>
<SO>Digestion</SO>
<YR>1986</YR>
<VL>34</VL>
<NO>3</NO>
<PG>196-201</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:37:40 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuiken-2003" MODIFIED="2010-06-08 13:38:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Kuiken 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-08 13:38:01 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2548; ID: 1263; LR: 20061115; JID: 101160775; 0 (Antidepressive Agents, Second-Generation); 0 (Serotonin Uptake Inhibitors); 54910-89-3 (Fluoxetine); ppublish" NOTES_MODIFIED="2010-06-08 13:38:01 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuiken S D, Tytgat G N, Boeckxstaens G E</AU>
<TI>The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study</TI>
<SO>Clin Gastroenterol Hepatol</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>3</NO>
<PG>219-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lech-1988" MODIFIED="2010-06-08 13:38:38 -0400" MODIFIED_BY="John K MacDonald" NAME="Lech 1988" YEAR="3-10-">
<REFERENCE MODIFIED="2010-06-08 13:38:38 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Vilien M, Ostergaard O</AU>
<TI>Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo</TI>
<TO>Behandling af colon irritabile med pebermynteolie. En dobbeltblind undersogelse med placebo</TO>
<SO>Ugeskr Laeger</SO>
<YR>1988</YR>
<VL>150</VL>
<NO>40</NO>
<PG>2388-9</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:38:38 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1977" MODIFIED="2010-06-08 13:38:58 -0400" MODIFIED_BY="John K MacDonald" NAME="Levy 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-06-08 13:38:58 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy C, Charbonnier A, Cachin M</AU>
<TI>Pinaverium bromide and functional colonic disease (double-blind study)</TI>
<TO>Bromure de pinaverium et colopathie fonctionnelle (etude a double insu)</TO>
<SO>Sem Hop Ther</SO>
<YR>1977</YR>
<VL>53</VL>
<NO>7-8</NO>
<PG>372-4</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:38:58 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1997" MODIFIED="2010-06-08 13:39:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Liu 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-08 13:39:15 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK</AU>
<TI>Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial</TI>
<SO>J Gastroenterol</SO>
<YR>1997</YR>
<VL>32</VL>
<NO>6</NO>
<PG>765-8</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:39:15 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longstreth-1981" MODIFIED="2010-06-08 13:44:06 -0400" MODIFIED_BY="John K MacDonald" NAME="Longstreth 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 13:44:06 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth GF, Fox DD, Youkeles L, Forsythe AB, Wolochow DA</AU>
<TI>Psyllium therapy in the irritable bowel syndrome. A double-blind trial</TI>
<SO>Ann Intern Med</SO>
<YR>1981</YR>
<VL>95</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:44:06 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucey-1987" MODIFIED="2010-06-08 13:44:18 -0400" MODIFIED_BY="John K MacDonald" NAME="Lucey 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-08 13:44:18 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucey MR, Clark ML, Lowndes J, Dawson AM</AU>
<TI>Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study</TI>
<SO>Gut</SO>
<YR>1987</YR>
<VL>28</VL>
<NO>2</NO>
<PG>221-5</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:44:18 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masand-2009" MODIFIED="2010-06-08 13:44:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Masand 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-08 13:44:41 -0400" MODIFIED_BY="John K MacDonald" NOTES="JID: 0376506; ppublish" NOTES_MODIFIED="2010-06-08 13:44:41 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia I M, et al</AU>
<TI>A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome</TI>
<SO>Psychosomatics</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>1</NO>
<PG>78-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-2002" MODIFIED="2010-06-08 13:45:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Mitchell 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-08 13:45:24 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1910; ID: 962; LR: 20061115; JID: 8707234; 0 (Propylamines); 150-59-4 (alverine); ppublish" NOTES_MODIFIED="2010-06-08 13:45:24 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW</AU>
<TI>Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moshal-1979" MODIFIED="2010-06-08 13:45:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Moshal 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 13:45:42 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moshal MG, Herron M</AU>
<TI>A clinical trial of trimebutine (Mebutin) in spastic colon</TI>
<SO>J Int Med Res</SO>
<YR>1979</YR>
<VL>7</VL>
<NO>3</NO>
<PG>231-4</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:45:42 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myren-1982" MODIFIED="2010-06-08 13:45:57 -0400" MODIFIED_BY="John K MacDonald" NAME="Myren 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-06-08 13:45:57 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myren J, Groth H, Larssen SE, Larsen S</AU>
<TI>The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study</TI>
<SO>Scand J Gastroenterol</SO>
<YR>1982</YR>
<VL>17</VL>
<NO>7</NO>
<PG>871-5</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:45:57 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nigam-1984" MODIFIED="2010-06-08 13:48:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Nigam 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 13:48:01 -0400" MODIFIED_BY="John K MacDonald" NOTES="LR: 20061115; JID: 7505585; 149-64-4 (Butylscopolammonium Bromide); 50-48-6 (Amitriptyline); 58-25-3 (Chlordiazepoxide); ppublish" NOTES_MODIFIED="2010-06-08 13:48:01 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK</AU>
<TI>Different therapeutic regimens in irritable bowel syndrome</TI>
<SO>J Assoc Physicians India</SO>
<YR>1984</YR>
<VL>32</VL>
<NO>12</NO>
<PG>1041-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Page-1981" MODIFIED="2010-06-08 13:48:17 -0400" MODIFIED_BY="John K MacDonald" NAME="Page 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 13:48:17 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Page JG, Dirnberger GM</AU>
<TI>Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)</TI>
<SO>J Clin Gastroenterol</SO>
<YR>1981</YR>
<VL>3</VL>
<NO>2</NO>
<PG>153-6</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:48:17 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passaretti-1989a" MODIFIED="2010-06-09 09:54:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Passaretti 1989a" YEAR="1989">
<REFERENCE MODIFIED="2010-06-08 13:48:37 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passaretti S, Guslandi M, Imbimbo BP, Daniotti S, Tittobello A</AU>
<TI>Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>3</NO>
<PG>267-76</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:48:37 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piai-1979" MODIFIED="2009-05-15 08:00:14 -0400" MODIFIED_BY="[Empty name]" NAME="Piai 1979" YEAR="1979">
<REFERENCE MODIFIED="2009-05-15 07:46:55 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 1976; ID: 3049; PM: PUBMED 37142; XR: EMBASE 1979221270; CC: SR-IBD" NOTES_MODIFIED="2009-05-15 07:46:55 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piai G, Mazzacca G</AU>
<TI>Prifinium bromide in the treatment of the irritable colon syndrome</TI>
<SO>Gastroenterology</SO>
<YR>1979</YR>
<VL>77</VL>
<NO>3</NO>
<PG>500-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prior-1987" MODIFIED="2010-06-08 13:48:57 -0400" MODIFIED_BY="John K MacDonald" NAME="Prior 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-08 13:48:57 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prior A, Whorwell PJ</AU>
<TI>Double blind study of ispaghula in irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>1987</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1510-3</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:48:57 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pulpeiro-2000" MODIFIED="2010-06-08 13:49:13 -0400" MODIFIED_BY="John K MacDonald" NAME="Pulpeiro 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-08 13:49:13 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pulpeiro A, Marti ML, De Los Santos AR, Di Girolamo G</AU>
<TI>Propinox in the treatment of irritable bowel syndrome</TI>
<TO>Propinox en sindrome de intestino irritable</TO>
<SO>Prensa Medica Argentina</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>3</NO>
<PG>299-307</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:49:13 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rajagopalan-1998" MODIFIED="2010-06-08 13:49:29 -0400" MODIFIED_BY="John K MacDonald" NAME="Rajagopalan 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-08 13:49:29 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajagopalan M, Kurian G, John J</AU>
<TI>Symptom relief with amitriptyline in the irritable bowel syndrome</TI>
<SO>J Gastroenterol Hepatol</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>7</NO>
<PG>738-41</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:49:29 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-2005" MODIFIED="2010-06-08 13:49:47 -0400" MODIFIED_BY="John K MacDonald" NAME="Rees 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-08 13:49:47 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1101; ID: 212; LR: 20061115; JID: 8303144; 0 (Placebos); ppublish" NOTES_MODIFIED="2010-06-08 13:49:47 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees G, Davies J, Thompson R, Parker M, Liepins P</AU>
<TI>Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome</TI>
<SO>J R Soc Health</SO>
<YR>2005</YR>
<VL>125</VL>
<NO>1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-1979" MODIFIED="2010-06-08 13:50:13 -0400" MODIFIED_BY="John K MacDonald" NAME="Ritchie 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 13:50:13 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2018; ID: 1106; LR: 20081120; JID: 0372673; 0 (Anti-Anxiety Agents); 0 (Scopolamine Derivatives); 149-64-4 (Butylscopolammonium Bromide); 846-49-1 (Lorazepam); 9004-34-6 (Cellulose); OID: NLM: PMC1597979; ppublish" NOTES_MODIFIED="2010-06-08 13:50:13 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie JA, Truelove SC</AU>
<TI>Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk</TI>
<SO>Br Med J</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>6160</NO>
<PG>376-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schafer-1990" MODIFIED="2010-06-08 13:50:29 -0400" MODIFIED_BY="John K MacDonald" NAME="Schafer 1990" YEAR="30-8-">
<REFERENCE MODIFIED="2010-06-08 13:50:29 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schafer E, Ewe K</AU>
<TI>The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon</TI>
<TO>Behandlung des Colon irritabile. Wirksamkeit und Vertraglichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile</TO>
<SO>Fortschr Med</SO>
<YR>1990</YR>
<VL>108</VL>
<NO>25</NO>
<PG>488-92</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:50:29 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soltoft-1976" MODIFIED="2010-06-08 13:50:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Soltoft 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-06-08 13:50:52 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1223; ID: 843; LR: 20071115; JID: 2985213R; 0 (Placebos); ppublish" NOTES_MODIFIED="2010-06-08 13:50:52 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soltoft J, Krag B, Gudmand-Hoyer E, Kristensen E, Wulff HR</AU>
<TI>A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>7954</NO>
<PG>270-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabas-2004" MODIFIED="2010-06-08 13:51:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Tabas 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 13:51:24 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2004351458" NOTES_MODIFIED="2010-06-08 13:51:24 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G</AU>
<TI>Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: A double-blind, placebo-controlled trial</TI>
<SO>Am J Gastroenterol</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>5</NO>
<PG>914-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tack-2006a" MODIFIED="2011-06-06 12:38:18 -0400" MODIFIED_BY="John K MacDonald" NAME="Tack 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-05-15 07:46:08 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 2806; ID: 2587; ID: 2006346696" NOTES_MODIFIED="2009-05-15 07:46:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers A M, Janssens J</AU>
<TI>A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>8</NO>
<PG>1095-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talley-2008a" MODIFIED="2010-06-09 11:32:48 -0400" MODIFIED_BY="John K MacDonald" NAME="Talley 2008a" YEAR="2008">
<REFERENCE MODIFIED="2010-06-08 13:52:17 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M</AU>
<TI>Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial</TI>
<SO>Dig Dis Sci</SO>
<YR>2008</YR>
<VL>53</VL>
<NO>1</NO>
<PG>108-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vahedi-2005" MODIFIED="2010-06-08 13:52:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Vahedi 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-08 13:52:42 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2849; ID: 1218; LR: 20061115; JID: 8707234; 0 (Serotonin Uptake Inhibitors); 54910-89-3 (Fluoxetine); ppublish" NOTES_MODIFIED="2010-06-08 13:52:42 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R</AU>
<TI>The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>5</NO>
<PG>381-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vahedi-2008" MODIFIED="2010-06-08 13:53:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Vahedi 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-08 13:53:05 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2846; ID: 1157; JID: 8707234; 0 (Analgesics, Non-Narcotic); 0 (Gastrointestinal Agents); 50-48-6 (Amitriptyline); 2008/01/30 [aheadofprint]; ppublish" NOTES_MODIFIED="2010-06-08 13:53:05 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vahedi H, Merat S, Momtahen S, Kazzazi A S, Ghaffari N, Olfati G, et al</AU>
<TI>Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>8</NO>
<PG>678-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vij-1991" MODIFIED="2010-06-08 13:53:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Vij 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-08 13:53:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vij JG, Jiloha RC, Kumar N</AU>
<TI>Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients</TI>
<SO>Indian J Psychiatry</SO>
<YR>1991</YR>
<VL>33</VL>
<PG>243-6</PG>
<EN>33</EN>
<IDENTIFIERS MODIFIED="2010-06-08 13:53:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Virat-1987" MODIFIED="2010-06-08 13:53:37 -0400" MODIFIED_BY="John K MacDonald" NAME="Virat 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-08 13:53:37 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Virat J, Hueber D</AU>
<TI>Colopathy pain and dicetel</TI>
<SO>Prat Med</SO>
<YR>1987</YR>
<VL>43</VL>
<PG>32-4</PG>
<IDENTIFIERS MODIFIED="2010-06-08 13:53:37 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-06-06 12:22:09 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Achord-1979" MODIFIED="2010-06-08 13:54:29 -0400" MODIFIED_BY="John K MacDonald" NAME="Achord 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 13:54:29 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Achord JL</AU>
<TI>Irritable bowel syndrome and dietary fiber</TI>
<SO>J Am Diet Assoc</SO>
<YR>1979</YR>
<VL>75</VL>
<NO>4</NO>
<PG>452-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alevizos-1989" MODIFIED="2010-06-08 13:55:03 -0400" MODIFIED_BY="John K MacDonald" NAME="Alevizos 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-08 13:55:03 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alevizos B, Christodoulou GN, Ioannidis C, Voulgari A, Mantidis A, Spiliadis C</AU>
<TI>The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome</TI>
<SO>Clin Neuropharmacol</SO>
<YR>1989</YR>
<VL>12 Suppl 2</VL>
<PG>S66-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andre-1979" MODIFIED="2010-06-08 13:55:43 -0400" MODIFIED_BY="John K MacDonald" NAME="Andre 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 13:55:43 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1446; ID: 2496; ID: 1980026928" NOTES_MODIFIED="2010-06-08 13:55:43 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andre PP, De Windt J, Dony A</AU>
<TI>Basic treatment of spastic colon (multicenter trial with oxazepam plus scopolamine butyl nitrate)</TI>
<SO>ARS MED INT TIJDSCHR PRAKT THER</SO>
<YR>1979</YR>
<VL>8</VL>
<NO>19</NO>
<PG>1673-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1966" MODIFIED="2010-06-08 13:57:06 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 1966" YEAR="1966">
<REFERENCE MODIFIED="2010-06-08 13:57:06 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1428; ID: 1124; LR: 20061107; JID: 7501160; 0 (Cholinergic Antagonists); 0 (Parasympatholytics); 0 (Thioxanthenes); 4969-02-2 (methixene); ppublish" NOTES_MODIFIED="2010-06-08 13:57:06 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Evaluation of an antispasmodic agent. Methixene hydrochloride (Trest)</TI>
<SO>JAMA</SO>
<YR>1966</YR>
<VL>195</VL>
<NO>10</NO>
<PG>851</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1976" MODIFIED="2010-06-08 13:57:33 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-06-08 13:57:33 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1426; ID: 1112; LR: 20081121; JID: 0404245; 0 (Cyclohexanecarboxylic Acids); 77-19-0 (Dicyclomine); ppublish" NOTES_MODIFIED="2010-06-08 13:57:33 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Irritable colon syndrome treated with an antispasmodic drug</TI>
<SO>Practitioner</SO>
<YR>1976</YR>
<VL>217</VL>
<NO>1298</NO>
<PG>276-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1982" MODIFIED="2010-06-08 13:58:16 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-06-08 13:58:16 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1425; ID: 2484; ID: 1983013375" NOTES_MODIFIED="2010-06-08 13:58:16 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Is pinaverium bromide suitable for treatment of spastic colon?</TI>
<SO>Ned Tijdschr Geneeskd</SO>
<YR>1982</YR>
<VL>126</VL>
<NO>38</NO>
<PG>1746</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1986" MODIFIED="2010-06-08 13:57:55 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-08 13:57:55 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1422; ID: 1078; LR: 20041117; JID: 0112037; 0 (Parasympatholytics); ppublish" NOTES_MODIFIED="2010-06-08 13:57:55 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Some antispasmodic drugs for the irritable bowel syndrome</TI>
<SO>Drug Ther Bull</SO>
<YR>1986</YR>
<VL>24</VL>
<NO>24</NO>
<PG>93-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1995" MODIFIED="2010-06-08 13:59:34 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-06-08 13:59:34 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1421; ID: 2396; ID: 1995097878" NOTES_MODIFIED="2010-06-08 13:59:34 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Effective and well-tolerated spasmolytic agent in the treatment of irritable colon syndrome</TI>
<SO>Therapiewoche</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>9</NO>
<PG>560, 562-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1998" MODIFIED="2011-06-06 11:09:13 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-06-06 11:09:13 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1420; ID: 2378; ID: 1999008035" NOTES_MODIFIED="2011-06-06 11:09:13 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Mebeverine suspension in childhood irritable bowel syndrome</TI>
<SO>Arztliche Prax Padiatr</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>26-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2002a" MODIFIED="2010-06-08 14:01:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 2002a" YEAR="2002">
<REFERENCE MODIFIED="2010-06-08 14:01:42 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>SSRIs to treat irritable bowel?</TI>
<SO>Pharm J</SO>
<YR>2002</YR>
<VL>268</VL>
<PG>755</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2002b" MODIFIED="2010-06-08 14:01:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 2002b" YEAR="2002">
<REFERENCE MODIFIED="2010-06-08 14:01:15 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1417; ID: 2327; ID: 2002326658" NOTES_MODIFIED="2010-06-08 14:01:15 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Trimebutine: Another therapeutic choice for irritable bowel syndrome</TI>
<SO>Chin J Gastroenterol</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>4</NO>
<PG>206-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2008" MODIFIED="2010-06-08 14:02:18 -0400" MODIFIED_BY="John K MacDonald" NAME="Anonymous 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-08 14:02:18 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1416; ID: 2238; ID: 2009011928" NOTES_MODIFIED="2010-06-08 14:02:18 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Peppermint oil can relieve symptoms of irritable bowel syndrome</TI>
<SO>Dtsch Apoth</SO>
<YR>2008</YR>
<VL>148</VL>
<NO>50</NO>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arffmann-1985" MODIFIED="2010-06-08 14:23:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Arffmann 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-08 14:23:26 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arffmann S, Andersen JR, Hegnhoj J, Schaffalitzky de Muckadell OB, Mogensen NB, Krag E</AU>
<TI>The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study</TI>
<SO>Scand J Gastroenterol</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>3</NO>
<PG>295-8</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:23:26 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awad-1997" MODIFIED="2010-06-08 14:24:03 -0400" MODIFIED_BY="John K MacDonald" NAME="Awad 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-08 14:24:03 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1459; ID: 1023; LR: 20061214; JID: 0261505; 0 (Calcium Channel Blockers); 0 (Morpholines); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-08 14:24:03 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awad RA, Cordova VH, Dibildox M, Santiago R, Camacho S</AU>
<TI>Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome</TI>
<SO>Acta Gastroenterol Latinoam</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>4</NO>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldi-1992" MODIFIED="2010-06-08 14:24:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Baldi 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-08 14:24:42 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, et al</AU>
<TI>Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study</TI>
<SO>Hepatogastroenterology</SO>
<YR>1992</YR>
<VL>39</VL>
<NO>5</NO>
<PG>392-5</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:24:42 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbier-1981" MODIFIED="2010-06-08 14:25:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Barbier 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 14:25:53 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbier P</AU>
<TI>Double blind controlled trial of a new colonic antispasmodic agent, actylonium bromide</TI>
<TO>Etude controlee en double aveugle d'un nouvel antspasmodique colique</TO>
<SO>Ars Medici</SO>
<YR>1981</YR>
<VL>36</VL>
<NO>21</NO>
<PG>1879-80</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:25:53 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bassotti-1988" MODIFIED="2010-06-08 14:26:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Bassotti 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-08 14:26:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassotti G</AU>
<TI>Dietary fibers in gastroenterology</TI>
<SO>MED RIV ENCICL MED ITAL</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>2</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baume-1972" MODIFIED="2010-06-08 14:26:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Baume 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-06-08 14:26:46 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1475; ID: 1119; LR: 20071115; JID: 1264322; 0 (Amino Acids); 0 (Placebos); ppublish" NOTES_MODIFIED="2010-06-08 14:26:46 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baume P</AU>
<TI>Mebeverine, an effective agent in the irritable colon syndrome</TI>
<SO>Aust NZ J Med</SO>
<YR>1972</YR>
<VL>2</VL>
<NO>1</NO>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bazzocchi-1992" MODIFIED="2010-06-08 14:27:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Bazzocchi 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-08 14:27:24 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1478; ID: 2412; ID: 1992225641" NOTES_MODIFIED="2010-06-08 14:27:24 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bazzocchi G, Difalco A, Bensi G, Lanfranchi GA</AU>
<TI>The effect of muscarinic blockade on anorectal function in patients with constipation-predominant irritable bowel syndrome</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1992</YR>
<VL>52</VL>
<NO>1</NO>
<PG>135-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berthelot-1981" MODIFIED="2010-06-08 14:27:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Berthelot 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 14:27:41 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berthelot J, Centonze V</AU>
<TI>Etude controlee en double aveugle Duspatalin (Mebeverine) contre placebo, dans le traitement du colon irritable</TI>
<SO>Gaz Med Fr</SO>
<YR>1981</YR>
<VL>88</VL>
<NO>16</NO>
<PG>2341-3</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:27:41 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birt-1989" MODIFIED="2010-06-08 14:28:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Birt 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-08 14:28:24 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birt M, Dumitrascu D</AU>
<TI>Treatment with antidepressants in biliary dyskinesia and irritable colon</TI>
<SO>Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna</SO>
<YR>1989</YR>
<VL>41</VL>
<NO>3</NO>
<PG>277-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bixquert_x002d_Jimenez-2005" MODIFIED="2010-06-08 14:28:44 -0400" MODIFIED_BY="John K MacDonald" NAME="Bixquert-Jimenez 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-08 14:28:44 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bixquert-Jimenez M, Bixquert-Pla L</AU>
<TI>Antidepressant therapy in functional gastrointestinal disorders</TI>
<SO>Gastroenterol Hepatol</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>8</NO>
<PG>485-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-1983" MODIFIED="2010-06-08 14:29:04 -0400" MODIFIED_BY="John K MacDonald" NAME="Block 1983" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 14:29:04 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block J, Myren J, Larssen SE, Larsen S</AU>
<TI>Trimipramin (Surmontil) and placebo in irritable colon syndrome. A double-blind study</TI>
<TO>Trimipramin (Surmontil) og placebo ved irritable colon syndrom. En dobbeltblind studie</TO>
<SO>Tidsskr Nor Laegeforen</SO>
<YR>1983</YR>
<VL>103</VL>
<NO>11</NO>
<PG>903-5</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:29:04 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosaeus-2004" MODIFIED="2010-06-08 14:29:31 -0400" MODIFIED_BY="John K MacDonald" NAME="Bosaeus 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 14:29:31 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosaeus I</AU>
<TI>Fiber effects on intestinal functions (diarrhoea, constipation and irritable bowel syndrome)</TI>
<SO>Clin Nutr Suppl</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>2</NO>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouchoucha-2000" MODIFIED="2010-06-08 14:31:36 -0400" MODIFIED_BY="John K MacDonald" NAME="Bouchoucha 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-08 14:31:36 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1495; ID: 993; LR: 20041117; JID: 8213295; 0 (Morpholines); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-08 14:31:36 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouchoucha M, Faye A, Devroede G, Arsac M</AU>
<TI>Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients</TI>
<SO>Biomed Pharmacother</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>7</NO>
<PG>381-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Budavari-2002" MODIFIED="2010-06-08 14:31:57 -0400" MODIFIED_BY="John K MacDonald" NAME="Budavari 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-08 14:31:57 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Budavari AI, Olden KW</AU>
<TI>The use of antidepressants in irritable bowel syndrome</TI>
<SO>Pract Gastroenterol</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>3</NO>
<PG>13-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burden-2001" MODIFIED="2010-06-08 14:32:22 -0400" MODIFIED_BY="John K MacDonald" NAME="Burden 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-08 14:32:22 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burden S</AU>
<TI>Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice</TI>
<SO>J Hum Nutr Diet</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>3</NO>
<PG>231-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camarri-1981" MODIFIED="2010-06-08 14:32:44 -0400" MODIFIED_BY="John K MacDonald" NAME="Camarri 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 14:32:44 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camarri E, Guidoni G, Marini G, Schiaroli G</AU>
<TI>La terapia del colon irritabile. Risultati del trattamento con un nuovo antispastico: l'ottilonio bromuro</TI>
<SO>Policlinico [Prat]</SO>
<YR>1981</YR>
<VL>88</VL>
<PG>174-84</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:32:44 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camarri-1986" MODIFIED="2010-06-08 14:33:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Camarri 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-08 14:33:15 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1506; ID: 2459; ID: 1986134141" NOTES_MODIFIED="2010-06-08 14:33:15 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camarri E</AU>
<TI>Fenoverine: Smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation</TI>
<SO>Curr Med Res Opin</SO>
<YR>1986</YR>
<VL>10</VL>
<NO>1</NO>
<PG>52-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camatte-1966" MODIFIED="2010-06-08 14:33:38 -0400" MODIFIED_BY="John K MacDonald" NAME="Camatte 1966" YEAR="1966">
<REFERENCE MODIFIED="2010-06-08 14:33:38 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1508; ID: 1123; LR: 20041117; JID: 0205463; 0 (Phenethylamines); ppublish" NOTES_MODIFIED="2010-06-08 14:33:38 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camatte R, Sarles H</AU>
<TI>Functional colonic diseases and Mebeverine</TI>
<SO>Sem Ther</SO>
<YR>1966</YR>
<VL>42</VL>
<NO>9</NO>
<PG>509-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cann-1984" MODIFIED="2010-06-08 14:33:57 -0400" MODIFIED_BY="John K MacDonald" NAME="Cann 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 14:33:57 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cann PA, Read NW, Holdsworth CD</AU>
<TI>What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?</TI>
<SO>Gut</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>2</NO>
<PG>168-73</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:33:57 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-06 05:58:12 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capron-1981" MODIFIED="2010-06-08 14:34:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Capron 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 14:34:15 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capron JP, Zeitoun P, Julien D</AU>
<TI>A multicenter controlled trial of a combination of kaolin, sterculia gum, meprobamate, and magnesium salts, in the irritable bowel syndrome (author's transl)</TI>
<TO>Effets d'un medicament associant kaolin, gomme sterculia, magnesium et meprobamate le traitement du colon irritable. Resultats d'une etude controlee multicentrique</TO>
<SO>Gastroenterol Clin Biol</SO>
<YR>1981</YR>
<VL>5</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:34:15 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capurso-1984" MODIFIED="2010-06-08 14:34:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Capurso 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 14:34:28 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capurso L, Koch M, Tarquini M, Dezi A, Papi C, Fracasso P</AU>
<TI>The irritable bowel syndrome. A cross-over study of octilonium bromide, mebeverine and placebo</TI>
<SO>Clin Trials J</SO>
<YR>1984</YR>
<VL>21</VL>
<NO>5</NO>
<PG>285-91</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:34:28 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capurso-1992" MODIFIED="2010-06-08 14:34:58 -0400" MODIFIED_BY="John K MacDonald" NAME="Capurso 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-08 14:34:58 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1521; ID: 2409; ID: 1992314964" NOTES_MODIFIED="2010-06-08 14:34:58 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capurso L, Del Sette F, Ferrario F, Tarquini M</AU>
<TI>The octylonium bromide-benzodiazepine combination for management of the irritable bowel syndrome</TI>
<SO>Clin Ter</SO>
<YR>1992</YR>
<VL>141</VL>
<NO>8</NO>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carling-1989" MODIFIED="2010-06-08 14:35:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Carling 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-08 14:35:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carling L, Svedberg LE, Hulten S</AU>
<TI>Short term treatment of the irritable bowel syndrome: A placebo-controlled trial of peppermint oil against hyoscyamine</TI>
<SO>Opuscula Medica</SO>
<YR>1989</YR>
<VL>34</VL>
<NO>3</NO>
<PG>55-7</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:35:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerrato-2001" MODIFIED="2010-06-08 14:36:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Cerrato 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-08 14:36:02 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1418; ID: 3200; Accession Number: 2002026439. Language: English. Entry Date: 20020215. Publication Type: journal article. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Online/Print; Peer Reviewed; USA. Special Interest: Obstetric Care; Women's Health. No. of Refs: 1 ref. NLM UID: 0367022." NOTES_MODIFIED="2010-06-08 14:36:02 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerrato PL</AU>
<TI>Altmed watch. Peppermint oil holds its own as a treatment for IBS</TI>
<SO>Contemp Ob Gyn</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>5</NO>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapman-1990" MODIFIED="2010-03-31 13:34:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Chapman 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-03-31 13:34:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapman ND, Grillage MG, Mazumder R, Atkinson SN</AU>
<TI>A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study</TI>
<SO>Br J Clin Pract</SO>
<YR>1990</YR>
<VL>44</VL>
<NO>11</NO>
<PG>461</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chassany-2007" MODIFIED="2010-06-08 14:37:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Chassany 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-08 14:37:07 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1540; ID: 880; JID: 8707234; 0 (Drug Combinations); 108-73-6 (Phloroglucinol); 4463-03-0 (trimethylphloroglucinol); ppublish" NOTES_MODIFIED="2010-06-08 14:37:07 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chassany O, Bonaz B, Bruley Des Varannes S, Bueno L, Cargill G, Coffin B, et al</AU>
<TI>Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1115-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1999" MODIFIED="2010-06-08 14:37:35 -0400" MODIFIED_BY="John K MacDonald" NAME="Chen 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-06-08 14:37:35 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1544; ID: 2951; DE: RCT; CC: HS-HANDSRCH" NOTES_MODIFIED="2010-06-08 14:37:35 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen ZY, Yao JH</AU>
<TI>Alverine/dimeticone versus nifedipine in treating irritable bowel syndrome</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>2</NO>
<PG>94-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004a" MODIFIED="2010-06-08 14:38:22 -0400" MODIFIED_BY="John K MacDonald" NAME="Chen 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 14:38:22 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Y, Wang X, Shang J</AU>
<TI>Paroxetine and Polyethylene Glycol (PEG) 4000 Therapy in Irritable Bowel Syndrome</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>11</NO>
<PG>806-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chevrel-1978" MODIFIED="2010-06-08 14:40:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Chevrel 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-06-08 14:40:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chevrel B</AU>
<TI>Treatment of functional intestinal disorders with carbomucil</TI>
<TO>Traitement des troubles fonctionnels intestinaux par le carbomucil</TO>
<SO>Med Chir Dig</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>5</NO>
<PG>443-5</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:40:11 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chicharro-2007" MODIFIED="2011-06-06 12:22:09 -0400" MODIFIED_BY="John K MacDonald" NAME="Chicharro 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-06 12:22:09 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chicharro Serrano L</AU>
<TI>Fiber in the treatment of intestinal diseases</TI>
<SO>Farm Hosp</SO>
<YR>2007</YR>
<VL>187</VL>
<PG>7-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christen-1990" MODIFIED="2010-06-08 14:40:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Christen 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-08 14:40:56 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1548; ID: 1064; LR: 20061115; JID: 7602417; 0 (Calcium Channels); 0 (Morpholines); 0 (Parasympatholytics); 59995-65-2 (pinaverium); 7440-70-2 (Calcium); RF: 53; ppublish" NOTES_MODIFIED="2010-06-08 14:40:56 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christen MO</AU>
<TI>Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders</TI>
<SO>Gen Pharmacol</SO>
<YR>1990</YR>
<VL>21</VL>
<NO>6</NO>
<PG>821-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clouse-1994" MODIFIED="2010-06-08 14:41:22 -0400" MODIFIED_BY="John K MacDonald" NAME="Clouse 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-08 14:41:22 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clouse RE, Lustman PJ, Geisman RA, Alpers DH</AU>
<TI>Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>4</NO>
<PG>409-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clouse-2003" MODIFIED="2010-06-08 14:41:37 -0400" MODIFIED_BY="John K MacDonald" NAME="Clouse 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-08 14:41:37 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clouse RE</AU>
<TI>Antidepressants for irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>4</NO>
<PG>598-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cook-1990" MODIFIED="2010-06-08 14:41:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Cook 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-08 14:41:53 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM</AU>
<TI>Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>1</NO>
<PG>66-72</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:41:53 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cop_x00e9_-1981" MODIFIED="2010-03-31 13:41:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Copé 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-03-31 13:41:08 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1553; ID: 3038; PM: PUBMED 6896078; CC: HS-HANDSRCH; SR-IBD" NOTES_MODIFIED="2010-03-31 13:41:08 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Copé R</AU>
<TI>Comparative clinical study of the combination of clidinium(br)-chlordiazepoxide and trimebutine in the treatment of functional colopathies</TI>
<SO>Med Chir Dig</SO>
<YR>1981</YR>
<VL>10</VL>
<NO>8</NO>
<PG>713-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corazza-1983" MODIFIED="2010-06-08 14:42:29 -0400" MODIFIED_BY="John K MacDonald" NAME="Corazza 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-06-08 14:42:29 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1554; ID: 2478; ID: 1984049625" NOTES_MODIFIED="2010-06-08 14:42:29 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corazza GR, Vaira D, Milletti S</AU>
<TI>Controlled clinical evaluation of pinaverium bromide and trimebutine in functional disorders of the colon</TI>
<SO>Acta Ther</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>4</NO>
<PG>383-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corazziari-1999" MODIFIED="2010-06-08 14:42:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Corazziari 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-06-08 14:42:56 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1555; ID: 1007; LR: 20051116; JID: 8807867; 0 (Enkephalins); 0 (Gastrointestinal Agents); 0 (Ligands); 0 (Opioid Peptides); 0 (Parasympathomimetics); 0 (Receptors, Opioid); 0 (Receptors, Opioid, mu); RF: 42; ppublish" NOTES_MODIFIED="2010-06-08 14:42:56 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corazziari E</AU>
<TI>Role of opioid ligands in the irritable bowel syndrome</TI>
<SO>Can J Gastroenterol</SO>
<YR>1999</YR>
<VL>13 Suppl A</VL>
<PG>71A-5A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creed-2003" MODIFIED="2010-06-08 14:44:12 -0400" MODIFIED_BY="John K MacDonald" NAME="Creed 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-08 14:44:12 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al</AU>
<TI>The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>303-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creed-2006" MODIFIED="2009-05-08 05:15:10 -0400" MODIFIED_BY="[Empty name]" NAME="Creed 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-08 05:15:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creed F</AU>
<TI>How do SSRIs help patients with irritable bowel syndrome?</TI>
<SO>Gut</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>8</NO>
<PG>1065-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crowell-2004" MODIFIED="2010-06-08 14:44:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Crowell 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 14:44:52 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crowell MD, Jones MP, Harris LA, Dineen TN, Schettler VA, Olden KW</AU>
<TI>Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes</TI>
<SO>Curr Opin Investig Drugs</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>7</NO>
<PG>736-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curtiss-2008" MODIFIED="2010-06-08 14:45:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Curtiss 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-08 14:45:15 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curtiss FR</AU>
<TI>Irritable bowel syndrome and antidepressants</TI>
<SO>J Manag Care Pharm</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>9</NO>
<PG>882-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czimmer-2001" MODIFIED="2010-06-08 14:45:37 -0400" MODIFIED_BY="John K MacDonald" NAME="Czimmer 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-08 14:45:37 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1561; ID: 972; LR: 20061115; JID: 9309351; 0 (Gastrointestinal Agents); 0 (Quaternary Ammonium Compounds); 26095-59-0 (octylonium); ppublish" NOTES_MODIFIED="2010-06-08 14:45:37 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czimmer J, Suto G, Kiraly A, Mozsik G</AU>
<TI>Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome</TI>
<SO>J Physiol Paris</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>1-6</NO>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Darnis-1980" MODIFIED="2010-06-08 14:45:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Darnis 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-06-08 14:45:53 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Darnis F</AU>
<TI>Clinical study of a new medication in the treatment of functional colopathies</TI>
<TO>Etude clinique d'une medication nouvelle dans le traitement des colopathies fonctionnelles</TO>
<SO>Med Chir Dig</SO>
<YR>1981</YR>
<VL>10</VL>
<NO>5</NO>
<PG>461-2</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:45:53 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Defrance-1991" MODIFIED="2010-06-08 14:51:16 -0400" MODIFIED_BY="John K MacDonald" NAME="Defrance 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-08 14:51:16 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1571; ID: 1050; LR: 20061115; JID: 8000544; 0 (Morpholines); 0 (Parasympatholytics); 0 (Quaternary Ammonium Compounds); 26095-59-0 (octylonium); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-08 14:51:16 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Defrance P, Casini A</AU>
<TI>A comparison of the action of otilonium bromide and pinaverium bromide: study conducted under clinical control</TI>
<SO>Ital J Gastroenterol</SO>
<YR>1991</YR>
<VL>23</VL>
<NO>8 Suppl 1</NO>
<PG>64-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Groote-1968" MODIFIED="2010-06-08 14:46:16 -0400" MODIFIED_BY="John K MacDonald" NAME="De Groote 1968" YEAR="1968">
<REFERENCE MODIFIED="2010-06-08 14:46:16 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1564; ID: 1121; LR: 20041117; JID: 0404414; 0 (Benzoates); 0 (Phenethylamines); ppublish" NOTES_MODIFIED="2010-06-08 14:46:16 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Groote J, Standaert L</AU>
<TI>The effect of a new musculotropic subtance 9 (Mebeverine) on irritable colon</TI>
<SO>Tijdschr Gastroenterol</SO>
<YR>1968</YR>
<VL>11</VL>
<NO>5</NO>
<PG>524-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-la-Garoullaye-1991" MODIFIED="2010-06-08 14:46:55 -0400" MODIFIED_BY="John K MacDonald" NAME="de la Garoullaye 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-08 14:46:55 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de la Garoullaye G, Bordet P</AU>
<TI>The combination fenoverine/PVPP + karaya gum in the treatment of irritable bowel</TI>
<SO>Comptes Rendus de Therapeutique et de Pharmacologie Clinique</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>93</NO>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delvaux-1997" MODIFIED="2010-06-08 14:51:37 -0400" MODIFIED_BY="John K MacDonald" NAME="Delvaux 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-08 14:51:37 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1579; ID: 1019; LR: 20081121; JID: 0346411; 0 (Gastrointestinal Agents); 39133-31-8 (Trimebutine); RF: 116; ppublish" NOTES_MODIFIED="2010-06-08 14:51:37 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delvaux M, Wingate D</AU>
<TI>Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results</TI>
<SO>J Int Med Res</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>5</NO>
<PG>225-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dettmar-1998" MODIFIED="2010-06-08 14:52:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Dettmar 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-08 14:52:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dettmar PW, Sykes J</AU>
<TI>A comparison between a fixed combination of ispaghula husk and mebeverine hydrochloride or mebeverine hydrochloride plus high-fibre dietary advice in the treatment of irritable bowel syndrome</TI>
<SO>J Clin Res</SO>
<YR>1998</YR>
<VL>1</VL>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dettmar-1999" MODIFIED="2010-06-08 14:53:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Dettmar 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-06-08 14:53:24 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dettmar PW, Sykes J</AU>
<TI>A multicentre, general practice study of the effectiveness and acceptability of an ispaghula husk-mebeverine hydrochloride combination product in irritable bowel syndrome</TI>
<SO>J Clin Res</SO>
<YR>1998</YR>
<VL>1</VL>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dew-1984" MODIFIED="2010-06-08 14:53:40 -0400" MODIFIED_BY="John K MacDonald" NAME="Dew 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 14:53:40 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dew MJ, Evans BK, Rhodes J</AU>
<TI>Peppermint oil for the irritable bowel syndrome: a multicentre trial</TI>
<SO>Br J Clin Pract</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>11-12</NO>
<PG>394, 398</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:53:40 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz_x002d_Rubio-1985" MODIFIED="2010-06-08 14:54:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Diaz-Rubio 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-08 14:54:59 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 365; ID: 2080; ID: 1986035357" NOTES_MODIFIED="2010-06-08 14:54:59 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz-Rubio M, De Onis Sanz, Enriquez Gonzalez L, Esteban Bernaldez JM</AU>
<TI>Effects of wheat bran in the irritable bowel syndrome</TI>
<SO>Ann Med Interna</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>9</NO>
<PG>420-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dioguardi-1991" MODIFIED="2010-06-08 14:55:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Dioguardi 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-08 14:55:52 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1591; ID: 2982; XR: EMBASE 1991298683; DE: RCT" NOTES_MODIFIED="2010-06-08 14:55:52 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dioguardi N, De FR, Agape D, Antoniozzi F, Ballarin E, Ferrara A, et al</AU>
<TI>Octilonium bromide-diazepam versus propantheline bromide-bromazepam in the treatment of irritable bowel-syndrome: A multicenter, randomized, controlled, double-blind trial</TI>
<SO>Ter Mod</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>4</NO>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubinin-1987" MODIFIED="2010-06-08 14:56:48 -0400" MODIFIED_BY="John K MacDonald" NAME="Dubinin 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-08 14:56:48 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubinin AV, Kabanov AV, Kirkin BV, Kolkunova GK, Igorianova NA</AU>
<TI>Bran in the treatment of irritable bowel syndrome</TI>
<SO>Vopr Pitan</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehsanullah-1985" MODIFIED="2010-06-08 14:57:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Ehsanullah 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-08 14:57:01 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehsanullah M, Lee DA, Williams T, Pollard P, Gazzard B</AU>
<TI>The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome</TI>
<SO>Br J Clin Pharmacol</SO>
<YR>1985</YR>
<VL>19</VL>
<NO>3</NO>
<PG>301-5</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:57:01 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisenburg-1978" MODIFIED="2010-06-08 14:57:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Eisenburg 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-06-08 14:57:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisenburg J, Kruis W, Schussler P, Weinzierl M</AU>
<TI>The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome</TI>
<TO>Das irritable kolon-syndrom. Neue therapeuische wege bei der behandlung eines haufigen krakheitsbildes</TO>
<SO>Fortschr Med</SO>
<YR>1978</YR>
<VL>96</VL>
<NO>41</NO>
<PG>2064-70</PG>
<IDENTIFIERS MODIFIED="2010-06-08 14:57:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evangelista-2004" MODIFIED="2010-06-08 14:57:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Evangelista 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-08 14:57:39 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1622; ID: 930; LR: 20071115; JID: 9602487; 0 (Morpholines); 0 (Parasympatholytics); 0 (Quaternary Ammonium Compounds); 0 (Scopolamine Derivatives); 149-64-4 (Butylscopolammonium Bromide); 26095-59-0 (octylonium); 51598-60-8 (DA 3177); 59995-65-2 (pinaverium); RF: 62; ppublish" NOTES_MODIFIED="2010-06-08 14:57:39 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evangelista S</AU>
<TI>Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome</TI>
<SO>Curr Pharm Des</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>28</NO>
<PG>3561-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1996" MODIFIED="2010-06-08 14:58:58 -0400" MODIFIED_BY="John K MacDonald" NAME="Evans 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-08 14:58:58 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans JM, Fleming KC, Talley NJ, Schleck CD, Zinsmeister AR, Melton LJ</AU>
<TI>Relation of colonic transit to functional bowel disease in older people: a population-based study</TI>
<SO>J Am Geriatr Soc</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>1</NO>
<PG>83-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-1986" MODIFIED="2010-06-08 14:59:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Ferrari 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-08 14:59:24 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1636; ID: 2455; ID: 1986169417" NOTES_MODIFIED="2010-06-08 14:59:24 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari A, Cavallero M, Spandre M</AU>
<TI>Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome</TI>
<SO>Clin Ther</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>3</NO>
<PG>320-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fielding-1979" MODIFIED="2010-06-08 14:59:49 -0400" MODIFIED_BY="John K MacDonald" NAME="Fielding 1979" YEAR="">
<REFERENCE MODIFIED="2010-06-08 14:59:49 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fielding JF, Melvin K</AU>
<TI>Dietary fibre and the irritable bowel syndrome</TI>
<SO>J Hum Nutr</SO>
<YR>1979</YR>
<VL>33</VL>
<NO>4</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fielding-1984" MODIFIED="2010-06-08 15:00:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Fielding 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 15:00:05 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fielding JF, Kehoe M</AU>
<TI>Different dietary fibre formulations and the irritable bowel syndrome</TI>
<SO>Ir J Med Sci</SO>
<YR>1984</YR>
<VL>153</VL>
<NO>5</NO>
<PG>178-80</PG>
<IDENTIFIERS MODIFIED="2010-06-08 15:00:05 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fioramonti-1988" MODIFIED="2010-06-08 15:00:48 -0400" MODIFIED_BY="John K MacDonald" NAME="Fioramonti 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-08 15:00:48 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1646; ID: 1072; LR: 20041117; JID: 8710411; 0 (Morpholines); 0 (Parasympatholytics); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-08 15:00:48 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fioramonti J, Frexinos J, Staumont G, Bueno L</AU>
<TI>Inhibition of the colonic motor response to eating by pinaverium bromide in irritable bowel syndrome patients</TI>
<SO>Fundam Clin Pharmacol</SO>
<YR>1988</YR>
<VL>2</VL>
<NO>1</NO>
<PG>19-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Floch-1988" MODIFIED="2010-06-08 15:01:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Floch 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-08 15:01:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Floch MH</AU>
<TI>The irritable bowel syndrome: the possible link between dietary fiber deficiency and disturbed intestinal motility</TI>
<SO>Am J Gastroenterol</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>9</NO>
<PG>963-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-1994" MODIFIED="2010-06-08 15:01:44 -0400" MODIFIED_BY="John K MacDonald" NAME="Francis 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-08 15:01:44 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis CY, Whorwell PJ</AU>
<TI>Bran and irritable bowel syndrome: time for reappraisal</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8914</NO>
<PG>39-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frexinos-1985" MODIFIED="2010-06-08 15:02:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Frexinos 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-08 15:02:05 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1658; ID: 1087; LR: 20041117; JID: 1256165; 0 (Benzoates); 39133-31-8 (Trimebutine); ppublish" NOTES_MODIFIED="2010-06-08 15:02:05 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frexinos J, Fioramonti J, Bueno L</AU>
<TI>Effect of trimebutine on colonic myoelectrical activity in IBS patients</TI>
<SO>Eur J Clin Pharmacol</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>2</NO>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fritz-1967" MODIFIED="2010-06-08 15:02:30 -0400" MODIFIED_BY="John K MacDonald" NAME="Fritz 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-06-08 15:02:30 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1665; ID: 1122; LR: 20041117; JID: 0360137; 0 (Benzoates); ppublish" NOTES_MODIFIED="2010-06-08 15:02:30 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fritz A, Sardet M, Tendil H</AU>
<TI>Contribution to the treatment of colonic diseases. (Apropos of the uses of a new synthetic spasmolytic drug, mebeverine hydrochloride)</TI>
<SO>Rev Corps Sante.Armees Terre Mer Air</SO>
<YR>1967</YR>
<VL>8</VL>
<NO>3</NO>
<PG>349-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galeone-1986a" MODIFIED="2010-06-08 15:03:36 -0400" MODIFIED_BY="John K MacDonald" NAME="Galeone 1986a" YEAR="1986">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 1671; ID: 2451; ID: 1986203491" NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galeone M, Benazzi E, Bossi M</AU>
<TI>Clinical and instrumental evaluation by multiple colonic manometry of tiropramide, trimebutine and octilonium bromide in irritable colon: II. Multiple dose oral administration</TI>
<SO>Pharmatherapeutica</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>8</NO>
<PG>496-509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galeone-1986b" MODIFIED="2010-06-08 15:03:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Galeone 1986b" YEAR="1986">
<REFERENCE MODIFIED="2010-06-08 15:03:27 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1678; ID: 2462; ID: 1987094804" NOTES_MODIFIED="2010-06-08 15:03:27 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galeone M, Stock F, Moise G</AU>
<TI>Pinaverium bromide versus otilonium bromide in patients with irritable bowel syndrome</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1986</YR>
<VL>39</VL>
<NO>4</NO>
<PG>613-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geismar-1971" MODIFIED="2010-06-08 15:06:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Geismar 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-06-08 15:06:53 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geismar P</AU>
<TI>Investigation of the effect of a new spasmolytic preparation (Spasmeks) on spastic colon</TI>
<TO>Undersogelse over virkningen of et nyt spasmolytikum (Spasmeks) pa colon irritabile</TO>
<SO>Ugeskr Laeger</SO>
<YR>1971</YR>
<VL>133</VL>
<NO>33</NO>
<PG>1610-2</PG>
<IDENTIFIERS MODIFIED="2010-06-08 15:06:53 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geoffroy-1977" MODIFIED="2010-06-08 15:07:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Geoffroy 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-06-08 15:07:15 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1686; ID: 2503; ID: 1978053987" NOTES_MODIFIED="2010-06-08 15:07:15 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geoffroy H</AU>
<TI>The treatment of the irritable colon syndrome by a musculotropic antispasmodic: Duspatalin</TI>
<SO>Gaz Med Fr</SO>
<YR>1977</YR>
<VL>84</VL>
<NO>12</NO>
<PG>1331-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giaccari-2001" MODIFIED="2010-06-08 15:08:36 -0400" MODIFIED_BY="John K MacDonald" NAME="Giaccari 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-08 15:08:36 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giaccari S, Grasso G, Tronci S, Allegretta L, Sponziello G, Montefusco A, et al</AU>
<TI>Partially hyrdrolyzed guar gum: A fiber as coadiuvant in irritable bowel syndrome</TI>
<SO>Clinica Terapeutica</SO>
<YR>2001</YR>
<VL>152</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannini-2006" MODIFIED="2009-05-08 08:53:43 -0400" MODIFIED_BY="[Empty name]" NAME="Giannini 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-08 08:53:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannini E G, Mansi C, Dulbecco P, Savarino V</AU>
<TI>Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome</TI>
<SO>Nutrition</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>3</NO>
<PG>334-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibbons-1979" MODIFIED="2010-06-08 15:09:03 -0400" MODIFIED_BY="John K MacDonald" NAME="Gibbons 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 15:09:03 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1692; ID: 1105; LR: 20081120; JID: 0372673; 0 (Scopolamine Derivatives); 149-64-4 (Butylscopolammonium Bromide); OID: NLM: PMC1598819; ppublish" NOTES_MODIFIED="2010-06-08 15:09:03 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibbons D</AU>
<TI>Oral hyoscine butylbromide for irritable bowel syndrome?</TI>
<SO>Br Med J</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>6165</NO>
<PG>752</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilbody-2000" MODIFIED="2010-06-08 15:09:31 -0400" MODIFIED_BY="John K MacDonald" NAME="Gilbody 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-08 15:09:31 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1694; ID: 991; LR: 20070214; JID: 9712381; 0 (Delayed-Action Preparations); 0 (Parasympatholytics); 0 (Phenethylamines); 3625-06-7 (mebeverine); ppublish" NOTES_MODIFIED="2010-06-08 15:09:31 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbody JS, Fletcher CP, Hughes IW, Kidman SP</AU>
<TI>Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome</TI>
<SO>Int J Clin Pract</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>7</NO>
<PG>461-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glende-2002" MODIFIED="2011-05-26 14:50:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Glende 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-05-26 14:50:59 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glende M, Morselli-Labate AM, Battaglia G, Evangelista S</AU>
<TI>Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome</TI>
<SO>Eur J Gastroenterol Hepatol</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>12</NO>
<PG>1331-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gnauck-1977" MODIFIED="2009-05-08 08:53:43 -0400" MODIFIED_BY="[Empty name]" NAME="Gnauck 1977" YEAR="1977">
<REFERENCE MODIFIED="2009-05-08 08:53:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gnauck R</AU>
<TI>Value of high fiber diet in treatment of diverticulosis, constipation and irritable colon</TI>
<SO>Therapiewoche</SO>
<YR>1977</YR>
<VL>27</VL>
<NO>37</NO>
<PG>6411-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golechha-1982" MODIFIED="2010-06-08 15:10:03 -0400" MODIFIED_BY="John K MacDonald" NAME="Golechha 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-06-08 15:10:03 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golechha AC, Chadda VS, Chadda S, Sharma SK, Mishra SN</AU>
<TI>Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study)</TI>
<SO>J Assoc Physicians India</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>6</NO>
<PG>353-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorard-1994" MODIFIED="2010-06-08 15:10:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Gorard 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-08 15:10:39 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorard DA, Libby GW, Farthing MJ</AU>
<TI>Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>2</NO>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorard-1995" MODIFIED="2010-06-08 15:11:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Gorard 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-06-08 15:11:02 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorard DA, Libby GW, Farthing MJ</AU>
<TI>Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome</TI>
<SO>Dig Dis Sci</SO>
<YR>1995</YR>
<VL>40</VL>
<NO>1</NO>
<PG>86-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenbaum-1981" MODIFIED="2010-06-08 15:11:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Greenbaum 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-08 15:11:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenbaum DS, Stein GE</AU>
<TI>Psyllium and the irritable bowel syndrome</TI>
<SO>Ann Intern Med</SO>
<YR>1981</YR>
<VL>95</VL>
<NO>5</NO>
<PG>660</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenbaum-1984" MODIFIED="2010-06-08 15:11:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Greenbaum 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-08 15:11:46 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenbaum DS</AU>
<TI>Preliminary report on antidepressant treatment of irritable bowel syndrome: comments on comparison with anxiolytic therapy</TI>
<SO>Psychopharmacol Bull</SO>
<YR>1984</YR>
<VL>20</VL>
<NO>4</NO>
<PG>622-8</PG>
<IDENTIFIERS MODIFIED="2010-06-08 15:11:46 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenbaum-1987" MODIFIED="2010-06-08 15:12:32 -0400" MODIFIED_BY="John K MacDonald" NAME="Greenbaum 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-08 15:12:32 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, et al</AU>
<TI>Effects of desipramine on irritable bowel syndrome compared with atropine and placebo</TI>
<SO>Dig Dis Sci</SO>
<YR>1987</YR>
<VL>32</VL>
<NO>3</NO>
<PG>257-66</PG>
<IDENTIFIERS MODIFIED="2010-06-08 15:12:32 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grigoleit-2005" MODIFIED="2009-05-14 06:02:45 -0400" MODIFIED_BY="[Empty name]" NAME="Grigoleit 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 1720; ID: 3223; Accession Number: 2009088415. Language: English. Entry Date: 20060127. Publication Type: journal article; review; tables/charts. Journal Subset: Alternative/Complementary Therapies; Peer Reviewed; UK &amp;amp; Ireland. No. of Refs: 27 ref. NLM UID: 9438794." NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grigoleit H, Grigoleit P</AU>
<TI>Peppermint oil in irritable bowel syndrome</TI>
<SO>Phytomedicine</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>8</NO>
<PG>601-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerre-1979" MODIFIED="2010-06-08 15:13:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Guerre 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 15:13:08 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerre J, Neuman M</AU>
<TI>Treatment of chronic colonic diseases with a new topical digestive agent, mucilage (karaya gum) combined with polyvinylpolypyrrolidone (P.V.P.P.)</TI>
<SO>Med Chir Dig</SO>
<YR>1979</YR>
<VL>8</VL>
<NO>7</NO>
<PG>679-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halpert-2005" MODIFIED="2010-03-31 13:47:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Halpert 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-31 13:47:59 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halpert A, Dalton CB, Diamant NE, Toner BB, Hu Y, Morris CB, et al</AU>
<TI>Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage</TI>
<SO>Am J Gastroenterol</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>664-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2009" MODIFIED="2010-06-08 15:13:49 -0400" MODIFIED_BY="John K MacDonald" NAME="Han 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-08 15:13:49 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han C, Masand PS, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al</AU>
<TI>Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release</TI>
<SO>J Clin Pharm Ther</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>1</NO>
<PG>79-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebden-2002" MODIFIED="2010-06-08 15:14:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Hebden 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-08 15:14:08 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebden JM, Blackshaw E, D'Amato M, Perkins AC, Spiller RC</AU>
<TI>Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms</TI>
<SO>Am J Gastroenterol</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>2315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herxheimer-1979" MODIFIED="2010-06-08 15:22:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Herxheimer 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-08 15:22:01 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1741; ID: 1104; LR: 20081120; JID: 0372673; 0 (Scopolamine Derivatives); 149-64-4 (Butylscopolammonium Bromide); OID: NLM: PMC1598812; ppublish" NOTES_MODIFIED="2010-06-08 15:22:01 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herxheimer A, Misiewicz JJ</AU>
<TI>Oral hyoscine butylbromide for irritable bowel syndrome?</TI>
<SO>Br Med J</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>6165</NO>
<PG>752</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hotz-1994" MODIFIED="2010-03-31 13:50:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Hotz 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-03-31 13:50:01 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hotz J, Plein K</AU>
<TI>Effect of psyllium seeds compared to wheat bran on stool frequency and complaints in patients with irritable bowel syndrome and constipation</TI>
<SO>Medizinische Klinik</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>12</NO>
<PG>645-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houghton-1997" MODIFIED="2010-06-08 15:22:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Houghton 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-08 15:22:42 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1752; ID: 1020; LR: 20061115; JID: 8707234; 0 (Dioxoles); 0 (Muscarinic Antagonists); 0 (Piperidines); 127263-13-2 (zamifenacin); ppublish" NOTES_MODIFIED="2010-06-08 15:22:42 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houghton LA, Rogers J, Whorwell PJ, Campbell FC, Williams NS, Goka J</AU>
<TI>Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>3</NO>
<PG>561-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inauen-1994" MODIFIED="2010-06-08 15:23:04 -0400" MODIFIED_BY="John K MacDonald" NAME="Inauen 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-08 15:23:04 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1763; ID: 2398; ID: 1994328677" NOTES_MODIFIED="2010-06-08 15:23:04 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inauen W, Halter F</AU>
<TI>Clinical efficacy, safety and tolerance of mebeverine slow release (200 mg) vs mebeverine tablets in patients with irritable bowel syndrome</TI>
<SO>Drug Invest</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>4</NO>
<PG>234-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwanaga-2002" MODIFIED="2009-05-08 08:53:43 -0400" MODIFIED_BY="[Empty name]" NAME="Iwanaga 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-08 08:53:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwanaga Y</AU>
<TI>Physicochemical and pharmacological characteristic and clinical efficacy of an anti-irritable bowel syndrome agent, polycarbophil calcium (Polyful)</TI>
<SO>Nippon Yakurigaku Zasshi</SO>
<YR>2002</YR>
<VL>119</VL>
<NO>3</NO>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-1998" MODIFIED="2010-06-09 08:17:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Jackson 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 08:17:28 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1768; ID: 2369; ID: 1999400802" NOTES_MODIFIED="2010-06-09 08:17:28 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson II A, Ofman J</AU>
<TI>Peppermint oil for irritable bowel syndrome: Remedy or herbal folklore</TI>
<SO>Integr Med</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>4</NO>
<PG>163-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jafri-2006" MODIFIED="2010-06-09 08:17:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Jafri 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-09 08:17:51 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1769; ID: 905; LR: 20080212; JID: 7501162; 0 (Parasympatholytics); 108-73-6 (Phloroglucinol); ppublish" NOTES_MODIFIED="2010-06-09 08:17:51 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jafri W, Yakoob J, Hussain S, Jafri N, Islam M</AU>
<TI>Phloroglucinol in irritable bowel syndrome</TI>
<SO>J Pak Med Assoc</SO>
<YR>2006</YR>
<VL>56</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jayanthi-1998" MODIFIED="2010-06-09 08:18:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Jayanthi 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 08:18:08 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1774; ID: 982; LR: 20041117; JID: 7505585; 0 (Morpholines); 0 (Parasympatholytics); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-09 08:18:08 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jayanthi V, Malathi S, Ramathilakam B, Dinakaran N, Balasubramanian V, Mathew S</AU>
<TI>Role of pinaverium bromide in south Indian patients with irritable bowel syndrome</TI>
<SO>J Assoc Physicians India</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>4</NO>
<PG>369-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ji-2007" MODIFIED="2010-06-09 08:18:43 -0400" MODIFIED_BY="John K MacDonald" NAME="Ji 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-09 08:18:43 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1775; ID: 2245; ID: 2007292029" NOTES_MODIFIED="2010-06-09 08:18:43 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ji HZ, Wu XW, Xu XB, Sun Q, Liu Y, Zhang L, et al</AU>
<TI>Evaluating the clinical effect and quality of life in the elderly with functional bowel disorder after treatment with pinaverium bromide</TI>
<SO>J Clin Rehab Tissue Eng Res</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>12</NO>
<PG>2275-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jing-2004" MODIFIED="2010-06-09 08:19:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Jing 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-09 08:19:52 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jing D, Xu M, Chen Z, Zhang J, Wang P, Jiang H, et al</AU>
<TI>Emotional disorders and treatment in patients with refractory irritable bowel syndrome</TI>
<SO>Chin J Gastroenterol</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>2</NO>
<PG>90-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaushik-2002" MODIFIED="2010-06-09 08:23:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Kaushik 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-09 08:23:52 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaushik A, Pursnani ML, Kar P</AU>
<TI>Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome</TI>
<SO>Indian Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirsch-2000" MODIFIED="2010-06-09 08:22:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Kirsch 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 08:22:02 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirsch MA, Louie AK</AU>
<TI>Paroxetine and irritable bowel syndrome</TI>
<SO>Am J Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>9</NO>
<PG>1523-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koch-1998" MODIFIED="2010-06-09 08:22:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Koch 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 08:22:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch TR</AU>
<TI>Peppermint oil and irritable bowel syndrome</TI>
<SO>Am J Gastroenterol</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>11</NO>
<PG>2304-5</PG>
<IDENTIFIERS MODIFIED="2010-06-09 08:22:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koruda-1993" MODIFIED="2010-06-09 08:22:45 -0400" MODIFIED_BY="John K MacDonald" NAME="Koruda 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-06-09 08:22:45 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koruda M J</AU>
<TI>Dietary fiber and gastrointestinal disease</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1993</YR>
<VL>177</VL>
<NO>2</NO>
<PG>209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kountouras-2002" MODIFIED="2010-03-31 13:52:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Kountouras 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-31 13:52:26 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A</AU>
<TI>Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2002</YR>
<VL>49</VL>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-1987" MODIFIED="2010-06-09 08:24:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Kumar 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 08:24:24 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Kumar N, Vij JC, Sarin SK, Anand BS</AU>
<TI>Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight</TI>
<SO>Gut</SO>
<YR>1987</YR>
<VL>28</VL>
<NO>2</NO>
<PG>150-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kunze-1990" MODIFIED="2010-06-09 08:24:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Kunze 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-09 08:24:59 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1822; ID: 1059; LR: 20061115; JID: 21730470R; 58-74-2 (Papaverine); ppublish" NOTES_MODIFIED="2010-06-09 08:24:59 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kunze M, Seidel HJ, Stube G</AU>
<TI>Comparative studies of the effectiveness of brief psychotherapy, acupuncture and papaverin therapy in patients with irritable bowel syndrome</TI>
<SO>Z Gesamte Inn Med</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>20</NO>
<PG>625-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lafon-1982" MODIFIED="2011-06-06 12:05:40 -0400" MODIFIED_BY="John K MacDonald" NAME="Lafon 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-06-06 12:05:40 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lafon J, Cougard A, Pin G, Julien D</AU>
<TI>Is the combination of kaolin, sterculia gum and magnesium superior to sound in the treatment of irritable colon? Controlled clinical trial</TI>
<TO>L'association kaolin, gomme sterculia,magnesium est-elle suerieure au son dans le traitement symptomatique du colon irritable? Etude clinique controlee</TO>
<SO>Rev Proct</SO>
<YR>1982</YR>
<VL>1</VL>
<PG>67-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1989" MODIFIED="2010-06-09 08:27:35 -0400" MODIFIED_BY="John K MacDonald" NAME="Lambert 1989" YEAR="">
<REFERENCE MODIFIED="2010-06-09 08:27:35 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert JP, Dickerson JW</AU>
<TI>A survey of high-fibre diet-sheets used in the treatment of irritable bowel syndrome in Great Britain</TI>
<SO>J Hum Nutr Diet</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>6</NO>
<PG>429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1991a" MODIFIED="2010-06-09 08:29:16 -0400" MODIFIED_BY="John K MacDonald" NAME="Lambert 1991a" YEAR="1991">
<REFERENCE MODIFIED="2010-06-09 08:28:50 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert JP, Brunt PW, Mowat NA, Khin CC, Lai CK, Morrison V, et al</AU>
<TI>The value of prescribed 'high-fibre' diets for the treatment of the irritable bowel syndrome</TI>
<SO>Eur J Clin Nutr</SO>
<YR>1991</YR>
<VL>45</VL>
<NO>12</NO>
<PG>601-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1991b" MODIFIED="2010-06-09 08:29:54 -0400" MODIFIED_BY="John K MacDonald" NAME="Lambert 1991b" YEAR="1991">
<REFERENCE MODIFIED="2010-06-09 08:29:54 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert JP, Morrison V, Brunt PW, Mowat NA, Eastwood MA, Dickerson JW</AU>
<TI>Dietary fibre intake of irritable bowel patients prescribed a high fibre diet</TI>
<SO>J Hum Nutr Diet</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>3</NO>
<PG>155-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawson-1988" MODIFIED="2010-06-09 08:30:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Lawson 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-09 08:30:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawson MJ, Knight RE, Tran K, Walker G, Roberts-Thomson IC</AU>
<TI>Failure of enteric-coated peppermint oil in the irritable bowel syndrome: A randomized, double-blind crossover study</TI>
<SO>J Gastroenterol Hepatol</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>3</NO>
<PG>235-8</PG>
<IDENTIFIERS MODIFIED="2010-06-09 08:30:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levitan-1981" MODIFIED="2010-06-09 08:32:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Levitan 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-09 08:32:08 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levitan MK, Dubinin AV, Beiul EA, Iurkov M, Shechovskaia AK</AU>
<TI>Treatment of colonic diverticulosis and irritable colon with wheat bran</TI>
<SO>Sov Med</SO>
<YR>1981</YR>
<VL>8</VL>
<NO>8</NO>
<PG>109-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2003" MODIFIED="2010-06-09 08:32:38 -0400" MODIFIED_BY="John K MacDonald" NAME="Lin 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-09 08:32:38 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1850; ID: 2317; ID: 2004009916" NOTES_MODIFIED="2010-06-09 08:32:38 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin JK, Hu PJ, Wang WA, Chen Q, Chen MH</AU>
<TI>Effects of otilonium bromide on anorectal visceral sensorimotor functions of patients with diarrhea-predominant irritable bowel syndrome</TI>
<SO>World Chin J Dig</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1926-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2010-06-09 08:34:16 -0400" MODIFIED_BY="John K MacDonald" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-09 08:34:16 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu DL, Huo JR, Wu XP</AU>
<TI>Effect of subclincal dosage of antidepressants on refractory irritable bowel syndrome</TI>
<SO>Chinese Journal of Clinical Psychology</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>4</NO>
<PG>424-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locke-2004" MODIFIED="2010-06-09 08:38:54 -0400" MODIFIED_BY="John K MacDonald" NAME="Locke 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-09 08:38:54 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locke GR III</AU>
<TI>Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome</TI>
<SO>Evid Based Med</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>6</NO>
<PG>172</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2000" MODIFIED="2010-06-09 08:39:30 -0400" MODIFIED_BY="John K MacDonald" NAME="Lu 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 08:39:30 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1869; ID: 992; LR: 20061115; JID: 8607909; 0 (Calcium Channel Blockers); 0 (Morpholines); 0 (Neuropeptide Y); 0 (Parasympatholytics); 0 (Phenethylamines); 33507-63-0 (Substance P); 3625-06-7 (mebeverine); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-09 08:39:30 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, et al</AU>
<TI>Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome</TI>
<SO>J Gastroenterol Hepatol</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>8</NO>
<PG>925-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luttecke-1978" MODIFIED="2010-06-09 08:39:43 -0400" MODIFIED_BY="John K MacDonald" NAME="Luttecke 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-06-09 08:39:43 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luttecke K</AU>
<TI>A trial of trimebutine in spastic colon</TI>
<SO>J Int Med Res</SO>
<YR>1978</YR>
<VL>6</VL>
<NO>2</NO>
<PG>86-8</PG>
<IDENTIFIERS MODIFIED="2010-06-09 08:39:43 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luttecke-1980" MODIFIED="2010-06-09 08:40:00 -0400" MODIFIED_BY="John K MacDonald" NAME="Luttecke 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-06-09 08:40:00 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luttecke K</AU>
<TI>A three-part controlled study of trimebutine in the treatment of irritable colon syndrome</TI>
<SO>Curr Med Res Opin</SO>
<YR>1980</YR>
<VL>6</VL>
<NO>6</NO>
<PG>437-43</PG>
<IDENTIFIERS MODIFIED="2010-06-09 08:40:00 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lydiard-2007" MODIFIED="2010-06-09 08:40:21 -0400" MODIFIED_BY="John K MacDonald" NAME="Lydiard 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-09 08:40:21 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lydiard RB</AU>
<TI>Psychopharmacology in the treatment of irritable bowel syndrome</TI>
<SO>Prim Psychiatry</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>4</NO>
<PG>40-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacRae-1979" MODIFIED="2010-06-09 08:40:44 -0400" MODIFIED_BY="John K MacDonald" NAME="MacRae 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-09 08:40:44 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1879; ID: 1103; LR: 20081120; JID: 0372673; 0 (Scopolamine Derivatives); 149-64-4 (Butylscopolammonium Bromide); OID: NLM: PMC1598859; ppublish" NOTES_MODIFIED="2010-06-09 08:40:44 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacRae KD</AU>
<TI>Oral hyoscine butylbromide for irritable bowel syndrome?</TI>
<SO>Br Med J</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>6165</NO>
<PG>752</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manning-1976" MODIFIED="2010-06-09 08:40:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Manning 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-06-09 08:40:59 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manning AP, Heaton KW, Harvey RF, Uglow P</AU>
<TI>Cereal fibre and the irritable bowel: a controlled trial</TI>
<SO>Gut</SO>
<YR>1976</YR>
<VL>17</VL>
<NO>10</NO>
<PG>822-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manning-1977" MODIFIED="2010-06-09 08:41:25 -0400" MODIFIED_BY="John K MacDonald" NAME="Manning 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-06-09 08:41:25 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manning AP, Heaton KW, Harvey RF</AU>
<TI>Wheat fibre and irritable bowel syndrome. A controlled trial</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<NO>8035</NO>
<PG>417-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marks-2008" MODIFIED="2010-06-09 08:46:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Marks 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-09 08:46:39 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marks DM, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, et al</AU>
<TI>History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study</TI>
<SO>Prim Care Companion J Clin Psychiatry</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>5</NO>
<PG>368-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masamune-1998" MODIFIED="2010-06-09 09:27:33 -0400" MODIFIED_BY="John K MacDonald" NAME="Masamune 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 09:27:33 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1886; ID: 2380; ID: 1998408430" NOTES_MODIFIED="2010-06-09 09:27:33 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masamune O, Miwa T, Fukutomi H, Matsuo Y, Sasaki D, Chiba M, et al</AU>
<TI>Clinical phase III comparative study of calcium polycarbophil tablet on irritable bowel syndrome - A double-blind study in comparison with torimebutine maleate</TI>
<SO>Jpn Pharmacol Ther</SO>
<YR>1998</YR>
<VL>26</VL>
<PG>63-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masand-2002" MODIFIED="2010-06-09 09:28:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Masand 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-09 09:28:56 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masand PS, Gupta S, Schwartz TL, Virk S, Lockwood K, Hameed A, et al</AU>
<TI>Paroxetine in patients with irritable bowel syndrome: A pilot open-label study</TI>
<SO>Prim Care Companion J Clin Psychiatry</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>1</NO>
<PG>12-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masand-2005" MODIFIED="2010-06-09 09:29:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Masand 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-09 09:29:39 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masand PS, Gupta S, Schwartz TL, Virk S, Hameed A, Kaplan DS</AU>
<TI>Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study</TI>
<SO>Prim Care Companion J Clin Psychiatry</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>4</NO>
<PG>162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matts-1967" MODIFIED="2010-06-09 09:30:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Matts 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-06-09 09:30:01 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matts SG</AU>
<TI>An assessment of dicyclomine hydrochloride ('Merbentyl') in the irritable colon syndrome</TI>
<SO>Br J Clin Pract</SO>
<YR>1967</YR>
<VL>21</VL>
<NO>11</NO>
<PG>549-51</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:30:01 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier-1996" MODIFIED="2010-06-09 09:31:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Meier 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-09 09:31:05 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meier R, Beglinger Ch, Brignoli R, the IBS-CIS study group</AU>
<TI>Symptoms and colonic transit time in the irritable bowel syndrome treated with psyllium and cisapride or placebo (abstract)</TI>
<SO>Gut</SO>
<YR>1996</YR>
<VL>39 Suppl 3</VL>
<PG>A33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2006" MODIFIED="2010-06-09 09:31:35 -0400" MODIFIED_BY="John K MacDonald" NAME="Miller 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-09 09:31:35 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller V, Lea R, Agrawal A, Whorwell PJ</AU>
<TI>Bran and irritable bowel syndrome: the primary-care perspective</TI>
<SO>Dig Liver Dis</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>10</NO>
<PG>737-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Misra-1989" MODIFIED="2010-06-09 09:31:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Misra 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-09 09:31:53 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Misra SP, Thorat VK, Sachdev GK, Anand BS</AU>
<TI>Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial</TI>
<SO>Q J Med</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>270</NO>
<PG>931-9</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:31:53 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modena-1993" MODIFIED="2010-06-09 09:32:06 -0400" MODIFIED_BY="John K MacDonald" NAME="Modena 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-06-09 09:32:06 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1915; ID: 2403; ID: 1993194858" NOTES_MODIFIED="2010-06-09 09:32:06 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modena L</AU>
<TI>Single drug treatment for irritable colon syndrome: Rociverine 20 mg t.i.d</TI>
<SO>Minerva Med</SO>
<YR>1993</YR>
<VL>84</VL>
<NO>5</NO>
<PG>263-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mollica-1992" MODIFIED="2010-06-09 09:32:25 -0400" MODIFIED_BY="John K MacDonald" NAME="Mollica 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-09 09:32:25 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1918; ID: 1043; LR: 20061115; JID: 0372604; 0 (Parasympatholytics); 0 (Quaternary Ammonium Compounds); 26095-59-0 (octylonium); 439-14-5 (Diazepam); ppublish" NOTES_MODIFIED="2010-06-09 09:32:25 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mollica G, Manno G</AU>
<TI>Otilonium bromide-diazepam in the treatment of the irritable colon. A controlled study versus otilonium bromide</TI>
<SO>Clin Ter</SO>
<YR>1992</YR>
<VL>141</VL>
<NO>8</NO>
<PG>129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-2005" MODIFIED="2009-05-08 05:15:10 -0400" MODIFIED_BY="[Empty name]" NAME="Morgan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-08 05:15:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan V, Pickens D, Gautam S, Kessler R, Mertz H</AU>
<TI>Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>5</NO>
<PG>601-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrison-1987" MODIFIED="2010-06-09 09:34:47 -0400" MODIFIED_BY="John K MacDonald" NAME="Morrison 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 09:34:47 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrison V, Lai C KW, Khin CC</AU>
<TI>High fibre diets and irritable bowel syndrome - The role of the dietitian</TI>
<SO>Scott Med J</SO>
<YR>1987</YR>
<VL>32</VL>
<NO>4</NO>
<PG>124</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortensen-1987" MODIFIED="2010-06-09 09:33:33 -0400" MODIFIED_BY="John K MacDonald" NAME="Mortensen 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 09:33:33 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mortensen PB, Andersen JR, Arffmann S, Krag E</AU>
<TI>Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran</TI>
<SO>Scand J Gastroenterol</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>2</NO>
<PG>185-92</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:33:33 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nash-1986" MODIFIED="2010-06-09 09:35:30 -0400" MODIFIED_BY="John K MacDonald" NAME="Nash 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-09 09:35:30 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nash P, Gould SR, Bernardo DE</AU>
<TI>Peppermint oil does not relieve the pain of irritable bowel syndrome</TI>
<SO>Br J Clin Pract</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>7</NO>
<PG>292-3</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:35:30 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nedogoda-2000" MODIFIED="2010-06-09 09:39:40 -0400" MODIFIED_BY="John K MacDonald" NAME="Nedogoda 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 09:39:40 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1944; ID: 984; LR: 20061115; JID: 2985204R; 0 (Gastrointestinal Agents); 0 (Morpholines); 0 (Parasympatholytics); 0 (Quaternary Ammonium Compounds); 26095-59-0 (octylonium); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-09 09:39:40 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nedogoda SV, Parshev VV</AU>
<TI>Treatment of irritable bowel syndrome with dicetelium and spasmomen</TI>
<SO>Klin Med</SO>
<YR>2000</YR>
<VL>78</VL>
<NO>10</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noel-1989" MODIFIED="2010-06-09 09:40:04 -0400" MODIFIED_BY="John K MacDonald" NAME="Noel 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-09 09:40:04 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noel B</AU>
<TI>A multicentric study of pinaverium bromide on irritable bowel syndrome, performed in Mexico</TI>
<SO>Investigacion Medica Internacional</SO>
<YR>1989</YR>
<VL>15</VL>
<NO>4</NO>
<PG>190-6</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:40:04 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olden-2005" MODIFIED="2010-06-09 09:51:36 -0400" MODIFIED_BY="John K MacDonald" NAME="Olden 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-09 09:51:36 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olden KW</AU>
<TI>The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs</TI>
<SO>CNS Spectr</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>11</NO>
<PG>891-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardell-1982" MODIFIED="2010-06-09 09:52:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Pardell 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-06-09 09:52:05 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1959; ID: 2482; ID: 1982210818" NOTES_MODIFIED="2010-06-09 09:52:05 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardell H, Marcillas J, Celdran E</AU>
<TI>Double-blind parallel study of clebopride and hyoscine N-butylbromide in patients with irritable colon syndrome</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1982</YR>
<VL>31</VL>
<NO>1</NO>
<PG>S74-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parisi-2002" MODIFIED="2010-06-09 09:52:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Parisi 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-09 09:52:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, et al</AU>
<TI>High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG)</TI>
<SO>Dig Dis Sci</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>8</NO>
<PG>1697-1704</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parisi-2005" MODIFIED="2010-06-09 09:52:50 -0400" MODIFIED_BY="John K MacDonald" NAME="Parisi 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-09 09:52:50 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, et al</AU>
<TI>Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial</TI>
<SO>Dig Dis Sci</SO>
<YR>2005</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1107-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passaretti-1985" MODIFIED="2010-06-09 09:53:04 -0400" MODIFIED_BY="John K MacDonald" NAME="Passaretti 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-09 09:53:04 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1961; ID: 2465; ID: 1985172602" NOTES_MODIFIED="2010-06-09 09:53:04 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passaretti S, Fesce E, Fanti L</AU>
<TI>Effect of tiropramide hydrochloride on the intestinal transit time in patients with irritable bowel syndrome</TI>
<SO>Minerva Med</SO>
<YR>1985</YR>
<VL>76</VL>
<NO>19-20</NO>
<PG>923-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passaretti-1989b" MODIFIED="2010-06-09 09:54:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Passaretti 1989b" YEAR="1989">
<REFERENCE MODIFIED="2010-06-09 09:54:05 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1968; ID: 1066; LR: 20041117; JID: 8003415; 0 (Morpholines); 0 (Parasympatholytics); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-09 09:54:05 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passaretti S, Sorghi M, Colombo E, Mazzotti G, Tittobello A, Guslandi M</AU>
<TI>Motor effects of locally administered pinaverium bromide in the sigmoid tract of patients with irritable bowel syndrome</TI>
<SO>Int J Clin Pharmacol Ther Toxicol</SO>
<YR>1989</YR>
<VL>27</VL>
<NO>1</NO>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearson-2000" MODIFIED="2010-06-09 09:55:13 -0400" MODIFIED_BY="John K MacDonald" NAME="Pearson 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 09:55:13 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearson RL</AU>
<TI>How effective are antidepressant medications in the treatment of irritable bowel syndrome and nonulcer dyspepsia?</TI>
<SO>J Fam Pract</SO>
<YR>2000</YR>
<VL>49</VL>
<NO>5</NO>
<PG>396</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piai-1987a" MODIFIED="2010-06-09 09:55:44 -0400" MODIFIED_BY="John K MacDonald" NAME="Piai 1987a" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 09:55:44 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piai G, Visconti M, d'Angelo V, Sauro A, Sparano R, Mazzacca G</AU>
<TI>Glucomannan in treatment of irritable colon. Results of a controlled clinical trial</TI>
<TO>Il glucomannano nel trattamento del colon irritabile; risultati di uno studio clinico controllato</TO>
<SO>Quaderni di Medicina e Chirurgia</SO>
<YR>1987</YR>
<VL>3</VL>
<NO>1</NO>
<PG>83-6</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:55:44 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piai-1987b" MODIFIED="2010-06-09 09:56:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Piai 1987b" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 09:56:05 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piai G, Visconti M, Imbimbo BP, Minieri M, Sollazzo R, Mazzacca G</AU>
<TI>Long-term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>6</NO>
<PG>967-77</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:56:05 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pittler-1998" MODIFIED="2010-06-09 09:56:17 -0400" MODIFIED_BY="John K MacDonald" NAME="Pittler 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 09:56:17 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pittler MH, Ernst E</AU>
<TI>Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis</TI>
<SO>Am J Gastroenterol</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>7</NO>
<PG>1131-5</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:56:17 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prior-1986a" MODIFIED="2010-06-09 09:56:49 -0400" MODIFIED_BY="John K MacDonald" NAME="Prior 1986a" YEAR="1986">
<REFERENCE MODIFIED="2010-06-09 09:56:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prior A, Whorwell PJ</AU>
<TI>Management of irritable bowel syndrome</TI>
<SO>Biomed Pharmacother</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>1</NO>
<PG>4-5</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:56:27 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prior-1986b" MODIFIED="2010-06-09 09:57:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Prior 1986b" YEAR="1986">
<REFERENCE MODIFIED="2010-06-09 09:57:15 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prior A, Akbar FA, Shroff NE, Whorwell PJ</AU>
<TI>A double blind study of ispaghula in irritable bowel syndrome (abstract)</TI>
<SO>Gut</SO>
<YR>1986</YR>
<VL>27</VL>
<NO>Suppl 5</NO>
<PG>A625</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prout-1983" MODIFIED="2009-05-14 06:02:45 -0400" MODIFIED_BY="[Empty name]" NAME="Prout 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 1998; ID: 1095; LR: 20071115; JID: 0404245; 0 (Parasympatholytics); 0 (Phenethylamines); 3625-06-7 (mebeverine); ppublish" NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prout B J</AU>
<TI>The treatment of irritable bowel syndrome. Two doses of mebeverine compared</TI>
<SO>Practitioner</SO>
<YR>1983</YR>
<VL>227</VL>
<NO>1384</NO>
<PG>1607-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quilici-1998" MODIFIED="2010-06-09 09:58:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Quilici 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 09:58:07 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2006; ID: 2372; ID: 1998264048" NOTES_MODIFIED="2010-06-09 09:58:07 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quilici FA, Dos Reis Neto, Cordeiro F, Ciquini S, Dos Reis J</AU>
<TI>Treatment of irritable bowel syndrome with pinaverium bromide</TI>
<SO>GED Gastrentologia Endosc Dig</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3</NO>
<PG>79-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quilici-2003" MODIFIED="2010-06-09 09:58:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Quilici 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-09 09:58:41 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2005; ID: 2315; ID: 2004185543" NOTES_MODIFIED="2010-06-09 09:58:41 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quilici FA, Cordeiro F, Ciquini SA, Cunha HA, Bertocello LC, Sugahara R, et al</AU>
<TI>Treatment of irritable bowel syndrome: Single drug therapy with mebeverine</TI>
<SO>GED Gastrentologia Endosc Dig</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>6</NO>
<PG>219-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1982" MODIFIED="2010-06-09 09:59:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Rasmussen 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-06-09 09:59:01 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen SN, Bondesen S, Edmund C, Frandsen I, Andersen I, Kempel K, et al</AU>
<TI>Treatment of irritable bowel with dietary fiber. A controlled clinical study</TI>
<TO>Behandling af colon irritabile med kostfiberrig diaet. En kontrolleret klinisk undersogelse</TO>
<SO>Ugeskr Laeger</SO>
<YR>1982</YR>
<VL>144</VL>
<NO>33</NO>
<PG>2415-7</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:59:01 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1979" MODIFIED="2010-06-09 09:59:16 -0400" MODIFIED_BY="John K MacDonald" NAME="Rees 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-09 09:59:16 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees WD, Evans BK, Rhodes J</AU>
<TI>Treating irritable bowel syndrome with peppermint oil</TI>
<SO>Br Med J</SO>
<YR>1979</YR>
<VL>2</VL>
<NO>6194</NO>
<PG>835-6</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:59:16 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rhodes-1978" MODIFIED="2010-06-09 09:59:45 -0400" MODIFIED_BY="John K MacDonald" NAME="Rhodes 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-06-09 09:59:45 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rhodes JB, Abrams JH, Manning RT</AU>
<TI>Controlled clinical trial of sedative-anticholinergic drugs in patients with the irritable bowel syndrome</TI>
<SO>J Clin Pharmacol</SO>
<YR>1978</YR>
<VL>18</VL>
<NO>7</NO>
<PG>340-5</PG>
<IDENTIFIERS MODIFIED="2010-06-09 09:59:45 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rhodes-1980" MODIFIED="2010-06-09 10:00:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Rhodes 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-06-09 10:00:42 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2012; ID: 3047; XR: EMBASE 1981008783; DE: CCT" NOTES_MODIFIED="2010-06-09 10:00:42 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rhodes J, Evans BK, Rees WD</AU>
<TI>Peppermint oil in enteric coated capsules for the treatment of irritable bowel syndrome: A double blind controlled trial</TI>
<SO>Hepatogastroenterology</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>Suppl</NO>
<PG>E31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-1980" MODIFIED="2010-06-09 10:01:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Ritchie 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-06-09 10:01:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie JA, Truelove SC</AU>
<TI>Comparison of various treatments for irritable bowel syndrome</TI>
<SO>Br Med J</SO>
<YR>1980</YR>
<VL>281</VL>
<NO>6251</NO>
<PG>1317-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sagduyu-2002" MODIFIED="2009-05-14 06:02:45 -0400" MODIFIED_BY="[Empty name]" NAME="Sagduyu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 2034; ID: 954; LR: 20041117; JID: 0376506; 0 (Plant Oils); 8006-90-4 (peppermint oil); ppublish" NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sagduyu K</AU>
<TI>Peppermint oil for irritable bowel syndrome</TI>
<SO>Psychosomatics</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>6</NO>
<PG>508-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2006" MODIFIED="2009-05-08 05:15:10 -0400" MODIFIED_BY="[Empty name]" NAME="Sato 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-08 05:15:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato M, Murakami M</AU>
<TI>Treatment for irritable bowel syndrome--psychotropic drugs, antidepressants and so on</TI>
<SO>Nippon Rinsho</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>8</NO>
<PG>1495-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaffstein-1990" MODIFIED="2010-06-09 10:01:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Schaffstein 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-09 10:01:56 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2050; ID: 2429; ID: 1990032214" NOTES_MODIFIED="2010-06-09 10:01:56 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaffstein W, Panijel M, Luttecke K</AU>
<TI>Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>1</NO>
<PG>136-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schutz-1992" MODIFIED="2010-06-09 10:02:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Schutz 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-09 10:02:52 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2057; ID: 2406; ID: 1992335394" NOTES_MODIFIED="2010-06-09 10:02:52 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schutz E, Peters-Hartel W, Mauersberger H, Munster U</AU>
<TI>The treatment of irritable colon with mebeverine. Pain relief most important</TI>
<SO>Therapiewoche Schweiz</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>10</NO>
<PG>759-760, 762</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Secco-1983" MODIFIED="2009-05-14 06:02:45 -0400" MODIFIED_BY="[Empty name]" NAME="Secco 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 2060; ID: 1096; LR: 20071115; JID: 0400732; 0 (Parasympatholytics); 0 (Phenethylamines); 3625-06-7 (mebeverine); ppublish" NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Secco G B, Di Somma C, Arnulfo G, Ricci C</AU>
<TI>Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon</TI>
<SO>Minerva Med.</SO>
<YR>1983</YR>
<VL>74</VL>
<NO>13</NO>
<PG>699-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1987" MODIFIED="2010-06-09 10:15:54 -0400" MODIFIED_BY="John K MacDonald" NAME="Sharma 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 10:15:54 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma S, Saini RK, Goswami SK, Sharma A, Singh S</AU>
<TI>Role of dietary fibre in irritable bowel syndrome: a clinical study</TI>
<SO>Indian J Med Sci</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>2</NO>
<PG>29-33</PG>
<IDENTIFIERS MODIFIED="2010-06-09 10:15:54 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaughnessy-2000" MODIFIED="2010-06-09 10:16:32 -0400" MODIFIED_BY="John K MacDonald" NAME="Shaughnessy 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 10:16:32 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaughnessy A</AU>
<TI>Are antidepressants effective in the treatment of the functional gastrointestinal (GI) disorders of irritable bowel syndrome and nonulcer dyspepsia?</TI>
<SO>Evid Based Pract</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>5</NO>
<PG>4, insert 2p</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shrivastava-1984" MODIFIED="2010-06-09 10:17:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Shrivastava 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-09 10:17:23 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2769; ID: 3112; PM: PUBMED 6149597; CC: SR-IBD; SR-UPPERGI" NOTES_MODIFIED="2010-06-09 10:17:23 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shrivastava R K, Siegel H</AU>
<TI>The role of tricyclics and benzodiazepine compounds in the treatment of irritable gut syndrome and peptic ulcer disease</TI>
<SO>Psychopharmacol Bull</SO>
<YR>1984</YR>
<VL>20</VL>
<NO>4</NO>
<PG>616-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2007" MODIFIED="2010-06-09 11:26:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Singh 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-09 11:26:24 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh B</AU>
<TI>Psyllium as therapeutic and drug delivery agent</TI>
<SO>Int J Pharm</SO>
<YR>2007</YR>
<VL>334</VL>
<NO>1-2</NO>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slawson-2002" MODIFIED="2010-06-09 11:27:12 -0400" MODIFIED_BY="John K MacDonald" NAME="Slawson 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-09 11:27:12 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slawson D</AU>
<TI>How do high-fiber supplements compare with guar gum for irritable bowel syndrome?</TI>
<SO>Evid Based Pract</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>11</NO>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snook-1994" MODIFIED="2010-06-09 11:27:29 -0400" MODIFIED_BY="John K MacDonald" NAME="Snook 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-09 11:27:29 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snook J, Shepherd HA</AU>
<TI>Bran supplementation in the treatment of irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>5</NO>
<PG>511-4</PG>
<IDENTIFIERS MODIFIED="2010-06-09 11:27:29 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soifer-1987" MODIFIED="2010-06-09 11:28:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Soifer 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 11:28:02 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soifer LO, De Paula JA, Caruso P</AU>
<TI>Effects of medicinal fiber on colonic transit in patients with irritable colon syndrome</TI>
<SO>Acta Gastroenterol Latinoam</SO>
<YR>1987</YR>
<VL>17</VL>
<NO>4</NO>
<PG>317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soifer-1992" MODIFIED="2010-06-09 11:28:22 -0400" MODIFIED_BY="John K MacDonald" NAME="Soifer 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-09 11:28:22 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soifer L, Varela E, Olmos J</AU>
<TI>Manometric effects of pinaverium bromide in irritable bowel syndrome</TI>
<TO>Efectos manometricos del bromuro de pinaverio en el sindrome de intestino irritable</TO>
<SO>Acta Gastroenterol Latinoam</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS MODIFIED="2010-06-09 11:28:22 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soriano-1992" MODIFIED="2010-06-09 11:28:40 -0400" MODIFIED_BY="John K MacDonald" NAME="Soriano 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-09 11:28:40 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2082; ID: 1045; LR: 20041117; JID: 9108294; 0 (Calcium Channel Blockers); 0 (Morpholines); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-09 11:28:40 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soriano C, Espejo H, Garcia L</AU>
<TI>Treatment of irritable bowel syndrome with a calcium antagonist (pinaverium bromide): experience with 40 cases</TI>
<SO>Rev Gastroenterol Peru</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1</NO>
<PG>36-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiefelhagen-2008" MODIFIED="2010-06-09 11:29:04 -0400" MODIFIED_BY="John K MacDonald" NAME="Stiefelhagen 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-09 11:29:04 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2091; ID: 2223; ID: 2008574997" NOTES_MODIFIED="2010-06-09 11:29:04 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiefelhagen P</AU>
<TI>Peppermint oil is helpful in irritable bowel syndrome</TI>
<SO>MMW-Fortschr Med</SO>
<YR>2008</YR>
<VL>150</VL>
<NO>47</NO>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swiatczak-1998" MODIFIED="2010-06-09 11:29:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Swiatczak 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-09 11:29:56 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swiatczak C, Jawien A, Swiatkowski M, Slominski JM, Kowianski Z, Zasieczny W</AU>
<TI>Duodenogastric reflux in patients with irritable bowel syndrome treated with wheat bran</TI>
<SO>Pol Merkuriusz Lek</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>22</NO>
<PG>196-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talley-2003" MODIFIED="2010-06-09 11:31:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Talley 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-09 11:31:01 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ</AU>
<TI>SSRIs in IBS: sensing a dash of disappointment</TI>
<SO>Clin Gastroenterol Hepatol</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>3</NO>
<PG>155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talley-2004" MODIFIED="2010-06-09 11:31:20 -0400" MODIFIED_BY="John K MacDonald" NAME="Talley 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-09 11:31:20 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ</AU>
<TI>Antidepressants in IBS: are we deluding ourselves?</TI>
<SO>Am J Gastroenterol</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>5</NO>
<PG>921-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talley-2008b" MODIFIED="2010-06-09 11:33:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Talley 2008b" YEAR="2008">
<REFERENCE MODIFIED="2010-06-09 11:33:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ</AU>
<TI>Newer antidepressants in irritable bowel syndrome: What is the evidence?</TI>
<SO>Arch Med Sci</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>1</NO>
<PG>77-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2007" MODIFIED="2010-06-09 11:33:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Tan 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-09 11:33:51 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan KY, Seow-Choen F</AU>
<TI>Fiber and colorectal diseases: Separating fact from fiction</TI>
<SO>World J Gastroenterol</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>31</NO>
<PG>4161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanum-1996" MODIFIED="2010-06-09 11:34:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Tanum 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-09 11:34:23 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanum L, Malt UF</AU>
<TI>A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin</TI>
<SO>Scand J Gastroenterol</SO>
<YR>1996</YR>
<VL>31</VL>
<NO>4</NO>
<PG>318-25</PG>
<IDENTIFIERS MODIFIED="2010-06-09 11:34:23 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanum-2000" MODIFIED="2010-06-09 11:34:38 -0400" MODIFIED_BY="John K MacDonald" NAME="Tanum 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 11:34:38 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanum L, Malt UF</AU>
<TI>Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder</TI>
<SO>Scand J Gastroenterol</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>9</NO>
<PG>935-41</PG>
<IDENTIFIERS MODIFIED="2010-06-09 11:34:38 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarpila-2004" MODIFIED="2010-06-09 11:36:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Tarpila 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-09 11:36:52 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarpila S, Tarpila A, Grohn P, Silvennoinen T, Lindberg L</AU>
<TI>Efficacy of ground flaxseed on constipation in patients with irritable bowel syndrome</TI>
<SO>Current Topics in Nutraceuticals Research</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>2</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarquini-1984" MODIFIED="2009-05-14 06:02:45 -0400" MODIFIED_BY="[Empty name]" NAME="Tarquini 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 2110; ID: 3027; XR: EMBASE 1985056591; DE: CCT" NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarquini M, Sannino L, Bazuro G</AU>
<TI>The irritable bowel syndrome: therapeutic effect of octilonium bromide alone and combined with a benzodiazepine. A double-blind study</TI>
<SO>Clinica Terapeutica</SO>
<YR>1984</YR>
<VL>109</VL>
<NO>6</NO>
<PG>525-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tasman_x002d_Jones-1973" MODIFIED="2010-06-09 11:37:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Tasman-Jones 1973" YEAR="1973">
<REFERENCE MODIFIED="2010-06-09 11:37:28 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasman-Jones C</AU>
<TI>Mebeverine in patients with the irritable colon syndrome: double blind study</TI>
<SO>N Z Med J</SO>
<YR>1973</YR>
<VL>77</VL>
<NO>491</NO>
<PG>232-5</PG>
<IDENTIFIERS MODIFIED="2010-06-09 11:37:28 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tinozzi-1984" MODIFIED="2010-06-09 11:37:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Tinozzi 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-09 11:37:46 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2127; ID: 2473; ID: 1984052506" NOTES_MODIFIED="2010-06-09 11:37:46 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tinozzi S, Valesi MG</AU>
<TI>Controlled clinical trial of the effectiveness of tiropramide hydrochloride versus octylonium bromide in the treatment of irritable colon syndrome</TI>
<SO>Minerva Med</SO>
<YR>1984</YR>
<VL>75</VL>
<NO>1-2</NO>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomas_x002d_Ridocci-1992" MODIFIED="2010-06-09 11:38:19 -0400" MODIFIED_BY="John K MacDonald" NAME="Tomas-Ridocci 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-09 11:38:19 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 1304; ID: 594; LR: 20061115; JID: 9007566; 0 (Placebos); 8063-16-9 (Psyllium); ppublish" NOTES_MODIFIED="2010-06-09 11:38:19 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomas-Ridocci M, Anon R, Minguez M, Zaragoza A, Ballester J, Benages A</AU>
<TI>The efficacy of Plantago ovata as a regulator of intestinal transit. A double-blind study compared to placebo</TI>
<SO>Rev Esp Enferm Dig</SO>
<YR>1992</YR>
<VL>82</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toussaint-1981" MODIFIED="2010-06-09 11:38:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Toussaint 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-06-09 11:38:41 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2129; ID: 2486; ID: 1981232633" NOTES_MODIFIED="2010-06-09 11:38:41 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toussaint J, Cremer M, Pintens H</AU>
<TI>Single blind study of trimebutine and mebeverine in irritable colon and dyspepsia</TI>
<SO>Acta Ther</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>3</NO>
<PG>261-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tripathi-1983" MODIFIED="2010-06-09 11:39:03 -0400" MODIFIED_BY="John K MacDonald" NAME="Tripathi 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-06-09 11:39:03 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tripathi BM, Misra NP, Gupta AK</AU>
<TI>Evaluation of tricyclic compound (trimipramine) vis-a-vis placebo in irritable bowel syndrome. (Double blind randomised study)</TI>
<SO>J Assoc Physicians India</SO>
<YR>1983</YR>
<VL>31</VL>
<NO>4</NO>
<PG>201-3</PG>
<IDENTIFIERS MODIFIED="2010-06-09 11:39:03 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuneoka-1987" MODIFIED="2010-06-09 11:41:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Tsuneoka 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-09 11:41:02 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2133; ID: 3006; DE: RCT; CC: HS-HANDSRCH; SR-COLOCA" NOTES_MODIFIED="2010-06-09 11:41:02 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuneoka K, Miyoshi A, Kawakami K, Sekiguchi T, Nakazawa S</AU>
<TI>Clinical evaluation of TM 906 (trimebutine maleate) in the treatment of irritable bowel syndrome. Multi center double blind study in comparison with mepenzolate bromide</TI>
<SO>Rinsho Hyoka (Clinical Evaluation)</SO>
<YR>1987</YR>
<VL>15</VL>
<PG>307-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tudor-1986" MODIFIED="2010-06-09 11:48:12 -0400" MODIFIED_BY="John K MacDonald" NAME="Tudor 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-09 11:48:12 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2134; ID: 1080; LR: 20071115; JID: 0372546; 0 (Phenethylamines); 0 (Propylamines); 150-59-4 (alverine); 3625-06-7 (mebeverine); ppublish" NOTES_MODIFIED="2010-06-09 11:48:12 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tudor GJ</AU>
<TI>A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome</TI>
<SO>Br J Clin Pract</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>7</NO>
<PG>276-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Kerkhoven-2007" MODIFIED="2010-06-09 11:48:33 -0400" MODIFIED_BY="John K MacDonald" NAME="van Kerkhoven 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-09 11:48:33 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Kerkhoven LA, Laheij RJ, Jansen JB</AU>
<TI>The role of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>5</NO>
<PG>733; author reply 733</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Outryve-1995" MODIFIED="2010-06-09 11:49:16 -0400" MODIFIED_BY="John K MacDonald" NAME="Van Outryve 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-06-09 11:49:16 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2140; ID: 2394; ID: 1995326346" NOTES_MODIFIED="2010-06-09 11:49:16 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Outryve M, Mayeur S, Meeus MA, Rosillon D, Hendrickx B, Ceuppens M</AU>
<TI>A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome</TI>
<SO>J Clin Pharm Ther</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>5</NO>
<PG>277-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Steensel-1990" MODIFIED="2010-06-09 11:49:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Van Steensel 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-09 11:49:27 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Steensel CJ</AU>
<TI>Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>99</VL>
<NO>5</NO>
<PG>1538</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villagrasa-1991" MODIFIED="2011-06-06 12:11:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Villagrasa 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-06-06 12:11:59 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villagrasa M, Boix J, Humbert P, Quer JC</AU>
<TI>Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome</TI>
<SO>Ital J Gastroenterol</SO>
<YR>1991</YR>
<VL>8 Suppl 1</VL>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wald-1990" MODIFIED="2010-06-09 11:50:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Wald 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-09 11:50:26 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wald A</AU>
<TI>Fiber supplements for irritable bowel syndrome: do they really make a difference?</TI>
<SO>Am J Gastroenterol</SO>
<YR>1990</YR>
<VL>85</VL>
<NO>12</NO>
<PG>1652-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wald-2002" MODIFIED="2010-06-09 11:50:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Wald 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-09 11:50:42 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wald A</AU>
<TI>Psychotropic agents in irritable bowel syndrome</TI>
<SO>J Clin Gastroenterol</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>1 Suppl</NO>
<PG>S53-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2010-06-09 11:51:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-09 11:51:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang WA, Qian JM, Pan GZ</AU>
<TI>Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants</TI>
<SO>Chung-Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>1</NO>
<PG>74-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wittmann-1999" MODIFIED="2010-06-09 11:51:33 -0400" MODIFIED_BY="John K MacDonald" NAME="Wittmann 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-06-09 11:51:33 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2169; ID: 1005; LR: 20061115; JID: 0376412; 0 (Calcium Channel Blockers); 0 (Morpholines); 0 (Parasympatholytics); 59995-65-2 (pinaverium); ppublish" NOTES_MODIFIED="2010-06-09 11:51:33 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wittmann T, Feher A, Rosztoczy A, Janosi J</AU>
<TI>Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome</TI>
<SO>Orv Hetil</SO>
<YR>1999</YR>
<VL>140</VL>
<NO>9</NO>
<PG>469-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woolner-2000" MODIFIED="2010-06-09 11:52:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Woolner 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-09 11:52:41 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woolner JT, Kirby GA</AU>
<TI>Clinical audit of the effects of low-fibre diet on irritable bowel syndrome</TI>
<SO>J Hum Nutr Diet</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>4</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2003" MODIFIED="2010-06-09 11:53:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Yuan 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-09 11:53:02 -0400" MODIFIED_BY="John K MacDonald" NOTES="ID: 2175; ID: 2318; ID: 2004001960" NOTES_MODIFIED="2010-06-09 11:53:02 -0400" NOTES_MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan Y, Xu B, Ke M, Liu Y, Fu L, Li Z, et al</AU>
<TI>Efficacy and safety of otilonium bromide for irritable bowel syndrome</TI>
<SO>Chin J Gastroenterol</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>5</NO>
<PG>279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2005" MODIFIED="2009-05-15 08:09:32 -0400" MODIFIED_BY="[Empty name]" NAME="Yuan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-14 06:02:44 -0400" MODIFIED_BY="[Empty name]" NOTES="ID: 2176; ID: 2293; ID: 2006012892" NOTES_MODIFIED="2009-05-14 06:02:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan Y, Xu B, Mo J, Wang J, Li Z</AU>
<TI>Efficacy and safety use of trimebutine maleate in treatment of irritable bowel syndrome</TI>
<SO>Chin.J.Gastroenterol.</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>3</NO>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2010-03-31 13:59:22 -0400" MODIFIED_BY="John K MacDonald" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-31 13:59:22 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HB, Han GH, Zhou XM, Guo XG, Wang BL, Wu KC, et al</AU>
<TI>Effects of treatments with otilonium bromide, collodal bismuth tartrate and compound diphenoxylate in the irritable bowel syndrome: a double-blind random controlled study</TI>
<SO>The Chinese Journal of Clinical Pharmacology</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>5</NO>
<PG>328-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2002" MODIFIED="2010-06-09 11:53:58 -0400" MODIFIED_BY="John K MacDonald" NAME="Zhou 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-09 11:53:58 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou HQ, Li DG, Sogn GH</AU>
<TI>Effect of paroxetine hydrochloride and pinaverium bromide therapy in patients with irritable bowel syndrome</TI>
<SO>Chin J Clin Rehab</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>23</NO>
<PG>3576-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuckerman-2006" MODIFIED="2010-06-09 11:54:21 -0400" MODIFIED_BY="John K MacDonald" NAME="Zuckerman 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-09 11:54:21 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckerman MJ</AU>
<TI>The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations</TI>
<SO>J Clin Gastroenterol</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>2</NO>
<PG>104-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-06-03 12:17:41 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdul_x002d_Baki-2009" MODIFIED="2011-06-03 10:52:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Abdul-Baki 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-03 10:52:52 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdul-Baki H, El Hajj II, Elzahabi L, Azar C, Aoun E, Skoury A, et al</AU>
<TI>A randomized controlled trial of imipramine in patients with irritable bowel syndrome</TI>
<SO>World J Gastroenterol</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>29</NO>
<PG>3636-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bijkerk-2009" MODIFIED="2011-06-03 10:55:25 -0400" MODIFIED_BY="John K MacDonald" NAME="Bijkerk 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-03 10:55:22 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW</AU>
<TI>Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Everitt-2010" MODIFIED="2011-06-03 10:57:43 -0400" MODIFIED_BY="John K MacDonald" NAME="Everitt 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-03 10:57:41 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Everitt HA, Moss-Morris RE, Sibelli A, Tapp L, Coleman NS, Yardley L, et al</AU>
<TI>Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial)</TI>
<SO>BMC Gastroenterol</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khalif-2009" MODIFIED="2011-06-03 11:01:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Khalif 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-03 11:01:44 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA</AU>
<TI>Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics)</TI>
<SO>J Gastrointestin Liver Dis</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladabaum-2010" MODIFIED="2011-06-03 11:04:33 -0400" MODIFIED_BY="John K MacDonald" NAME="Ladabaum 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-03 11:04:30 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, et al</AU>
<TI>Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome</TI>
<SO>Clin Gastroenterol Hepatol</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merat-2010" MODIFIED="2011-06-03 11:07:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Merat 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-03 11:07:36 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R</AU>
<TI>The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome</TI>
<SO>Dig Dis Sci</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>5</NO>
<PG>1385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pace-2010" MODIFIED="2011-06-03 12:09:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Pace 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-03 12:09:36 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, et al</AU>
<TI>Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial</TI>
<SO>Eur Rev Med Pharmacol Sci</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>3</NO>
<PG>155-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reme-2010" MODIFIED="2011-06-03 12:12:14 -0400" MODIFIED_BY="John K MacDonald" NAME="Reme 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-03 12:12:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reme SE, Kennedy T, Jones R, Darnley S, Chalder T</AU>
<TI>Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care</TI>
<SO>J Psychosom Res</SO>
<YR>2010</YR>
<VL>68</VL>
<NO>4</NO>
<PG>385-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saps-2009" MODIFIED="2011-06-03 12:14:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Saps 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-03 12:14:52 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, et al</AU>
<TI>Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>137</VL>
<NO>4</NO>
<PG>1261-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wittmann-2010" MODIFIED="2011-06-03 12:17:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Wittmann 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-03 12:17:39 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC</AU>
<TI>Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>6</NO>
<PG>615-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-06-06 12:52:36 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2011-06-06 12:52:36 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Akehurst-2001" MODIFIED="2010-06-09 12:03:35 -0400" MODIFIED_BY="John K MacDonald" NAME="Akehurst 2001" TYPE="JOURNAL_ARTICLE">
<AU>Akehurst R, Kaltenthaler E</AU>
<TI>Treatment of irritable bowel syndrome: A review of randomised controlled trials</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>48</VL>
<NO>2</NO>
<PG>272-82</PG>
<IDENTIFIERS MODIFIED="2010-06-09 12:03:35 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<REFERENCE ID="REF-Bijkerk-2004" MODIFIED="2010-06-09 12:04:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Bijkerk 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ</AU>
<TI>Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>3</NO>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2002" MODIFIED="2010-06-09 12:05:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Brandt 2002" TYPE="JOURNAL_ARTICLE">
<AU>Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al</AU>
<TI>Systematic review on the management of irritable bowel syndrome in North America</TI>
<SO>Am J Gastroenterol</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>11 Suppl</NO>
<PG>S7-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burkitt-1972" MODIFIED="2010-06-09 12:05:45 -0400" MODIFIED_BY="John K MacDonald" NAME="Burkitt 1972" TYPE="JOURNAL_ARTICLE">
<AU>Burkitt DP, Walker AR, Painter NS</AU>
<TI>Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>2</VL>
<NO>7792</NO>
<PG>1408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creed-2001" MODIFIED="2010-06-09 12:06:09 -0400" MODIFIED_BY="John K MacDonald" NAME="Creed 2001" TYPE="JOURNAL_ARTICLE">
<AU>Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, et al</AU>
<TI>Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome</TI>
<SO>Ann Intern Med</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>9 Pt 2</NO>
<PG>860-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drossman-2006" MODIFIED="2010-06-09 12:06:45 -0400" MODIFIED_BY="John K MacDonald" NAME="Drossman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Drossman DA</AU>
<TI>The functional gastrointestinal disorders and the Rome III process</TI>
<SO>Gastroenterology</SO>
<YR>2006</YR>
<VL>130</VL>
<NO>5</NO>
<PG>1377-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ford-2008" MODIFIED="2010-06-09 12:07:10 -0400" MODIFIED_BY="John K MacDonald" NAME="Ford 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al</AU>
<TI>Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis</TI>
<SO>BMJ (Clinical research ed)</SO>
<YR>2008</YR>
<VL>337</VL>
<PG>a2313</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ford-2009" MODIFIED="2010-06-09 12:10:35 -0400" MODIFIED_BY="John K MacDonald" NAME="Ford 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ford A C, Talley N J, Schoenfeld P S, Quigley E M, Moayyedi P</AU>
<TI>Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis</TI>
<SO>Gut</SO>
<YR>2009</YR>
<VL>58</VL>
<NO>3</NO>
<PG>367-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ford-2010" MODIFIED="2010-06-09 12:09:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Ford 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ford AC, Guyatt GH, Talley NJ, Moayyedi P</AU>
<TI>Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>2</NO>
<PG>280-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillila-2004" MODIFIED="2010-06-09 12:11:27 -0400" MODIFIED_BY="John K MacDonald" NAME="Hillila 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hillila MT, Farkkila MA</AU>
<TI>Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>3</NO>
<PG>339-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hungin-2003" MODIFIED="2010-06-09 12:17:22 -0400" MODIFIED_BY="John K MacDonald" NAME="Hungin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hungin AP, Whorwell PJ, Tack J, Mearin F</AU>
<TI>The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>5</NO>
<PG>643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Irvine-2006" MODIFIED="2010-06-09 12:17:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Irvine 2006" TYPE="JOURNAL_ARTICLE">
<AU>Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, et al</AU>
<TI>Design of treatment trials for functional gastrointestinal disorders</TI>
<SO>Gastroenterology</SO>
<YR>2006</YR>
<VL>130</VL>
<NO>5</NO>
<PG>1538-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2000" MODIFIED="2010-06-09 12:18:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Jackson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K</AU>
<TI>Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis</TI>
<SO>Am J Med</SO>
<YR>2000</YR>
<VL>108</VL>
<NO>1</NO>
<PG>65-72</PG>
<IDENTIFIERS MODIFIED="2010-06-09 12:18:01 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<REFERENCE ID="REF-Jailwala-2000" MODIFIED="2010-06-09 12:18:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Jailwala 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jailwala J, Imperiale TF, Kroenke K</AU>
<TI>Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials</TI>
<SO>Ann Intern Med</SO>
<YR>2000</YR>
<VL>133</VL>
<NO>2</NO>
<PG>136-47</PG>
<IDENTIFIERS MODIFIED="2010-06-09 12:18:26 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2000a" MODIFIED="2010-06-09 12:18:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Jones 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al</AU>
<TI>British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47 Suppl 2</VL>
<PG>ii1-19</PG>
<IDENTIFIERS MODIFIED="2010-06-09 12:18:56 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2000b" MODIFIED="2010-06-09 12:18:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Jones 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Jones R</AU>
<TI>IBS: prime problem in primary care</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>1</NO>
<PG>7-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lesbros_x002d_Pantoflickova-2004" MODIFIED="2010-06-09 12:19:31 -0400" MODIFIED_BY="John K MacDonald" NAME="Lesbros-Pantoflickova 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum A L</AU>
<TI>Meta-analysis: The treatment of irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>11-12</NO>
<PG>1253-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Longstreth-2003" MODIFIED="2010-06-09 12:19:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Longstreth 2003" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, et al</AU>
<TI>Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective</TI>
<SO>Am J Gastroenterol</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>3</NO>
<PG>600-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manning-1978" MODIFIED="2010-06-09 12:20:50 -0400" MODIFIED_BY="John K MacDonald" NAME="Manning 1978" TYPE="JOURNAL_ARTICLE">
<AU>Manning AP, Thompson WG, Heaton KW, Morris AF</AU>
<TI>Towards positive diagnosis of the irritable bowel</TI>
<SO>Br Med J</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>6138</NO>
<PG>653-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pare-2006" MODIFIED="2010-06-09 12:23:45 -0400" MODIFIED_BY="John K MacDonald" NAME="Pare 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pare P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, et al</AU>
<TI>Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study</TI>
<SO>Clin Ther</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>10</NO>
<PG>1726-35; discussion 1710-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poynard-1994" NAME="Poynard 1994" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Naveau S, Mory B, Chaput JC</AU>
<TI>Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>5</NO>
<PG>499-510</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poynard-2001" MODIFIED="2010-06-09 12:24:20 -0400" MODIFIED_BY="John K MacDonald" NAME="Poynard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Regimbeau C, Benhamou Y</AU>
<TI>Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>355-61</PG>
<IDENTIFIERS MODIFIED="2010-06-09 12:24:20 -0400" MODIFIED_BY="John K MacDonald"/>
</REFERENCE>
<REFERENCE ID="REF-Rahimi-2009" MODIFIED="2010-06-09 12:31:55 -0400" MODIFIED_BY="John K MacDonald" NAME="Rahimi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Rahimi R, Nikfar S, Rezaie A, Abdollahi M</AU>
<TI>Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis</TI>
<SO>World J Gastroenterol</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>13</NO>
<PG>1548-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riedl-2008" MODIFIED="2010-06-09 12:38:38 -0400" MODIFIED_BY="John K MacDonald" NAME="Riedl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, et al</AU>
<TI>Somatic comorbidities of irritable bowel syndrome: a systematic analysis</TI>
<SO>J Psychosom Res</SO>
<YR>2008</YR>
<VL>64</VL>
<NO>6</NO>
<PG>573-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoenfeld-2006" MODIFIED="2010-06-09 12:39:56 -0400" MODIFIED_BY="John K MacDonald" NAME="Schoenfeld 2006" TYPE="JOURNAL_ARTICLE">
<AU>Schoenfeld P, Talley NJ</AU>
<TI>Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough?</TI>
<SO>Am J Gastroenterol</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>5</NO>
<PG>1066-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tack-2006b" MODIFIED="2011-06-06 12:38:54 -0400" MODIFIED_BY="John K MacDonald" NAME="Tack 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Tack J, Fried M, Houghton LA, Spicak J, Fisher G</AU>
<TI>Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>183-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talley-2006" MODIFIED="2010-06-09 12:40:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Talley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ</AU>
<TI>A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut?</TI>
<SO>Rev Gastroenterol Disord</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>2</NO>
<PG>72-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verdu-2008" MODIFIED="2010-06-09 11:59:06 -0400" MODIFIED_BY="John K MacDonald" NAME="Verdu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A</AU>
<TI>Antidepressants for the treatment of chronic pain</TI>
<SO>Drugs</SO>
<YR>2008</YR>
<VL>68</VL>
<NO>18</NO>
<PG>2611-32</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-06-20 13:33:14 -0400" MODIFIED_BY="John K MacDonald">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-06-20 13:32:25 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-06-20 13:30:59 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Aller-2004">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:30:59 -0400" MODIFIED_BY="John K MacDonald">
<P>56 patients</P>
<P>Rome II criteria</P>
<P>53% diarrhea-predominant</P>
<P>Setting unclear</P>
<P>Mean age 46 years</P>
<P>67% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-02 11:19:51 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent</P>
<P>30 g fibre of which 25 g insoluble, over the day for 13 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:26:47 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous</P>
<P>Symptom score, continuous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Half a week run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-25 10:09:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arthurs-1983">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:08:04 -0400" MODIFIED_BY="[Empty name]">
<P>80 patients</P>
<P>Setting unclear</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 27.7 years</P>
<P>78% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-25 10:08:14 -0400" MODIFIED_BY="[Empty name]">
<P>Bulking agent<BR/>4 weeks ispaghula husk 2 sachets/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:09:10 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unclear setting<BR/>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-02 11:20:19 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Awad-1995">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-26 09:49:17 -0400" MODIFIED_BY="[Empty name]">
<P>40 patients</P>
<P>Tertiary care</P>
<P>Rome criteria</P>
<P>Mean age 31.3 years</P>
<P>100% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-02 11:20:19 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>pinaverium 50 mg od for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 09:49:51 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, continuous <BR/>symptom score, continuous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-27 10:08:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bahar-2008">
<CHAR_METHODS MODIFIED="2009-05-27 10:04:33 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-27 10:05:26 -0400" MODIFIED_BY="[Empty name]">
<P>33 adolescent patients</P>
<P>secondary care</P>
<P>Rome criteria</P>
<P>mean age 15 years</P>
<P>65% female </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-27 10:07:07 -0400" MODIFIED_BY="[Empty name]">
<P>Antidepressant</P>
<P>amitriptyline 10 to 30 mg dd for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-27 10:08:04 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, change score (not included</P>
<P>global assessment, change score ( not included) and dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 10:08:33 -0400" MODIFIED_BY="[Empty name]">
<P>2 weeks run in period</P>
<P>adolescents </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-02 11:20:42 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Baldi-1991">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-26 09:50:27 -0400" MODIFIED_BY="[Empty name]">
<P>71 patients with IBS </P>
<P>8 GI centres</P>
<P>Mean age 40 years</P>
<P>60.6% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-02 11:20:42 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>4 weeks<BR/>otilonium 40 mg tds</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>abdominal pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 wk run-in with placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:00 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Battaglia-1998">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-26 09:51:33 -0400" MODIFIED_BY="[Empty name]">
<P>325 patients</P>
<P>multicentre GI outpatients</P>
<P>Rome criteria</P>
<P>Mean age 47.7 years</P>
<P>69% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:00 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>15 weeks otilonium 40 mg tds</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 09:52:05 -0400" MODIFIED_BY="[Empty name]">
<P>abdominal pain, dichotomous<BR/>global assessment, continuous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-26 09:52:16 -0400" MODIFIED_BY="[Empty name]">
<P>2 weeks run-in, with placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-12 13:48:01 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Bergmann-1991">
<CHAR_METHODS MODIFIED="2011-05-12 13:46:00 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-12 13:46:34 -0400" MODIFIED_BY="John K MacDonald">
<P>35 patients</P>
<P>Secondary care</P>
<P>Clinical diagnosis and investigations</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-12 13:47:24 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>3 months Trimipramine 50 mg OD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-12 13:48:01 -0400" MODIFIED_BY="John K MacDonald">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-02 11:21:03 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Boerner-1988">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:47:27 -0400" MODIFIED_BY="[Empty name]">
<P>79 IBS patients</P>
<P>partly from primary care</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-02 11:21:03 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressive<BR/>doxepine od 50 mg for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:48:57 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, continuous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:00 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Capanni-2005">
<CHAR_METHODS MODIFIED="2009-05-20 08:48:20 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:00 -0400" MODIFIED_BY="John K MacDonald">
<P>178 patients</P>
<P>secondary care</P>
<P>Rome II criteria</P>
<P>Mean age 42 years</P>
<P>75% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-25 11:16:36 -0400" MODIFIED_BY="[Empty name]">
<P>Spasmolytics</P>
<P>peppermint oil for 3 months, dose not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 11:18:10 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
<P>IBS-symptoms, dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-25 11:16:41 -0400" MODIFIED_BY="[Empty name]">
<P>4 weeks run-in</P>
<P>Dosage of intervention not clear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Cappello-2007">
<CHAR_METHODS MODIFIED="2009-05-20 08:48:39 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 11:24:22 -0400" MODIFIED_BY="[Empty name]">
<P>57 patients</P>
<P>Setting unclear </P>
<P>Rome II criteria</P>
<P>mean age 41 years</P>
<P>76% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:01 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmodic</P>
<P>peppermint oil capsules 500 mg for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:27:54 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous</P>
<P>IBS-symptom score, continuous and dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-20 13:31:02 -0400" MODIFIED_BY="John K MacDonald">
<P>No run in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Centonze-1988">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-26 09:59:29 -0400" MODIFIED_BY="[Empty name]">
<P>48 patients </P>
<P>Outclinic </P>
<P>50% female</P>
<P>Mean duration of symptoms 4 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:02 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>cimetropium tds 50 mg for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:28:00 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3 weeks run-in without placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:03 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Chen-2004">
<CHAR_METHODS MODIFIED="2009-05-20 08:49:04 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-02 11:22:06 -0400" MODIFIED_BY="John K MacDonald">
<P>120 IBS patients</P>
<P>Setting unclear</P>
<P>Rome II criteria</P>
<P>Mean age 43 years</P>
<P>48% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:03 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic</P>
<P>pinaverium bromide 100 mg tds for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:28:21 -0400" MODIFIED_BY="John K MacDonald">
<P>Global assessment, dichotomous</P>
<P>Symptom score, continuous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-20 08:49:04 -0400" MODIFIED_BY="[Empty name]">
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-03 14:28:35 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Czalbert-1990">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-03 14:28:35 -0400" MODIFIED_BY="John K MacDonald">
<P>34 IBS</P>
<P>Hospital out clinic</P>
<P>Mean age 49.3 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-02 11:22:36 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>peppermint oil 0.2 ml tds for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 10:22:41 -0400" MODIFIED_BY="[Empty name]">
<P>Symptom score, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:04 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-d_x0027_Arienzo-1980">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:03 -0400" MODIFIED_BY="John K MacDonald">
<P>28 IBS patients</P>
<P>Unclear setting</P>
<P>Diagnostic criteria not defined</P>
<P>39% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:04 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>otilonium tds 20 mg 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 10:23:31 -0400" MODIFIED_BY="[Empty name]">
<P>Symptom score, continuous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:05 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Delmont-1981">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:05 -0400" MODIFIED_BY="John K MacDonald">
<P>60 IBS patients</P>
<P>Setting unclear</P>
<P>Mean age 57 years</P>
<P>67% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Spasmolytic<BR/>pinaverium tds for 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 10:26:01 -0400" MODIFIED_BY="[Empty name]">
<P>abdominal pain, dichotomous<BR/>global assessment, dichotomous<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>unclear setting<BR/>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-03 14:28:48 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Dobrilla-1990">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-03 14:28:42 -0400" MODIFIED_BY="John K MacDonald">
<P>70 IBS patients</P>
<P>Hospital out clinic</P>
<P>Mean age 45 years</P>
<P>67% female</P>
<P>Mean duration of symptoms 3 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Spasmolytic<BR/>13 weeks cimetropium tds 50mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:28:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 weeks run-in without placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-10 13:05:05 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Drossman-2003">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:50:43 -0400" MODIFIED_BY="[Empty name]">
<P>216 patients with functional bowel disorders, 80% with IBS </P>
<P>Secondary care </P>
<P>Rome criteria</P>
<P>Mean age 39.9 years</P>
<P>100% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-25 10:50:46 -0400" MODIFIED_BY="[Empty name]">
<P>Antidepressant </P>
<P>desipramine 50-100-150mg od for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:51:26 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, continuous and dichotomous<BR/>Global assessment, continuous and dichotomous<BR/>Symptom score, continuous and dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-05-10 13:05:05 -0400" MODIFIED_BY="John K MacDonald">
<P>No run-in; minimum duration of symptoms of 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:05 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Dubarry-1977">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-26 10:29:39 -0400" MODIFIED_BY="[Empty name]">
<P>20 IBS patients</P>
<P>Outpatient setting</P>
<P>Diagnostic criteria not defined</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:05 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>6 days pinaverium 50 mg tds</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 10:30:05 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:07 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Fielding-1980">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:06 -0400" MODIFIED_BY="John K MacDonald">
<P>60 IBS patients</P>
<P>Unclear setting</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 26 years</P>
<P>75% female</P>
<P>mean duration of symptoms 2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:07 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>trimebutine tds 200 mg for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 10:32:10 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:09 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Fowlie-1992">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:08 -0400" MODIFIED_BY="John K MacDonald">
<P>49 patients</P>
<P>Gastro intestinal outpatient clinic</P>
<P>Mean age 40 years</P>
<P>65% female</P>
<P>Mean duration of symptoms 3.8 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-02 11:26:07 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>3 months mixed cereal and fruit fibre 4.1 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:31:09 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain<BR/>Global assessment<BR/>Symptom score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GI Outpatients<BR/>1 week run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:12 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Ghidini-1986">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:10 -0400" MODIFIED_BY="John K MacDonald">
<P>60 IBS patients</P>
<P>Hospital setting</P>
<P>Mean age 42 years</P>
<P>60% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:12 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>rociverine tds 20 mg for 60 days</P>
<P>trimebutine 3 dd 100 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 10:33:41 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:40 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Gilvarry-1989">
<CHAR_METHODS MODIFIED="2009-05-18 03:17:44 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:13 -0400" MODIFIED_BY="John K MacDonald">
<P>24 IBS patients</P>
<P>Unclear setting</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 32 years</P>
<P>79% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:38 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic pirenzepine 100 mg for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 11:20:23 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous </P>
<P>Global assessment, dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-20 13:31:40 -0400" MODIFIED_BY="John K MacDonald">
<P>4 to 8 weeks run-in with high fibre diet (&gt; 30 g/day)</P>
<P>continued high fibre diet during study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:42 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Heefner-1978">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:41 -0400" MODIFIED_BY="John K MacDonald">
<P>31 patients</P>
<P>Outpatients clinic</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 48 years</P>
<P>13% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:41 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressive<BR/>desipramine od 150 mg, 2months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:53:31 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-20 13:31:42 -0400" MODIFIED_BY="John K MacDonald">
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:44 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Jalihal-1990">
<CHAR_METHODS>
<P>RCT with Cross-over design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:43 -0400" MODIFIED_BY="John K MacDonald">
<P>20 patients</P>
<P>Gastro intestinal outpatients clinic</P>
<P>Diagnoses on clinical grounds</P>
<P>Mean age 38 years</P>
<P>20% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:43 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>4 weeks ispaghula husk 30 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:15:35 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-20 13:31:44 -0400" MODIFIED_BY="John K MacDonald">
<P>GI Outpatients<BR/>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:46 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Kruis-1986">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:14:36 -0400" MODIFIED_BY="[Empty name]">
<P>80 patients</P>
<P>Outpatients clinic </P>
<P>Mean age 41 years</P>
<P>61% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:46 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>16 weeks wheat bran fibre 8 g/day<BR/>Spasmolitic agent<BR/>16 weeks mebeverine 100 mg 4 dd</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:17:34 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous<BR/>Abdomianl pain, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GI patients<BR/>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:48 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Kuiken-2003">
<CHAR_METHODS MODIFIED="2009-05-20 08:51:13 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:47 -0400" MODIFIED_BY="John K MacDonald">
<P>40 patients,</P>
<P>GI out clinic</P>
<P>Rome I criteria</P>
<P>Mean age 40 years</P>
<P>55% female</P>
<P>Mean duration of symptoms 5.9 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressive</P>
<P>fluoxetine (SSRI) 20 mg od for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:55:14 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-20 08:51:13 -0400" MODIFIED_BY="[Empty name]">
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:50 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Lech-1988">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-26 10:39:41 -0400" MODIFIED_BY="[Empty name]">
<P>47 IBS patients</P>
<P>Hospitals outpatients clinic</P>
<P>Mean age 42 years</P>
<P>76% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:49 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>4 weeks peppermint oil 3 dd 200 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:31:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-26 10:39:13 -0400" MODIFIED_BY="[Empty name]">
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:31:51 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Levy-1977">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:51 -0400" MODIFIED_BY="John K MacDonald">
<P>50 IBS patients</P>
<P>Unclear setting</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 48 years</P>
<P>46% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:51 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>Pinaverium tds 50 mg 15 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 11:12:48 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:00 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Liu-1997">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:31:52 -0400" MODIFIED_BY="John K MacDonald">
<P>101 IBS patients</P>
<P>Unclear setting</P>
<P>40% females</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:31:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>4 weeks peppermint oil tds-qid 187 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:00 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:01 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Longstreth-1981">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:19:15 -0400" MODIFIED_BY="[Empty name]">
<P>77 patients</P>
<P>Setting unclear</P>
<P>Mean age 38.4 years</P>
<P>83% female</P>
<P>Mean duration of symptoms 7.9 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:01 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>8 weeks psyllium 19 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:29:39 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unclear setting<BR/>2 weeks run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-03 14:29:46 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Lucey-1987">
<CHAR_METHODS>
<P>RCT with Cross-over design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:21:18 -0400" MODIFIED_BY="[Empty name]">
<P>44 Patients</P>
<P>Gastrointestinal outpatient clinic </P>
<P>Manning criteria </P>
<P>Mean age 32 years</P>
<P>68% female</P>
<P>Mean duration of symptoms 60 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-03 14:29:42 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>3 months wheat bran fibre 13g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:29:46 -0400" MODIFIED_BY="John K MacDonald">
<P>IBS symptom score, continuous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GI Outpatients<BR/>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Masand-2009">
<CHAR_METHODS MODIFIED="2009-05-20 08:51:50 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:56:41 -0400" MODIFIED_BY="[Empty name]">
<P>72 patient </P>
<P>Secondary care</P>
<P>Rome II criteria</P>
<P>Mean age 49 years</P>
<P>88% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:02 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>paroxetine 12.5-50 mg for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:59:22 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
<P>IBS-symptoms, continuous, dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-25 10:57:25 -0400" MODIFIED_BY="[Empty name]">
<P>run in with placebo, time period not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Mitchell-2002">
<CHAR_METHODS MODIFIED="2009-05-20 08:52:24 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-02 11:35:18 -0400" MODIFIED_BY="John K MacDonald">
<P>107 IBS patients</P>
<P>Secondary care 3 different hospitals</P>
<P>Rome criteria</P>
<P>Mean age 53 years</P>
<P>80% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:02 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic</P>
<P>Alverine citrate 360 mg for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-20 08:52:24 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment</P>
<P>Abdominal pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-20 08:52:24 -0400" MODIFIED_BY="[Empty name]">
<P>2 weeks run-in without placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:04 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Moshal-1979">
<CHAR_METHODS>
<P>RCT with cross-over design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:03 -0400" MODIFIED_BY="John K MacDonald">
<P>20 IBS patients</P>
<P>Unclear setting</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 27 years</P>
<P>35% females</P>
<P>Mean duration of symptoms 1 year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:04 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>trimebutine tds 200 mg for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 11:16:01 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:06 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Myren-1982">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:05 -0400" MODIFIED_BY="John K MacDonald">
<P>61 patients</P>
<P>Primary care setting</P>
<P>Mean age 38.9 years</P>
<P>54% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:06 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressive<BR/>trimipramine 1 dd 50 mg 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:47:03 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-25 10:25:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nigam-1984">
<CHAR_METHODS MODIFIED="2009-05-25 10:22:05 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-25 10:23:24 -0400" MODIFIED_BY="[Empty name]">
<P>168 patients</P>
<P>Secondary care</P>
<P>Mean age 34.5 years</P>
<P>45% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-25 10:24:46 -0400" MODIFIED_BY="[Empty name]">
<P>Bulking agents</P>
<P>Ispaghula husk, unclear dose, 12 weeks</P>
<P>Spasmolitic agent</P>
<P>Hyoscinebutylbromide, unclear dose, 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:25:10 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-25 10:25:33 -0400" MODIFIED_BY="[Empty name]">
<P>Inclear dose of intervention</P>
<P>No run in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:07 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Page-1981">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:07 -0400" MODIFIED_BY="John K MacDonald">
<P>97 patients</P>
<P>Unclear setting</P>
<P>Mean age 36.7 years</P>
<P>83% females</P>
<P>Mean duration of symptoms 2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:07 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>dicyclomine qid 40 mg for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 11:17:45 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 weeks placebo run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:08 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Passaretti-1989a">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:08 -0400" MODIFIED_BY="John K MacDonald">
<P>40 patients</P>
<P>Out patient clinic</P>
<P>Mean age 39 years</P>
<P>60% females</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:08 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>4 weeks cimetropium tds 50 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:29:51 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 weeks run-in without placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:09 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Piai-1979">
<CHAR_METHODS MODIFIED="2009-05-20 08:53:21 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with cross-over design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:09 -0400" MODIFIED_BY="John K MacDonald">
<P>18 patients</P>
<P>Unclear setting</P>
<P>Diagnostic criteria not defined</P>
<P>56% females</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:09 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>prifinium 30 mg tds for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-26 11:19:46 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-20 08:53:21 -0400" MODIFIED_BY="[Empty name]">
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:11 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Prior-1987">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:10 -0400" MODIFIED_BY="John K MacDonald">
<P>80 patients</P>
<P>Outpatients</P>
<P>90% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:11 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agents<BR/>12 weeks ispaghula husk 19 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Outpatients<BR/>2 weeks run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:12 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Pulpeiro-2000">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:12 -0400" MODIFIED_BY="John K MacDonald">
<P>85 IBS patients</P>
<P>Hospital GI department</P>
<P>Mean age 45.2 years</P>
<P>69% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:12 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>Propinox 4 dd for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:29:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, continuous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-26 11:21:07 -0400" MODIFIED_BY="[Empty name]">
<P>No run-in</P>
<P>Dose unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:13 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Rajagopalan-1998">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-27 09:45:19 -0400" MODIFIED_BY="[Empty name]">
<P>22 patients</P>
<P>Outpatients clinic</P>
<P>Rome criteria</P>
<P>Mean age 35 years</P>
<P>50% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:13 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressive<BR/>amitriptyline to 75 mg od for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-27 09:45:36 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, continuous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 week run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:14 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Rees-2005">
<CHAR_METHODS MODIFIED="2009-05-18 08:21:57 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-03 14:29:58 -0400" MODIFIED_BY="John K MacDonald">
<P>28 patients</P>
<P>GI out clinic</P>
<P>Rome criteria</P>
<P>Mean age 36.1 years</P>
<P>86% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:14 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>10-20 g coarse wheat bran once daily for 8 to 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:34:45 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, continuous</P>
<P>Global assessment, dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-26 02:54:37 -0400" MODIFIED_BY="[Empty name]">
<P>No run in period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:16 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Ritchie-1979">
<CHAR_METHODS MODIFIED="2009-05-18 08:22:32 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:15 -0400" MODIFIED_BY="John K MacDonald">
<P>24 patients</P>
<P>Secondary setting</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 38 years</P>
<P>77% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:16 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent</P>
<P>4 weeks ispaghula husk, 1 sachet 2 dd<BR/>Spasmolytics<BR/>hyoscine 4 dd 10 mg 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:37:33 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-18 08:22:32 -0400" MODIFIED_BY="[Empty name]">
<P>Hospital setting<BR/>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:18 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Schafer-1990">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:17 -0400" MODIFIED_BY="John K MacDonald">
<P>360 IBS pat from various origin (prim care, GI clinic, int med)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:18 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>4 weeks butylscopamine 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abdominal pain<BR/>Global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-02 11:54:46 -0400" MODIFIED_BY="John K MacDonald">
<P>0.5 wk run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:19 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Soltoft-1976">
<CHAR_METHODS MODIFIED="2009-05-18 06:16:39 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:18 -0400" MODIFIED_BY="John K MacDonald">
<P>59 patients</P>
<P>Setting unclear</P>
<P>Mean age 40 years</P>
<P>64% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:19 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent<BR/>6 weeks wheat bran 30 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 10:40:31 -0400" MODIFIED_BY="[Empty name]">
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-18 06:16:39 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear setting<BR/>&gt;1 week run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:20 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tabas-2004">
<CHAR_METHODS MODIFIED="2009-05-20 08:54:25 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:20 -0400" MODIFIED_BY="John K MacDonald">
<P>90 patients</P>
<P>Voluntary participants through advertisement</P>
<P>Rome I criteria</P>
<P>Mean age 46 years</P>
<P>74% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:20 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>paroxetine (SSRI) 10 or 20 mg od for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 11:02:04 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous</P>
<P>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-25 11:01:36 -0400" MODIFIED_BY="[Empty name]">
<P>69 of 81 took part in high-fibre open label trial 7 weeks before</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:22 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tack-2006a">
<CHAR_METHODS MODIFIED="2009-05-20 08:54:53 -0400" MODIFIED_BY="[Empty name]">
<P>Crossoveer with first phase data reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:21 -0400" MODIFIED_BY="John K MacDonald">
<P>23 IBS patients</P>
<P>Tertiary setting</P>
<P>Rome II criteria</P>
<P>Mean age 40 years</P>
<P>78% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:22 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>citalopram (SSRI) 20-40mg for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 11:03:20 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, continuous </P>
<P>Global assessment, continuous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-20 08:54:53 -0400" MODIFIED_BY="[Empty name]">
<P>2 weeks run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-12 12:19:25 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Talley-2008a">
<CHAR_METHODS MODIFIED="2009-05-27 09:10:38 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-12 12:19:25 -0400" MODIFIED_BY="John K MacDonald">
<P>51 patients</P>
<P>Setting secondary care</P>
<P>Rome criteria</P>
<P>60% female</P>
<P>70% diarrhea predominant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-27 09:12:49 -0400" MODIFIED_BY="[Empty name]">
<P>Antidepressive</P>
<P>Imipramine (TCA) 50 mg dd for 12 weeks</P>
<P>Citalopram (SSRI) 40 mg dd for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-27 09:13:59 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, changes score (not included)</P>
<P>global assessment, dichotomous and change score (not included)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 09:15:09 -0400" MODIFIED_BY="[Empty name]">
<P>2 weeks run-in period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-27 09:40:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vahedi-2005">
<CHAR_METHODS MODIFIED="2009-05-20 08:56:02 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-27 09:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>44 IBS patients</P>
<P>GI clinic</P>
<P>Rome II criteria</P>
<P>Mean age 35 years</P>
<P>61% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-20 08:56:02 -0400" MODIFIED_BY="[Empty name]">
<P>Antidepressant fluoxetine(SSRI) 20mg od for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-20 08:56:02 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 09:40:38 -0400" MODIFIED_BY="[Empty name]">
<P>Only 44 of 64 eligible patients included. No run-in</P>
<P>No run in period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:24 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Vahedi-2008">
<CHAR_METHODS MODIFIED="2009-05-20 08:56:38 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:22 -0400" MODIFIED_BY="John K MacDonald">
<P>50 diarrhoea-predominant IBS patients</P>
<P>Tertiary GI clinic</P>
<P>Rome II criteria</P>
<P>Mean age 36 years</P>
<P>42% female</P>
<P>Mean duration of symptoms 39 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:23 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>amitriptyline 10 mg for 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-25 11:11:25 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous</P>
<P>IBS-symptom score, continuous and dichotomous </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-20 13:32:24 -0400" MODIFIED_BY="John K MacDonald">
<P>No run-in</P>
<P>Only diarrhoea-predominant IBS</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:24 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Vij-1991">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:24 -0400" MODIFIED_BY="John K MacDonald">
<P>50 IBS patient</P>
<P>Unclear setting</P>
<P>Mean age 32 Years</P>
<P>28% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-27 09:42:13 -0400" MODIFIED_BY="[Empty name]">
<P>Antidepressive<BR/>doxepin od 75mg for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 14:30:23 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 09:41:51 -0400" MODIFIED_BY="[Empty name]">
<P>No run-un</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-20 13:32:25 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Virat-1987">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:25 -0400" MODIFIED_BY="John K MacDonald">
<P>78 IBS patients</P>
<P>GI Outpatients</P>
<P>Diagnostic criteria not defined</P>
<P>Mean age 44 years</P>
<P>67% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:25 -0400" MODIFIED_BY="John K MacDonald">
<P>Spasmolytic<BR/>pinaverium 50 mg tds 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-27 10:15:20 -0400" MODIFIED_BY="[Empty name]">
<P>Abdominal pain, dichotomous<BR/>Global assessment, dichotomous</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-06-02 12:45:28 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:00:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Achord-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:00:59 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:03:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alevizos-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:03:22 -0400" MODIFIED_BY="[Empty name]">
<P>Not appropriate patients: depressive patients with IBS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:06:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andre-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:06:18 -0400" MODIFIED_BY="[Empty name]">
<P>Mixed intervention: composite of oxazepam and scopolamine butyl nitrate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:00:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:00:55 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:56:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:56:10 -0400" MODIFIED_BY="[Empty name]">
<P>No extractable results </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:00:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:00:52 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:01:12 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:01:12 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:01:16 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:01:16 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:01:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:01:21 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:01:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:01:26 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:01:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:01:46 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:01:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:01:39 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a report from Ford 2008</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:22:40 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Arffmann-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:22:40 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:21:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Awad-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:21:08 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; post-prandial motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:23:05 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Baldi-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:23:05 -0400" MODIFIED_BY="John K MacDonald">
<P>Duplicate publication with Baldi 1991</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:23:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Barbier-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:23:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:02:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bassotti-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:02:41 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:24:22 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Baume-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:24:22 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:24:37 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Bazzocchi-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:24:37 -0400" MODIFIED_BY="John K MacDonald">
<P>Not outcome of interest; anorectal function</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:24:53 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Berthelot-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:24:53 -0400" MODIFIED_BY="John K MacDonald">
<P>Only 28% of patients had true IBS. Separate results were not available for these patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 05:24:14 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Birt-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 05:24:14 -0400" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:03:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bixquert_x002d_Jimenez-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:03:06 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:25:07 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Block-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:25:07 -0400" MODIFIED_BY="John K MacDonald">
<P>Duplicate publication with Myren 1982</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:03:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosaeus-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:03:26 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:21:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bouchoucha-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:21:47 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; colonic response to food</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:03:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Budavari-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:03:35 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:03:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burden-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:03:46 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:25:35 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Camarri-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:25:35 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:13:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Camarri-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:13:41 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo group; comparing fenoverine and trimebutine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:04:14 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Camatte-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:04:14 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:26:10 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Cann-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:26:10 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:06:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capron-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:06:29 -0400" MODIFIED_BY="[Empty name]">
<P>Mixed intervention; composite of bulk, sedative and laxative</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:19:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capurso-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:19:55 -0400" MODIFIED_BY="[Empty name]">
<P>Cross over design with no parallel placebo administration in the first phase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:05:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capurso-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:05:38 -0400" MODIFIED_BY="[Empty name]">
<P>Mixed intervention; composite of octylonium bromide and diazepam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-05 14:32:49 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Carling-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-05 14:32:49 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study with no reporting of outcomes before first cross-over </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:27:12 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Cerrato-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:27:12 -0400" MODIFIED_BY="John K MacDonald">
<P>Inappropriate patients; children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:07:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chapman-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:07:01 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing mebeverine with high-fibre dietary advice and mebeverine with ispaghula</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:23:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chassany-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:23:29 -0400" MODIFIED_BY="[Empty name]">
<P>Inapproptiate patients; acute exacerbation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:07:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:07:15 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing Alverine/dimeticone and nifedipine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 05:35:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 05:35:27 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chevrel-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:07:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chicharro-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:07:23 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:07:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:07:27 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:07:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clouse-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:07:38 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a chart review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:07:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clouse-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:07:51 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:27:49 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Cook-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:27:49 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:08:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cop_x00e9_-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:08:26 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing clidiniumbromide-chlordiazepoxide and trimebutine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:29:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corazza-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:29:08 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing pinaverium bromide and trimebutine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:08:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corazziari-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:08:19 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:28:00 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Creed-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:28:00 -0400" MODIFIED_BY="John K MacDonald">
<P>No placebo; comparing SSRI and psychotherapy with usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:09:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Creed-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:09:28 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:09:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crowell-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:09:55 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:09:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Curtiss-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:09:59 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:22:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czimmer-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:22:27 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; sensory thresholds and recto-sigmoideal distention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:26:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Darnis-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:26:49 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing bran and kaologenis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:10:16 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Groote-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:10:16 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:26:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-la-Garoullaye-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:26:04 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing fenoverine with PVOO and karaya gum</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:35:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Defrance-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:35:44 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing otilonium and pinaverium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:10:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delvaux-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:10:23 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:25:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dettmar-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:25:13 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:28:20 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Dettmar-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:28:20 -0400" MODIFIED_BY="John K MacDonald">
<P>No placebo; comparing ispaghula husk with mebeverine and mebeverine with high fibre diet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:28:41 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Dew-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:28:41 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:24:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diaz_x002d_Rubio-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:24:04 -0400" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:38:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dioguardi-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:38:51 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing octilonium bromide-diazepam and propantheline bromide-bromazepam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:27:32 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubinin-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:27:32 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing bran and bran with other drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:23:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ehsanullah-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:23:34 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; motility index</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:11:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eisenburg-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:11:29 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:11:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evangelista-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:11:39 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:24:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:24:23 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; motility index</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:42:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrari-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:42:01 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing octylonium bromide and cimetropium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:11:53 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fielding-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:11:53 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:28:12 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fielding-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:28:12 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing different dietary fibres</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:28:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fioramonti-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:28:40 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; colonic motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:12:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Floch-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:12:00 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:12:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Francis-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:12:03 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:29:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frexinos-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:29:01 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; colonic motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:12:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fritz-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:12:09 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:49:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galeone-1986a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:49:28 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing tiropramide, trimebutine and octilonium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:48:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galeone-1986b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:48:58 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing pinaverium bromide and otilonium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:51:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geismar-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:51:01 -0400" MODIFIED_BY="[Empty name]">
<P>No extractable results; no clinically relevant data, only preferences</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:51:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geoffroy-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:51:27 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:29:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giaccari-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:29:55 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; patients divided in two groups bases on BMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:12:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannini-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:12:24 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:12:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gibbons-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:12:29 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:52:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilbody-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:52:45 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing two different formulations of mebeverine hydrochloride</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-26 14:53:59 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Glende-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-26 14:53:59 -0400" MODIFIED_BY="John K MacDonald">
<P>Double-publication with Battaglia 1998</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:12:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gnauck-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:12:37 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:29:21 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Golechha-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:29:21 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:30:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorard-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:30:33 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; whole gut and orocaecal transit times</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:30:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorard-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:30:47 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; small intestinal motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:14:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenbaum-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:14:03 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:29:43 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Greenbaum-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:29:43 -0400" MODIFIED_BY="John K MacDonald">
<P>Duplicate publication with Greenbaum 1987</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:30:07 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Greenbaum-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:30:07 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:15:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grigoleit-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:15:07 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:15:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guerre-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:15:22 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing karay gum and polyvinylpolypyrrolidone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:15:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halpert-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:15:49 -0400" MODIFIED_BY="[Empty name]">
<P>Duplicate publication; paper based on same patients as Drossman 2003</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:16:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:16:11 -0400" MODIFIED_BY="[Empty name]">
<P>Duplicate publication; same patients as Masand 2009</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:30:40 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Hebden-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:30:40 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:16:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herxheimer-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:16:25 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hotz-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:31:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Houghton-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:31:27 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; colonic motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 06:57:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inauen-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 06:57:30 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing mebeverine slow release and mebeverine tablets</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:32:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwanaga-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:32:20 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:16:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jackson-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:16:40 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:16:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jafri-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:16:50 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:16:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jayanthi-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:16:55 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:32:05 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ji-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:32:05 -0400" MODIFIED_BY="[Empty name]">
<P>Inappropriate patients; patients with functional bowel disorder not specified as IBS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 05:56:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jing-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 05:56:27 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:17:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaushik-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:17:08 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:17:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirsch-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:17:30 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koch-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double publication with Liu 1997</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:17:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koruda-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:17:37 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:18:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kountouras-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:18:08 -0400" MODIFIED_BY="[Empty name]">
<P>Inappropriate patients; patients with GERD, who also have IBS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:33:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:33:02 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing different doses of ispaghula husk</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 04:51:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kunze-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 04:51:42 -0400" MODIFIED_BY="[Empty name]">
<P>No Placebo; comparing brief psychotherapy, acupuncture and papaverin </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:33:14 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lafon-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:33:14 -0400" MODIFIED_BY="[Empty name]">
<P>No data extractable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:18:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:18:33 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:18:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-1991a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:18:35 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:18:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-1991b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:18:47 -0400" MODIFIED_BY="[Empty name]">
<P>Inappropriate intervention; dietary advice</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:31:11 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Lawson-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:31:11 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:35:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levitan-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:35:51 -0400" MODIFIED_BY="[Empty name]">
<P>Inappropriate patients; mixed IBS and diverticulosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:36:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:36:02 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; anorectal visceral sensorimotor functions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:19:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:19:01 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-01 10:31:12 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Locke-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-01 10:31:12 -0400" MODIFIED_BY="John K MacDonald">
<P>Not an RCT; a review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 04:54:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 04:54:18 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing pinaverlum bromide and mebeverine </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:36:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luttecke-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:36:35 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; only preference</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:33:25 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Luttecke-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:33:25 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:19:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lydiard-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:19:18 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:19:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacRae-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:19:23 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:19:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manning-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:19:30 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:19:53 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manning-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:19:53 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; Comparing high and low-fibre diet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-01 10:35:33 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Marks-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-01 10:35:33 -0400" MODIFIED_BY="John K MacDonald">
<P>Duplicate publication; same patients as Masand 2009</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 05:21:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masamune-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 05:21:21 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing calcium polycarbophil and torimebutine maleate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:37:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masand-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:37:28 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:37:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masand-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:37:34 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:37:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matts-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:33:56 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Meier-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:33:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Mixed intervention; psyllium and Cisapride versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:38:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:38:21 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:38:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Misra-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:38:27 -0400" MODIFIED_BY="[Empty name]">
<P>Not the appropriate patients; patients who had recovered completely after treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 05:22:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Modena-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 05:22:42 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 05:23:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mollica-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 05:23:52 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing Otilonium bromide-diazepam and otilonium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:34:19 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Morgan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:34:19 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:39:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morrison-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:39:07 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; the role of the dietitian</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:39:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortensen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:39:26 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; short-chain fatty acids (SCFA) in faeces</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:34:57 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Nash-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:34:57 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 05:24:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nedogoda-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 05:24:48 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing pinaverium bromide and otilonium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:39:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noel-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:39:55 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:40:12 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olden-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:40:12 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 05:51:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pardell-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 05:51:29 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing clebopride and hyoscine N-butylbromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:40:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parisi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:40:24 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing guargum and wheat bran</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:40:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parisi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:40:43 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo group; comparing different doses of guar gum</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:40:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Passaretti-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:40:51 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:41:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Passaretti-1989b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:41:04 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; sigmoid-rectal motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:41:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:41:10 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-31 14:10:12 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Piai-1987a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-31 14:10:12 -0400" MODIFIED_BY="John K MacDonald">
<P>Inappropriate patients; mixture of IBS and functional constipation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-31 14:05:50 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Piai-1987b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-31 14:05:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Inappropriate patients; IBS in remission</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:36:06 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Pittler-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:36:06 -0400" MODIFIED_BY="John K MacDonald">
<P>Not an RCT; a meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:41:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prior-1986a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:41:49 -0400" MODIFIED_BY="[Empty name]">
<P>Only abstract; full text not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-01 10:41:26 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Prior-1986b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-01 10:41:26 -0400" MODIFIED_BY="John K MacDonald">
<P>Duplicate publication; abstract publication of Prior 1987</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 05:58:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prout-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 05:58:06 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing two doses of mebeverine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:42:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quilici-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:42:03 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-01 10:41:40 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Quilici-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-01 10:41:40 -0400" MODIFIED_BY="John K MacDonald">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:42:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:42:29 -0400" MODIFIED_BY="[Empty name]">
<P>Inappropriate intervention; diet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:43:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Rees-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:43:02 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:02:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rhodes-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:02:09 -0400" MODIFIED_BY="[Empty name]">
<P>Inaprporiate intervention; sedative-anticholinergic drug combinations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:01:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rhodes-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:01:35 -0400" MODIFIED_BY="[Empty name]">
<P>No extractable results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:03:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritchie-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:03:10 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing psychotropic drug, smooth-muscle relaxant, and bulking agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:42:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sagduyu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:42:49 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sato-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:34 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:04:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaffstein-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:04:09 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing trimebutine and mebeverine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schutz-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:00 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Secco-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:10 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:15 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaughnessy-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:19 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-31 13:15:32 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Shrivastava-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-31 13:15:32 -0400" MODIFIED_BY="John K MacDonald">
<P>Not outcome of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:22 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:43:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slawson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:43:47 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:43:33 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Snook-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:43:33 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:44:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soifer-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:44:09 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:44:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soifer-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:44:23 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; colon motility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:44:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soriano-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:44:35 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:44:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiefelhagen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:44:38 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:45:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swiatczak-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:45:21 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; comparing before and after treatment with bran</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:44:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talley-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:44:49 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:45:32 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talley-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:45:32 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:44:01 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Talley-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:44:01 -0400" MODIFIED_BY="John K MacDonald">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:44:09 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:44:09 -0400" MODIFIED_BY="John K MacDonald">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:46:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanum-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:46:37 -0400" MODIFIED_BY="[Empty name]">
<P>Inappropriate patients; mixture of IBS and NUD patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:47:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanum-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:47:47 -0400" MODIFIED_BY="[Empty name]">
<P>Not outcome of interest; assessment of personality traits </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:47:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarpila-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:47:11 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing flaxseed and psyllium</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:48:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarquini-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:48:00 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing octilonium bromide and octilonium bromide with a benzodiazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:44:35 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tasman_x002d_Jones-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:44:35 -0400" MODIFIED_BY="John K MacDonald">
<P>Cross-over study; no first phase data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:43:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tinozzi-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:43:39 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing tiropramide hydrochloride and octylonium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 07:57:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomas_x002d_Ridocci-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 07:57:46 -0400" MODIFIED_BY="[Empty name]">
<P>Not the appropriate patients; patients with chronic constipation with or without IBS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:44:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Toussaint-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:44:17 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing trimebutine and mebeverine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:48:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tripathi-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:48:41 -0400" MODIFIED_BY="[Empty name]">
<P>Duplicate publication with Shrivastava 1984</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:45:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsuneoka-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:45:29 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing trimebutine maleate and mepenzolate bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:46:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tudor-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:46:09 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing alverine citrate and mebeverine hydrochloride</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:49:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Kerkhoven-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:49:01 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; a letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:47:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Outryve-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:47:04 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing mebeverine and mebeverine sustained release</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:48:53 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Steensel-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:48:53 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:48:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villagrasa-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:48:03 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing fibre-rich diet and otilonium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:49:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wald-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:49:15 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:44:56 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Wald-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:44:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Not an RCT; a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:49:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:49:50 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing fluoxetine, paroxetine and doxepin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:50:14 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wittmann-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:50:14 -0400" MODIFIED_BY="[Empty name]">
<P>No RCT; healthy patients compared with IBS patients </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:49:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Woolner-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:49:57 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; preliminary before-after study of low-fibre diet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:50:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:50:08 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:50:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:50:46 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing trimebutine maleat and pinaveriumbromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-15 06:52:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-15 06:52:31 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo; comparing otilonium bromide, collodal bismuth tartrate and compound diphenoxylate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-02 12:45:28 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Zhou-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-02 12:45:28 -0400" MODIFIED_BY="John K MacDonald">
<P>No placebo; comparing paroxetine and pinaverium bromide versus paroxetine versus pinaverium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 09:50:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zuckerman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 09:50:57 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT; therapeutic recommendations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-06-20 13:33:14 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-06-20 13:32:28 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Abdul_x002d_Baki-2009">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:26 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:26 -0400" MODIFIED_BY="John K MacDonald">
<P>107 IBS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:28 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>imipramine 25 mg versus matched placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:28 -0400" MODIFIED_BY="John K MacDonald">
<P>Global symptom relief</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:32:38 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Bijkerk-2009">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:29 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:30 -0400" MODIFIED_BY="John K MacDonald">
<P>275 patients with IBS</P>
<P>General practice</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:35 -0400" MODIFIED_BY="John K MacDonald">
<P>Bulking agent </P>
<P>12 weeks of treatment with: psyllium 10 g or bran 10 g or placebo 10 g (rice flour) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:38 -0400" MODIFIED_BY="John K MacDonald">
<P>Adequate symptom relief</P>
<P>IBS symptom severity score</P>
<P>Severity of abdominal pain</P>
<P>IBS quality of life scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:32:43 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Everitt-2010">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:39 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:39 -0400" MODIFIED_BY="John K MacDonald">
<P>135 IBS patients (Rome III)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:41 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic and bulking agent</P>
<P>mebeverine</P>
<P>methylcellulose</P>
<P>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:43 -0400" MODIFIED_BY="John K MacDonald">
<P>IBS severity scale</P>
<P>IBS-QOL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:32:48 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Khalif-2009">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:43 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:44 -0400" MODIFIED_BY="John K MacDonald">
<P>118 IBS patients (Rome II)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic</P>
<P>oral buscopan (20 mg TID)</P>
<P>buscopan suppository (30 mg OD)</P>
<P>oral drotaverine (80 mg TID)</P>
<P>calcium gluconate tablets (1 TID)</P>
<P>calendula suppository (OD)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Pain score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:32:53 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Ladabaum-2010">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:49 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:50 -0400" MODIFIED_BY="John K MacDonald">
<P>54 non-depressed IBS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:52 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>citalopram (20 mg/.day for 4 weeks, then 40 mg/day for 4 weeks)</P>
<P>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:53 -0400" MODIFIED_BY="John K MacDonald">
<P>Adequate relief of IBS symptoms</P>
<P>IBS-QOL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:32:57 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Merat-2010">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:53 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:54 -0400" MODIFIED_BY="John K MacDonald">
<P>90 IBS outpatients </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:32:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic</P>
<P>Peppermint oil, colpermin (1 capsule TID for 8 weeks)</P>
<P>Placebo (1 capsule TID for 8 weeks) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:32:57 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain</P>
<P>QOL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:33:03 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Pace-2010">
<CHAR_METHODS MODIFIED="2011-06-20 13:32:58 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:32:58 -0400" MODIFIED_BY="John K MacDonald">
<P>186 IBS patients (Rome II)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:33:00 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic</P>
<P>octatropine (40 mg BID) and diazepam (2.5 mg BID) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:33:03 -0400" MODIFIED_BY="John K MacDonald">
<P>Satisfactory relief of abdominal pain</P>
<P>abdominal swelling</P>
<P>abdominal pain and discomfort</P>
<P>symptom severity</P>
<P>number of bowel movements</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:33:06 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Reme-2010">
<CHAR_METHODS MODIFIED="2011-06-20 13:33:04 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:33:04 -0400" MODIFIED_BY="John K MacDonald">
<P>149 IBS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:33:05 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic</P>
<P>mebeverine or mebeverine and cognitive behavior therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:33:06 -0400" MODIFIED_BY="John K MacDonald">
<P>Psychological distress (anxiety and depression)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:33:10 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Saps-2009">
<CHAR_METHODS MODIFIED="2011-06-20 13:33:07 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:33:08 -0400" MODIFIED_BY="John K MacDonald">
<P>90 children with functional gastrointestinal disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:33:09 -0400" MODIFIED_BY="John K MacDonald">
<P>Antidepressant</P>
<P>amitriptyline (dose based on weight) or placebo </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:33:10 -0400" MODIFIED_BY="John K MacDonald">
<P>Therapeutic response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-20 13:33:14 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Wittmann-2010">
<CHAR_METHODS MODIFIED="2011-06-20 13:33:11 -0400" MODIFIED_BY="John K MacDonald">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-20 13:33:12 -0400" MODIFIED_BY="John K MacDonald">
<P>412 IBS patients (Rome III)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-20 13:33:14 -0400" MODIFIED_BY="John K MacDonald">
<P>Antispasmodic</P>
<P>alverine citrate (60 mg) with simeticone (300 mg) BID or matching placebo </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-20 13:33:14 -0400" MODIFIED_BY="John K MacDonald">
<P>Abdominal pain </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-06-03 14:30:03 -0400" MODIFIED_BY="John K MacDonald">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-05-12 14:20:24 -0400" MODIFIED_BY="John K MacDonald" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:31:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Aller-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:55:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Arthurs-1983">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:03:22 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Awad-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:23:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bahar-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:49:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Baldi-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:57:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 14:20:24 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bergmann-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 14:38:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Boerner-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 11:07:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Capanni-2005">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 11:59:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Cappello-2007">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:15:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Centonze-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:20:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:23:21 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Czalbert-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:39:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Delmont-1981">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:43:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Dobrilla-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:07:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Drossman-2003">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:28:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Dubarry-1977">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:34:56 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Fielding-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:38:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Fowlie-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:48:22 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Ghidini-1986">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:06:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Gilvarry-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:33:23 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Heefner-1978">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:14:00 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Jalihal-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:28:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Kruis-1986">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:35:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kuiken-2003">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 11:00:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lech-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:34:52 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1977">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:45:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:57:16 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Longstreth-1981">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:04:09 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lucey-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:20:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Masand-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:41:07 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:52:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Moshal-1979">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:01:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Myren-1982">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:04:07 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Nigam-1984">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:07:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Page-1981">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:39:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Passaretti-1989a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:48:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Piai-1979">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:54:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Prior-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:01:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Pulpeiro-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:21:32 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Rajagopalan-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:23:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Rees-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:29:45 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Ritchie-1979">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:38:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Schafer-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:14:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Soltoft-1976">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:18:00 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tabas-2004">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:13:17 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Tack-2006a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:20:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Talley-2008a">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:43:34 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2005">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:49:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2008">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:53:21 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vij-1991">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 13:07:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Virat-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:25:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Arienzo-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-05-30 14:01:30 -0400" MODIFIED_BY="John K MacDonald" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:33:53 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Aller-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:55:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Arthurs-1983">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:07:46 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Awad-1995">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:23:34 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bahar-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:49:56 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Baldi-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:57:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 14:20:29 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bergmann-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 14:38:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Boerner-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 11:07:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Capanni-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:02:20 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Cappello-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:15:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Centonze-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:20:45 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Chen-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:23:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Czalbert-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:39:13 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Delmont-1981">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:43:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Dobrilla-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:08:45 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Drossman-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:28:57 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Dubarry-1977">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:35:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Fielding-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:38:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fowlie-1992">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:48:13 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Ghidini-1986">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:06:57 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Gilvarry-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:33:31 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Heefner-1978">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:14:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Jalihal-1990">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:28:39 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Kruis-1986">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:35:17 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kuiken-2003">
<DESCRIPTION>
<P>Centralized randomization by pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 11:00:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lech-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:42:20 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1977">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:45:50 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:57:08 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Longstreth-1981">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:07:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lucey-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:20:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Masand-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:41:11 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:52:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Moshal-1979">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:01:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Myren-1982">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:04:13 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Nigam-1984">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:08:02 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Page-1981">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:39:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Passaretti-1989a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:49:43 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Piai-1979">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:54:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Prior-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:01:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pulpeiro-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:21:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Rajagopalan-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:23:57 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Rees-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:30:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ritchie-1979">
<DESCRIPTION>
<P>Centralized randomization by hospital pharmacist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:38:21 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Schafer-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-30 14:01:30 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Soltoft-1976">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:20:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tabas-2004">
<DESCRIPTION>
<P>Centralized randomization by hospital pharmacist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:13:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Tack-2006a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:21:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Talley-2008a">
<DESCRIPTION>
<P>Centralized randomization by hospital pharmacy </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:45:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:49:23 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2008">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:54:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Vij-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 13:07:33 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Virat-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:25:24 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Arienzo-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-04-22 06:57:25 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-05-12 14:27:44 -0400" MODIFIED_BY="John K MacDonald" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 12:34:12 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Aller-2004">
<DESCRIPTION>
<P>Single-blind - not described in detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 12:56:08 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Arthurs-1983">
<DESCRIPTION>
<P>Double-blind but procedures not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 13:12:21 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Awad-1995">
<DESCRIPTION>
<P>Double-blind, identical placebo, neither doctors nor patients knew which treatment was given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 13:25:07 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bahar-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 13:50:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Baldi-1991">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 14:05:46 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1998">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 14:27:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bergmann-1991">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-05 14:40:58 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Boerner-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 11:50:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Capanni-2005">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:02:37 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Cappello-2007">
<DESCRIPTION>
<P>Double blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:15:48 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Centonze-1988">
<DESCRIPTION>
<P>Double-blind, procedures not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:21:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:23:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Czalbert-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:39:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Delmont-1981">
<DESCRIPTION>
<P>Double blind - procedures not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:53:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Dobrilla-1990">
<DESCRIPTION>
<P>Double-blind - procedures not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 13:09:00 -0400" MODIFIED_BY="John K MacDonald" RESULT="NO" STUDY_ID="STD-Drossman-2003">
<DESCRIPTION>
<P>Investigator-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 13:29:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Dubarry-1977">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 13:33:07 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fielding-1980">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 13:38:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fowlie-1992">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 13:48:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ghidini-1986">
<DESCRIPTION>
<P>Double-blind design with preparations that were<BR/>outwardly indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 14:09:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Gilvarry-1989">
<DESCRIPTION>
<P>Double blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 14:33:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Heefner-1978">
<DESCRIPTION>
<P>Double blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 10:15:06 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Jalihal-1990">
<DESCRIPTION>
<P>Double-blind, treatment was indistinguishable from the placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 10:29:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Kruis-1986">
<DESCRIPTION>
<P>Mebeverine and placebo arms were double-blind. Methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 10:49:11 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kuiken-2003">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 11:01:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lech-1988">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 12:42:31 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1977">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 12:46:08 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Liu-1997">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 12:57:29 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Longstreth-1981">
<DESCRIPTION>
<P>Double-blind, identical sachets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 13:07:42 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lucey-1987">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 13:23:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Masand-2009">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 13:38:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Mitchell-2002">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 13:51:54 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Moshal-1979">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 14:02:06 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Myren-1982">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 14:04:54 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Nigam-1984">
<DESCRIPTION>
<P>Double-blind, double-dummy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 14:09:37 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Page-1981">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-11 14:40:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Passaretti-1989a">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 08:51:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Piai-1979">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 08:57:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Prior-1987">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 09:01:56 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pulpeiro-2000">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 09:17:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Rajagopalan-1998">
<DESCRIPTION>
<P>Double-blind, identical placebo, all investigators and patients were blind to the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 09:24:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="NO" STUDY_ID="STD-Rees-2005">
<DESCRIPTION>
<P>Single-blind (patients)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 09:31:08 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ritchie-1979">
<DESCRIPTION>
<P>Double-blind, double-dummy. Dummy preparations were identical to active</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 09:39:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Schafer-1990">
<DESCRIPTION>
<P>Double-blind, methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 10:12:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Soltoft-1976">
<DESCRIPTION>
<P>Double-blind, placebo of similar appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 10:22:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tabas-2004">
<DESCRIPTION>
<P>Double-blind, researchers and patients were unaware of assignment until the conclusion of the last visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 12:16:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tack-2006a">
<DESCRIPTION>
<P>Double-blind, matching placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 12:21:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Talley-2008a">
<DESCRIPTION>
<P>Double-blind, double-dummy, identical capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 12:44:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2005">
<DESCRIPTION>
<P>Double-blind, identical placebo. Both patients and<BR/>researchers were unaware of the true identity of the<BR/>prescribed medicine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 12:49:42 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2008">
<DESCRIPTION>
<P>Double-blind, identical placebo. Both patients and<BR/>researchers were unaware of the true identity of the<BR/>prescribed medicine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 12:53:50 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vij-1991">
<DESCRIPTION>
<P>Double-blind, identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-12 13:07:39 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Virat-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-10 12:25:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Arienzo-1980">
<DESCRIPTION>
<P>Double blind, procedures not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-03 14:30:03 -0400" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 12:35:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Aller-2004">
<DESCRIPTION>
<P>No patients dropped out of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 12:56:20 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Arthurs-1983">
<DESCRIPTION>
<P>Two dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 13:12:43 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Awad-1995">
<DESCRIPTION>
<P>Two dropouts one from each treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 13:26:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bahar-2008">
<DESCRIPTION>
<P>2 drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 13:53:21 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baldi-1991">
<DESCRIPTION>
<P>One drop-out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 14:08:37 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Battaglia-1998">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 14:27:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bergmann-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-05 14:41:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Boerner-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-03 14:27:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Capanni-2005">
<DESCRIPTION>
<P>3 drop-outs from peppermint oil group and 2 drop-outs from placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 12:04:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Cappello-2007">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 12:16:37 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Centonze-1988">
<DESCRIPTION>
<P>Four patients (one in the drug group, three in the<BR/>placebo group) did not complete the study, three because of noncompliance and one because he moved<BR/>away.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 12:21:34 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 12:23:29 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Czalbert-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 12:40:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Delmont-1981">
<DESCRIPTION>
<P>3 drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:02:58 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Dobrilla-1990">
<DESCRIPTION>
<P>1 drop-out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:10:59 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Drossman-2003">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:31:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Dubarry-1977">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:36:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fielding-1980">
<DESCRIPTION>
<P>7 drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:39:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fowlie-1992">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:52:57 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ghidini-1986">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 13:56:30 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Gilvarry-1989">
<DESCRIPTION>
<P>2 drop outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 14:34:46 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Heefner-1978">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 10:16:42 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Jalihal-1990">
<DESCRIPTION>
<P>No drop-outs. Two patients were eligible but dropped out before the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 10:30:45 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kruis-1986">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 10:50:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kuiken-2003">
<DESCRIPTION>
<P>6 patients dropped out (2 from treatment group and 4 from placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 11:01:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Lech-1988">
<DESCRIPTION>
<P>No drop-outs </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 12:42:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Levy-1977">
<DESCRIPTION>
<P>No drop outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 12:47:39 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Liu-1997">
<DESCRIPTION>
<P>9 drop-outs: 3 patients on Colpermin and 6 on placebo did not return for follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 12:57:56 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Longstreth-1981">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 13:11:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Lucey-1987">
<DESCRIPTION>
<P>16 patients dropped out. Reasons for withdrawal not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 13:19:46 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Masand-2009">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 13:40:35 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Mitchell-2002">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 13:53:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Moshal-1979">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 14:02:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Myren-1982">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 14:05:54 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Nigam-1984">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-11 14:29:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Page-1981">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 08:55:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Passaretti-1989a">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 08:52:29 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Piai-1979">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 08:56:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Prior-1987">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 09:15:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pulpeiro-2000">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 09:20:58 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Rajagopalan-1998">
<DESCRIPTION>
<P>The same number of patients dropped out from each group. Reasons for drop-out were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-03 14:30:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Rees-2005">
<DESCRIPTION>
<P>2 patients dropped out from treatment group and 4 dropped out from placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 09:32:17 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ritchie-1979">
<DESCRIPTION>
<P>4 drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-02 11:56:23 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Schafer-1990">
<DESCRIPTION>
<P>Drop outs not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 10:15:31 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Soltoft-1976">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 10:23:31 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tabas-2004">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 12:15:20 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tack-2006a">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 12:25:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Talley-2008a">
<DESCRIPTION>
<P>Reasons for drop-out not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 12:46:23 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2005">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 12:50:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2008">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 12:54:48 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vij-1991">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-12 13:08:58 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Virat-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 12:25:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Arienzo-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-05-12 14:28:03 -0400" MODIFIED_BY="John K MacDonald" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:36:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Aller-2004">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:56:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Arthurs-1983">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:13:24 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Awad-1995">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:38:54 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bahar-2008">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:53:19 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baldi-1991">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 14:09:37 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Battaglia-1998">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 14:28:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bergmann-1991">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 14:41:24 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Boerner-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 11:52:34 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Capanni-2005">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:04:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Cappello-2007">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:16:53 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Centonze-1988">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:21:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:23:31 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Czalbert-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:40:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Delmont-1981">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:03:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Dobrilla-1990">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:21:32 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Drossman-2003">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:31:54 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Dubarry-1977">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:36:22 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fielding-1980">
<DESCRIPTION>
<P>All expected outcomes were reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:40:42 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fowlie-1992">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:53:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ghidini-1986">
<DESCRIPTION>
<P>Expected outcomes are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:09:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Gilvarry-1989">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:35:20 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Heefner-1978">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:17:11 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Jalihal-1990">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:31:42 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kruis-1986">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:50:48 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kuiken-2003">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 11:01:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Lech-1988">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:44:12 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Levy-1977">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:48:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Liu-1997">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:58:40 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Longstreth-1981">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:12:11 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Lucey-1987">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:23:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Masand-2009">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:41:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Mitchell-2002">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:53:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Moshal-1979">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:02:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Myren-1982">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:06:06 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Nigam-1984">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:29:50 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Page-1981">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:40:56 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Passaretti-1989a">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:52:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Piai-1979">
<DESCRIPTION>
<P>All expected outcomes are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:58:08 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Prior-1987">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:15:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pulpeiro-2000">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:22:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Rajagopalan-1998">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:27:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Rees-2005">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:32:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ritchie-1979">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:09:44 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Schafer-1990">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:16:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Soltoft-1976">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:23:40 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tabas-2004">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:18:50 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tack-2006a">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:25:57 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Talley-2008a">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:47:30 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2005">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:51:24 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2008">
<DESCRIPTION>
<P>Expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:55:11 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vij-1991">
<DESCRIPTION>
<P>Expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 13:08:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Virat-1987">
<DESCRIPTION>
<P>Expected outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:25:53 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Arienzo-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-05-12 14:28:17 -0400" MODIFIED_BY="John K MacDonald" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:51:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Aller-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 12:56:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Arthurs-1983">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:13:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Awad-1995">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:39:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bahar-2008">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 13:54:07 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baldi-1991">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 14:09:52 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Battaglia-1998">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 14:28:17 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bergmann-1991">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-05 14:41:29 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Boerner-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 11:52:47 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Capanni-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:04:58 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Cappello-2007">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:17:03 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Centonze-1988">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:21:38 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:23:33 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Czalbert-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:40:46 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Delmont-1981">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:03:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Dobrilla-1990">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:21:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Drossman-2003">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:32:05 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Dubarry-1977">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:36:33 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fielding-1980">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:40:54 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fowlie-1992">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 13:53:29 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ghidini-1986">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:09:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Gilvarry-1989">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 14:35:41 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Heefner-1978">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:18:16 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Jalihal-1990">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:31:52 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kruis-1986">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:50:58 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Kuiken-2003">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 11:02:06 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Lech-1988">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:44:28 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Levy-1977">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:48:13 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Liu-1997">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 12:58:50 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Longstreth-1981">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:12:21 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Lucey-1987">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:24:16 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Masand-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:41:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Mitchell-2002">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 13:54:04 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Moshal-1979">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:02:43 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Myren-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:06:11 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Nigam-1984">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:30:00 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Page-1981">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 14:41:09 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Passaretti-1989a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:52:59 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Piai-1979">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 08:58:26 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Prior-1987">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:15:56 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pulpeiro-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:22:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Rajagopalan-1998">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:27:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Rees-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 09:32:46 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Ritchie-1979">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:09:53 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Schafer-1990">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:16:13 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Soltoft-1976">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 10:23:52 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tabas-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:19:06 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Tack-2006a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:26:08 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Talley-2008a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:47:45 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:51:34 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vahedi-2008">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 12:55:24 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Vij-1991">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 13:08:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Virat-1987">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 12:25:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Arienzo-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2011-05-05 12:28:16 -0400" MODIFIED_BY="John K MacDonald" NO="7">
<NAME>Risk of bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-04-26 12:57:45 -0400" MODIFIED_BY="John K MacDonald"/>
<ADDITIONAL_TABLES MODIFIED="2013-02-21 09:50:02 -0500" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-02-20 14:32:28 -0500" MODIFIED_BY="John K MacDonald" NO="1">
<TITLE MODIFIED="2011-04-26 12:57:33 -0400" MODIFIED_BY="John K MacDonald">Bulking agents: main results</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Dichotomous outcomes</B>
</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>
<B>Continuous outcomes</B>
</P>
<P>SMD (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal pain</P>
</TD>
<TD>
<P>0.91 (0.61 to 1.36)</P>
<P/>
</TD>
<TD>
<P>0.03 (-0.34 to 0.40)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment</P>
</TD>
<TD>
<P>1.11 (0.91 to 1.35)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symptom score</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.00 (-0.43 to 0.43)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-02-21 09:10:53 -0500" MODIFIED_BY="John K MacDonald" NO="2">
<TITLE MODIFIED="2013-02-20 14:16:07 -0500" MODIFIED_BY="John K MacDonald">Antispasmodics: main results</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Dichotomous outcomes</B>
</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>
<B>Continuous outcomes</B>
</P>
<P>SMD (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal pain</P>
</TD>
<TD>
<P>1.32 (1.12 to 1.55)</P>
<P/>
</TD>
<TD>
<P>1.14 (0.47 to 1.81)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment</P>
</TD>
<TD>
<P>1.49 (1.25 to 1.77)</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symptom score</P>
</TD>
<TD>
<P>1.86 (1.26 to 2.76)</P>
<P/>
</TD>
<TD>
<P>2.39 (0.50 to 4.29)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-02-21 09:50:02 -0500" MODIFIED_BY="John K MacDonald" NO="3">
<TITLE MODIFIED="2013-02-20 14:15:29 -0500" MODIFIED_BY="John K MacDonald">Antidepressants: main results</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Dichotomous outcomes</B>
</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>
<B>Continuous outcomes</B>
</P>
<P>SMD (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal pain</P>
</TD>
<TD>
<P>1.49 (1.05 to 2.12)</P>
<P/>
</TD>
<TD>
<P>1.80 (-0.57 to 4.16)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Global assessment</P>
</TD>
<TD>
<P>1.57 (1.23 to 2.00)</P>
<P/>
</TD>
<TD VALIGN="BOTTOM">
<P>3.32 (1.95 to 4.68)</P>
</TD>
</TR>
<TR>
<TD>
<P>Symptom score</P>
</TD>
<TD>
<P>1.99 (1.32 to 2.99)</P>
<P/>
</TD>
<TD>
<P>0.38 (-0.30 to 1.06)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-02-20 14:39:27 -0500" MODIFIED_BY="John K MacDonald">
<COMPARISON ID="CMP-001" MODIFIED="2013-02-20 14:39:27 -0500" MODIFIED_BY="John K MacDonald" NO="1">
<NAME>Bulking agents: Abdominal pain</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3584731079881218" CI_START="0.6136657312483186" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.13305104564830553" LOG_CI_START="-0.21206812821565285" LOG_EFFECT_SIZE="-0.039508541283673634" METHOD="MH" MODIFIED="2010-05-11 13:29:31 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6536153433395866" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.4487453834033472">
<NAME>Comparing nr(%) of successfully treated IBS patients</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bulking agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-03-31 14:09:06 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Insoluble fibres</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3584731079881218" CI_START="0.6136657312483186" DF="0" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.13305104564830553" LOG_CI_START="-0.21206812821565285" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2009-05-12 10:31:17 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6536153433395866" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.4487453834033472">
<NAME>Soluble fibres</NAME>
<DICH_DATA CI_END="1.3584731079881218" CI_START="0.6136657312483186" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.13305104564830553" LOG_CI_START="-0.21206812821565285" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2009-05-12 10:16:00 -0400" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.20272471109515197" STUDY_ID="STD-Prior-1987" TOTAL_1="40" TOTAL_2="40" VAR="0.04109730848861284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.023660435691969656" CI_END="0.3951164250724343" CI_START="-0.33624710505086297" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.029434660010785634" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-02-20 14:39:27 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.8777520807868788" P_Q="0.8777520807868788" P_Z="0.8746439405085928" Q="0.023660435691969656" RANDOM="NO" SCALE="2.99" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="95" UNITS="" WEIGHT="100.0" Z="0.15776251109648678">
<NAME>Comparing scores on abdominal pain in IBS patients</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bulking agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5238224086117986" CI_START="-0.5238224086117986" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2010-03-31 14:09:06 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="61" WEIGHT="48.734718594280245" Z="0.0">
<NAME>Insoluble fibres</NAME>
<CONT_DATA CI_END="0.5238224086117986" CI_START="-0.5238224086117986" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.6" MODIFIED="2009-05-12 10:33:16 -0400" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="1.5" SD_2="1.9" SE="0.2672612419124244" STUDY_ID="STD-Aller-2004" TOTAL_1="28" TOTAL_2="28" WEIGHT="48.734718594280245"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-5.0" MEAN_2="-5.0" MODIFIED="2009-05-18 08:27:32 -0400" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Fowlie-1992" TOTAL_1="23" TOTAL_2="19" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.8" MEAN_2="-0.9" MODIFIED="2009-05-18 08:28:38 -0400" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Rees-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5681466720378079" CI_START="-0.45331394624884314" DF="0" EFFECT_SIZE="0.05741636289448235" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2009-05-12 10:30:00 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8256068473474821" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="34" WEIGHT="51.26528140571975" Z="0.2203393873083947">
<NAME>Soluble fibres</NAME>
<CONT_DATA CI_END="0.5681466720378079" CI_START="-0.45331394624884314" EFFECT_SIZE="0.05741636289448235" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="-0.62" MODIFIED="2009-05-12 10:30:00 -0400" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="0.51" SD_2="0.52" SE="0.26058147658421327" STUDY_ID="STD-Longstreth-1981" TOTAL_1="26" TOTAL_2="34" WEIGHT="51.26528140571975"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-06-01 10:57:53 -0400" MODIFIED_BY="John K MacDonald" NO="2">
<NAME>Bulking agents: Global assessment</NAME>
<DICH_OUTCOME CHI2="15.486203708618646" CI_END="1.334926402517544" CI_START="0.9110937729066672" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1028341364967051" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="136" I2="35.426395079417496" I2_Q="52.3299238823906" ID="CMP-002.01" LOG_CI_END="0.12545732273310956" LOG_CI_START="-0.04043692164383577" LOG_EFFECT_SIZE="0.042510200544636875" METHOD="MH" MODIFIED="2010-03-31 10:14:36 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.11531554137208544" P_Q="0.14751593143214936" P_Z="0.3151488491937138" Q="2.0977520521109434" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03342635814018944" TOTALS="YES" TOTAL_1="286" TOTAL_2="279" WEIGHT="100.0" Z="1.0044768262574184">
<NAME>Comparing nr(%) of successfully treated patients with IBS</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bulking agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.264560728107374" CI_END="1.1880350331931715" CI_START="0.7556502777875558" DF="4" EFFECT_SIZE="0.9474908985598585" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="61" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.07482924746179688" LOG_CI_START="-0.12167915366277017" LOG_EFFECT_SIZE="-0.023424953100486666" MODIFIED="2010-03-31 10:14:36 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.8673590129435726" P_Z="0.6403007185868748" STUDIES="5" TAU2="0.0" TOTAL_1="125" TOTAL_2="119" WEIGHT="45.60690024883193" Z="0.46727838762873025">
<NAME>Insoluble fibres</NAME>
<DICH_DATA CI_END="1.2767465679991774" CI_START="0.5619820475753912" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.10610469910950646" LOG_CI_START="-0.25027755767555504" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2010-03-31 10:14:36 -0400" MODIFIED_BY="John K MacDonald" ORDER="145" O_E="0.0" SE="0.20934070175616756" STUDY_ID="STD-Fowlie-1992" TOTAL_1="25" TOTAL_2="24" VAR="0.0438235294117647" WEIGHT="12.292493445583737"/>
<DICH_DATA CI_END="1.8291245961295475" CI_START="0.4593879386652046" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2622432897128899" LOG_CI_START="-0.3378204114916895" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-30 14:08:53 -0400" MODIFIED_BY="John K MacDonald" ORDER="146" O_E="0.0" SE="0.3524803884507963" STUDY_ID="STD-Kruis-1986" TOTAL_1="40" TOTAL_2="40" VAR="0.12424242424242427" WEIGHT="6.022712435871451"/>
<DICH_DATA CI_END="1.690372762834315" CI_START="0.7158184434841136" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.22798248626499776" LOG_CI_START="-0.14519711594854762" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2010-03-30 14:15:17 -0400" MODIFIED_BY="John K MacDonald" ORDER="135" O_E="0.0" SE="0.2192075456090599" STUDY_ID="STD-Lucey-1987" TOTAL_1="14" TOTAL_2="14" VAR="0.04805194805194807" WEIGHT="11.654559118659135"/>
<DICH_DATA CI_END="2.2852680015509117" CI_START="0.571540164257839" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3589371386595261" LOG_CI_START="-0.24295324470415264" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2010-03-30 14:18:39 -0400" MODIFIED_BY="John K MacDonald" ORDER="270" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Rees-2005" TOTAL_1="14" TOTAL_2="14" VAR="0.125" WEIGHT="5.9939125506135404"/>
<DICH_DATA CI_END="1.390931429155334" CI_START="0.5118254196990297" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.14330572044963152" LOG_CI_START="-0.2908781487714688" LOG_EFFECT_SIZE="-0.07378621416091867" MODIFIED="2010-03-30 14:05:16 -0400" MODIFIED_BY="John K MacDonald" ORDER="271" O_E="0.0" SE="0.25504175402528956" STUDY_ID="STD-Soltoft-1976" TOTAL_1="32" TOTAL_2="27" VAR="0.0650462962962963" WEIGHT="9.643222698104063"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.711754779860577" CI_END="1.783607515789597" CI_START="0.9139855152895192" DF="5" EFFECT_SIZE="1.27678950277374" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="75" I2="57.30784930198544" ID="CMP-002.01.02" LOG_CI_END="0.25129929371741716" LOG_CI_START="-0.03906068684787537" LOG_EFFECT_SIZE="0.10611930343477088" MODIFIED="2010-03-31 09:58:49 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.03895817785870226" P_Z="0.15196202153418523" STUDIES="6" TAU2="0.08054670870695162" TOTAL_1="161" TOTAL_2="160" WEIGHT="54.393099751168066" Z="1.4326355332556475">
<NAME>Soluble fibre</NAME>
<DICH_DATA CI_END="1.5633225299711984" CI_START="0.8428923963856568" EFFECT_SIZE="1.1479166666666667" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.19404858680771975" LOG_CI_START="-0.07422786385532405" LOG_EFFECT_SIZE="0.05991036147619784" MODIFIED="2009-05-18 08:32:17 -0400" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.15758691510932027" STUDY_ID="STD-Arthurs-1983" TOTAL_1="40" TOTAL_2="38" VAR="0.024833635813672116" WEIGHT="16.299241931890666"/>
<DICH_DATA CI_END="2.1048763927551986" CI_START="0.7155756757459211" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.32322659731158015" LOG_CI_START="-0.14534443063801805" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2009-05-12 10:53:10 -0400" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.27524094128159016" STUDY_ID="STD-Jalihal-1990" TOTAL_1="11" TOTAL_2="9" VAR="0.07575757575757577" WEIGHT="8.69719291570528"/>
<DICH_DATA CI_END="1.3309101791105258" CI_START="0.6098251001329621" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.12414874665953987" LOG_CI_START="-0.2147947042328547" LOG_EFFECT_SIZE="-0.04532297878665743" MODIFIED="2010-03-31 09:45:09 -0400" MODIFIED_BY="John K MacDonald" ORDER="151" O_E="0.0" SE="0.19909706085133363" STUDY_ID="STD-Longstreth-1981" TOTAL_1="37" TOTAL_2="40" VAR="0.039639639639639644" WEIGHT="12.996383615616976"/>
<DICH_DATA CI_END="276.8532558969522" CI_START="1.0438743046878565" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.442249635342138" LOG_CI_START="0.0186482074144104" LOG_EFFECT_SIZE="1.2304489213782739" MODIFIED="2010-03-31 09:58:49 -0400" MODIFIED_BY="John K MacDonald" ORDER="273" O_E="0.0" SE="1.4236354757853005" STUDY_ID="STD-Nigam-1984" TOTAL_1="21" TOTAL_2="21" VAR="2.0267379679144386" WEIGHT="0.46093106476754775"/>
<DICH_DATA CI_END="2.1803668839594432" CI_START="1.1325560726815613" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.3385295772160079" LOG_CI_START="0.05405971307192849" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2009-05-12 10:53:27 -0400" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.1670990063467701" STUDY_ID="STD-Prior-1987" TOTAL_1="40" TOTAL_2="40" VAR="0.027922077922077918" WEIGHT="15.478695095677088"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2010-03-30 14:27:56 -0400" MODIFIED_BY="John K MacDonald" ORDER="272" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Ritchie-1979" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.46065512751050725"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.306389140482648" CI_START="-0.7446320345394954" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2191214470284237" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2011-06-01 10:57:53 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4137892601353452" Q="0.0" RANDOM="NO" SCALE="2.7574215797236072" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="0.817243562018555">
<NAME>Comparing scores on global assessment in IBS patients</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bulking agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.306389140482648" CI_START="-0.7446320345394954" DF="0" EFFECT_SIZE="-0.2191214470284237" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2009-05-18 08:36:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4137892601353452" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.817243562018555">
<NAME>Insoluble fibres</NAME>
<CONT_DATA CI_END="0.306389140482648" CI_START="-0.7446320345394954" EFFECT_SIZE="-0.2191214470284237" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.3" MODIFIED="2009-05-18 08:36:28 -0400" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="0.9" SD_2="0.9" SE="0.2681225735045297" STUDY_ID="STD-Aller-2004" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2009-05-12 10:47:54 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Soluble fibres</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-06-02 13:21:16 -0400" MODIFIED_BY="John K MacDonald" NO="3">
<NAME>Bulking agents: Outcome on symptom score</NAME>
<CONT_OUTCOME CHI2="2.0130225567305504" CI_END="0.4295431169718472" CI_START="-0.4317296082599984" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.0010932456440755876" ESTIMABLE="YES" I2="50.323457794524195" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-06-02 13:21:16 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.15595471938929517" P_Q="1.0" P_Z="0.9960299733910923" Q="0.0" RANDOM="NO" SCALE="2.543477685929533" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.004975711005051619">
<NAME>Comparing symptom scores in IBS patients</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bulking agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0130225567305504" CI_END="0.4295431169718472" CI_START="-0.4317296082599984" DF="1" EFFECT_SIZE="-0.0010932456440755876" ESTIMABLE="YES" I2="50.323457794524195" ID="CMP-003.01.01" MODIFIED="2009-05-14 07:23:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15595471938929517" P_Z="0.9960299733910923" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="61" WEIGHT="100.0" Z="0.004975711005051619">
<NAME>Insoluble fibres</NAME>
<CONT_DATA CI_END="0.306389140482648" CI_START="-0.7446320345394954" EFFECT_SIZE="-0.2191214470284237" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.3" MODIFIED="2009-05-14 07:22:44 -0400" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="0.9" SD_2="0.9" SE="0.2681225735045297" STUDY_ID="STD-Aller-2004" TOTAL_1="28" TOTAL_2="28" WEIGHT="67.1519234253408"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-5.0" MEAN_2="-3.0" MODIFIED="2009-05-14 07:23:17 -0400" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Fowlie-1992" TOTAL_1="23" TOTAL_2="19" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.1959990366769468" CI_START="-0.30674745239622864" EFFECT_SIZE="0.4446257921403591" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-3.5" MODIFIED="2009-05-14 07:23:38 -0400" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="4.6" SD_2="6.2" SE="0.38336074053570574" STUDY_ID="STD-Lucey-1987" TOTAL_1="14" TOTAL_2="14" WEIGHT="32.848076574659196"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" MODIFIED="2009-05-14 07:13:34 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Soluble fibres</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-06-03 09:26:35 -0400" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Spasmolytics: Abdominal pain</NAME>
<DICH_OUTCOME CHI2="25.95187837161857" CI_END="1.545219309030622" CI_START="1.1240613261764474" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3179230879464914" ESTIMABLE="YES" EVENTS_1="407" EVENTS_2="323" I2="53.76057244040027" I2_Q="64.55726862280665" ID="CMP-004.01" LOG_CI_END="0.18899012644214297" LOG_CI_START="0.05079000597813114" LOG_EFFECT_SIZE="0.1198900662101371" METHOD="MH" MODIFIED="2011-06-03 09:26:35 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.010903428785947411" P_Q="0.003960061356574784" P_Z="6.72433091013812E-4" Q="22.571623825662122" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03858206709757511" TOTALS="YES" TOTAL_1="696" TOTAL_2="696" WEIGHT="100.0" Z="3.400578973260469">
<NAME>Comparing nr(%) of successfully treated IBS patients on Abdominal pain</NAME>
<GROUP_LABEL_1>Spasmolytic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6156548796135919" CI_START="0.8745421847174054" DF="0" EFFECT_SIZE="1.1886792452830188" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.2083485966077298" LOG_CI_START="-0.05821923690214449" LOG_EFFECT_SIZE="0.07506467985279265" MODIFIED="2009-05-19 06:12:31 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2696627290085629" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="10.443835714713856" Z="1.1038396274999416">
<NAME>Alverine</NAME>
<DICH_DATA CI_END="1.6156548796135919" CI_START="0.8745421847174054" EFFECT_SIZE="1.1886792452830188" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.2083485966077298" LOG_CI_START="-0.05821923690214449" LOG_EFFECT_SIZE="0.07506467985279265" MODIFIED="2009-05-19 05:26:13 -0400" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.15658326493575714" STUDY_ID="STD-Mitchell-2002" TOTAL_1="53" TOTAL_2="54" VAR="0.024518318857941507" WEIGHT="10.443835714713856"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2757783352397944E-31" CI_END="2.27509789729734" CI_START="1.0635819624703857" DF="0" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" I2="100.0" ID="CMP-004.01.02" LOG_CI_END="0.35700008905523195" LOG_CI_START="0.02677096342259433" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2010-03-31 12:04:49 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Z="0.022741828846459065" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="8.64733455866702" Z="2.27774409578375">
<NAME>Cimetropium/dicylomine</NAME>
<DICH_DATA CI_END="2.27509789729734" CI_START="1.0635819624703857" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" LOG_CI_END="0.35700008905523195" LOG_CI_START="0.02677096342259433" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2010-03-31 12:04:49 -0400" MODIFIED_BY="John K MacDonald" ORDER="132" O_E="0.0" SE="0.19397822305714674" STUDY_ID="STD-Page-1981" TOTAL_1="48" TOTAL_2="49" VAR="0.03762755102040817" WEIGHT="8.64733455866702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.756836446165568" CI_START="0.3810380238094276" DF="0" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.24473133244919257" LOG_CI_START="-0.4190316838869928" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2009-11-05 04:17:51 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6067799575937851" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="3.4575142652013073" Z="0.5146752725037884">
<NAME>Mebeverine</NAME>
<DICH_DATA CI_END="1.756836446165568" CI_START="0.3810380238094276" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.24473133244919257" LOG_CI_START="-0.4190316838869928" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="37" O_E="0.0" SE="0.38989768147579695" STUDY_ID="STD-Kruis-1986" TOTAL_1="40" TOTAL_2="40" VAR="0.15202020202020203" WEIGHT="3.4575142652013073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6769545282361786" CI_START="0.9627837775373562" DF="0" EFFECT_SIZE="1.2706473214285714" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="56" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.22452128657516762" LOG_CI_START="-0.016471235997094852" LOG_EFFECT_SIZE="0.10402502528903639" MODIFIED="2009-11-05 04:17:48 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0906370669697046" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="165" WEIGHT="11.241808316362622" Z="1.6920467148207383">
<NAME>Otilonium</NAME>
<DICH_DATA CI_END="1.6769545282361786" CI_START="0.9627837775373562" EFFECT_SIZE="1.2706473214285714" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="56" LOG_CI_END="0.22452128657516762" LOG_CI_START="-0.016471235997094852" LOG_EFFECT_SIZE="0.10402502528903639" ORDER="28" O_E="0.0" SE="0.1415602006911731" STUDY_ID="STD-Battaglia-1998" TOTAL_1="160" TOTAL_2="165" VAR="0.020039290419725204" WEIGHT="11.241808316362622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.004014981098871" CI_START="1.5442843273507578" DF="0" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="21" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="0.4777020941751232" LOG_CI_START="0.18872726389564168" LOG_EFFECT_SIZE="0.33321467903538243" MODIFIED="2009-11-05 04:17:45 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="6.182820281644868E-6" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="49" WEIGHT="9.778247989327928" Z="4.52003912865207">
<NAME>Peppermint oil</NAME>
<DICH_DATA CI_END="3.004014981098871" CI_START="1.5442843273507578" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="21" LOG_CI_END="0.4777020941751232" LOG_CI_START="0.18872726389564168" LOG_EFFECT_SIZE="0.33321467903538243" ORDER="27" O_E="0.0" SE="0.16974524575464725" STUDY_ID="STD-Liu-1997" TOTAL_1="52" TOTAL_2="49" VAR="0.028813448456305592" WEIGHT="9.778247989327928"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0413922523895716" CI_END="2.2588047770456066" CI_START="1.0846874112964866" DF="2" EFFECT_SIZE="1.565278603392296" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="36" I2="34.2406426389548" ID="CMP-004.01.06" LOG_CI_END="0.3538786975358673" LOG_CI_START="0.035304599835794835" LOG_EFFECT_SIZE="0.1945916486858311" MODIFIED="2009-11-05 04:17:41 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.21855976778988295" P_Z="0.016648804011399267" STUDIES="3" TAU2="0.03859946642088766" TOTAL_1="79" TOTAL_2="79" WEIGHT="18.82266938518729" Z="2.3943730885212715">
<NAME>Pinaverium</NAME>
<DICH_DATA CI_END="4.359544801048567" CI_START="1.1612450911807022" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6394411450682944" LOG_CI_START="0.06492389115443047" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="29" O_E="0.0" SE="0.3374742788552765" STUDY_ID="STD-Delmont-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.1138888888888889" WEIGHT="4.322200645957505"/>
<DICH_DATA CI_END="3.4594443824994294" CI_START="0.9365665817292654" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5390063528415914" LOG_CI_START="-0.02846134263497925" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="30" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dubarry-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.1111111111111111" WEIGHT="4.402405455883446"/>
<DICH_DATA CI_END="1.7366122058970768" CI_START="0.9154559982320631" EFFECT_SIZE="1.2608695652173914" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.23970284916571025" LOG_CI_START="-0.03836252540298379" LOG_EFFECT_SIZE="0.10067016188136323" ORDER="31" O_E="0.0" SE="0.16333697746745404" STUDY_ID="STD-Virat-1987" TOTAL_1="39" TOTAL_2="39" VAR="0.02667896820820359" WEIGHT="10.09806328334634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7762721743685985" CI_START="0.2502119049421176" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-004.01.07" LOG_CI_END="0.2495095125517467" LOG_CI_START="-0.6016920306631093" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-11-05 04:17:38 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.41740575426480886" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.283614055032842" Z="0.8109302162163289">
<NAME>Pirenzepine</NAME>
<DICH_DATA CI_END="1.7762721743685985" CI_START="0.2502119049421176" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2495095125517467" LOG_CI_START="-0.6016920306631093" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-05-19 07:14:18 -0400" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.5" STUDY_ID="STD-Gilvarry-1989" TOTAL_1="12" TOTAL_2="12" VAR="0.25" WEIGHT="2.283614055032842"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:17:34 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Propinox</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1870086975047789" CI_START="0.8371212749891146" DF="0" EFFECT_SIZE="0.9968300929839391" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="104" I2="0.0" ID="CMP-004.01.09" LOG_CI_END="0.07445390114877255" LOG_CI_START="-0.07721162056915441" LOG_EFFECT_SIZE="-0.0013788597101909467" MODIFIED="2009-11-05 04:41:23 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.9715711400004021" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="178" WEIGHT="14.166492026629157" Z="0.035637834375222464">
<NAME>Scopolamine derivatives</NAME>
<DICH_DATA CI_END="1.1870086975047789" CI_START="0.8371212749891146" EFFECT_SIZE="0.9968300929839391" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="104" LOG_CI_END="0.07445390114877255" LOG_CI_START="-0.07721162056915441" LOG_EFFECT_SIZE="-0.0013788597101909467" ORDER="33" O_E="0.0" SE="0.08908907821355082" STUDY_ID="STD-Schafer-1990" TOTAL_1="182" TOTAL_2="178" VAR="0.007936863856940174" WEIGHT="14.166492026629157"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7724544212831737" CI_END="1.6368808683165925" CI_START="1.0651085343755948" DF="2" EFFECT_SIZE="1.320399857088805" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" I2="0.0" ID="CMP-004.01.10" LOG_CI_END="0.21401707274399745" LOG_CI_START="0.02739386456233121" LOG_EFFECT_SIZE="0.12070546865316427" MODIFIED="2009-11-05 04:17:26 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6796162737222348" P_Z="0.01123322910124487" STUDIES="3" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="21.158483688877965" Z="2.535358529116443">
<NAME>Trimebutine</NAME>
<DICH_DATA CI_END="2.074779612387376" CI_START="0.5735947266508528" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3169719717915858" LOG_CI_START="-0.24139485001278627" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="34" O_E="0.0" SE="0.32798743508823264" STUDY_ID="STD-Fielding-1980" TOTAL_1="30" TOTAL_2="30" VAR="0.1075757575757576" WEIGHT="4.508893491863067"/>
<DICH_DATA CI_END="1.761694028995675" CI_START="1.0824975546663056" EFFECT_SIZE="1.380952380952381" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.24593048236345064" LOG_CI_START="0.034426923966623" LOG_EFFECT_SIZE="0.1401787031650368" ORDER="35" O_E="0.0" SE="0.12423823716179574" STUDY_ID="STD-Ghidini-1986" TOTAL_1="30" TOTAL_2="30" VAR="0.015435139573070605" WEIGHT="12.200002648648164"/>
<DICH_DATA CI_END="2.231755823837059" CI_START="0.6098835260440598" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.34864667675249594" LOG_CI_START="-0.21475309749126947" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="36" O_E="0.0" SE="0.33094381626464864" STUDY_ID="STD-Moshal-1979" TOTAL_1="10" TOTAL_2="10" VAR="0.10952380952380952" WEIGHT="4.449587548366735"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="53.252485949142695" CI_END="1.8102251934869473" CI_START="0.46716371281658386" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="1.1386944531517655" ESTIMABLE="YES" I2="88.73292036407439" I2_Q="92.3103989801724" ID="CMP-004.02" MODIFIED="2010-05-05 13:42:20 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="1.0436477237973918E-9" P_Q="1.367365110027663E-10" P_Z="8.891075308087321E-4" Q="52.018303546387116" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.7175843922957509" TOTALS="YES" TOTAL_1="227" TOTAL_2="228" UNITS="" WEIGHT="100.0" Z="3.32345190401713">
<NAME>Comparing scores on abdominal pain in IBS patients</NAME>
<GROUP_LABEL_1>Spasmolitic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.01" MODIFIED="2009-05-19 06:16:19 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Alvarine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2341824027555806" CI_END="1.4331109575608134" CI_START="0.7327874174086766" DF="2" EFFECT_SIZE="1.082949187484745" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2009-11-05 04:42:43 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.539511789566471" P_Z="1.347720915675816E-9" STUDIES="3" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="42.94754982311262" Z="6.0616023391014915">
<NAME>Cimetropium/dicyclomine</NAME>
<CONT_DATA CI_END="1.9079473782411103" CI_START="0.6032830371528768" EFFECT_SIZE="1.2556152076969935" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-1.48" MODIFIED="2009-11-05 04:42:32 -0500" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="0.48" SD_2="1.3" SE="0.3328286517964767" STUDY_ID="STD-Centonze-1988" TOTAL_1="23" TOTAL_2="21" WEIGHT="14.171533881824653"/>
<CONT_DATA CI_END="1.6665184497038394" CI_START="0.6426157320494545" EFFECT_SIZE="1.154567090876647" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="-0.91" MODIFIED="2009-11-05 04:42:40 -0500" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="0.53" SD_2="0.71" SE="0.2612044725644958" STUDY_ID="STD-Dobrilla-1990" TOTAL_1="35" TOTAL_2="34" WEIGHT="14.938839592705541"/>
<CONT_DATA CI_END="1.4506158298185232" CI_START="0.03297158220208718" EFFECT_SIZE="0.7417937060103051" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="-0.82" MODIFIED="2009-11-05 04:42:43 -0500" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="0.51" SD_2="0.49" SE="0.36165058613286594" STUDY_ID="STD-Passaretti-1989a" TOTAL_1="16" TOTAL_2="17" WEIGHT="13.837176348582425"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.03" MODIFIED="2010-05-05 13:42:20 -0400" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mebeverine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9091309328622623" CI_START="-0.04104523217720962" DF="0" EFFECT_SIZE="0.4340428503425264" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.04" MODIFIED="2009-11-05 04:19:41 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.07335222270479498" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="37" WEIGHT="15.121101935261999" Z="1.7906329072843465">
<NAME>Otilonium</NAME>
<CONT_DATA CI_END="0.9091309328622623" CI_START="-0.04104523217720962" EFFECT_SIZE="0.4340428503425264" ESTIMABLE="YES" MEAN_1="-2.57" MEAN_2="-3.43" MODIFIED="2009-05-20 11:15:46 -0400" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="1.72" SD_2="2.15" SE="0.24239633292609974" STUDY_ID="STD-Baldi-1991" TOTAL_1="33" TOTAL_2="37" WEIGHT="15.121101935261999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.785091956845082" CI_START="2.979288364194568" DF="0" EFFECT_SIZE="3.882190160519825" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.05" MODIFIED="2009-11-05 04:19:39 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="3.5397123330201525E-17" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="12.625376942255869" Z="8.427220907880017">
<NAME>Peppermint oil</NAME>
<CONT_DATA CI_END="4.785091956845082" CI_START="2.979288364194568" EFFECT_SIZE="3.882190160519825" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-2.5" MODIFIED="2009-05-19 05:28:30 -0400" MODIFIED_BY="[Empty name]" ORDER="182" SD_1="0.3" SD_2="0.2" SE="0.46067264676658903" STUDY_ID="STD-Cappello-2007" TOTAL_1="28" TOTAL_2="29" WEIGHT="12.625376942255869"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0844333165919042" CI_START="-0.20441445904495653" DF="0" EFFECT_SIZE="0.4400094287734739" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.06" MODIFIED="2009-11-05 04:19:37 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.1808137588198883" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="57" WEIGHT="14.217352741360529" Z="1.3382536705359334">
<NAME>Pinaverium</NAME>
<CONT_DATA CI_END="1.0844333165919042" CI_START="-0.20441445904495653" EFFECT_SIZE="0.4400094287734739" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-3.1" MODIFIED="2009-05-20 11:15:57 -0400" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="1.78" SD_2="1.78" SE="0.32879373952866675" STUDY_ID="STD-Awad-1995" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.217352741360529"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.8" MEAN_2="-1.1" MODIFIED="2009-05-20 11:15:59 -0400" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Virat-1987" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.07" MODIFIED="2009-11-05 04:19:35 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pirenzepine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.927838526242378" CI_START="-0.035756940886329525" DF="0" EFFECT_SIZE="0.4460407926780242" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.08" MODIFIED="2009-11-05 04:19:32 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.06960017560472931" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="15.08861855800898" Z="1.8145039471586775">
<NAME>Propinox</NAME>
<CONT_DATA CI_END="0.927838526242378" CI_START="-0.035756940886329525" EFFECT_SIZE="0.4460407926780242" ESTIMABLE="YES" MEAN_1="-1.63" MEAN_2="-2.09" MODIFIED="2009-05-20 11:16:06 -0400" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="0.99" SD_2="1.05" SE="0.24581968718033226" STUDY_ID="STD-Pulpeiro-2000" TOTAL_1="35" TOTAL_2="33" WEIGHT="15.08861855800898"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.09" MODIFIED="2009-11-05 04:42:43 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Scopolamine derivatives</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.10" MODIFIED="2009-11-05 04:19:26 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trimebutine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-06-03 09:13:11 -0400" MODIFIED_BY="John K MacDonald" NO="5">
<NAME>Spasmolytics: Global assessment</NAME>
<DICH_OUTCOME CHI2="58.37177373774374" CI_END="1.7739618130414014" CI_START="1.2503017080692138" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4892909335973357" ESTIMABLE="YES" EVENTS_1="579" EVENTS_2="382" I2="64.02370759821335" I2_Q="68.28945594407583" ID="CMP-005.01" LOG_CI_END="0.2489442668125624" LOG_CI_START="0.09701482447926274" LOG_EFFECT_SIZE="0.17297954564591259" METHOD="MH" MODIFIED="2011-06-03 09:13:11 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="2.245380364862548E-5" P_Q="8.233577452638752E-4" P_Z="8.080451232717851E-6" Q="28.38172686071786" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08447670676653188" TOTALS="YES" TOTAL_1="1008" TOTAL_2="975" WEIGHT="100.00000000000001" Z="4.463041189663898">
<NAME>Comparing nr (%) of successfully treated patients</NAME>
<GROUP_LABEL_1>Spasmolitic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7969127689500324" CI_START="0.7961238634852725" DF="0" EFFECT_SIZE="1.1960623461853979" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.25452699481449725" LOG_CI_START="-0.09901935808734945" LOG_EFFECT_SIZE="0.0777538183635739" MODIFIED="2009-05-19 06:33:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38863708146551756" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="6.2415073775732" Z="0.8620916742726659">
<NAME>Alverine</NAME>
<DICH_DATA CI_END="1.7969127689500324" CI_START="0.7961238634852725" EFFECT_SIZE="1.1960623461853979" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.25452699481449725" LOG_CI_START="-0.09901935808734945" LOG_EFFECT_SIZE="0.0777538183635739" MODIFIED="2009-05-19 06:33:03 -0400" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.2076748777772166" STUDY_ID="STD-Mitchell-2002" TOTAL_1="53" TOTAL_2="54" VAR="0.04312885485978185" WEIGHT="6.2415073775732"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.305282169376117" CI_END="2.7494599815437284" CI_START="1.1470694867673" DF="3" EFFECT_SIZE="1.7759002364763044" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="53" I2="67.76024686416211" ID="CMP-005.01.02" LOG_CI_END="0.43924740289725267" LOG_CI_START="0.05958972723477911" LOG_EFFECT_SIZE="0.24941856506601584" MODIFIED="2009-11-05 04:53:45 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.025495707684913826" P_Z="0.010017575857562699" STUDIES="4" TAU2="0.12717194322202308" TOTAL_1="127" TOTAL_2="128" WEIGHT="20.888100495693564" Z="2.575222027327871">
<NAME>Cimtetropium/dicyclomine</NAME>
<DICH_DATA CI_END="8.903516465434748" CI_START="1.7970427821541335" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.9495615661856293" LOG_CI_START="0.2545584164702954" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2009-11-05 04:42:58 -0500" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Centonze-1988" TOTAL_1="24" TOTAL_2="24" VAR="0.16666666666666669" WEIGHT="3.17130029521506"/>
<DICH_DATA CI_END="1.6650192068123952" CI_START="1.002032151311852" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.22141924767088333" LOG_CI_START="8.816565744499658E-4" LOG_EFFECT_SIZE="0.11115045212266668" MODIFIED="2009-11-05 04:43:03 -0500" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.12954487268872725" STUDY_ID="STD-Dobrilla-1990" TOTAL_1="35" TOTAL_2="35" VAR="0.01678187403993855" WEIGHT="7.865516660086504"/>
<DICH_DATA CI_END="2.765137427267147" CI_START="1.07319966320696" EFFECT_SIZE="1.72265625" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.44171672060296524" LOG_CI_START="0.030680527709012695" LOG_EFFECT_SIZE="0.23619862415598897" MODIFIED="2009-11-05 04:43:20 -0500" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.2414446943678771" STUDY_ID="STD-Page-1981" TOTAL_1="48" TOTAL_2="49" VAR="0.05829554043839759" WEIGHT="5.578472496596732"/>
<DICH_DATA CI_END="3.038105213819742" CI_START="0.8691683842904179" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.4826028100106731" LOG_CI_START="-0.060896079380886786" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2009-11-05 04:53:45 -0500" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.3192539379914944" STUDY_ID="STD-Passaretti-1989a" TOTAL_1="20" TOTAL_2="20" VAR="0.10192307692307694" WEIGHT="4.272811043795263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.073885965358995" CI_START="0.16166624456543088" DF="0" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.030958166610538202" LOG_CI_START="-0.7913806500337502" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2010-05-05 13:42:20 -0400" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="1.0" P_Z="0.0699255752415821" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="2.5060600793472116" Z="1.8123924717865907">
<NAME>Mebeverine</NAME>
<DICH_DATA CI_END="1.0738859653589952" CI_START="0.16166624456543086" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03095816661053829" LOG_CI_START="-0.7913806500337504" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2010-03-31 11:57:52 -0400" MODIFIED_BY="John K MacDonald" ORDER="62" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Kruis-1986" TOTAL_1="40" TOTAL_2="40" VAR="0.2333333333333333" WEIGHT="2.5060600793472116"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2078453523786552" CI_END="2.4388586795657954" CI_START="1.3072586934601462" DF="2" EFFECT_SIZE="1.785558515138364" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="43" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="0.38718663571229206" LOG_CI_START="0.11636153863266759" LOG_EFFECT_SIZE="0.25177408717247984" MODIFIED="2010-05-05 13:12:15 -0400" MODIFIED_BY="John K MacDonald" NO="4" P_CHI2="0.5466632996679052" P_Z="2.682422437167271E-4" STUDIES="3" TAU2="0.0" TOTAL_1="180" TOTAL_2="183" WEIGHT="11.832075941322723" Z="3.6441832638090075">
<NAME>Otilonium</NAME>
<DICH_DATA CI_END="2.33647674701265" CI_START="1.1537990654937098" EFFECT_SIZE="1.6418966737438074" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="36" LOG_CI_END="0.36856146321423955" LOG_CI_START="0.06213018287044253" LOG_EFFECT_SIZE="0.21534582304234104" MODIFIED="2010-05-05 13:12:15 -0400" MODIFIED_BY="John K MacDonald" ORDER="135" O_E="0.0" SE="0.17999925093324765" STUDY_ID="STD-Battaglia-1998" TOTAL_1="157" TOTAL_2="160" VAR="0.03239973033653025" WEIGHT="6.814470684178154"/>
<DICH_DATA CI_END="6.57874651507462" CI_START="1.1495350949715413" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8181431529688242" LOG_CI_START="0.06052223469170105" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2010-03-31 11:59:03 -0400" MODIFIED_BY="John K MacDonald" ORDER="136" O_E="0.0" SE="0.44503027768001147" STUDY_ID="STD-d_x0027_Arienzo-1980" TOTAL_1="14" TOTAL_2="14" VAR="0.19805194805194812" WEIGHT="2.819009826885402"/>
<DICH_DATA CI_END="5.61891677725605" CI_START="0.7118809832156592" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.7496525997321793" LOG_CI_START="-0.14759260840421695" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-05-20 11:30:52 -0400" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Piai-1979" TOTAL_1="9" TOTAL_2="9" VAR="0.2777777777777778" WEIGHT="2.1985954302591657"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.895829270467422E-5" CI_END="2.981155836244922" CI_START="1.7020303778756973" DF="1" EFFECT_SIZE="2.252558055738028" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="37" I2="0.0" ID="CMP-005.01.05" LOG_CI_END="0.47438467883447777" LOG_CI_START="0.23096730711522748" LOG_EFFECT_SIZE="0.35267599297485264" MODIFIED="2009-11-05 04:20:38 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9920629522077469" P_Z="1.351684749460873E-8" STUDIES="2" TAU2="0.0" TOTAL_1="114" TOTAL_2="111" WEIGHT="10.656588315951309" Z="5.679399457487015">
<NAME>Peppermint oil</NAME>
<DICH_DATA CI_END="3.0398486902216213" CI_START="1.6673473599817894" EFFECT_SIZE="2.251329315845445" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="31" LOG_CI_END="0.4828519669517711" LOG_CI_START="0.22202608621564535" LOG_EFFECT_SIZE="0.3524390265837082" MODIFIED="2009-05-19 06:32:10 -0400" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.1532104134533326" STUDY_ID="STD-Capanni-2005" TOTAL_1="91" TOTAL_2="87" VAR="0.023473430790541122" WEIGHT="7.377953121078025"/>
<DICH_DATA CI_END="4.932843822548056" CI_START="1.0362240068419435" EFFECT_SIZE="2.260869565217391" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.6930973655981048" LOG_CI_START="0.01545364963630778" LOG_EFFECT_SIZE="0.3542755076172062" ORDER="46" O_E="0.0" SE="0.39805127314645244" STUDY_ID="STD-Lech-1988" TOTAL_1="23" TOTAL_2="24" VAR="0.1584448160535117" WEIGHT="3.2786351948732846"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.932346771015391" CI_END="2.190267222061734" CI_START="1.2512822793393976" DF="3" EFFECT_SIZE="1.6554886172921204" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="51" I2="23.70967835002621" ID="CMP-005.01.06" LOG_CI_END="0.34049710387531384" LOG_CI_START="0.09735529413025822" LOG_EFFECT_SIZE="0.218926199002786" MODIFIED="2010-03-31 10:30:18 -0400" MODIFIED_BY="John K MacDonald" NO="6" P_CHI2="0.2688627984001095" P_Z="4.1630744003492374E-4" STUDIES="4" TAU2="0.019676155661119212" TOTAL_1="168" TOTAL_2="140" WEIGHT="21.193139948260438" Z="3.529524319717992">
<NAME>Pinaverium</NAME>
<DICH_DATA CI_END="2.2332394433414455" CI_START="0.7945173259447946" EFFECT_SIZE="1.332046332046332" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.3489352897292883" LOG_CI_START="-0.09989662774524374" LOG_EFFECT_SIZE="0.1245193309920223" MODIFIED="2009-05-20 11:31:19 -0400" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.26364609007836365" STUDY_ID="STD-Chen-2004" TOTAL_1="74" TOTAL_2="46" VAR="0.06950926081360863" WEIGHT="5.172231384626028"/>
<DICH_DATA CI_END="2.024455711455886" CI_START="0.9845014506846212" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.30630828024954926" LOG_CI_START="-0.006783639582885014" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2010-03-31 10:30:18 -0400" MODIFIED_BY="John K MacDonald" ORDER="48" O_E="0.0" SE="0.1839117435395704" STUDY_ID="STD-Delmont-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.03382352941176472" WEIGHT="6.73245531910549"/>
<DICH_DATA CI_END="5.283537056442066" CI_START="1.394396757337533" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.7229247577236109" LOG_CI_START="0.14438636415353348" LOG_EFFECT_SIZE="0.43365556093857216" ORDER="49" O_E="0.0" SE="0.33983631619429855" STUDY_ID="STD-Levy-1977" TOTAL_1="25" TOTAL_2="25" VAR="0.11548872180451125" WEIGHT="3.9829437518348225"/>
<DICH_DATA CI_END="3.177450451453412" CI_START="1.1638969383076878" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.5020787869748585" LOG_CI_START="0.06591452575554325" LOG_EFFECT_SIZE="0.28399665636520083" ORDER="50" O_E="0.0" SE="0.2562050460881395" STUDY_ID="STD-Virat-1987" TOTAL_1="39" TOTAL_2="39" VAR="0.06564102564102567" WEIGHT="5.305509492694097"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.002108717336782" CI_START="0.34685651105310555" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-005.01.07" LOG_CI_END="0.3014876565886039" LOG_CI_START="-0.45985014868385343" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2009-11-05 04:20:43 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.6835061309928883" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.7997056889569896" Z="0.407683394754871">
<NAME>Pirenzepine</NAME>
<DICH_DATA CI_END="2.002108717336782" CI_START="0.34685651105310555" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3014876565886039" LOG_CI_START="-0.45985014868385343" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2009-05-19 07:14:42 -0400" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.44721359549995804" STUDY_ID="STD-Gilvarry-1989" TOTAL_1="12" TOTAL_2="12" VAR="0.20000000000000007" WEIGHT="2.7997056889569896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.303890385114592" CI_START="0.256833389363674" DF="0" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-005.01.08" LOG_CI_END="0.362461812306586" LOG_CI_START="-0.5903485169202596" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2009-11-05 04:20:53 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.6392334203485748" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="2.0025191158825875" Z="0.46877087694961306">
<NAME>Propinox</NAME>
<DICH_DATA CI_END="2.303890385114592" CI_START="0.256833389363674" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.362461812306586" LOG_CI_START="-0.5903485169202596" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="60" O_E="0.0" SE="0.5596855038750452" STUDY_ID="STD-Pulpeiro-2000" TOTAL_1="39" TOTAL_2="36" VAR="0.31324786324786325" WEIGHT="2.0025191158825875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.526779086498852" CI_END="41.67226954630438" CI_START="0.47173737443344405" DF="2" EFFECT_SIZE="4.433775707278887" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="114" I2="73.42820910490788" ID="CMP-005.01.09" LOG_CI_END="1.6198471535553283" LOG_CI_START="-0.32629971445346406" LOG_EFFECT_SIZE="0.6467737195509321" MODIFIED="2010-03-31 10:29:30 -0400" MODIFIED_BY="John K MacDonald" NO="9" P_CHI2="0.023205056073084096" P_Z="0.19266652037572227" STUDIES="3" TAU2="2.8230779622699584" TOTAL_1="215" TOTAL_2="211" WEIGHT="9.66183611256723" Z="1.3027312761485887">
<NAME>Scopolamine derivatives</NAME>
<DICH_DATA CI_END="336.74577093495503" CI_START="1.3095932839055089" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.527302150286202" LOG_CI_START="0.11713643918163659" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2010-03-31 10:28:11 -0400" MODIFIED_BY="John K MacDonald" ORDER="129" O_E="0.0" SE="1.4157432692155045" STUDY_ID="STD-Nigam-1984" TOTAL_1="21" TOTAL_2="21" VAR="2.0043290043290045" WEIGHT="0.3812949428849877"/>
<DICH_DATA CI_END="150.80918509370878" CI_START="0.5371025640757144" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1784277932183316" LOG_CI_START="-0.2699427743396819" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2010-03-31 10:23:54 -0400" MODIFIED_BY="John K MacDonald" ORDER="245" O_E="0.0" SE="1.4381849910133495" STUDY_ID="STD-Ritchie-1979" TOTAL_1="12" TOTAL_2="12" VAR="2.068376068376068" WEIGHT="0.3699514725326508"/>
<DICH_DATA CI_END="1.3581331647313561" CI_START="1.0320561930205419" EFFECT_SIZE="1.1839213418160786" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="114" LOG_CI_END="0.1329423545340821" LOG_CI_START="0.01370334424308403" LOG_EFFECT_SIZE="0.07332284938858306" MODIFIED="2010-03-31 10:29:30 -0400" MODIFIED_BY="John K MacDonald" ORDER="57" O_E="0.0" SE="0.07004158488755251" STUDY_ID="STD-Schafer-1990" TOTAL_1="182" TOTAL_2="178" VAR="0.004905823613560224" WEIGHT="8.91058969714959"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4456527082634278" CI_END="1.375258921491664" CI_START="0.6783745445418076" DF="1" EFFECT_SIZE="0.9658885259148516" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="37" I2="30.82709323726599" ID="CMP-005.01.10" LOG_CI_END="0.13838447095831155" LOG_CI_START="-0.16853045699609903" LOG_EFFECT_SIZE="-0.015072993018893746" MODIFIED="2009-11-05 04:20:55 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.22922707405897713" P_Z="0.8473405559334033" STUDIES="2" TAU2="0.021807529173386932" TOTAL_1="60" TOTAL_2="60" WEIGHT="12.218466924444762" Z="0.19251278296012797">
<NAME>Trimebutine</NAME>
<DICH_DATA CI_END="1.280018563748969" CI_START="0.45684891068491834" EFFECT_SIZE="0.7647058823529411" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.10721626814418003" LOG_CI_START="-0.34022740628705445" LOG_EFFECT_SIZE="-0.11650556907143719" ORDER="58" O_E="0.0" SE="0.26283062924281675" STUDY_ID="STD-Fielding-1980" TOTAL_1="30" TOTAL_2="30" VAR="0.069079939668175" WEIGHT="5.186692160854555"/>
<DICH_DATA CI_END="1.5339668539839801" CI_START="0.7888045278536616" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.1858159754621286" LOG_CI_START="-0.10303060514567847" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="59" O_E="0.0" SE="0.16966991126265962" STUDY_ID="STD-Ghidini-1986" TOTAL_1="30" TOTAL_2="30" VAR="0.028787878787878793" WEIGHT="7.031774763590206"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2009-11-05 04:33:56 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="163" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Comparing scores on global assessment in IBS patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.01" MODIFIED="2009-11-05 04:33:56 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Alvarine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.02" MODIFIED="2009-11-05 04:33:56 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cimetropium/dicyclomine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.03" MODIFIED="2009-11-05 04:33:50 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mebeverine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.04" MODIFIED="2009-11-05 04:33:48 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="133" WEIGHT="0.0" Z="0.0">
<NAME>Otilonium</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-3.19" MEAN_2="-3.46" MODIFIED="2009-05-20 11:17:51 -0400" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Battaglia-1998" TOTAL_1="138" TOTAL_2="133" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.05" MODIFIED="2009-11-05 04:33:45 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Peppermint oil</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.06" MODIFIED="2009-11-05 04:33:44 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Pinaverium</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-4.0" MEAN_2="-3.87" MODIFIED="2009-05-20 11:18:10 -0400" MODIFIED_BY="[Empty name]" ORDER="64" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Delmont-1981" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.07" MODIFIED="2009-11-05 04:33:42 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pirenzepine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.08" MODIFIED="2009-11-05 04:33:40 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Propinox</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.09" MODIFIED="2009-11-05 04:33:38 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Scopolamine derivatives</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.10" MODIFIED="2009-11-05 04:33:35 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trimebutine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-06-03 09:18:02 -0400" MODIFIED_BY="John K MacDonald" NO="6">
<NAME>Spasmolytics: Outcome on symptom score</NAME>
<DICH_OUTCOME CHI2="13.37708312087016" CI_END="2.755436625791104" CI_START="1.2602258849512826" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.863457152757951" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="87" I2="77.57358631255292" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.44019042683464243" LOG_CI_START="0.10044839574891741" LOG_EFFECT_SIZE="0.2703194112917799" METHOD="MH" MODIFIED="2011-06-03 09:18:02 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.003888214353562569" P_Q="0.6266887141227783" P_Z="0.001815072501829189" Q="0.23657796322896285" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12028609666738205" TOTALS="YES" TOTAL_1="293" TOTAL_2="293" WEIGHT="100.00000000000001" Z="3.1189329666441736">
<NAME>Comparing nr (%) of patients successfully treated</NAME>
<GROUP_LABEL_1>Spasmolytic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-05-19 06:26:17 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Alvarine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:35:14 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cimetropium/dicyclomine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:35:14 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mebeverine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.33647674701265" CI_START="1.1537990654937098" DF="0" EFFECT_SIZE="1.6418966737438074" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="36" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="0.36856146321423955" LOG_CI_START="0.06213018287044253" LOG_EFFECT_SIZE="0.21534582304234104" MODIFIED="2010-05-05 13:13:53 -0400" MODIFIED_BY="John K MacDonald" NO="4" P_CHI2="1.0" P_Z="0.005873784947301166" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="160" WEIGHT="26.084050714197527" Z="2.754745252577267">
<NAME>Otilonium</NAME>
<DICH_DATA CI_END="2.33647674701265" CI_START="1.1537990654937098" EFFECT_SIZE="1.6418966737438074" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="36" LOG_CI_END="0.36856146321423955" LOG_CI_START="0.06213018287044253" LOG_EFFECT_SIZE="0.21534582304234104" MODIFIED="2010-05-05 13:13:53 -0400" MODIFIED_BY="John K MacDonald" ORDER="136" O_E="0.0" SE="0.17999925093324765" STUDY_ID="STD-Battaglia-1998" TOTAL_1="157" TOTAL_2="160" VAR="0.03239973033653025" WEIGHT="26.084050714197527"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.781039253582575" CI_END="3.460230314834581" CI_START="1.0900960249171994" DF="2" EFFECT_SIZE="1.9421594454367455" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="51" I2="85.48730641283043" ID="CMP-006.01.05" LOG_CI_END="0.5391050066346389" LOG_CI_START="0.037464755972577486" LOG_EFFECT_SIZE="0.28828488130360824" MODIFIED="2009-11-05 04:35:09 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0010173903454342437" P_Z="0.024276690386646437" STUDIES="3" TAU2="0.21765266160286018" TOTAL_1="136" TOTAL_2="133" WEIGHT="73.91594928580248" Z="2.2527218814549124">
<NAME>Peppermint oil</NAME>
<DICH_DATA CI_END="3.9144316517749647" CI_START="2.1500885908024268" EFFECT_SIZE="2.901098901098901" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="29" LOG_CI_END="0.5926687144358268" LOG_CI_START="0.332456354661648" LOG_EFFECT_SIZE="0.46256253454873747" MODIFIED="2009-05-19 06:42:23 -0400" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.15285002820330723" STUDY_ID="STD-Capanni-2005" TOTAL_1="91" TOTAL_2="87" VAR="0.023363131121751812" WEIGHT="27.72493048661207"/>
<DICH_DATA CI_END="3.305225066299671" CI_START="1.0515354188514683" EFFECT_SIZE="1.8642857142857143" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5192010377169703" LOG_CI_START="0.021823905603115663" LOG_EFFECT_SIZE="0.27051247166004294" MODIFIED="2009-05-19 06:42:32 -0400" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.29216178946018967" STUDY_ID="STD-Cappello-2007" TOTAL_1="28" TOTAL_2="29" VAR="0.08535851122058019" WEIGHT="19.366736117287573"/>
<DICH_DATA CI_END="1.8528701827197092" CI_START="0.9594723874115626" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.2678449924956527" LOG_CI_START="-0.017967519279052817" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="65" O_E="0.0" SE="0.16788768421121278" STUDY_ID="STD-Czalbert-1990" TOTAL_1="17" TOTAL_2="17" VAR="0.028186274509803905" WEIGHT="26.82428268190284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:35:06 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pinaverium</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:35:04 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pirenzepine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:35:02 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Propinox</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:35:00 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Scopolamine derivatives</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-05 04:34:57 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trimebutine</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="88.09203869515079" CI_END="4.285586311825876" CI_START="0.5026544482279403" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="2.3941203800269077" ESTIMABLE="YES" I2="96.59447091424262" I2_Q="97.72954326766944" ID="CMP-006.02" MODIFIED="2010-05-05 14:31:24 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="2.220446049250313E-16" P_Q="1.6653345369377348E-15" P_Z="0.013107992406942066" Q="88.08800324272511" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="3.4421636967694016" TOTALS="YES" TOTAL_1="135" TOTAL_2="108" UNITS="" WEIGHT="100.00000000000001" Z="2.4808216952885687">
<NAME>Comparing symptom scores in IBS patients</NAME>
<GROUP_LABEL_1>Spasmolytic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.01" MODIFIED="2009-05-19 06:28:59 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Alvarine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.02" MODIFIED="2009-11-05 04:36:03 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cimetropium/dicyclomine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.03" MODIFIED="2009-11-05 04:36:03 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mebeverine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9399693814173111" CI_START="-0.5458039365193006" DF="0" EFFECT_SIZE="0.1970827224490053" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.04" MODIFIED="2009-11-05 04:36:00 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6030879940753955" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="25.972359645517734" Z="0.5199649681575906">
<NAME>Otilonium</NAME>
<CONT_DATA CI_END="0.9399693814173111" CI_START="-0.5458039365193006" EFFECT_SIZE="0.1970827224490053" ESTIMABLE="YES" MEAN_1="-5.64" MEAN_2="-7.07" MODIFIED="2009-05-20 11:18:56 -0400" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="5.8" SD_2="8.1" SE="0.37903077037542576" STUDY_ID="STD-d_x0027_Arienzo-1980" TOTAL_1="14" TOTAL_2="14" WEIGHT="25.972359645517734"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.810083854519116" CI_START="7.91594354274116" DF="0" EFFECT_SIZE="9.863013698630137" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.05" MODIFIED="2010-05-05 14:31:24 -0400" MODIFIED_BY="John K MacDonald" NO="5" P_CHI2="1.0" P_Z="3.134667660034104E-23" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="21.02762893765849" Z="9.928328247378534">
<NAME>Peppermint oil</NAME>
<CONT_DATA CI_END="11.810083854519116" CI_START="7.91594354274116" EFFECT_SIZE="9.863013698630137" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-2.1" MODIFIED="2009-05-19 06:44:35 -0400" MODIFIED_BY="[Empty name]" ORDER="183" SD_1="0.1" SD_2="0.1" SE="0.99342139511094" STUDY_ID="STD-Cappello-2007" TOTAL_1="28" TOTAL_2="29" WEIGHT="21.02762893765849"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.004035452425680934" CI_END="0.8371783797704331" CI_START="0.18964813176585876" DF="1" EFFECT_SIZE="0.5134132557681459" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.06" MODIFIED="2009-11-05 04:35:56 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.949348284383424" P_Z="0.0018833939730787592" STUDIES="2" TAU2="0.0" TOTAL_1="93" TOTAL_2="65" WEIGHT="53.00001141682379" Z="3.108029296212611">
<NAME>Pinaverium</NAME>
<CONT_DATA CI_END="1.1419507422249309" CI_START="-0.15141186933311646" EFFECT_SIZE="0.49526943644590715" ESTIMABLE="YES" MEAN_1="-14.7" MEAN_2="-19.0" MODIFIED="2009-05-20 11:20:24 -0400" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="8.5" SD_2="8.5" SE="0.32994550455006477" STUDY_ID="STD-Awad-1995" TOTAL_1="19" TOTAL_2="19" WEIGHT="26.22689035819781"/>
<CONT_DATA CI_END="0.8934979715729942" CI_START="0.14546682865346605" EFFECT_SIZE="0.5194824001132301" ESTIMABLE="YES" MEAN_1="56.5" MEAN_2="52.5" MODIFIED="2009-05-20 11:21:01 -0400" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="8.9" SD_2="5.0" SE="0.19082777765813613" STUDY_ID="STD-Chen-2004" TOTAL_1="74" TOTAL_2="46" WEIGHT="26.77312105862598"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.07" MODIFIED="2009-11-05 04:35:54 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pirenzepine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.08" MODIFIED="2009-11-05 04:35:51 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Propinox</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.09" MODIFIED="2010-05-05 14:31:24 -0400" MODIFIED_BY="John K MacDonald" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Scopolamine derivatives</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.10" MODIFIED="2009-11-05 04:35:47 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trimebutine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-06-03 09:56:13 -0400" MODIFIED_BY="John K MacDonald" NO="7">
<NAME>Antidepressants: Abdominal pain</NAME>
<DICH_OUTCOME CHI2="17.41190602860534" CI_END="2.1184363968189404" CI_START="1.048894150709825" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4906426618321993" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="86" I2="59.797623600196474" I2_Q="13.790999813677836" ID="CMP-007.01" LOG_CI_END="0.32601542942965617" LOG_CI_START="0.02073166352045907" LOG_EFFECT_SIZE="0.17337354647505762" METHOD="MH" MODIFIED="2011-06-03 09:56:13 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.014924775102220011" P_Q="0.28147145960967246" P_Z="0.02600317982508985" Q="1.159971694183572" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12468292129434505" TOTALS="YES" TOTAL_1="285" TOTAL_2="232" WEIGHT="100.0" Z="2.2261642767088072">
<NAME>Comparing nr(%) of successfully treated patients with IBS</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.045092835535275" CI_END="6.676038557964414" CI_START="0.7882930320422806" DF="3" EFFECT_SIZE="2.294052021399895" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="28" I2="78.64022662484831" ID="CMP-007.01.01" LOG_CI_END="0.8245188363150013" LOG_CI_START="-0.10331231227887938" LOG_EFFECT_SIZE="0.36060326201806103" MODIFIED="2010-03-30 11:57:08 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0028444272814373006" P_Z="0.12763687846875557" STUDIES="4" TAU2="0.8699193411485223" TOTAL_1="96" TOTAL_2="101" WEIGHT="35.689834369301146" Z="1.5234871287392375">
<NAME>SSRI's</NAME>
<DICH_DATA CI_END="4.893347927287065" CI_START="0.8088543056779071" EFFECT_SIZE="1.9894736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6896060961051012" LOG_CI_START="-0.09212969833630846" LOG_EFFECT_SIZE="0.29873819888439634" MODIFIED="2010-03-30 09:38:00 -0400" MODIFIED_BY="John K MacDonald" ORDER="134" O_E="0.0" SE="0.45919547530947546" STUDY_ID="STD-Kuiken-2003" TOTAL_1="19" TOTAL_2="21" VAR="0.21086048454469508" WEIGHT="9.583715579113859"/>
<DICH_DATA CI_END="1.339132857229599" CI_START="0.4431344496155992" EFFECT_SIZE="0.7703349282296651" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1268236661078971" LOG_CI_START="-0.3534644862663057" LOG_EFFECT_SIZE="-0.11332041007920428" MODIFIED="2010-03-30 11:09:03 -0400" MODIFIED_BY="John K MacDonald" ORDER="135" O_E="0.0" SE="0.28212363816930425" STUDY_ID="STD-Tabas-2004" TOTAL_1="44" TOTAL_2="46" VAR="0.0795937472138845" WEIGHT="15.742143189881629"/>
<DICH_DATA CI_END="46.12230213881659" CI_START="0.9288993224506645" EFFECT_SIZE="6.545454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6639109764464288" LOG_CI_START="-0.03203135390034192" LOG_EFFECT_SIZE="0.8159398112730435" MODIFIED="2010-03-30 11:57:08 -0400" MODIFIED_BY="John K MacDonald" ORDER="131" O_E="0.0" SE="0.996204919895622" STUDY_ID="STD-Tack-2006a" TOTAL_1="11" TOTAL_2="12" VAR="0.9924242424242425" WEIGHT="2.878642864757976"/>
<DICH_DATA CI_END="15.740979724845397" CI_START="1.8070313882399602" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.1970317595257496" LOG_CI_START="0.256965696346775" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2010-03-30 11:09:28 -0400" MODIFIED_BY="John K MacDonald" ORDER="136" O_E="0.0" SE="0.5521994589133915" STUDY_ID="STD-Vahedi-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.3049242424242424" WEIGHT="7.4853327355476775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.989925660587783" CI_END="1.5487778467300584" CI_START="1.028196756294435" DF="3" EFFECT_SIZE="1.2619224850316781" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.1899891279862065" LOG_CI_START="0.012076229441878838" LOG_EFFECT_SIZE="0.10103267871404273" MODIFIED="2010-03-30 13:45:32 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.39318124018068634" P_Z="0.026011654939787365" STUDIES="4" TAU2="0.0" TOTAL_1="189" TOTAL_2="131" WEIGHT="64.31016563069885" Z="2.226037720270099">
<NAME>TCA's</NAME>
<DICH_DATA CI_END="1.6156827769740898" CI_START="0.8543392414853476" EFFECT_SIZE="1.17487922705314" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="27" LOG_CI_END="0.2083560954648669" LOG_CI_START="-0.06836964517730774" LOG_EFFECT_SIZE="0.06999322514377956" MODIFIED="2010-03-30 13:30:55 -0400" MODIFIED_BY="John K MacDonald" ORDER="160" O_E="0.0" SE="0.16255006986772164" STUDY_ID="STD-Drossman-2003" TOTAL_1="115" TOTAL_2="57" VAR="0.026422525214001187" WEIGHT="21.281513276431845"/>
<DICH_DATA CI_END="2.177499451796657" CI_START="0.6613090069032413" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.33795805434251747" LOG_CI_START="-0.1795955622472679" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-03-30 12:22:00 -0400" MODIFIED_BY="John K MacDonald" ORDER="161" O_E="0.0" SE="0.30401355631656035" STUDY_ID="STD-Heefner-1978" TOTAL_1="22" TOTAL_2="22" VAR="0.09242424242424242" WEIGHT="14.811821548996722"/>
<DICH_DATA CI_END="1.7415410091911223" CI_START="0.9375122611330574" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.24093370552736879" LOG_CI_START="-0.02802304369879524" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2010-03-30 13:45:32 -0400" MODIFIED_BY="John K MacDonald" ORDER="137" O_E="0.0" SE="0.1579865258528293" STUDY_ID="STD-Vahedi-2008" TOTAL_1="27" TOTAL_2="27" VAR="0.0249597423510467" WEIGHT="21.4895437415422"/>
<DICH_DATA CI_END="10.686824455387573" CI_START="1.0397018457161658" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0288486756127089" LOG_CI_START="0.01690881494796644" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2010-03-30 13:30:30 -0400" MODIFIED_BY="John K MacDonald" ORDER="163" O_E="0.0" SE="0.594418483337567" STUDY_ID="STD-Vij-1991" TOTAL_1="25" TOTAL_2="25" VAR="0.3533333333333334" WEIGHT="6.727287063728087"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="38.404658172506245" CI_END="4.159985626097752" CI_START="-0.5664513110485223" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="1.7967671575246151" ESTIMABLE="YES" I2="94.79229839511554" I2_Q="90.7348889221175" ID="CMP-007.02" MODIFIED="2010-05-10 14:21:53 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="4.5765902179084605E-9" P_Q="0.0010187552983083048" P_Z="0.13617935856203464" Q="10.793178749763529" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4.038137066387485" TOTALS="YES" TOTAL_1="62" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="1.490170699063181">
<NAME>Comparing scores on abdominal pain in patients with IBS</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.278156758707797" CI_START="2.928624300660089" DF="0" EFFECT_SIZE="4.603390529683943" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" MODIFIED="2009-05-19 08:30:34 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.152125387208994E-8" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="30.489419123613754" Z="5.387306890115697">
<NAME>SSRI's</NAME>
<CONT_DATA CI_END="6.278156758707797" CI_START="2.928624300660089" EFFECT_SIZE="4.603390529683943" ESTIMABLE="YES" MEAN_1="-4.9" MEAN_2="-7.0" MODIFIED="2009-05-19 08:30:34 -0400" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="0.1" SD_2="0.6" SE="0.8544882672509271" STUDY_ID="STD-Tack-2006a" TOTAL_1="11" TOTAL_2="12" WEIGHT="30.489419123613754"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.983760505909325" CI_END="2.2914024925452834" CI_START="-1.225446674255748" DF="1" EFFECT_SIZE="0.5329779091447678" ESTIMABLE="YES" I2="90.89564999653813" ID="CMP-007.02.02" MODIFIED="2010-05-10 14:21:53 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="9.191475074984412E-4" P_Z="0.5524690201790159" STUDIES="2" TAU2="1.468432506400625" TOTAL_1="51" TOTAL_2="50" WEIGHT="69.51058087638624" Z="0.5940644349154177">
<NAME>TCA's</NAME>
<CONT_DATA CI_END="0.13140080399098553" CI_START="-0.7563696990132968" EFFECT_SIZE="-0.3124844475111556" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.4" MODIFIED="2009-05-14 08:06:18 -0400" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="0.9" SD_2="1.0" SE="0.22647622864677686" STUDY_ID="STD-Boerner-1988" TOTAL_1="40" TOTAL_2="39" WEIGHT="35.55076392873658"/>
<CONT_DATA CI_END="2.4509337288654236" CI_START="0.5191101559921188" EFFECT_SIZE="1.4850219424287712" ESTIMABLE="YES" MEAN_1="-1.45" MEAN_2="-4.0" MODIFIED="2009-05-14 08:06:58 -0400" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="1.57" SD_2="1.73" SE="0.4928211916421124" STUDY_ID="STD-Rajagopalan-1998" TOTAL_1="11" TOTAL_2="11" WEIGHT="33.959816947649664"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-06-03 10:01:24 -0400" MODIFIED_BY="John K MacDonald" NO="8">
<NAME>Antidepressants: Global assessment</NAME>
<DICH_OUTCOME CHI2="24.09095059815812" CI_END="2.0037265930089028" CI_START="1.2329091182584992" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5717546841087233" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="118" I2="54.339701311574615" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.30183846208137943" LOG_CI_START="0.09093106451664473" LOG_EFFECT_SIZE="0.19638476329901203" METHOD="MH" MODIFIED="2011-06-03 10:01:24 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.01235517309713352" P_Q="0.5063176362429753" P_Z="2.622300214582326E-4" Q="0.44166980210833773" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08581015474922321" TOTALS="YES" TOTAL_1="413" TOTAL_2="337" WEIGHT="100.00000000000001" Z="3.65001007667686">
<NAME>Comparing nr (%) of successfully treated patients with IBS</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive agents</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.053072060616753" CI_END="3.2003774002924703" CI_START="1.0053343923016278" DF="3" EFFECT_SIZE="1.7937250259889042" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="30" I2="66.86207753663213" ID="CMP-008.01.01" LOG_CI_END="0.5052011949449353" LOG_CI_START="0.002310539942110388" LOG_EFFECT_SIZE="0.2537558674435229" MODIFIED="2010-05-11 10:25:43 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.028593557669092995" P_Z="0.047931621523667985" STUDIES="4" TAU2="0.2327056055009069" TOTAL_1="116" TOTAL_2="111" WEIGHT="30.476744590192123" Z="1.9779741624040763">
<NAME>SSRI's</NAME>
<DICH_DATA CI_END="2.3585052691612187" CI_START="0.6394543084222777" EFFECT_SIZE="1.2280701754385965" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.37263685084463577" LOG_CI_START="-0.19419048216110493" LOG_EFFECT_SIZE="0.08922318434176545" MODIFIED="2009-05-19 08:32:56 -0400" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.33295718124812246" STUDY_ID="STD-Kuiken-2003" TOTAL_1="19" TOTAL_2="21" VAR="0.11086048454469508" WEIGHT="7.804036649228783"/>
<DICH_DATA CI_END="8.926402006921345" CI_START="1.9449170110924507" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="6" LOG_CI_END="0.9506764417086545" LOG_CI_START="0.2889010748681335" LOG_EFFECT_SIZE="0.619788758288394" MODIFIED="2009-05-19 08:32:43 -0400" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.38873012632302" STUDY_ID="STD-Masand-2009" TOTAL_1="36" TOTAL_2="36" VAR="0.15111111111111108" WEIGHT="6.478206467889531"/>
<DICH_DATA CI_END="3.7844777741117794" CI_START="1.0425851944113516" EFFECT_SIZE="1.9863636363636363" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.578005959009389" LOG_CI_START="0.01811155328704215" LOG_EFFECT_SIZE="0.2980587561482156" MODIFIED="2010-03-30 11:06:29 -0400" MODIFIED_BY="John K MacDonald" ORDER="141" O_E="0.0" SE="0.3288847454433134" STUDY_ID="STD-Tabas-2004" TOTAL_1="44" TOTAL_2="46" VAR="0.10816517578531308" WEIGHT="7.912474605134002"/>
<DICH_DATA CI_END="2.0958747239924738" CI_START="0.6086102950973113" EFFECT_SIZE="1.1294117647058823" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.3213653201510177" LOG_CI_START="-0.21566070550046634" LOG_EFFECT_SIZE="0.052852307325275676" MODIFIED="2010-05-11 10:25:43 -0400" MODIFIED_BY="John K MacDonald" ORDER="127" O_E="0.0" SE="0.31545174578938157" STUDY_ID="STD-Talley-2008a" TOTAL_1="17" TOTAL_2="8" VAR="0.09950980392156861" WEIGHT="8.282026867939807"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.598194212763563" CI_END="1.856551115331138" CI_START="1.1305788077451002" DF="7" EFFECT_SIZE="1.4487847826674995" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="88" I2="44.43648127833975" ID="CMP-008.01.02" LOG_CI_END="0.2687069109016087" LOG_CI_START="0.053300840521215406" LOG_EFFECT_SIZE="0.16100387571141203" MODIFIED="2010-05-11 10:25:49 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.08252499574200445" P_Z="0.003390440027026811" STUDIES="8" TAU2="0.049290489584892905" TOTAL_1="297" TOTAL_2="226" WEIGHT="69.52325540980789" Z="2.9299248364585924">
<NAME>TCA's</NAME>
<DICH_DATA CI_END="22.153839843444736" CI_START="1.5684830568076418" EFFECT_SIZE="5.894736842105263" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.3454490117459783" LOG_CI_START="0.195479831688727" LOG_EFFECT_SIZE="0.7704644217173526" MODIFIED="2010-03-30 13:14:00 -0400" MODIFIED_BY="John K MacDonald" ORDER="133" O_E="0.0" SE="0.6754975888048772" STUDY_ID="STD-Bergmann-1991" TOTAL_1="19" TOTAL_2="16" VAR="0.45629699248120303" WEIGHT="2.831220515571999"/>
<DICH_DATA CI_END="1.6709050729358375" CI_START="0.7965603581392172" EFFECT_SIZE="1.1536796536796536" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.22295177755874365" LOG_CI_START="-0.09878131061785016" LOG_EFFECT_SIZE="0.06208523347044675" MODIFIED="2010-03-30 12:55:24 -0400" MODIFIED_BY="John K MacDonald" ORDER="172" O_E="0.0" SE="0.18898760859940286" STUDY_ID="STD-Boerner-1988" TOTAL_1="42" TOTAL_2="41" VAR="0.035716316204121086" WEIGHT="12.62955193906876"/>
<DICH_DATA CI_END="1.9170114422643985" CI_START="0.8790551346948886" EFFECT_SIZE="1.2981366459627328" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="21" LOG_CI_END="0.2826247051041754" LOG_CI_START="-0.055983884945766914" LOG_EFFECT_SIZE="0.11332041007920426" MODIFIED="2010-03-30 13:32:48 -0400" MODIFIED_BY="John K MacDonald" ORDER="173" O_E="0.0" SE="0.1989003619348893" STUDY_ID="STD-Drossman-2003" TOTAL_1="115" TOTAL_2="57" VAR="0.039561353977829956" WEIGHT="12.242214299410454"/>
<DICH_DATA CI_END="1.6454854949794269" CI_START="0.9196620122164371" EFFECT_SIZE="1.2301587301587302" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.21629405832400544" LOG_CI_START="-0.036371752218548235" LOG_EFFECT_SIZE="0.08996115305272862" MODIFIED="2010-03-30 12:53:29 -0400" MODIFIED_BY="John K MacDonald" ORDER="171" O_E="0.0" SE="0.1484171478286295" STUDY_ID="STD-Myren-1982" TOTAL_1="30" TOTAL_2="31" VAR="0.02202764976958526" WEIGHT="14.23271628837081"/>
<DICH_DATA CI_END="246.92917220635877" CI_START="0.9111924605326395" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.392572400502366" LOG_CI_START="-0.04038988239100344" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2010-03-30 12:54:34 -0400" MODIFIED_BY="John K MacDonald" ORDER="132" O_E="0.0" SE="1.4291340883290982" STUDY_ID="STD-Nigam-1984" TOTAL_1="21" TOTAL_2="21" VAR="2.0424242424242425" WEIGHT="0.7211728552622835"/>
<DICH_DATA CI_END="2.035242373594399" CI_START="0.8930554485421494" EFFECT_SIZE="1.3481781376518218" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.30861613604116483" LOG_CI_START="-0.049121575547856504" LOG_EFFECT_SIZE="0.12974728024665413" MODIFIED="2010-05-11 10:25:49 -0400" MODIFIED_BY="John K MacDonald" ORDER="128" O_E="0.0" SE="0.21013690261762305" STUDY_ID="STD-Talley-2008a" TOTAL_1="18" TOTAL_2="8" VAR="0.04415751784172839" WEIGHT="11.809281848937625"/>
<DICH_DATA CI_END="2.8953961347922945" CI_START="1.0304189601310596" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.4617079903035391" LOG_CI_START="0.01301384128566877" LOG_EFFECT_SIZE="0.23736091579460392" MODIFIED="2010-03-30 13:47:17 -0400" MODIFIED_BY="John K MacDonald" ORDER="134" O_E="0.0" SE="0.2635651642049557" STUDY_ID="STD-Vahedi-2008" TOTAL_1="27" TOTAL_2="27" VAR="0.06946659578238526" WEIGHT="9.884447424500685"/>
<DICH_DATA CI_END="5.411723831385193" CI_START="0.8943545810542861" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7333356257737456" LOG_CI_START="-0.04849026412933306" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2009-05-14 08:28:34 -0400" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.4592483978296396" STUDY_ID="STD-Vij-1991" TOTAL_1="25" TOTAL_2="25" VAR="0.2109090909090909" WEIGHT="5.172650238685274"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.683857208483297" CI_START="1.9499726262750101" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="3.3169149173791537" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2010-05-10 14:21:34 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.97569308660423E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="4.755894831957829">
<NAME>Comparing scores on global assessment in patients with IBS</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.683857208483297" CI_START="1.9499726262750101" DF="0" EFFECT_SIZE="3.3169149173791537" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" MODIFIED="2009-05-19 08:35:54 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.97569308660423E-6" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="4.755894831957829">
<NAME>SSRI's</NAME>
<CONT_DATA CI_END="4.683857208483297" CI_START="1.9499726262750101" EFFECT_SIZE="3.3169149173791537" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-7.3" MODIFIED="2009-05-19 08:35:54 -0400" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="0.8" SD_2="0.5" SE="0.6974323517607517" STUDY_ID="STD-Tack-2006a" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.02.02" MODIFIED="2010-05-10 14:21:34 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>TCA's</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-06-03 10:05:55 -0400" MODIFIED_BY="John K MacDonald" NO="9">
<NAME>Antidepressants: Outcome on symptom score</NAME>
<DICH_OUTCOME CHI2="4.2731911910066405" CI_END="2.9920233606472904" CI_START="1.3191692939166069" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9867021276595742" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="21" I2="53.19657111974768" I2_Q="73.27447868944813" ID="CMP-009.01" LOG_CI_END="0.4759649800215033" LOG_CI_START="0.12030053375397207" LOG_EFFECT_SIZE="0.29813275688773766" METHOD="MH" MODIFIED="2011-06-03 10:05:55 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.11805613541507087" P_Q="0.05306935980389893" P_Z="0.0010167624326805366" Q="3.741741791974609" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="80" WEIGHT="99.99999999999999" Z="3.2858469394046117">
<NAME>Comparing nr (%) of successfully treated IBS patients</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive agent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2668031135491256" CI_START="0.8125261182521144" DF="0" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.35541380049154936" LOG_CI_START="-0.09016266994236738" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2009-05-19 08:36:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2433056387240512" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="65.1595744680851" Z="1.1667641745728858">
<NAME>SSRI's</NAME>
<DICH_DATA CI_END="2.2668031135491256" CI_START="0.8125261182521144" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.35541380049154936" LOG_CI_START="-0.09016266994236738" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2009-05-19 08:36:52 -0400" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.26173382437198345" STUDY_ID="STD-Masand-2009" TOTAL_1="36" TOTAL_2="36" VAR="0.06850459482038429" WEIGHT="65.1595744680851"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.608426025171236" CI_END="6.291849932804304" CI_START="1.5912122837220126" DF="1" EFFECT_SIZE="3.1641221374045805" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" I2="37.82741734152565" ID="CMP-009.01.02" LOG_CI_END="0.798778355697558" LOG_CI_START="0.20172812276349822" LOG_EFFECT_SIZE="0.5002532392305281" MODIFIED="2009-05-27 10:03:48 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20471324956942083" P_Z="0.001021967955230534" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="34.84042553191489" Z="3.284408171898736">
<NAME>TCA's</NAME>
<DICH_DATA CI_END="226.13464447187846" CI_START="0.8378509558770566" EFFECT_SIZE="13.764705882352942" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.354367102594669" LOG_CI_START="-0.07683323053093093" LOG_EFFECT_SIZE="1.1387669360318688" MODIFIED="2009-05-27 10:03:48 -0400" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="1.4280991103137184" STUDY_ID="STD-Bahar-2008" TOTAL_1="16" TOTAL_2="17" VAR="2.039467068878834" WEIGHT="2.2606382978723403"/>
<DICH_DATA CI_END="4.8912251712444546" CI_START="1.2058245075993659" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.6894176563559343" LOG_CI_START="0.08128410637209986" LOG_EFFECT_SIZE="0.3853508813640171" MODIFIED="2009-05-19 08:37:26 -0400" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.3572206575701264" STUDY_ID="STD-Vahedi-2008" TOTAL_1="27" TOTAL_2="27" VAR="0.1276065981948335" WEIGHT="32.57978723404255"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.3959843866657593" CI_END="1.056244274560309" CI_START="-0.30029813090055996" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.37797307182987444" ESTIMABLE="YES" I2="70.55345707929422" I2_Q="70.5534570792942" ID="CMP-009.02" MODIFIED="2010-05-12 13:45:58 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0653554333996722" P_Q="0.0653554333996722" P_Z="0.27474146156819756" Q="3.3959843866657584" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.16967040060734934" TOTALS="YES" TOTAL_1="61" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="1.0922085515798416">
<NAME>Comparing symptom scores of IBS patients</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive agent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5152396732215307" CI_START="-0.4088689945303526" DF="0" EFFECT_SIZE="0.053185339345589076" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" MODIFIED="2009-05-19 08:38:04 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8215093561392572" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="53.16821339918545" Z="0.22560409454114927">
<NAME>SSRI's</NAME>
<CONT_DATA CI_END="0.5152396732215307" CI_START="-0.40886899453035264" EFFECT_SIZE="0.053185339345589076" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-3.1" MODIFIED="2009-05-19 08:38:04 -0400" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="7.44" SD_2="7.44" SE="0.23574633897386243" STUDY_ID="STD-Masand-2009" TOTAL_1="36" TOTAL_2="36" WEIGHT="53.16821339918545"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3216553090624867" CI_START="0.1717550538189001" DF="0" EFFECT_SIZE="0.7467051814406934" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.02" MODIFIED="2010-05-10 14:21:13 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="1.0" P_Z="0.01091323926892027" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="46.83178660081456" Z="2.545464714908138">
<NAME>TCA's</NAME>
<CONT_DATA CI_END="1.3216553090624867" CI_START="0.1717550538189001" EFFECT_SIZE="0.7467051814406934" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-1.6" MODIFIED="2009-05-15 09:34:36 -0400" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="1.45" SD_2="1.45" SE="0.2933472921731861" STUDY_ID="STD-Vahedi-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="46.83178660081456"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-06-06 12:48:55 -0400" MODIFIED_BY="John K MacDonald" NO="10">
<NAME>Adequate concealment bulking agents: abdominal pain</NAME>
<CONT_OUTCOME CHI2="0.02242648414110926" CI_END="0.39753668200968384" CI_START="-0.3227518473088383" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.03739241735042277" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2011-06-06 12:48:55 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.8809581263038714" P_Q="1.0" P_Z="0.8387476453209737" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="0.20349565019745117">
<NAME>Comparing scores on abdominal pain</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bulking agent</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6076199403576706" CI_START="-0.6076199403576706" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-5.0" MODIFIED="2009-05-26 03:01:48 -0400" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="16.5" SD_2="16.5" SE="0.31001587026623917" STUDY_ID="STD-Fowlie-1992" TOTAL_1="23" TOTAL_2="19" WEIGHT="35.13087529467434"/>
<CONT_DATA CI_END="0.504797232578332" CI_START="-0.3895115168536895" EFFECT_SIZE="0.05764285786232122" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="-0.62" MODIFIED="2009-05-26 03:01:55 -0400" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="0.51" SD_2="0.52" SE="0.22814417930283787" STUDY_ID="STD-Longstreth-1981" TOTAL_1="37" TOTAL_2="40" WEIGHT="64.86912470532566"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2009-05-26 08:30:46 -0400" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Adequate concealment bulking agents: global assessment</NAME>
<DICH_OUTCOME CHI2="8.655817399052207" CI_END="1.2337361484775204" CI_START="0.6772464241040164" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9140806281965845" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" I2="53.78830426300362" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.09122228975181806" LOG_CI_START="-0.1692532793859621" LOG_EFFECT_SIZE="-0.03901549481707199" METHOD="MH" MODIFIED="2009-05-26 03:27:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07030239676462136" P_Q="1.0" P_Z="0.5571037486423445" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="97" WEIGHT="100.00000000000003" Z="0.5871488441975266">
<NAME>comparing nr of successfully treated IBS patient</NAME>
<GROUP_LABEL_1>Bulking agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bulking agent</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3924033145716261" CI_START="0.568402328236631" EFFECT_SIZE="0.8896321070234113" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.14376504843762694" LOG_CI_START="-0.24534415182435232" LOG_EFFECT_SIZE="-0.05078955169336268" ORDER="94" O_E="0.0" SE="0.228564670355492" STUDY_ID="STD-Fowlie-1992" TOTAL_1="23" TOTAL_2="19" VAR="0.05224180853471472" WEIGHT="31.20910178486837"/>
<DICH_DATA CI_END="2.1048763927551986" CI_START="0.7155756757459211" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.32322659731158015" LOG_CI_START="-0.14534443063801805" LOG_EFFECT_SIZE="0.08894108333678108" ORDER="95" O_E="0.0" SE="0.27524094128159016" STUDY_ID="STD-Jalihal-1990" TOTAL_1="11" TOTAL_2="9" VAR="0.07575757575757577" WEIGHT="14.466827783888816"/>
<DICH_DATA CI_END="1.384134411064323" CI_START="0.30886797516338965" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.14117826580654008" LOG_CI_START="-0.5102271189916282" LOG_EFFECT_SIZE="-0.18452442659254403" ORDER="96" O_E="0.0" SE="0.38263874753910304" STUDY_ID="STD-Longstreth-1981" TOTAL_1="26" TOTAL_2="34" VAR="0.14641241111829345" WEIGHT="26.59558239058348"/>
<DICH_DATA CI_END="281.8130260076303" CI_START="1.1337858633665463" EFFECT_SIZE="17.875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.449961063267627" LOG_CI_START="0.05453103767860931" LOG_EFFECT_SIZE="1.2522460504731183" MODIFIED="2009-05-26 03:27:46 -0400" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="1.407087454600852" STUDY_ID="STD-Ritchie-1979" TOTAL_1="7" TOTAL_2="12" VAR="1.9798951048951048" WEIGHT="0.8350261347121971"/>
<DICH_DATA CI_END="1.0940140676020023" CI_START="0.23283457912701064" EFFECT_SIZE="0.5047021943573667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.03902290649708566" LOG_CI_START="-0.6329525205477486" LOG_EFFECT_SIZE="-0.29696480702533146" MODIFIED="2009-05-26 03:27:52 -0400" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.39472169217814584" STUDY_ID="STD-Soltoft-1976" TOTAL_1="29" TOTAL_2="23" VAR="0.1558052142759789" WEIGHT="26.89346190594716"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2009-05-26 08:31:05 -0400" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Adequate concealment spasmolytic agents: abdominal pain</NAME>
<CONT_OUTCOME CHI2="0.023899582779330124" CI_END="0.7954223599279142" CI_START="0.055138040925731324" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4252802004268228" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" MODIFIED="2009-05-26 03:09:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8771407075912632" P_Q="1.0" P_Z="0.024326756928083042" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="2.2519290353145807">
<NAME>Comparing scores on abdominal pain in IBS patients</NAME>
<GROUP_LABEL_1>Spasmolytic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0115917629770572" CI_START="-0.24070107170538502" EFFECT_SIZE="0.3854453456358361" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-3.0" MODIFIED="2009-05-26 03:07:28 -0400" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="1.78" SD_2="1.78" SE="0.31946832813265147" STUDY_ID="STD-Awad-1995" TOTAL_1="20" TOTAL_2="20" WEIGHT="34.94502124491361"/>
<CONT_DATA CI_END="0.9055887520220238" CI_START="-0.012232861150629437" EFFECT_SIZE="0.4466779454356972" ESTIMABLE="YES" MEAN_1="-1.63" MEAN_2="-2.09" MODIFIED="2009-05-26 03:07:42 -0400" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="0.99" SD_2="1.05" SE="0.23414246904849095" STUDY_ID="STD-Pulpeiro-2000" TOTAL_1="39" TOTAL_2="36" WEIGHT="65.0549787550864"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2009-05-26 08:32:04 -0400" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Adequate concealment spasmolytic agents: global assessment</NAME>
<DICH_OUTCOME CHI2="2.745581711149266" CI_END="2.118965627661084" CI_START="0.8543137731704671" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3454595945570673" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="20" I2="27.15569192938625" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.32612391195468604" LOG_CI_START="-0.06838259192368856" LOG_EFFECT_SIZE="0.12887066001549877" METHOD="MH" MODIFIED="2009-05-26 03:31:37 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2533990060385267" P_Q="1.0" P_Z="0.2003710139762141" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.2804952507051899">
<NAME>comparing nrs of successfully treated IBS patients with spasmolytic agents</NAME>
<GROUP_LABEL_1>Spasmolytic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Spasmolytic</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2332394433414455" CI_START="0.7945173259447946" EFFECT_SIZE="1.332046332046332" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.3489352897292883" LOG_CI_START="-0.09989662774524374" LOG_EFFECT_SIZE="0.1245193309920223" MODIFIED="2009-05-26 03:11:43 -0400" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.26364609007836365" STUDY_ID="STD-Chen-2004" TOTAL_1="74" TOTAL_2="46" VAR="0.06950926081360863" WEIGHT="71.92446542627047"/>
<DICH_DATA CI_END="2.303890385114592" CI_START="0.256833389363674" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.362461812306586" LOG_CI_START="-0.5903485169202596" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="99" O_E="0.0" SE="0.5596855038750452" STUDY_ID="STD-Pulpeiro-2000" TOTAL_1="39" TOTAL_2="36" VAR="0.31324786324786325" WEIGHT="25.992779783393498"/>
<DICH_DATA CI_END="150.80918509370878" CI_START="0.5371025640757144" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1784277932183316" LOG_CI_START="-0.2699427743396819" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-05-26 03:31:37 -0400" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="1.4381849910133495" STUDY_ID="STD-Ritchie-1979" TOTAL_1="12" TOTAL_2="12" VAR="2.068376068376068" WEIGHT="2.0827547903360175"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2009-10-18 09:24:30 -0400" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Adequate concealment antidepressants: abdominal pain</NAME>
<DICH_OUTCOME CHI2="8.863661078099344" CI_END="1.8594335506698279" CI_START="0.9781427484948941" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3486257612457968" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="72" I2="54.87192070234561" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.2693806628815665" LOG_CI_START="-0.00959776038653116" LOG_EFFECT_SIZE="0.1298914512475176" METHOD="MH" MODIFIED="2009-10-18 09:24:30 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06459918210939408" P_Q="0.3843481383346976" P_Z="0.06798506819694039" Q="0.7567481407706678" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06430467636124473" TOTALS="YES" TOTAL_1="203" TOTAL_2="161" WEIGHT="100.0" Z="1.8251057795973105">
<NAME>Comparing nr (%) of successfully treated patients</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.914489696628799" CI_END="1.6683901986787828" CI_START="0.8676286784869593" DF="2" EFFECT_SIZE="1.2031388877765807" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" I2="31.377352189187448" ID="CMP-014.01.01" LOG_CI_END="0.22229762982386372" LOG_CI_START="-0.06166610130653956" LOG_EFFECT_SIZE="0.08031576425866206" MODIFIED="2009-05-26 09:26:18 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2328770532977713" P_Z="0.26755747866595625" STUDIES="3" TAU2="0.0288625962457591" TOTAL_1="74" TOTAL_2="82" WEIGHT="63.08584054787567" Z="1.108705007580687">
<NAME>SSRI</NAME>
<DICH_DATA CI_END="4.893347927287065" CI_START="0.8088543056779071" EFFECT_SIZE="1.9894736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6896060961051012" LOG_CI_START="-0.09212969833630846" LOG_EFFECT_SIZE="0.29873819888439634" MODIFIED="2009-05-26 03:36:37 -0400" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.45919547530947546" STUDY_ID="STD-Kuiken-2003" TOTAL_1="19" TOTAL_2="21" VAR="0.21086048454469508" WEIGHT="9.759397080250578"/>
<DICH_DATA CI_END="1.4458363667737397" CI_START="0.5407446325286646" EFFECT_SIZE="0.8842105263157894" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1601191442527877" LOG_CI_START="-0.26700778270672" LOG_EFFECT_SIZE="-0.053444319226966124" MODIFIED="2009-05-26 03:37:08 -0400" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.25089647120840247" STUDY_ID="STD-Tabas-2004" TOTAL_1="30" TOTAL_2="36" VAR="0.06294903926482874" WEIGHT="21.103085711250372"/>
<DICH_DATA CI_END="1.6745176629963872" CI_START="0.9750366242546099" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.22388973288598282" LOG_CI_START="-0.010979071057409265" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2009-05-26 03:37:16 -0400" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.13796309805567852" STUDY_ID="STD-Vahedi-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.019033816425120767" WEIGHT="32.22335775637472"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.391893527920505" CI_END="8.114579367344326" CI_START="0.5912074723795656" DF="1" EFFECT_SIZE="2.1902967737708545" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="30" I2="81.45363971262113" ID="CMP-014.01.02" LOG_CI_END="0.9092660123722439" LOG_CI_START="-0.22826008545101226" LOG_EFFECT_SIZE="0.3405029634606158" MODIFIED="2009-05-26 09:26:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02023057992483024" P_Z="0.24064463116514923" STUDIES="2" TAU2="0.7457988519781789" TOTAL_1="129" TOTAL_2="79" WEIGHT="36.91415945212434" Z="1.1733771142289142">
<NAME>TCA</NAME>
<DICH_DATA CI_END="1.7296463112630673" CI_START="0.9218436546242883" EFFECT_SIZE="1.2627206645898235" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="27" LOG_CI_END="0.23795730499541615" LOG_CI_START="-0.03534272937105295" LOG_EFFECT_SIZE="0.10130728781218161" ORDER="262" O_E="0.0" SE="0.16053779304385266" STUDY_ID="STD-Drossman-2003" TOTAL_1="107" TOTAL_2="57" VAR="0.025772382995390863" WEIGHT="29.81276350618659"/>
<DICH_DATA CI_END="13.991740612505684" CI_START="1.5564738070053283" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.1458717453269922" LOG_CI_START="0.1921418165901592" LOG_EFFECT_SIZE="0.6690067809585756" ORDER="261" O_E="0.0" SE="0.5602256811793028" STUDY_ID="STD-Vahedi-2008" TOTAL_1="22" TOTAL_2="22" VAR="0.31385281385281383" WEIGHT="7.101395945937749"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2010-05-12 14:09:18 -0400" MODIFIED_BY="John K MacDonald" NO="15">
<NAME>Adequate concealment antidepressants: global assessment</NAME>
<DICH_OUTCOME CHI2="5.593576132572472" CI_END="1.8026324531020368" CI_START="1.1222221821680731" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.422305918277483" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="51" I2="28.48939738734887" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.2559071854790805" LOG_CI_START="0.05007884884255867" LOG_EFFECT_SIZE="0.15299301716081956" METHOD="MH" MODIFIED="2010-05-12 14:09:18 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.23162597551302622" P_Q="1.0" P_Z="0.003571752849519258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="130" WEIGHT="100.0" Z="2.913697972022751">
<NAME>Comparing nr (%) of successfully treated IBS patients</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressives</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9170114422643985" CI_START="0.8790551346948886" EFFECT_SIZE="1.2981366459627328" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="21" LOG_CI_END="0.2826247051041754" LOG_CI_START="-0.055983884945766914" LOG_EFFECT_SIZE="0.11332041007920426" MODIFIED="2010-05-10 14:19:59 -0400" MODIFIED_BY="John K MacDonald" ORDER="256" O_E="0.0" SE="0.1989003619348893" STUDY_ID="STD-Drossman-2003" TOTAL_1="115" TOTAL_2="57" VAR="0.039561353977829956" WEIGHT="45.7749897399824"/>
<DICH_DATA CI_END="2.3585052691612187" CI_START="0.6394543084222777" EFFECT_SIZE="1.2280701754385965" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.37263685084463577" LOG_CI_START="-0.19419048216110493" LOG_EFFECT_SIZE="0.08922318434176545" MODIFIED="2009-05-26 08:35:30 -0400" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.33295718124812246" STUDY_ID="STD-Kuiken-2003" TOTAL_1="19" TOTAL_2="21" VAR="0.11086048454469508" WEIGHT="13.937204950645576"/>
<DICH_DATA CI_END="4.125183925298056" CI_START="1.2601619937768962" EFFECT_SIZE="2.28" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.6154433167553471" LOG_CI_START="0.10042637724556047" LOG_EFFECT_SIZE="0.35793484700045375" MODIFIED="2009-05-26 08:35:38 -0400" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.30252349964301506" STUDY_ID="STD-Tabas-2004" TOTAL_1="30" TOTAL_2="36" VAR="0.09152046783625732" WEIGHT="14.818931366980943"/>
<DICH_DATA CI_END="1.5582633338388099" CI_START="0.5684617802093249" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.19264085177635265" LOG_CI_START="-0.2452987292210509" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2010-05-12 14:09:10 -0400" MODIFIED_BY="John K MacDonald" ORDER="129" O_E="0.0" SE="0.25724787771376323" STUDY_ID="STD-Talley-2008a" TOTAL_1="17" TOTAL_2="8" VAR="0.06617647058823528" WEIGHT="13.301472795002093"/>
<DICH_DATA CI_END="2.6971473407366693" CI_START="0.9412201646261112" EFFECT_SIZE="1.5933014354066986" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.430904671896365" LOG_CI_START="-0.02630877710583325" LOG_EFFECT_SIZE="0.20229794739526585" MODIFIED="2010-05-12 14:09:18 -0400" MODIFIED_BY="John K MacDonald" ORDER="130" O_E="0.0" SE="0.2685694431869649" STUDY_ID="STD-Talley-2008a" TOTAL_1="18" TOTAL_2="8" VAR="0.07212954581375636" WEIGHT="12.167401147388993"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2010-05-10 14:20:41 -0400" MODIFIED_BY="John K MacDonald" NO="16">
<NAME>Adequate concealment antidepressants: Outcome on symptom score</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3216553090624867" CI_START="0.1717550538189001" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.7467051814406934" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2010-05-10 14:20:41 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.01091323926892027" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="2.545464714908138">
<NAME>Comparing symptom scores in IBS patients</NAME>
<GROUP_LABEL_1>Antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Antidepressive</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3216553090624867" CI_START="0.1717550538189001" EFFECT_SIZE="0.7467051814406934" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-1.6" MODIFIED="2009-05-26 09:15:29 -0400" MODIFIED_BY="[Empty name]" ORDER="260" SD_1="1.45" SD_2="1.45" SE="0.2933472921731861" STUDY_ID="STD-Vahedi-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-06-03 14:30:04 -0400" MODIFIED_BY="John K MacDonald">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-06-03 14:30:04 -0400" MODIFIED_BY="John K MacDonald" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATMAAAeLCAIAAABHc9crAABUzElEQVR42u3dwY4cRdbF8ZaQEAsv
vPAT8AxeIYsVrHgnWHqBBEveAvEII5hZAit2iMEejb2YhQ27mcGKr3v6EypXVWZGZGZkxo38HbVG
TLn7VHV2/OtGREbdc3NDRG0qEVFLQiYRMokImUTIJCJkEiGTiJBJRMgkQiYRIZM2HD1OkiGTmho3
OQ8SMmm7QTP7XwmZRMikYxdPowiZ1CKW5rHIJGQikwiZyKSgoweWyCRCJhEhkwKPHgf0kElNDZ3T
/zCKkEktkglOZBIykUmUB6dRhEwiZBIRMinQJFZADjKJkElEyKQeRo+pLDKptdXm+COETEImMoku
UDSKkEltLS8tNZFJhEwiQiYRIZMImUSETNph9Og2gkxqaugM/Qchk5CJTCJkIpMCrTONImQSIZOI
kElxl5oWmcikFrEEJzIJmcgkyhk99maRSYRMIkImxZ/NGkjIpCaGjouATEImMonAiUzqZpFpICGT
CJlEhEwKPaF1TZBJ+w+d0/8wipBJLZIJTmQSMpFJlAenUYRMImQSETIp5Ohx1wSZ1OAik5B5oPqD
TOMBmU38DXIeBCcyqYnB3fifxjoTmaRgIpN2HejWmYTMFrEMNO6NHGQiM8Ai00BCJjIJmbThX8JU
lpBJ4EQm9Tp0rDORebSB7poYDwZBK9NCPXUIme2SmeJsAinyyERmo6955BFCZldwBr1rYiAhk5CJ
TCLrTGQes/LEujdowCCTmn43cSmQSU3PY01okWnNZk6LTNpvlGvPZUggE5ngRCZljPKIR/MMJGT2
vLw0ygmZRMikrgu+NScyqbmFsa5iyCRkIpMImcikiHuzNpOReZT6Q4RMZBIyqUc4zWaRebhFpg5d
hgQyCZnIpE7hNIqQeYgJbdAZuOGETDND71PIJGRmv7aFr/zqgDzgKEVm/2TWqD+V+KnKPDKpc37M
OZFJB60/4VJekEkHek858qdYkNnEKKx67yFuyhgykan+eM3IpIxV34qbNBFH+emwtM6k/f4A1Waz
Nch0+geZx62Z6o8hgUwKMJVAJu1fNqP8RSr1mz2r8NaZ1NBstt7pvPb3luzNIrN/MuvVH2Qi84gr
q4Pz43QeMo9SjSvx45YJMkn9QSbtN5tNB77ruMEpYmRSK3POzdbGBhIykbl//TFskInMpl/zBtUY
mdTKzDDWG0ptW+tMwvz8RWa9eTIyqdt5cqxRrvs7MtsqaAevPz75icyDls11/9b4QSYFqMaEzJ5B
irgUJGR2PuEMdwYo+lQCmdQbmeH2aWJlGSETmTGwr1reG7zayDTLMkk2m6Uu6k/td5PaJ3Ibn8ci
U/1Z2bl9OAOtGpDZ4lIzRP2p2lUsXL8/ZPaPZbj6E2h9iExqZcTUzv+L+Mm1EBvgyPRe3vC49Mlp
bHgvb/B9KtA8GZnUUP3ZbNeq/SwJZPZfH9YdkREzcyNmSSCz83ns+IMHITMFzJJApjnnIcisPUNB
JnW+zgy3a+V0HtFMbPQBQiatOU8mZFIT9SfQub9w1RiZtM7yda3PN+tqiczWB3qz9cc8GZnWbOpP
3cuCTNqnSmyT2LXWE22fLGidSb1N4fpIFkQmFc88awzHECfdtukDlJybpS6rRKw+DOFW3chE5mrD
PcQMItg0yghubUIbwpmQqbK5GsgkY3GnauweLDKPuBpMlTdpJHMi0zqzeJRH7AlSwzlKQUbmUapx
7XsbUWazV1+zLDDqh8x6FG2f+IBMSkMjQyf1HdfzyCSaWZCrvk8hk7be8+hgBi49gZooDvoDSHlB
Zrs109VIm/SYdqKd1PmZcEbJmUemPY+ZzqsPzSifdUQmNbfnEesMUO38pRSqlzwye15ZhTudVzt/
yTqTOicz+UwpMo8Gp1FO/lp0oDc+s1nqc1tictnmT4lMcO48T444bPSbpaXFJ+LebLgrbDZL+1eJ
EF1ha8+TnTSg/sncrM47nUdNTLdShTN0sT60EbTOI1NlczWaq/PINBbXKQ6VDrvVuCDOAFFvVaL2
GdRKq0FCZovrzCin8yJ2sk0yp0mdX2sdKHOaqInV4Pb9ZpFJBeXCNUGmQdDciHFBDt4XG5mdkxmx
k61dX2T2DKd+s8ikKhQddp4ctEMKMqlFhCr1y6y962sHiBoqyIedcyKT5vOT4nyEMuJqMEr3amR2
vrKKReYGZ4Ci7Ioh8xB7HlVHT41nCZfLgExkrlAlrAaRSTMRirVgqz0DD5G/hExq600k0Bm6QLtW
yDwQSOmo3a6QSStXoUONRWQis/VlW41uQEdOVo+4nkdmc1iePtIymYYNMpHZYpXoI9cEmTSHn8b/
NBukJ6SaZxiQSf2/lURJSdIJmtpFKMqc0yenkXmgFWyg1xyrYz0yqRUyY50BqtqxHpnUCpxB+2i5
n0kzR0yqk9Knp4F1JjU0yoP2NNAXG5nIXOdlH/wMAzKR2f9ANyCR2f/ORMSeBuBEJrX4bpJq7lpF
eatCJq1W1mKtjVPbu8rIbHGg1/iISaCU2O3zl5BJW4/yWO8mtX99ZFL/ZNarydv3/kImlY2YSgi5
2mHGgwvRfTU+ckosMql1MtN6n6iK2G820AwCme0u25olM+6qWx8gamjE1MufRSYykdn6y46SDK1D
F3UO5za5QIc9RYzMRheZ7adfydJDJq2zyIxS2QiZyDzKCnaDOz3I7HxCW2nO6a6Jmkmdzzlr15+g
adbIROaBZhArvpsE+tg0MpF5rDmnkwa0f5W4Ohx9JhuZ1HllqzFsNphzOgNEyGzR2TqTWhkx28yT
CZlHLHSHejcJ2iMXmeB0KVqcQSDTcFxagg57NZw0oFbgCZpsi0xkqr1LnWuc9d3sfQqZ1BuccT/F
Yp1J86tE+12VnfVF5uEqW6BzKqfD6ICVDZmHm3Ae+Y8SscMQMo3F/uuPz2cis/+diaAd7pCJTNX4
WHU+ynoemcg80No4UGcDZDY3aFKck6IR95ODjQcXopHKFqvbSKzOOsikQ5BpboJMZJpzHu4dEJmN
Tg5rYBkITn2xkXmUKrEimbUHTD1+kEk9V+PaizQpSchsdAkUd2P2aJUNmXYmAsyTI666m31vRSYy
j77wbvMviExkBqhs7ffLRGbn64pYWK7OT9xzRcikFYZ7+5XNeysyLauaI5OQicwW15kpzulWZNKB
Jod97IdZZ1LZcDngbsoG1Xj1vtjI7PMdt48iH+jcrL1ZE84jvk8dkHlk9k+mUrzZPPn0gpvNgrPM
tup5mnBn8Vt/ncDodZ1Zu/fkSDlakXafNaHeZrPbd7VsvxDVuMKrv5sg0zrzQGSeXRA1k3aGc0vm
12qbsE2UtW4jVLy+8iZV6W2r0hWuEnyKjV7Hd+gzQDXWxlH2wJFJa5b6GgP9mJ9WRWbTa7bG68+W
c/uFl2WDGcS67ybI7Hb+VvveoGFT9Tojs/+V1ZYv+7DXuRbw2DBiVqkVza5gw50uQmbn68wU8PNl
W56Ian08AKP7ahyoc4cBiczDkZnWSxzabJ+zHvYtv2BktrhakxES/ZM3yOywuNX4G5/+sY88mw3U
/R2ZjY7FAB/qjXmn1CenqVsyt6zzR1/mYKO1QhRxz6P9XKBt/oLJ6Tzal5+gdX6DfrPJiXbakZ+I
ZW1dfpB5uNnskflJ+s0is9nK5mpUnYFXzWXQ0wCZfdZ5M3BkHgLO0AfoDjunQGajxefgydAdrI2t
M2nPmWHo976Wzy0hE5nN1XmLEWR2OxfqYGYYrjL7rEnP77iBPt8cdwa+7hkgHboORGZq/rMmKfiu
VfvXGZndkhk68S7uGaC13k2Q2SKc/iLeAZFJqnGVmmk2S/3z4wwQ7TkKq74HR5xzxn0fRGZXo/B0
z7PqAFr33STKidyz+N3GN5OR2RaZVQdljYEYqH1rpdc85GAHqLeaWQnIDeLoWj73h0xqhcx6C9cN
auZm1xmZpGb2SaZ1ZrdkbnBvY/V1ZqXXXPVqnFk1/rEBZB7xjcB1CPOW7UIQIZOIkEmETCJCJhEy
aeElJiq5G4TMLcjkzLnUGZnI5IxMZHLmjExkckYmGYuckYlMzsik2n/XN29evX799OXLJ8+fP/z1
15tnzx68ePH41avP3rz51wGdX/331dNnT5/8+OThXx/e/OXmwXcPHn//+LO/f/av/xzLGZk7k/n7
7189f/7odnBfft0O+t9++/JQzl/986tHf3t0O7gvv24H/Zf/OJAzMvck87bIXB3fp1+333MQ59si
c3V8n37dfs9BnJG5G5m3lWdyiN9/DVWhnpxvK8/kEL//GqpCPTkHJnOoyc2832Wo42vmg+NPffXx
23Xa6YTw229vPvzw5r337r4++eTmhx/Op4h//PGyY+fbddrQhPDqFPHlv3t2DkzmZWObJWRO+ow/
eHod88l8/frp6Th+//27H//mm5uvv777jw8+yJofduP89NnTzCE+Mj/sxrl/Mi/r22Svqs3IfPny
ydVJ4M8/3/m8++754y9ePO7Y+cmPT66M5ntdG+WPv+/ZuXMyh/51/JedR+Y48Fcfv7/ZcPb10083
H3109wq/+OL8n549e9Cx8/3NhvxR/uC7np2jkpkJ5Iy57mTjwxXJvFp8Pv747m/x6afX91Q6dr4+
vk91MdA7dg5M5uXH267+x8i3rUjmpHl+/XnnnbuX+ssvV4b4wsrWuLOaedCamXkhZm8LjX8QtmjN
NvS1fDXYsrN1Zngyh5phL5zNjvfYztkBKq2ZZ/uc91/3yr93342zvdkDkTmyN5szPd74fub4KF9y
1zGEs/uZnezNRtxJvpQzQKdyBgiZrZCZnJt9W87NIrMVMtP/f27j4fDnNj4/lPNtFbq+5/m/CeHn
zw/kjMydyUzDn3W8uk7r3nnos45X12kdOyNzfzI5c0YmMjkjk4xFzshEJmdkkrHIGZnI5IxMqnH1
iWSBqZmc1UwyFjkjE5mckUlGDGdkIpMzZ2QikzMySRZYmbMsMGQ2QaYssFPJAkNmE2TqaXAqPQ2Q
2QSZ+gCdVR59gBolszRupPazrxIQlmSBZTjrndcumZkBBJVe6lXYxp89swltkgWW4azfbCQy/3zk
tCKdPphD0WUn9cw3hRUhlAU26axHezAyh9JKMktZPlHbkykL7FRyTRolc+HUcR5FmWTmNG5P5fmZ
ssDeelAWWLNkjud2LXxwcpNmZAdoy5opC0zNPFbNzLkWs4Oo111nygKzzmyFzMkQoVSSYJmZQrvi
OnOVvVlZYPZmo5I5guvkzHPJbHab+5mywNzPbHRvtmM5A5Tj7AwQMlshMzk3+7acm0VmK2QmWWAX
VUgWGDKbIDPJArtYv8kCQ2YTZHLmjExkckYmGYuckYlMzsgkY5EzMpHJGZlU4+oTyQJTMzmrmWQs
ckYmMjkjk4wYzshEJmfOyEQmZ2SSXC3OyAxIplwtzshsjkz9ATgjszky9dThHJ7MFV9hfoe7Gb3z
8rtaytXiHJ7M8ZiwVchckgU2+drkanEOnAWWT2ZOCthQWUt57W3TGs3gx6++XC3OxyIzv4n7+DUq
InNGJ2i5WpxjkzmZjTky110lpS8/LDCVpCfI1eIcnsyhmLAhMjNjxTJ3gFJGjsMMMuVqcT5WzZyd
pVkUeZIazgKzZrPO3OFmSek+0DbrzBlkytXifCwy581CU0dZYO4Nup9J8++gJmeAOCOzTTKTc7Oc
kdkmmUmuFmdktklmkqvFGZltksmZMzKRyRmZZCxyRiYyOSOTjEXOyEQmZ2RSjatPJAtMzeSsZpKx
yBmZyOSMTDJiOCMTmZw5IxOZnJFJe2aBRXSWBYbMJsislwUW0VkWGDKbILNeT4OIznoaILMJMuv1
AYrorA9QDDIzTzCttUBf2CZvee+8FbPAIjrrnReJzHz2Fr7+ha1lV+k3u2IWWERn/WZ7IPOyQP3Z
SHaylE0G/m1GZr0ssIjOerSHJ7OoHfv4d+5LZr0ssIjOck26WmfOYCN/VlyabFu6zqyXBRbRWRZY
V7PZfGCqkrlizVwlCyyis5rZ7Wx2xoNF7wWbrTOXZ4FFdLbO7IfMyZo5+Z3jFyhuFlhEZ3uzPawz
L1O9xmezkzVz6LmCZoFFdHY/MwyZPckZoBxnZ4CQ2QqZybnZt+XcLDJbITPVzAKL6CwLDJmtkJlq
ZoFFdJYFhsxWyOTMGZnI5IxMMhY5IxOZnJFJxiJnZCKTMzKpxtUnkgWmZnJWM8lY5IxMZHJGJhkx
nJGJTM6ckYlMzsgkWWBlzrLAkNkEmbLATiULDJlNkKmnwan0NEBmE2TqA3RWefQBikfm8miweY0t
89vk5Xey/XOdJgvsdJ2md15UMvPn/flNX8+uwtD357fPzH89ssBOpd9sh2QOBX6dMTNSM68GhJV2
gi4lUxbYqfRo743Mye7slzUtczZb2o69lExZYKeSa9LzOjM/qK8U/nHU55EpC+ytB2WBdTybXZfM
qzPhoQfXqpmywNTMY81m55FZtKW01jpTFph1ZldkjtfMBteZssDszXa+zpyMBsuJA9v9fqYsMPcz
Q5IZWs4A5Tg7A4TMVshMzs2+LedmkdkKmUkW2EUVkgWGzCbITLLALtZvssCQ2QSZnDkjE5mckUnG
ImdkIpMzMslY5IxMZHJGJtW4+kSywNRMzmomGYuckYlMzsgkI4YzMpHJmTMykckZmSQLrMxZFhgy
myBTFtipZIEhswky9TQ4lZ4GyGyCTH2AziqPPkD7kDkvz2vGa5v3s0t652U2jz9bp8kCO12n6Z23
J5n5c/dVyCx91xgyyW8tnR9DJgvsVPrNNkrmZfzB1QJb2m92PDLs7JVsTKYssFPp0d4imfl5XuPf
VvqzRW8cq5MpC+xUck1aX2eOQzWb6pxrsSQLbMY6UxbYWw/KAmt8Nps5I52XOFTKT2YW2Io1UxaY
mtnbbHbGzxZdo9K6PXvNJgvMOrM5MjPXipPTy8yf3XedKQvM3myAdebVKeKfj1x9cN7ebKqTBbb8
fqYsMPczdyNz45rc/gtzBuhUzgB1RWb+oaI23zKcmz2Vc7N91sygxVwW2FkVkgWGzFam2bLAztZv
ssCQGXsBzLljZ2QikzMykcmZMzKRyRmZZCxyRiYyOSOTll99IllgaiZnNZOMRc7IRCZnZJIRwxmZ
yOTMGZnI5IxMkgXWirMsMCr4u8oC28ZZFhgVXH09DbZx1tOACq6+PkDbOOsDVJb21T4/RW3yStvV
ygLbxlnvvCtPEwjOJVlgabSNbZIFtquzfrMTZF6WmpEGs2ffMNLHecR28sGhV1JK5ngb2yQLbFdn
PdrHyBwa0JOt1jNbsKdZHdyL3lbGa+YMMmWBbeMs12RsnVk6M8z8hqJ3gclrsSQLbAaZssC2cZYF
Nj24c2K8SsksTQdL5ekJKS+FYZWaedgsMClj+89mc2Bb8g0rkplZpef9uCywbZytM+esMzOnjmlW
4HTaKnN6HpmywLZxtjc7cT9zfPGZShJjZ+TMLpnNbnM/8+BZYFLG6pJZ6Y5/dDmps6+zM0DrFNvU
nZxu3d3ZuVkqngXIAtvGWRYYFc/PZYFt4ywLjDZaOXPu2BmZyOSMTGRy5oxMZHJGJhmLnJGJTM7I
pOVXn0gWmJrJWc0kY5EzMpHJGZlkxHBGJjI5c0YmMjkjkyR2cUZmQDIldnFGZnNk6jzAGZnNkalb
D+fmyGwwNWxJ77zxX0RiF+ci553J3Gbvq+idYuglLWyZKbGLc5Fzo2QWtas9+9+in8p5sB6ZErs4
RyJzdjf3GUlhRW8Wq5MpsYtzpHXmch7yfyr/zWJGSZ+8+hK7OPdQM+dFiY3/VOYO0JY1UxYY56iz
2XEai35qxj9tsM6UBcY5/Dpzm9nsNnuzssA4t34/c0aU2GTu7byaueX9TFlgnJsg81By6oVzmDNA
yLyXk6KckdkimUliF2dktklmktjFGZltksmZMzKRyRmZZCxyRiYyOSOTjEXOyEQmZ2RSjatPJAtM
zeSsZpKxyBmZyOSMTDJiOCMTmZw5IxOZnJFJ03/XV/999fTZ0yc/Pnn414c3f7l58N2Dx98//uzv
n/3rP0fM1ap3NWI5I3NnMr/651eP/vbo9s95+XX7Z/7yH8fK1ap3NcI5I3NPMm/fVq/+RU+/br9n
hnPET/HXuxoRnZG5G5m377WTf9T7r6H33Z4639S7GhGd9yFz3wiwocaTS9rkjR+2uvrg7cpkaAp0
dVL08t89p1/VuxoRnfchM7PH5F6sLmxym/9e8PTZ08w/6siMqJv0q3pXI6LzDmRe7ek6Uo5mhHxl
Pjj5ClfpLj3yDU9+fHLl73eva3/Xx9/3nH5V72pEdG6CzMnCNSPkK//H1yJzRifo++31/L/rg+96
Tr+qdzUiOrdFZj4e9UrcuqlkEw9e/Yue6uJPm+kcMf2q3tWI6NwcmUWBXznfuQ2ZOdtLu9fMxtOv
1Mx215kLa9RyMmcnDs0jc/t1ZsvpV9aZ7e7NzgiTXrFmTm5NrY7rZnuzIdKv7M02fT9zKEl2aG92
rZo5EoBdLwtss/uZIdKv3M9sgszVd4walzNA+14NZ4CQWfxbODe7zdVwbpaK319u33ev7/L9bwr0
+fNj5WrVuxrhnJG5f+Uf+nTf1ZVJkXPEXK16VyOWMzIDz8k5d+yMTGRyRiYyOXNGJjI5I5OMRc7I
RCZnZNLyq08kC0zN5KxmkrHIGZnI5IxMMmI4IxOZnDkjE5mckUmywFq5GrLAqODvKgtsm6shC4wK
rr6eBttcDT0NqODq6wO0zdXQB2h6gG7zXPmJI+OvLfPBycNWssB2vBp65xXUjdpPV0pm9aAEWWD7
XQ39ZsumczMiwEpzwSafJZ/qTDKL+s3KAtvmaujRPn9r+CoAM4K9xru5Z1bs2WRm/o5/ShbYNldD
rsmi20GzqViXzCWJQ6VkygLb5mrIAptP5sJgr5Efb5lMWWBqZtPrzBrBXvPIXJIFNiMNXhaYdWbT
e7NFEWD11plLssDmkSkLzN5s6/czMyPA6u3NrpIFVkqmLDD3M1O4M0D5dwVDyBmgfa+GM0DILN4A
c252m6vh3CwVb03LAtvmasgCo+JqLwtsm6shC4w2modz7tgZmcjkjExkcuaMTGRyRiYZi5yRiUzO
yKTlV59IFpiayVnNJGORMzKRyRmZZMRwRiYyOXNGJjI5I5P6TOySBVbbGZk7kxkxsUsW2AbOyNyT
zIidB/Q02MYZmbuRGbFbjz5A2zinzfrNLnmWzVr75bzs/AfHX3/ExC5ZYNs4b0Tm8hSwbdrhzu4E
PS8gLGJilyywbZy3IHN5CthlMkL+j4z/4KXDlmRGTOySBbaN8z5kTg790lbrQ4Eoaav0hHlkRkzs
kgW2jXOjZI48ODsFaAmZsxu3jz9jxMQuWWDbOO9PZmkK2OyskZxPxOXHOtSrmY0ndskC67lmZsZ4
LSSzKHckv7xvsM5sObFLFlg/68z8mrYZmY2sMyMmdskC62dvdnwZNhLjlUYD/MZ/pHRvtoX7mSES
u2SBdXU/k5wBynF2BgiZrZCZnJt9W87NIrMVMlPMxC5ZYBs4I3NnMlPMxC5ZYLWdkbk/mZw5IxOZ
nJFJxiJnZCKTMzLJWOSMTGRyRibVuPpEssDUTM5qJhmLnJGJTM7IJCOGMzKRyZkzMpHJGZnUZ66W
/LLazsjcmcyIuVryyzZwRuaeZEbsD6APwzbOyNyNzIg9dfQu2sY5DJlDHetq+xe1yWskC6xeTzf5
Zds4hyEzp2Pt6v4zkhqKyIyYqyW/bBvnGGROdnnPKWtD3znydLXJjJirJb9sG+eoZF6FYXZe2Cpk
Xs35G/8VIuZqyS/bxrkHMpfXuqJp84pkRszVkl+2jXO3ZGZGjK1F5mQ17iZXS37ZNs6drDNz8Kid
ODT+QdhucrXkl23j3NXe7OpxXTN8luzNhsjVkl+2jXNX9zPHY6Enibpa9La8nxkiV0t+2TbOkcgM
LWeAOHd7BqhLMpNzs5yR2SaZKWaulvyyDZyRuTOZKWaulvyy2s7I3J9MzpyRiUzOyCRjkTMykckZ
mWQsckYmMjkjk2pcfSJZYGomZzWTjEXOyEQmZ2SSEcMZmcjkzBmZyOSMTJJ+xRmZAcmUfsUZmc2R
6VP8nJHZHJk633BukczJ00mTA33ey87vcLdKQFiSfsU5UO+8JZFeNcjMbJm5VjPbJP2Kc4NkDvVQ
Hgo+GGoeOy8LbAjCjcmUfsU5AJk5VfFqjsiKWWAbkyn9inNgMsdxXTcLbIjMIf4Xkin9inMwMoem
pkXlcUYW2NAOULoWzVCpZsrV4tziOrN0Slk1C2xGDV9lnSlXi3OLe7PLp5Srz2a32ZuVq8W53fuZ
I3uzIzUzf2926AZJC/cz5WpxboXM48ipF86ywCKRmZwU5YzMNslM0q84I7NNMpP0K87IbJNMzpyR
iUzOyCRjkTMykckZmWQsckYmMjkjk2pcfSJZYGomZzWTjEXOyEQmZ2SSEcMZmcjkzBmZyOSMTJJ+
xRmZAcmUfsUZmc2R6VP8nJHZHJk633ButN9sZu7QNi9PFhjno2eBjfSn3LGsyQLjfNAssJzOsWev
eCi8YCjn6+x7xjPFrj7XZmRKv+LcBJlXG6uPsLFKzlfLPdqlX3Fui8zVGcgMX5hN5lAj+ZxfbeRB
6VecA5CZmd5VlPNVBE/KywKrXTPlanEOXzPzfzytlwW2wTpTrhbnJtaZmWvOhQzLAuMsC6xgb7aU
zMxlXunebAv3M+Vqcd7/fubR5NQLZ1lgkchMTopyRmabZCbpV5yR2SaZSfoVZ2S2SSZnzshEJmdk
krHIGZnI5IxMMhY5IxOZnJFJNa4+kSwwNZOzmknGImdkIpMzMsmI4YxMZHLmjExkckYmSb8qc371
31dPnz198uOTh399ePOXmwffPXj8/ePP/v7Zv/5zLGdk7kym9KtTffXPrx797dHt4L78uh30X/7j
QM7I3JNMn+I/1W2RuTq+T79uv+cgzsjcjUydb84qz+QQv/8aqkI9OW9NZua5pKor79JO0Jlt8kqz
zKRfna3ThiaEV6eIL//ds/M+ZBaBtxmZS7LA0kBYy/gzSr861dNnTzOH+Mj8sBvn/clM2b1khwK/
xqvZSEzY5WtY2Am6lEzpV6d68uOTK6P5XtdG+ePve3Zui8xxEoaYnBETtnqP9nmzWelXp7q/2ZA/
yh9817NzMDJnV7OFZE5mgc0jU/rVWw9eHd+nuhjoHTs3R+ZIztf2ZKbsLLAVa+Zh06/UzBg1s2jr
pR6ZVWez0q+sM2PszTY7m61EpvQre7Nh7mdO7s3m3LrIYTgzS2/L+5kHT79yP3NnMo8pZ4BynJ0B
QmYrZCbnZt+Wc7PIbIXMJP3qogpd3/P834Tw8+cHckbmzmQm6VcX67ern3W8uk7r2BmZ+5PJmTMy
kckZmWQsckYmMjkjk4xFzshEJmdkUo2rTyQLTM3krGaSscgZmcjkjEwyYjgjE5mcOSMTmZyRSbLA
ypxlgSGzCTJlgZ1KFhgymyBTT4NT6WmAzCbI1AforPLoA9QEmavnguUHJWT65/fOG/8tZIFNOuud
1xaZ88DLdy76kYWJQyPPKAts0lm/2XbJTHnNY4ceTBn9o8c7zW5MpiywU+nRHoPMomCvESDz4dme
TFlgp5JrEpvM0gfzOUl5WWDjDxY9oyywtx6UBXZYMid3m3KywFJhQFhp/ZEFpmYei8wZs9npt8w6
60xZYNaZ7e7NzguQzlxwNrLOlAVmbzbk/cyivdn82WwqT7bd5n6mLDD3M1sh8zhyBijH2RkgZLZC
ZnJu9m05N4vMVshMssAuqpAsMGQ2QWaSBXaxfpMFhswmyOTMGZnI5IxMMhY5IxOZnJFJxiJnZCKT
MzKpxtUnkgWmZnJWM8lY5IxMZHJGJhkxnJGJTM6ckYlMzsikPtOv/vvq1bOnT3988uSvDx/+5ebm
uwcPvn/8+O+fffaff8kCkwXWBZkR06/++dVXf3v06OrnhG9B/ceXssBkgQUnM+Jn7W8L42R7jdvv
OcjV0NOgQzIj9qe5rZaZzeKGKqc+QFuTWZrt1Ro8S9rkzeidF7Gn2+3acmgSe3Va+++Xeuc10Duv
NNurzZq2VjfqyUsRsQ/qs6dPS4yvz2n1m92ZzMuxe9aOeV4tuuw6O++nJn+LFSHspnf4j0+eFJH5
/WM92hvo0T5O5orJCPO6tmeGam5GZsS8jfsbJPlf3z2Qa9JArklpTkmaFdo1aVX0AkrNR3xK15kR
M6oux9ujCWNZYA1kgS0hs3Q2m2m1JZlqpprZYc3MH9zz4KmabGudaZ0ZaZ1ZVOiWM7Z6+Ky9WXuz
/ezNDt3PXPE+Yf5sNh+eoVfufqb7mT3cz6T8ef69nAGKfjVkgfVJZnJuNv7VcG62TzJTzPSr28o5
tE97+/jzz2WByQKLT2aKmX419PnMq2vL7q+GLLA+yeTMGZnI5IxMMhY5IxOZnJFJxiJnZCKTMzKp
xtUnkgWmZnJWM8lY5IxMZHJGJhkxnJGJTM6ckYlMzsik6b/rmzevXr9++vLlk+fPH/76682zZw9e
vHj86tVnb97864DOssCQ2QSZv//+1fPnj24H9+XX7aD/7bcvD+UsCwyZTZB5W2Suju/Tr9vvOYiz
ngbIbILM28ozOcTvv4aqUE/O+gC1QmZpdljtFznSU2/8NU/+IlcfvF2nnU4Iv/325sMPb9577+7r
k09ufvjhfIr4xx8vO3bWO68tMovAq/oixztxLmz6fPXB16+fno7j99+/ewHffHPz9dd3//HBB1nz
w26c9Zttl8yU13C5KPlr6KeuQlhEZj6BQ4+/fPnk6iTw55/vXuq7754//uLF446d9WiPTea85K9L
8HK4miS56BJfPnh/s+Hs66efbj766O4Ff/HF+T89e/agY2e5JuFrZg4b433cS3NNJlvOzyPzavH5
+OO75/r00+t7Kh07ywLrkMz85K8iMofqbdWa+c47d8/4yy9XhvjCyta4s5rZG5kzUomKVoNLdoPm
rdmGvpavBlt2ts6MsTc7I2E6M/krv7ItTxYs2ue8/7pX/r37bpztzYa5nzmU5zW0N5uyk6GX3M9c
kcyze4Pjo3zJXccQzu5nNkTmLmpk3n4vZ4BO5QzQccnc69d0bjbT2bnZ49bMBt8R/ve5jYfDn9v4
/FDOssCQ2VCtHvqs49V1WvfOssCQGX4WzbljZ2QikzMykcmZMzKRyRmZZCxyRiYyOSOTll99Illg
aiZnNZOMRc7IRCZnZJIRwxmZyOTMGZnI5IxMktjFGZkByZTYxRmZzZGp8wBnZDZHpm49nJsjcyhU
q3R8Z/7sPH6GeudlPjj+yiV2cW6UzFV+ZK1XnpkFtjDW4VQSuziHIfNqJsLIv6aBltApry3tmfPG
ZErs4hyPzHEAJru2Z/7I+EuqTabELs6trzNnkznjX9PiLLDJYp559SV2cQ5ZM0f2h7YhM2XnMqxY
MyV2cQ4zm123oqZlWWAbrDMldnHudp05/rONrDMldnE+4t5szo80dT9TYhfnJsjcUe3cvHUGiPPR
ycxpiLTLe4Fzs5zVzEartMQuzshsdP4ssYszMrta2XLu2BmZyOSMTGRy5oxMZHJGJhmLnJGJTM7I
pOVXn0gWmJrJWc0kY5EzMpHJGZlkxHBGJjI5c0YmMjkjkyR2cUZmQDIldnFGZnNk6jzAGZnNkalb
D+cwZGYeXMokocihmywwfeiiOzdK5i4mPWWB6d0a3TkSmSNJm5f/PfRtQ7/pwiywydcvsYtzmB7t
RWSOsJdJ5pLEoUpkSuziHHWdmQPJ5f+uTuZkFmCp870kdnHusGbOIHNyYyknCyxlJOQuqZkSuzgf
jswl+0Y5c9TSH5fYxblPMnP+e7N15vgFlNjF+Sh7s6VkTt5yXHI/c3KqLLGLsyywFuUMEGdZYJHI
TM7NckZmm2QmiV2ckdkmmUliF2dktkkmZ87IRCZnZJKxyBmZyOSMTDIWOSMTmZyRSTWuPpEsMDWT
s5pJxiJnZCKTMzLJiOGMTGRy5oxMZHJGJu2ZBSZlLK4zMncms14WmJSx0M7I3JPMej0NdEuI7ozM
3cis1wdIh6Hozm2ROdkgL/PBGT0mU0dZYFLGoju3Rea8Vq5rbaD1lAUmZSy6c0NkjiQR/Nl/fQTd
8R7tIz979m3Lycx/y6iXBSZlLLpz02RerWaTySWZD+a8hlIyS2ez9bLApIxFd26UzJyozFX+NZPM
oY7s4+8dk1e/XhaYlLHozpFms9uTOT5PXr7OrJcFJmVMzeyczKo7QPWywKSMWWduvTc7Y525fDa7
zd7sillgUsbszW59P3Mk5KvebHab+5krZoFJGXM/kxbtPDsDxBmZjd4Tcm6WMzJbJDPVzAKTMhba
GZk7k5lqZoFJGYvrjMz9yeTMGZnI5IxMMhY5IxOZnJFJxiJnZCKTMzKpxtUnkgWmZnJWM8lY5IxM
ZHJGJhkxnJGJTM6ckYlMzsikPrPApIzVdkbmzmRGzAKTMraBMzL3JDNiTwPdErZxRuZuZEbsA6TD
0DbOqamuliON8zZ4hbLAdnTWO69RMue1bF39fWHyJR08C0zK2DbOrZCZ06D9Mq7rrAf05T+d/e8I
PytmgS3v0d5yFpiUsW2c2yVzaPQP4XeV1bP/LuWnNpkRs8CkjG3j3CKZQ0FgI4jmozLys2lZFtjQ
lHjk6kfMApMyto1zvNnsUKnMCfYrJTNlZ4ENVeYZ9afxLDApY8etmaVkFk0vS8lca+LaTRaYlLFj
rTNTSfhX5toyZ/W47zozYhaYlLFj7c2W3s+8ei8x/5vbvJ8ZIgtMytjh7me2sA+8/ZM6A3QqZ4CO
S+Zev6Zzs5nOzs0et2Y2+I4QMQtMytgGzsjcv1ZHzAKTMlbbGZmBZ9GcO3ZGJjI5IxOZnDkjE5mc
kUnGImdkIpMzMmn51SeSBaZmclYzyVjkjExkckYmGTGckYlMzpyRiUzOyCRZYGXOssCQ2QSZssBO
JQsMmU2QqafBqfQ0QGYTZOoDdFZ59AHan8yRHrOlPmu9+JzeeUPnqmSByQLrpHfeKmSu+LIzs8Cu
foMsMFlg/fSbHSczp6fr6f+9GviVpmLCch7MfLUzyJQFdio92gOQOaM5+nhIUcoIBSoic3Z1PZUs
sFPJNWmIzKGPw8wjcwbhmWSOT3RnrzNlgb31oCywEDXzKq4jDI8n3g5hn7kDtGXNlAWmZsaYzS7Z
gylNlc/8p/w157w1myww68yu1pn1ZrOVyJQFZm+2z73ZlB04O0lO0epxiD1ZYLLAZIEFkzNAOc7O
ACGzFTKTc7Nvy7lZZLZCZpIFdlGFZIEhswkykyywi/WbLDBkNkEmZ87IRCZnZJKxyBmZyOSMTDIW
OSMTmZyRSTWuPpEsMDWTs5pJxiJnZCKTMzLJiOGMTGRy5oxMZHJGJsnV4ozMgGTK1eKMzObI1B+A
MzKbI1NPHc7xyBx/SeONLec55/fOy3xw/BnlanHumcwZu2cjbSmHvm1GY9vJZ5SrxTk8mTmdZkvj
wC6fa2My5Wpxjk1mZnf2oryTnFpam0y5Wpz7mc2Ok1n6s5lkDjG/kEy5Wpz7mc3OIDM/DiwzC+zy
wdaywNQfNbMujaWz2RmTz/xrVDrfnr3OlKvFORiZM2rm5ORzx3WmXC3OkWazI3cL560zxyef7dzP
lKvFOcY6syc5A8RZFlgkMpNzs5yR2SaZSa4WZ2S2SWaSq8UZmW2SyZkzMpHJGZlkLHJGJjI5I5OM
Rc7IRCZnZFKNq08kC0zN5KxmkrHIGZnI5IxMMmI4IxOZnDkjE5mckUl7ZoFFdJYFhswmyKyXBRbR
WRYYMpsgs15Pg4jOehogswky6/UBiuisD1A8MmfnCxX9Xt1kgUV01juvBzJrvNqessAiOus3G57M
y/++GnBw9ZuHftMVs8Dya2a9LLCIznq0xyZzqEN0yg5ZSNV6tJfOZutlgUV0lmsSmMzx1WY+maVz
5sv4zauPlM5m62WBRXSWBRaVzPwJ54zZ7PgOUNowP3OVLLCIzmpmh+vM0hXgkiywDTKnl2eBRXS2
zuxqb3aIk13WmQv3ZlfMAovobG+2q/uZ+ZFhS2az4bLAIjq7nxmSzOhyBijH2RkgZLZCZnJu9m05
N4vMVshMNbPAIjrLAkNmK2SmmllgEZ1lgSGzFTI5c0YmMjkjk4xFzshEJmdkkrHIGZnI5IxMqnH1
iWSBqZmc1UwyFjkjE5mckUlGDGdkIpMzZ2QikzMySfoVZ2QGJFP6FWdkNkemT/FzRmZzZOp8wzkA
mUWBX0XN1zOffUmbvBm983SL4xySzBo5fDkmM1rLzus3q8Mq53hkzgssOWsGfTU1LD+3a0UIdSXn
HLhH+0jgVw6ZMxq370umJA/OkcjMDPy6TMibMTWdUbdHfErXmdKvOIchc0bC7FBm3tnjG5CpZnLu
uWbOXmfm53+tnjhkncn5EOvM8fI4e51ZCo+9Wc72ZifYGAn5KtqbHXmiq90f3M/k7H5mz3LqhbMs
sEhkJidFOSOzTTKT9CvOyGyTzCT9ijMy2ySTM2dkIpMzMslY5IxMZHJGJhmLnJGJTM7IpBpXn0gW
mJrJWc0kY5EzMpHJGZlkxHBGJjI5c0YmMjkjk6b/rm/evHr9+unLl0+eP3/46683z549ePHi8atX
n715868DOssCQ2YTZP7++1fPnz+6HdyXX7eD/rffvjyUsywwZDZB5m2RuTq+T79uv+cgznoaILMJ
Mm8rz+QQv/8aqkI9OesDFJXMJS8y52dHeurNe3D82W/XaacTwm+/vfnww5v33rv7+uSTmx9+OJ8i
/vHHy46d9c5D5thVGPqRGv1mX79+ejqO33//7gV8883N11/f/ccHH2TND7tx1m+2QzJHitjZzw79
pjNSG5aT+fLlk6uTwJ9/vnuR7757/viLF487dtajvTcy87MVJrPANibz/mbD2ddPP9189NHdS/3i
i/N/evbsQcfOck2OReb4t2WSObtx+/gzXi0+H398Z/Lpp9f3VDp2lgXWIZnjyV+zyUyjqQ2VauY7
79w94y+/XBniCytb485qZs81c5yxGWTuss4c+lq+GmzZ2TrzuOvM2bPZbfZm77/ulX/vvhtne7Ox
yRyau2buzc6bzW5zP3N8lC+56xjC2f3MwGTGlTNAOc7OACGzFTKTc7Nvy7lZZLZCZvr/z208HP7c
xueHcpYFhsxWyEzDn3W8uk7r3lkWGDJbIZMzZ2QikzMyyVjkjExkckYmGYuckYlMzsikGlefSBaY
mslZzSRjkTMykckZmWTEcEYmMjlzRiYyOSOTZIGVOcsCQ2YTZMoCO5UsMGQ2QaaeBqfS0wCZTZCp
D9BZ5dEHKDaZlV5tTu+88eZ947kpl+s0WWCn6zS985A5eBWGnmVJE+okCyzDWb/ZnskcyVAYaT+b
SrLAZhCYZIFlOOvR3i2ZVzP5MskcwXXynzIv8eWDssBOJdfkQGReInq1Nk7iNz7RnU2mLLC3HpQF
1jGZQ6Fg88hM17LAatdMWWBqZs81c2haW0rmwt2geWs2WWDWmf3PZjPLXdE6cy0yZYHZm+2QzKJQ
sNlzzhzD2WTKAnM/MzkDlInQxk/qDNCpnAE6Lpl7/ZrOzWY6Ozd73JrZ4DuCLLCzKiQLDJmt1GpZ
YGfrN1lgyIw9i+bcsTMykckZmcjkzBmZyOSMTDIWOSMTmZyRScuvPpEsMDWTs5pJxiJnZCKTMzLJ
iOGMTGRy5oxMZHJGJkns4ozMgGRK7OKMzObI1HmAMzKbI1O3Hs79kzmjpd3kNw/1zssJCJt8GRK7
OB+XzKIfz+k3u2JAmMQuzmpmVrDXcjK7zwLTSX0bZ2SOOZSSeYQsMOkj2zgjM4vMq5mcmb3bR/5J
YhdnZM4hMw1kgRUFhJVWNoldnJFZdo3GHzxIFpjVoHVmLTJHftkl68yDZIHZQbU3O/O2x9l9xZxZ
6PL7mekwWWDuOrqf2ZWcAeIsCywSmcm5Wc7IbJPMJLGLMzLbJDNJ7OKMzDbJ5MwZmcjkjEwyFjkj
E5mckUnGImdkIpMzMqnG1SeSBaZmclYzyVjkjExkckYmGTGckYlMzpyRiUzOyCSJXZyRGZBMiV2c
kdkcmToPcEZmc2Tq1sN5CzI3wzv/ia52o8y3ze+dl8rb1Urs4ozM6R9ZmAU2eQDy8kGJXZx3JvNq
4OQQDEN9Ys9aOZ9+29V/GvrOkYbRs8kcb2ObJHZx3rdHe37EwFCGz8i/VvrOkdcfNwtMRkh05z3J
nPFg0dwyn6hJ0oYSpheuMyV2cQ5M5shkeOjbxgtyWpYFVrtmSuziHIbMJZVw9SywFcmU2MU5GJlF
q8cNZrOVyJTYxXk7MoemlEPT0ZQR13X1x4d2U3O+s0YW2PL7mRK7ONcic5c7liHkDBDnwFlgOT2L
OiMzOTfL2bnZZqcAErs4I7PRybnELs7I7GrZzLljZ2QikzMykcmZMzKRyRmZZCxyRiYyOSOTll99
IllgaiZnNZOMRc7IRCZnZJIRwxmZyOTMGZnI5IxM2jMLjPOpZIFRwd+1XhYY51PJAqOCq1+vpwHn
U+lpQAVXv14fIM5nNU0foBjL7syny+ydN3nYauMsMM5nK0C98wKTuTALbMaD9bLAOJ9Kv9mNyMzP
yRtKUkgDTZyXk1nU/b1eFhjnU+nRvieZOU3ZS8td3CwwzqeSa9IEmTnf1n0WGOe3HpQF1hqZQ9Fg
3WeBcVYzY9TM8fVkEVo56SwLV1bLs8A4W2fuSeZkcHUpQkvWmTPIrJcFxtne7BZ3MobCxUr3ZmfM
OfOzwGaQWS8LjLP7mfG0y2/qpM6+zs4AwbL4eZ1u3cbZuVkqfkeolwXG+ay+yQKjslpdLwuM89nK
UBYYbTGL5tyxMzKRyRmZyOTMGZnI5IxMMhY5IxOZnJFJy68+kSwwNZOzmknGImdkIpMzMsmI4YxM
ZHLmjExkckYmSewqc46V2FXPGZk7kymx61ThEruSLLAuydR54FQROw/oadAhmbr1nFWecN16OuwD
VNTjfANOitrkZT44/owSu87WaeE63PXZO+9qJEELbwrjrWVXDAiT2HWqiF1h++w3O07mkmL1Zyva
q9+ZsnvD1iZTYtepInZS77NH+ykkOdkhRQ+O925vhEyJXaeKmD7SZ67JCJmTnKxF1PhlmkFmUea0
xK63HgyY2NVnFtg4mVc/vTY+m92RzMmpssQuNbOHmpk/OVxxwpnWyJxeZZ0pscs6s4m7Jplrwvxp
5FoTzo33ZiV22Zttncw0mvY1ueM6Y8I51P1hy/uZErvcz2yCzEPJGaAcZ2eAkNkKmcm52bfl3Cwy
WyEzSey6qEKxEruSLLBeyUwSuy7Wb4ESu+o5I3N/MjlzRiYyOSOTjEXOyEQmZ2SSscgZmcjkjEyq
cfWJZIGpmZzVTDIWOSMTmZyRSUYMZ2QikzNnZCKTMzJJYhdnZAYkU2IXZ2Q2R6bOA5yR2RyZuvVw
bpfMkXaSOQ3a81/5uJsssBxnHe62cW6FzMlQsNpkygLLdNYVdhvn1sk8TfUaauU8nvw1CVImwFv2
aJfYxbmh2ex4jEJpH/fJNu0tkCmxi3OHZC6ZiNZIHBp3ltjFOUwWWG0yRzLCGiFTYhfnQ9fM/HXm
wiyw0m0qiV2cY9w1WfgfC2ezS+bJ+WvXkR1UiV2cQ5I5vjd79b/z92YXZoFNNo+Q2MVZFliLcgaI
syywSGQm52Y5I7NNMpPELs7IbJPMJLGLMzLbJJMzZ2QikzMyyVjkjExkckYmGYuckYlMzsikGlef
SBaYmslZzSRjkTMykckZmWTEcEYmMjlzRiYyOSOTZIFxRmZAMmWBcUZmc2TqacAZmc2RqQ8Q56bJ
LIoYWr5Gz+/XnN8mTxaY3nkd9s7LiQOrTebV7pWTP1L6naeSBcY5Npn5TV9TYSjY5c/mk1nUEloW
GOd4PdpTXoBCzoMzOriPXKP8oIR5ZMoC49wzmQsnnzm8jU90x79z5BllgXHujczJOerQns28HaCU
ES409J2llU0WGOfYZOZPcWfXzKKCvOI6UxYY5+bumqwS9ZWyo6nnrTPzd4OKdlBlgXGORGbp3uzQ
j8+rmUNPPXgRF9zPlAXGuTkyu5czQJxlgUUiMzk3yxmZbZKZZIFxRmabZCZZYJyR2SaZnDkjE5mc
kUnGImdkIpMzMslY5IxMZHJGJtW4+kSywNRMzmomGYuckYlMzsgkI4YzMpHJmTMykckZmSQLjDMy
A5IpC4wzMpsjU08Dzshsjkx9gDiHJHOVjLCFT5fTti/JAtM771C981bJCJv3XGlxq9vJqy8LjHNv
ZF6NAEsXfZ9zksIuTWaQOXmhZYFxDtmjfXx6OZKtcBW5/KSw8WtUm0xZYJx7IzOVBBNlEpWyE75G
lpRF60xZYJwPR+Z4/teSLLD8gJN5lU0WGOdD1MzxQlp0jSZ9MqPEJleDssA4h7lrkj9rrTGbLX0B
83ZQZYFx7pzMVJIUtsr9zMnmEbLAOB8oCyzQa3YGiPNRssBivWDnZjnPcHZuduf3EVlgnJHZaIWX
BcYZmV3NvTl37IxMZHJGJjI5c0YmMjkjk4xFzshEJmdk0vKrTyQLTM3krGaSscgZmcjkjEwyYjgj
E5mcOSMTmZyRSbLAOCMzIJmywDgjszky9TTgjMzmyNQHiHMMMkd6K2/wCpdkgY2/SFlgnGP3zhsP
5NrxqTM7QReRKQuMc7CamYPE1e+czP+qmgVWSqYsMM5dkTkZ7zX0DVWzwK6yPX71ZYFxjrfOzPmP
NBVhsrBHe1EW2AwyZYFxDrkDNJQpNMJbZv7X6llgpdV4pLLJAuPcFZmrpAPNzgKbl2siC4xz1Lsm
Vwvg+NJxxZo5I1Nsyd6sLDDO4e9njuzNrlszt7yfKQuMc7tkLic51ut0BohzP2TmtDYK9A7i3Czn
DmtmH7VdFhhnZDY665YFxhmZXa2HOXfsjExkckYmMjlzRiYyOSOTjEXOyEQmZ2TS8qtPJAtMzeSs
ZpKxyBmZyOSMTDJiOCMTmZw5IxOZnJFJssA4IzMgmbLAOCOzOTL1NOCMzObI1AeIc2wyM08zrc5P
Ue+8nHa1ZytAWWCcw5NZe6NsYRbY5AHIywdlgXHumcyRspbznaeGs8kcDzVJssA4R+/RXkrmZMpI
fk5RWiOlr4hMWWCcD7HOnJdxksl/Tu0tJVMWGOfeauYQtONk5rM9MiuuXTNlgXHugcx5uWDz+F+d
TFlgnPsnc3Yu2I7rTFlgnPufzabssLAifra8nykLjHM8Mmsg3cLLcAaI84HIbDAszLlZzvN3NxPt
VLplgXFGZqOTallgnJHZ1XKXc8fOyEQmZ2QikzNnZCKTMzLJWOSMTGRyRiYtv/pEssDUTM5qJhmL
nJGJTM7IJCOGMzKRyZkzMpHJGZkkC4wzMgOSKQuMMzKbI1NPA87IbI5MfYA41yJzm5SuUgAm28wu
aZM345eVBcZ56955G6R0LSFz5BceetnLUxgyr74sMM77kLmwCl0+eBlkcNbr+bKAD3WFXZ3M0lyG
JAuM8y5kLhzrI9kkOT9VOput8Wonr74sMM47rzPHOZl86px6tRaZk7FfQ985g0xZYJy3q5lD0C6Z
zQ6ROfINs3eAUkm89NDrWVLZZIFxrkvmvAneWpPGGWSu8nRFv6wsMM57kpm/OExzc6PbWWcW1UxZ
YJz3nM0u3LAdwWxoqjz01FXvZ44/oywwzrLAWpQzQJxlgUUiMzk3yxmZbZKZZIFxRmabZCZZYJyR
2SaZnDkjE5mckUnGImdkIpMzMslY5IxMZHJGJtW4+kSywNRMzmomGYuckYlMzsgkI4YzMpHJmTMy
kckZmbRnRpWUsbjOyNyZzHoZVVLGQjsjc08y630iXreE6M7I3I3Mel1kdBiK7hybzKFTTpOJQ5mP
j3SyzulwPf6M9TqvSRmL7twDmWttoGUGhF39hnmdoOt1K5UyFt25WzIzs0nOHikic7It9eTVr9fh
W8pYdOf+yZzss55ZgceL8zwy66ViSBmL7nysdeZaAWFF3zn2eqolSUkZi+7cW80cKmIjmWI5O0A5
C9oZ6Qkb10wpY2pmQ2Qumc0WzVdDrDOljFlnNkfmjJqZv8fT+N6slDF7s+3OZtOCuNucezMt38+U
MuZ+JpW9gzgDtM3VcAaIUunVd252m6vh3CyVXf1UM6NKylhoZ2TuTGaqmVElZSyuMzL3J5MzZ2Qi
kzMyyVjkjExkckYmGYuckYlMzsikGlefSBaYmslZzSRjkTMykckZmWTEcEYmMjlzRiYyOSOT+kzs
kgVW2xmZO5MZMbFLFtgGzsjck8yInQf0NNjGGZm7kRmxW48+QNs4ByMz51jT7N8lv3deZkDY+EuK
mNglC2wb55BkVtoxy8wCm9datpvELllg2zj3Q+ZpR9mcILCrPsvJLCrjERO7ZIFt49wVmflBYEt6
tOcHhE3+U8TELllg2zj3s87MpyifnyGYh9aTpWRGTOySBbaNc/iaWZXMNJW8UKNmNp7YJQtMzWyC
zPzZ7IyAsIiJXbLArDP3J7NonTmDzIiJXbLA7M2uQObI3uy69zPnkRkxsUsWmPuZXckZoBxnZ4CQ
2QqZybnZt+XcLDJbITPFTOySBbaBMzJ3JjPFTOySBVbbGZn7k8mZMzKRyRmZZCxyRiYyOSOTjEXO
yEQmZ2RSjatPJAtMzeSsZpKxyBmZyOSMTDJiOCMTmZw5IxOZnJFJcrU4IzMgmXK1OCOzOTL1B+CM
zObI1FOHc0NkZh5Nmr3ynve7FLXJy3xw/CXJ1eLcHJn5IG3zwua1q10YECZXi3MMMscH/Z8pBjlp
lmc/klPWtidTrhbnTsjMT/sa+ZH8Kl2bTLlanGOsM3Nq5owyW0Tm8nyxfDLlanFuumYuJPMS8ihk
ytXi3DOZpdPRlJ0Mvdc6U64W50bJHCqAM9aZ+WSOJ9VusDcrV4tzo2Sm0STZ2XuzObccR5a+m93P
lKvFeWcyV+e5fTkDxLnbLLAuyUzOzXJ2brbZtxW5WpyR2WjBl6vFGZldTcU5d+yMTGRyRiYyOXNG
JjI5I5OMRc7IRCZnZNLyq08kC0zN5KxmkrHIGZnI5IxMMmI4IxOZnDkjE5mckUl7ZoFFTBmTjIbM
JsislwUWMWVMMhoymyCzXk+DiN0SdHhAZhNk1usDFLHDkK5Ic8jMP1JUe8Vc7xmvNraMmAUWMWVM
Mtp8MndnryqZV2G7/O8QWWARU8Yko1UhczKkZKjIZPoUtZkt8jn71y3JrJcFFjFlTDLa+mQuST2Y
jOtaqzX70BON/I5xs8AipoxJRqu7zlySOLJw0M/LOMkhczLNYd46s14WWMSUMcloK9TMkZ2SIRLG
/3UGmas8Y+YO0FXz1HAWWMSUMclo68xmq+ZepgqxmfPInFGuW8gCi5gyJhmtIpnja8L8hK/lnpnm
+64z62WBRUwZk4xWcW92ZLDmzAln7M3mP+OS2Wy4LLCIKWOS0WaSWe/u4vh39nE4yRmgXl9zsCyw
op3equcHGiczOTcb/zU7N9snmalmFljElDHJaMhshcxUMwssYsqYZDRktkImZ87IRCZnZJKxyBmZ
yOSMTDIWOSMTmZyRSTWuPpEsMDWTs5pJxiJnZCKTMzLJiOGMTGRy5oxMZHJGJvWZBfbfV6+ePX36
45Mnf3348C83N989ePD948d//+yz//zrWIld9ZyRuTOZEbPA/vnVV3979Ojq54RvQf3HlwdK7Eqy
wLokM2JPg9vCONle4/Z7ZjhH7Dygp0GHZEbsA3RbLTObxQ1Vzp669QTrA7T6sC6KIVv4LAsfzO9q
GTEL7HZtOTSJvTqt/ffLnjvcheydV7XgVO30N7tnfGnNjJgF9uzp05IGq9fntN10hW2i32yzZK7V
EnYJmfM6AEbMAvvxyZMiMr9/3HMn9SZ6tLdJ5opt1Beaz+gEHTEL7P4GSf7Xdw96Th9pItekzXXm
imUtc7K6YnpCxCywy/H2aCL8qufEriaywBqpmSP7LlcrWH6Q3hIyp/+EvWSBqZlqZhqhcQYGOd8w
O3FoHpkRs8CsM60zi8lcfcIpC8zerL3ZnfdmiybAR84Ccz/T/cyu5AxQjrMzQMhshczk3Ozbcm4W
ma2QmWJmgd1WzqF92tvHn39+oMSuJAusVzJTzCywoc9nXl1bFjnHSuyq54zM/cnkzBmZyOSMTDIW
OSMTmZyRScYiZ2QikzMyqcbVJ5IFpmZyVjPJWOSMTGRyRiYZMZyRiUzOnJGJTM7IpD0Tu+RqxXVG
5s5k1kvskqsV2hmZe5JZr/OA/gDRnZG5G5n1uvXoqRPduSEyc3qxj/8aCxfuV5v0DXXTK2ozvXFi
lz500Z2bI3PGI2vtnl1tVJmJ/Sr9ZldM7NK7NbpzGDLv/+NqSsLZN48Hn4znWxaRWRTXt3Fil37n
0Z2DkTn5HznflpalJ5R+58iD9RK7ZIREdw68ziwNO1hC5vhEd/w7R56xXmKXXK3ozu3WzJGhP5vM
GSmXf37zOJkj31laM1dJ7FJ/1MyKs9l6NXPenaXMraYWssCs2awz9yczM6VrxXVm/m5Q0d7siold
9jntze6wAzS+NzsO5GRzh8n7mSPstZMF5t6g+5k0803nXs4AcUZmi2Qm52Y5I7NNMlPNxC65WqGd
kbkzmalmYpdcrbjOyNyfTM6ckYlMzsgkY5EzMpHJGZlkLHJGJjI5I5NqXH0iWWBqJmc1k4xFzshE
JmdkkhHDGZnI5MwZmcjkjEzaMwuM86lkgVHB37VeFhjnU8kCo4KrX6+nAedT6WlABVe/Xh8gzmc1
TR+gOaN28phSKk/1mvEb5ffOy3xw/MXXywLjfLYC1DtvaTFZJepr3u+SmQWW/+DkS6qXBcb5VPrN
rkxmTtRXGggIG/q/aTT2a2My62WBcT6VHu1rLsBKo75SSdf2JT3aVySzXhYY51PJNVlznbkkoSCf
okwyh94UFpJZLwuM81sPygJbsYQWJclezmAv/2lenvzVhK/LB1esmatkgXFWM2utM0ujvlJ2/te8
TaYaafD1ssA4W2dWJzMfwnqz2W32ZlfMAuNsb7bi/cycqK+cueXkCraR+5krZoFxdj+TFm1BO6mz
jbMzQFS8gnW6dRtn52ap7OqnmllgnM/qmywwKvi7pppZYJzPVoaywKjg78qZMzKRyRmZZCxyRiYy
OSOTjEXOyEQmZ2RSjatPJAtMzeSsZpKxyBmZyOSMTDJiOCMTmZw5IxOZnJFJ0q84IzMgmdKvOCOz
OTJ9ip8zMpsjU+cbzvHIzMwIS3kdK888M6/R1dZ7Q03l28kCi9gtjnMMMvMzwvLJnOwQndNvdtKw
hSywiB1WOYcncyTeKycUbKhbbMrrBJ3P7eTVl37FOTyZ4zwsyQjLfzuY/M7S2az0K879rDN3IXN8
opuGc8HGr770K87h92ZLkVuFzDSQBVY6703Srzh3UzNzMsI2IHOtNaf0K859rjN3ITMn72jFvdmD
p19xDn8/c2TxObI3mzIC4fOzwJbfKU3Srzh3sM6MLmeAOMsCi0Rmcm6WMzLbJDNJv+KMzDbJTNKv
OCOzTTI5c0YmMjkjk4xFzshEJmdkkrHIGZnI5IxMqnH1iWSBqZmc1UwyFjkjE5mckUlGDGdkIpMz
Z2QikzMySfoVZ2QGJFP6FWdkNkemT/FzRmZzZOp8wzkMmaXHl1Z/3nkPjr8e3eI499M7L+clrfWy
x/vTprzYr9Kuljqscu6EzPEUsCW17urz1iZTV3LOPZCZ0/p5HlGrkHk1/mT8GSV5cO5tNjsjUjbz
F8zPHVtOpvQrzr3NZnM4KQ1sX0LmvCwjVYJzz7PZJYV0xWcc30m2suLc/zrzMlZopIItwXUG9vZm
OR93b/aSk6Ft2KEp7uRNVPczObufeQg59cJZFlgkMpOTopyR2SaZSfoVZ2S2SWaSfsUZmW2SyZkz
MpHJGZlkLHJGJjI5I5OMRc7IRCZnZFKNq08kC0zN5KxmkrHIGZnI5IxMMmI4IxOZnDkjE5mckUnT
f9c3b169fv305csnz58//PXXm2fPHrx48fjVq8/evPlXs84Su2o7I3NnMn///avnzx/dYnP5dYvT
b7992aCzxK4NnJG5J5m35esqOadft9/TlLPOA9s4I3M3Mm9r2iQ8919D9W17Z916tnFulMyiQ0yl
c4+FsV9rvZ7bFeDpVPPbb28+/PDmvffuvj755OaHH84nn3/88XJ3Zx3utnEOUDPnvbDMYL8ZHaXz
81EmX8/r109PCXn//bu/wjff3Hz99d1/fPBB1sxzY2ddYbdxDknmSB0bx2/EfB6Z+YX06uMvXz65
Or38+ec7n3ffPX/8xYvHuzvrpL6NczwyM2NFMoOGZpNZ+kZw9cH72xhnXz/9dPPRR3fmX3xx/k/P
nj3Y3Vn6yDbOsWezI/iNJ3ON45QTYVIK4dUHr5a1jz++8//00+u7Nbs7S+zaxjn2bHaczNqxXykj
fWxGZXvnnTuHX365As/CmrmKs8qmZs6ZzRYtC7fcFipaDQ59LV9nLne2GrTOnEBoMgWsiJO1yCyq
mWc7qPdf98o/FbCxsx1Ue7MTs9mrk8mcLZnlsV/jm8P5ZJ7ddRznZ8n9zBWd3XV0P7MrOQPEWRZY
sB1m52Y5I7NFMtP/fyLk4fAnQj5v0Fli1wbOyNyZzDT8KcqrK8BGnCV21XZG5v5kcuaMTGRyRiYZ
i5yRiUzOyCRjkTMykckZmVTj6hPJAlMzOauZZCxyRiYyOSOTjBjOyEQmZ87IRCZnZJL0qzJn+WXI
bIJM6Venkl+GzCbI9Cn+tyqPPgzIbIFMnW/OqqXeRW2RWXpkaeGivJEsMN3iztaW8svarZk5L2Mh
me1kgemweir5ZcHIvNoY9iokQ3kK9bLAJtvVjr8GXclPJb8sEpmlyV/pWtbQBmTOS0+Q5HEq+WVR
Z7NFZKaMOLB5iUPzyqP0q0ln+WVRZ7PjZA592+pkrpgFpmZO1szD5pd1OJsdmdbOfqJKs1nrzJx1
5jHzy8KQmZn8lbnCbCQLzN7syN7swfPLwsxmc4C8euNx8t7pujc5i2qm+5kj9zMPnl/WHJnb3x3d
95U4A3QqZ4AOQWZTv5Fzs5nOzs0eomZGeZuQfnVWOeWXIbOVAi796mzNKb8MmbGn1pw7dkYmMjkj
E5mcOSMTmZyRScYiZ2QikzMyafnVJ5IFpmZyVjPJWOSMTGRyRiYZMZyRiUzOnJGJTM7IJFlgnJEZ
kExZYJyR2RyZehpwRmZzZOoDxLl1Msc7Ta6yHJ/sT7tKQJjeeZy76p23JZnj/zS7R3vpU+s3yznG
bDY/R+TPzq7zOsFmUjQP13wy9WjnHJjMoQeLcoeGfmRFMmfEEMk14Ry7Zq5VzXLIXDeGaOJBWWCc
Y6UnTG6uTBaujcmc/hOqEpw7yAJbXrjyf3zkGtUm08qKc6T7mUVxYCuuM1cPCLMbybmfLLBUGAeW
8hLBJvdmKwWEuYPHWRZY03LqhbMssEhkJidFOSOzTTKTLDDOyGyTzCQLjDMy2ySTM2dkIpMzMslY
5IxMZHJGJhmLnJGJTM7IpBpXn0gWmJrJWc0kY5EzMpHJGZlkxHBGJjI5c0YmMjkjk6RfcUZmQDKl
X3FGZnNk+hQ/Z2Q2R6bON5wlDm2UBZb/gnWL44zMAsO1Mhomn1qHVc5JFljaKgtMj3bOssAKmKmd
BTaDTEkenJMssFQ5cWjGOlP6FeckCyy1l9KnSnBOssBSzSww60zOssBmMiMLjLO92fVvn8gCc2/Q
/Uza4u3mXk69cEZmi2QmJ0U5I7NNMpP0K87IbJPMJP2KMzLbJJMzZ2QikzMyyVjkjExkckYmGYuc
kYlMzsikGlefSBaYmslZzSRjkTMykckZmWTEcEYmMjlzRiYyOSOT9syoevPm1evXT1++fPL8+cNf
f7159uzBixePX7367M0biV2ywJC5U0bV779/9fz5o1sgL79uQf3tN4ldssCQOaB6n4i/LYxXmTz9
uv2epl4zZ2Q2QWa9LjK31XISy/uvocqpW8++zh2SOdSfsrTfbCpsk1cakVSv89rt2vJ0Evvttzcf
fnjz3nt3X598cvPDD+fT2j/+0OFO77z9yJz8qdmdoK/++OQLqNet9PXrp6fsvf/+3Wv75pubr7++
+48PPsia0+oKu6Nzt7PZya7Q40W1lMyrPz559et1+H758snVievPP995v/vu+eMvXuikrkd7k2Re
fby0HXspmfVSMe5vkJx9/fTTzUcf3Xl/8cX5Pz17Jn1ErklAModCAReSWS9J6mrB/PjjO8tPP72+
D7T7a+Z8lL3ZkfCi0h2goSVlrJr5zjt3xr/8cgVLNVPNDEbmxFvmMjK3X2cOfVlnWmfuuUnb2jpz
s73Z+6975Z83sINqb7ZRMru5nzlOpvuZ7mc2SuyOz+gMEGdk7oZlcm6Ws3OzEd8O6mVU/e+zJg+H
P2sisUsWGDJHVS+jaujzmVfXlo28Zs7IDD+F5tyxMzKRyRmZyOTMGZnI5IxMMhY5IxOZnJFJy68+
kSwwNZOzmknGImdkIpMzMsmI4YxMZHLmjExkckYm7ZnYxflUssCo4O9aL7GL86lkgVHB1a/XeYDz
qfQ0oIKrX69bD+ezmqYP0A6jfDJWJPNazO6dN3nYauPELs5nK0C98/Ykc2EFW5gFNuPBeoldnE+l
3+w+cA7FlpwFkAz935GqO4PMou7v9RK7OJ9Kj/aGyMwJ1Zu8RrV7tNdL7OJ8KrkmbdXMkZ9akgWW
1uvRXi+xi/NbD8oC2x7OnJJ4uTezJAusds1cJbGLs5rZOpmrZ4FNmi9fZy5P7OJsndnQJu3k2rLq
OnMGmfUSuzjbm22dzKEZaea9jfwssBlk1kvs4ux+Js2/g5qc1NnK2RkgSqVX3+nWbZydm6Wyq59q
JnZxPqtvssCo4O+aaiZ2cT5bGcoCo4K/K2fOyEQmZ2SSscgZmcjkjEwyFjkjE5mckUk1rj6RLDCi
jt7QXQgiZBIRMomQSUTIJEImESGTCJlE1KL+DxoYapj7nll4AAAAAElFTkSuQmCC
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>